miR-124 Regulated Genes and Pathways as Targets for Therapeutic Intervention

BACKGROUND OF THE INVENTION

I. Field of the Invention

The present invention relates to the fields of molecular biology and medicine. More specifically, the invention relates to methods and compositions for the treatment of diseases or conditions that are affected by microRNA (miRNA) miR-124 expression or lack thereof, and genes and cellular pathways directly and indirectly modulated by such.

II. Background

In 2001, several groups used a cloning method to isolate and identify a large group of “microRNAs” (miRNAs) from C. elegans, Drosophila, and humans (Lau et al., 2001; Lee and Ambros, 2001; Lagos-Quintana et al., 2003). Several hundreds of miRNAs have been identified in plants and animals—including humans—which do not appear to have endogenous siRNAs. Thus, while similar to siRNAs, miRNAs are distinct.

miRNAs thus far observed have been approximately 21-22 nucleotides in length, and they arise from longer precursors, which are transcribed from non-protein-encoding genes (Carrington and Ambros, 2003). The precursors form structures that fold back on themselves in self-complementary regions; they are then processed by the nuclease Dicer (in animals) or DCL1 (in plants) to generate the short double-stranded miRNA. One of the miRNA strands is incorporated into a complex of proteins and miRNA called the RNA-induced silencing complex (RISC). The miRNA guides the RISC complex to a target mRNA, which is then cleaved or translationally silenced, depending on the degree of sequence complementarity of the miRNA to its target mRNA. Currently, it is believed that perfect or nearly perfect complementarity leads to mRNA degradation, as is most commonly observed in plants. In contrast, imperfect base pairing, as is primarily found in animals, leads to translational silencing. However, recent data suggest additional complexity (Bagga et al., 2005; Lim et al., 2005), and mechanisms of gene silencing by miRNAs remain under intense study (Chendrimada et al., 2007; Kiriakidou et al., 2007).

Recent studies have shown that changes in the expression levels of numerous miRNAs are associated with various cancers (reviewed in (Calin and Croce, 2006; Esquela-Kerscher and Slack, 2006; Wiemer, 2007). miRNAs have also been implicated in regulating cell growth and cell and tissue differentiation—cellular processes that are associated with the development of cancer.

The inventors previously demonstrated that hsa-miR-124 is involved with the regulation of numerous cell activities that represent intervention points for cancer therapy and for therapy of other diseases and disorders (U.S. patent application Ser. No. 11/141,707 filed May 31, 2005 and Ser. No. 11/273,640 filed Nov. 14, 2005, each of which is incorporated herein by reference in its entirety). For example, cell proliferation, cell division, and cell survival are frequently altered in human cancers. Transfection of human lung carcinoma cells (A549) and human cervical cancer cells (HeLa) with synthetic hsa-miR-124 reduced viable cell numbers. In addition, the inventors showed that miR-124 significantly increased the capacity of two therapeutic compounds (TRAIL, an apoptosis pathway activator in cancer cells, and etoposide, a topoisomerase II inhibitor that activates the apoptosis pathway in cancer cells and normal cells) to induce cell death in A549 or HeLa cells. Overexpression of synthetic miR-124 in various cell lines decreased cell proliferation. In those studies, the inventors observed reduced proliferation of human breast cancer cells, (BT549), normal human breast epithelial cells (MCF12A), human cervical cancer cells (HeLa), human prostate carcinoma cells (22RV1), human basal cell carcinoma cells (TE 354.T), normal human skin cells (TE 353.5 k), and human lung carcinoma cells (A549, CRL-5826, HTB-57). Overexpression of miR-124 in HeLa cells significantly reduced the number of cells in the G2/M phase of the cell cycle when compared to cells transfected with a negative control miRNA. Also, others have recently observed that epigenetic silencing of miR-124a in cancers cells modulates activity the oncogene, CDK6 and the tumor suppressor gene, Rb (Lujambio et al., 2007).

Bioinformatics analyses suggest that any given miRNA may bind to and alter the expression of up to several hundred different genes. In addition, a single gene may be regulated by several miRNAs. Thus, each miRNA may regulate a complex interaction among genes, gene pathways, and gene networks. Mis-regulation or alteration of these regulatory pathways and networks involving miRNAs are likely to contribute to the development of disorders and diseases such as cancer. Although bioinformatics tools are helpful in predicting miRNA binding targets, all have limitations. Because of the imperfect complementarity with their target binding sites, it is difficult to accurately predict the mRNA targets of miRNAs with bioinformatics tools alone. Furthermore, the complicated interactive regulatory networks among miRNAs and target genes make it difficult to accurately predict which genes will actually be mis-regulated in response to a given miRNA.

Correcting gene expression errors by manipulating miRNA expression or by repairing miRNA mis-regulation represent promising methods to repair genetic disorders and cure diseases like cancer. A current, disabling limitation of this approach is that, as mentioned above, the details of the regulatory pathways and gene networks that are affected by any given miRNA, have been largely unknown. This represents a significant limitation for treatment of cancers in which a specific miRNA may play a role. A need exists to identify the genes, genetic pathways, and genetic networks that are regulated by or that may regulate expression of miRNAs.

SUMMARY OF THE INVENTION

The present invention provides additional compositions and methods by identifying genes that are direct targets for miR-124 regulation or that are indirect or downstream targets of regulation following the miR-124-mediated modification of another gene(s) expression. Furthermore, the invention describes gene, disease, and/or physiologic pathways and networks that are influenced by miR-124 and its family members. In certain aspects, compositions of the invention are administered to a subject having, suspected of having, or at risk of developing a metabolic, an immunologic, an infectious, a cardiovascular, a digestive, an endocrine, an ocular, a genitourinary, a blood, a musculoskeletal, a nervous system, a congenital, a respiratory, a skin, or a cancerous disease or condition.

In particular aspects, a subject or patient may be selected for treatment based on expression and/or aberrant expression of one or more miRNA or mRNA. In a further aspect, a subject or patient may be selected for treatment based on aberrations in one or more biologic or physiologic pathway(s), including aberrant expression of one or more gene associated with a pathway, or the aberrant expression of one or more protein encoded by one or more gene associated with a pathway. In still a further aspect, a subject or patient may be selected based on aberrations in miRNA expression, or biologic and/or physiologic pathway(s). A subject may be assessed for sensitivity, resistance, and/or efficacy of a therapy or treatment regime based on the evaluation and/or analysis of miRNA or mRNA expression or lack thereof. A subject may be evaluated for amenability to certain therapy prior to, during, or after administration of one or therapy to a subject or patient. Typically, evaluation or assessment may be done by analysis of miRNA and/or mRNA, as well as combination of other assessment methods that include but are not limited to histology, immunohistochemistry, blood work, etc.

In some embodiments, an infectious disease or condition includes a bacterial, viral, parasite, or fungal infection. Many of these genes and pathways are associated with various cancers and other diseases. Cancerous conditions include, but are not limited to astrocytoma, anaplastic large cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, angiosarcoma, breast carcinoma, B-cell lymphoma, Burkitt's lymphoma, bladder carcinoma, cholangiocarcinoma, cervical carcinoma, carcinoma of the head and neck, chronic lymphoblastic leukemia, chronic myeloid leukemia, colorectal carcinoma, endometrial carcinoma, Ewing's sarcoma, glioma, glioblastoma, glioblastoma multiforme, gastric carcinoma, hepatoblastoma, hepatocellular carcinoma, Hodgkin lymphoma, Kaposi's sarcoma, leukemia, lung carcinoma, lipoma, leiomyosarcoma, liposarcoma, laryngeal squamous cell carcinoma, melanoma, mucosa-associated lymphoid tissue B-cell lymphoma, medulloblastoma, mantle cell lymphoma, myxofibrosarcoma, meningioma, multiple myeloma, neuroblastoma, non-Hodgkin lymphoma, nasopharyngeal carcinoma, non-small cell lung carcinoma, ovarian carcinoma, oesophageal carcinoma, oropharyngeal carcinoma, osteosarcoma, pancreatic carcinoma, papillary carcinoma, prostate carcinoma, retinoblastoma, renal cell carcinoma, rhabdomyosarcoma, squamous cell carcinoma of the head and neck, schwannoma, small cell lung cancer, salivary gland tumor, thyroid carcinoma, testicular tumor, urothelial carcinoma, Wilm's tumor, wherein the modulation of one or more gene is sufficient for a therapeutic response. Typically a cancerous condition is an aberrant hyperproliferative condition associated with the uncontrolled growth or inability to undergo cell death, including apoptosis.

In still a further aspect, a nervous system condition can include a disease or injury to a neuronal cell or a nerve that includes, but is not limited to brain tumors; neuronal degeneration; mental retardation; Cerebral degeneration (Leukodystrophy (Krabbe disease, Pelizaeus-Merzbacher disease), Cerebral lipidoses (Tay-Sachs disease), Alzheimer's disease, Pick's disease, obstructive Hydrocephalus, Reye's syndrome, Parkinson's disease); extrapyramidal disease and abnormal movement disorders (Olivopontocerebellar atrophy, Shy-Drager syndrome, Essential tremor/familial tremor, Myoclonus (Lafora's disease or Unverricht disease), Huntington's chorea, torsion dystonia, Blepharospasm, Restless legs, Serotonin syndrome); Spinocerebellar disease (Friedreich's ataxia (Spinocerebellar ataxia), Hereditary spastic paraplegia, Primary cerebellar degeneration, cerebellar ataxia, ataxia-telangiectasia [Louis-Bar syndrome], Corticostriatal-spinal degeneration); Anterior horn cell disease (Motor neuron disease (Amyotrophic lateral sclerosis, Progressive muscular atrophy, Progressive bulbar palsy, Pseudobulbar palsy, Primary lateral sclerosis); Syringomyelia and syringobulbia; Disorders of the autonomic nervous system (Reflex sympathetic dystrophy); or multiple sclerosis. Nerve injuries include three main types of nerve fiber injury axonotmesis, neurapraxia and neurotmesis.

Axonotmesis involves loss of the relative continuity of the axon and its covering of myelin, but preservation of the connective tissue framework of the nerve (the encapsulating tissue, the epineurium and perineurium, are preserved). Because axonal continuity is lost, wallerian degeneration occurs. Typically, recovery occurs only through regeneration of the axons, a process requiring time. Axonotmesis is usually the result of a more severe crush or contusion than neurapraxia.

Neurapraxia is an interruption in conduction of the impulse down the nerve fiber, and recovery takes place without wallerian degeneration. This is the mildest form of nerve injury. This is probably a biochemical lesion caused by a concussion or other shock-like injuries to the fiber. In the case of the role nerve, neurapraxia is brought about by compression or relatively mind, blunt blows, including some low-velocity missile injuries close to the nerve.

Neurotmesis is the most severe lesion. It occurs on severe contusion, stretch, laceration, or Local Anesthetic Toxicity. Not only the axon, but the encapsulating connective tissue lose their continuity. The last (extreme) degree of neurotmesis is transsection, but most neurotmetic injuries do not produce gross loss of continuity of the nerve but rather than internal disruption of the architecture of the nerve sufficient to involve perineurium and endoneuruim as well as axons and their covering. There is typically a complete loss of motor, sensory and autonomic function. For neurotmesis, the Sunderland System is typically used for classification.

The present invention provides methods and compositions for identifying genes that are direct targets for miR-124 regulation or that are downstream targets of regulation following the miR-124-mediated modification of upstream gene expression. Furthermore, the invention describes gene pathways and networks that are influenced by miR-124 expression in biological samples. Many of these genes and pathways are associated with various cancers and other diseases. The altered expression or function of miR-124 in cells would lead to changes in the expression of these genes and contribute to the development of disease or other conditions. Introducing miR-124 (for diseases where the miRNA is down-regulated) or a miR-124 inhibitor (for diseases where the miRNA is up-regulated) into disease cells or tissues or subjects would result in a therapeutic response. The identities of key genes that are regulated directly or indirectly by miR-124 and the disease with which they are associated are provided herein.

In certain aspects a cell may be an epithelial, an endothelial, a mesothelial, a glial, a stromal, or a mucosal cell. The cell can be, but is not limited to a brain, a neuronal, a blood, an endometrial, a meninges, an esophageal, a lung, a cardiovascular, a liver, a lymphoid, a breast, a bone, a connective tissue, a fat, a retinal, a thyroid, a glandular, an adrenal, a pancreatic, a stomach, an intestinal, a kidney, a bladder, a colon, a prostate, a uterine, an ovarian, a cervical, a testicular, a splenic, a skin, a smooth muscle, a cardiac muscle, or a striated muscle cell. A cell, tissue, or subject may be a cancer cell, a cancerous tissue, harbor cancerous tissue, or be a subject or patient diagnosed or at risk of developing a disease or condition. In still a further aspect cancer includes, but is not limited to astrocytoma, anaplastic large cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, angiosarcoma, breast carcinoma, B-cell lymphoma, Burkitt's lymphoma, bladder carcinoma, cholangiocarcinoma, cervical carcinoma, carcinoma of the head and neck, chronic lymphoblastic leukemia, chronic myeloid leukemia, colorectal carcinoma, endometrial carcinoma, Ewing's sarcoma, glioma, glioblastoma, glioblastoma multiforme, gastric carcinoma, hepatoblastoma, hepatocellular carcinoma, Hodgkin lymphoma, Kaposi's sarcoma, leukemia, lung carcinoma, lipoma, leiomyosarcoma, liposarcoma, laryngeal squamous cell carcinoma, melanoma, mucosa-associated lymphoid tissue B-cell lymphoma, medulloblastoma, mantle cell lymphoma, myxofibrosarcoma, meningioma, multiple myeloma, neuroblastoma, non-Hodgkin lymphoma, nasopharyngeal carcinoma, non-small cell lung carcinoma, ovarian carcinoma, oesophageal carcinoma, oropharyngeal carcinoma, osteosarcoma, pancreatic carcinoma, papillary carcinoma, prostate carcinoma, retinoblastoma, renal cell carcinoma, rhabdomyosarcoma, squamous cell carcinoma of the head and neck, schwannoma, small cell lung cancer, salivary gland tumor, thyroid carcinoma, testicular tumor, urothelial carcinoma, or Wilm's tumor.

In certain aspects, the cell, tissue, or target may not be defective in miRNA expression yet may still respond therapeutically to expression or over expression of a miRNA. miR-124 could be used as a therapeutic target for any of these diseases. In certain embodiments miR-124 or its compliment can be used to modulate the activity of miR-124 in a subject, organ, tissue, or cell.

A cell, tissue, or subject may be a cancer cell, a cancerous tissue, harbor cancerous tissue, or be a subject or patient diagnosed or at risk of developing a disease or condition. In certain aspects a cancer cell is a neuronal, glial, lung, liver, brain, breast, bladder, blood, leukemic, colon, endometrial, stomach, skin, ovarian, fat, bone, cervical, esophageal, pancreatic, prostate, kidney, epithelial, intestinal, muscle, adrenal, salivary gland, or thyroid cell. In still a further aspect cancer includes, but is not limited to astrocytoma, anaplastic large cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, angiosarcoma, breast carcinoma, B-cell lymphoma, bladder carcinoma, cervical carcinoma, carcinoma of the head and neck, chronic lymphocytic leukemia, chronic myeloid leukemia, colorectal carcinoma, endometrial carcinoma, glioma, glioblastoma, gastric carcinoma, gastrinoma, hepatoblastoma, hepatocellular carcinoma, Hodgkin lymphoma, Kaposi's sarcoma, leukemia, lung carcinoma, leiomyosarcoma, laryngeal squamous cell carcinoma, melanoma, mucosa-associated lymphoid tissue B-cell lymphoma, medulloblastoma, mantle cell lymphoma, meningioma, myeloid leukemia, multiple myeloma, high-risk myelodysplastic syndrome, mesothelioma, neurofibroma, non-Hodgkin lymphoma, non-small cell lung carcinoma, ovarian carcinoma, esophageal carcinoma, oropharyngeal carcinoma, osteosarcoma, pancreatic carcinoma, papillary carcinoma, prostate carcinoma, pheochromocytoma, rhabdomyosarcoma, squamous cell carcinoma of the head and neck, schwannoma, small cell lung cancer, salivary gland tumor, sporadic papillary renal carcinoma, thyroid carcinoma, testicular tumor, or urothelial carcinoma.

Embodiments of the invention include methods of modulating gene expression, or biologic or physiologic pathways in a cell, a tissue, or a subject comprising administering to the cell, tissue, or subject an amount of an isolated nucleic acid or mimetic thereof comprising a miR-124 nucleic acid, mimetic, or inhibitor sequence in an amount sufficient to modulate the expression of a gene positively or negatively modulated by a miR-124 miRNA. A “miR-124 nucleic acid sequence” or “miR-124 inhibitor” includes the full length precursor of miR-124, or complement thereof or processed (i.e., mature) sequence of miR-124 and related sequences set forth herein, as well as 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or more nucleotides of a precursor miRNA or its processed sequence, or complement thereof, including all ranges and integers there between. In certain embodiments, the miR-124 nucleic acid sequence or miR-124 inhibitor contains the full-length processed miRNA sequence or complement thereof and is referred to as the “miR-124 full-length processed nucleic acid sequence” or “miR-124 full-length processed inhibitor sequence.” In still further aspects, the miR-124 nucleic acid comprises at least 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 nucleotide segment (including all ranges and integers there between) or complementary segment of a miR-124 that is at least 75, 80, 85, 90, 95, 98, 99 or 100% identical to SEQ ID NO:1 to SEQ ID NO:52. The general term miR-124 includes all members of the miR-124 family that share at least part of a mature miR-124 sequence. Mature miR-124 sequences include hsa-miR-124 (MIMAT0000422), rno-miR-124 (MIMAT0000828), mmu-miR-124 (MIMAT0000134), UAAGGCACGCGGUGAAUGCC (SEQ ID NO:1); fru-miR-124 (MIMAT0002896), tni-miR-124 (MIMAT0002897), dre-miR-124 (MIMAT0001819), UAAGGCACGCGGUGAAUGCCAA (SEQ ID NO:2); ame-miR-124 (MIMAT0001473), aga-miR-124 (MIMAT0001499), bmo-miR-124 (MIMAT0004198), dps-miR-124 (MIMAT0001229), dme-miR-124 (MIMAT0000351), UAAGGCACGCGGUGAAUGCCAAG (SEQ ID NO:3); mdo-miR-124a (MIMAT0004102), ggo-miR-124a (MIMAT0002465), lla-miR-124a (MIMAT0002471), ptr-miR-124a (MIMAT0002469), ppa-miR-124a (MIMAT0002467), gga-miR-124a (MIMAT0001128), xtr-miR-124 (MIMAT0003683), ppy-miR-124a (MIMAT0002468), mml-miR-124a (MIMAT0002470), age-miR-124a (MIMAT0002466), ssc-miR-124a (MIMAT0002156), UUAAGGCACGCGGUGAAUGCCA (SEQ ID NO:4); bta-miR-124a (MIMAT0003811), UUAAGGCACGCGGUGAAUGCCAA (SEQ ID NO:5); cbr-miR-124 (MIMAT0000494), cel-miR-124 (MIMAT0000282), UAAGGCACGCGGUGAAUGCCA (SEQ ID NO:6); gga-miR-124b (MIMAT0001174), UUAAGGCACGCAGUGAAUGCCA (SEQ ID NO:7), or a complement thereof. In certain aspects, a subset of these miRNAs will be used that include some but not all of the listed miR-124 family members. In one aspect, miR-124 sequences have a core consensus sequence of [U/-]UAAGGCACGCGGUGAAUGCC[-/A][-/A][-/G] (SEQ ID NO:8, wherein the bracketed nucleotides are optional). In one embodiment only sequences comprising the consensus sequence of UAAGGCACGCGGUGAAUGCC (SEQ ID NO:1)) will be included with all other miRNAs excluded. The term miR-124 includes all members of the miR-124 family unless specifically identified. In certain aspects, a subset of these miRNAs will be used that include some but not all of the listed miR-124 family members. For instance, in one embodiment only sequences comprising the consensus sequence of SEQ ID NO:1 will be included with all other miRNAs excluded.

In a further aspect, a “miR-124 nucleic acid sequence” includes all or a segment of the full length precursor of miR-124 family members. Stem-loop sequences of miR-124 family members include hsa-mir-124-1 (MI0000443, AGGCCUCUCUCUCCGUGUUCACAGCGGACCUUGAUUUAAAUGUCCAUACAAUUAA GGCACGCGGUGAAUGCCAAGAAUGGGGCUG (SEQ ID NO:9)), hsa-mir-124-2 (MI0000444, AUCAAGAUUAGAGGCUCUGCUCUCCGUGUUCACAGCGGACCUUGAUUUAAUGUC AUACAAUUAAGGCACGCGGUGAAUGCCAAGAGCGGAGCCUACGGCUGCACUUGA A (SEQ ID NO:10)), hsa-mir-124-3 (MI0000445, UGAGGGCCCCUCUGCGUGUUCACAGCGGACCUUGAUUUAAUGUCUAUACAAUUA AGGCACGCGGUGAAUGCCAAGAGAGGCGCCUCC (SEQ ID NO:11)), aga-mir-124 (MI0001604, CGUUUUUCUCCUGGUGUUCACUGUAGGCCUGUAUGUUCUAUUGCGGAUUUCAUA AGGCACGCGGUGAAUGCCAAGAGCGAACG (SEQ ID NO:12)), age-mir-124a (MI0002762, AUCAAGAUCAGAGGCUCUGCCCUCCGUGUUCACAGCGGACCUUGAUUUAAUGUCA UACAAUUAAGGCACGCGGUGAAUGCCAAGAGCGGAGCCUACGGCUGCACUUG (SEQ ID NO:13)), ame-mir-124 (MI0001577, UGCUCCUUGCGUUCACUGCGGGCUUCCAUGUGCCAACUUUUCAAAAUUCAUAAGG CACGCGGUGAAUGCCAAGAGCG (SEQ ID NO:14)), bmo-mir-124 (MI0004976, CAGUCCACCUCCUCGCGUUCACUGCCGGAGCCGUUAUGUAUAUUUAAAAUUCAUA AGGCACGCGGUGAAUGCCAAGAGCGGACUC (SEQ ID NO:15)), bta-mir-124a (MI0005027, AGGCCUCUCUCUCCGUGUUCACAGCGGACCUUGAUUUAAAUGUCCAUACAAUUAA GGCACGCGGUGAAUGCCAAGAAUGGGGCUG (SEQ ID NO:16)), cbr-mir-124 (MI0000525, UUUCCAGUCGUCAUAUGGCGUCCACCUGAGUGACUUUAGUGGACAUGUAUAGUU UCCAACUAAGGCACGCGGUGAAUGCCACGUGGCAAUUCUGGGAU (SEQ ID NO:17)), cel-mir-124 (MI0000302, GUCCCACUUGUCAUCUGGCAUGCACCCUAGUGACUUUAGUGGACAUCUAAGUCUU CCAACUAAGGCACGCGGUGAAUGCCACGUGGCCAUGAUGGG (SEQ ID NO:18)), dme-mir-124 (MI0000373, UCAUUUGGUACGUUUUUCUCCUGGUAUCCACUGUAGGCCUAUAUGUAUUUCCACC AUAAGGCACGCGGUGAAUGCCAAGAGCGAACGCAGUUCUACAAAU (SEQ ID NO:19)), dps-mir-124 (MI0001323, UCGUUUGGUACGUUUUUCUCCUGGUAUCCACUGUAGGCCUAUAUGUAUUUCGAC CAUAAGGCACGCGGUGAAUGCCAAGAGCGGACGAAACUCUACUA (SEQ ID NO:20)), dre-mir-124-1 (MI0001966, GGCUCUCGCUGUACGUGUUCACAGUGGACCUUGAUUUAUUGUAUUUCAAUUAAG GCACGCGGUGAAUGCCAACAGCACAGCC (SEQ ID NO:21)), dre-mir-124-2 (MI0001967, CCUGCUUUUCUUCGUGUUCACAGCGGACCUUGAUUUAAAUGUCCAUACAAUUAA GGCACGCGGUGAAUGCCAAGAGAGAUGGC (SEQ ID NO:22)), dre-mir-124-3 (MI0001968, GGCUCUGUGGGAUUUCAGACUCUGGCUUUCCGUGUUCACAGCGGACCUUGAUUU AAUGUCUUACAAUUAAGGCACGCGGUGAAUGCCAAGAGCGGAGCCUUUUAACAU CAGCAGGCC (SEQ ID NO:23)), dre-mir-124-4 (MI0001969, GGUUUUUGCUCUUUGUGUUCACAGUGGACCUUGAUUUAAUUUCAAUACAAUUAA GGCACGCGGUGAAUGCCAAGAGAGAAGCC (SEQ ID NO:24)), dre-mir-124-5 (MI0001970, GGGUUUUGCUCGUGCGUUCUUUUUGAGUUCUCGCUCUGCGUGUUCACAGCGGACC UUGAUUUAAUGUCCAUACAAUUAAGGCACGCGGUGAAUGCCAAGAGAAGAAUCU CUCCAGCAACGAGUUUGCGC (SEQ ID NO:25)), dre-mir-124-6 (MI0001971, GGGUGGUGACACAGGCCCGCCACUCUGCGUGUUCACGGCGGACCUUGAUUUAAUA UCCAUACAAUUAAGGCACGCGGUGAAUGCCAAGAGAGGGGUCUUAAAACGACAA ACCC (SEQ ID NO:26)), fru-mir-124-1 (MI0003287, GGUUGUGUCUCUCCGUGUUCACAGCGGACCUUGAUUUAAUGUCUUACAAUUAAG GCACGCGGUGAAUGCCAAGAGAU (SEQ ID NO:27)), fru-mir-124-2 (MI0003354, CUGGUCUCUCCUCGUGUUCACAGCGGACCUUGAUUUAAAUGUCCAUACAAUUAAG GCACGCGGUGAAUGCCAAGAGAG (SEQ ID NO:28)), fru-mir-124-3 (MI0003211, GGUUUGAGCUCUUUGUGUUCACAGUGGACCUUGAUUUAAUUUCAAUACAAUUAA GGCACGCGGUGAAUGCCAAGAGAGAAGCC (SEQ ID NO:29)), gga-mir-124a (MI0001197, AGGCUCUGCCUCUCCGUGUUCACAGCGGACCUUGAUUUAAUGUCAUACAAUUAAG GCACGCGGUGAAUGCCAAGAGCGGAUCCUCCAGGCGGCAUU (SEQ ID NO:30)), gga-mir-124b-1 (MI0001252, AGCCCCAGCGUUUUGUGUUCACUGCAGACCUUGAUUUAAUGUCACACGAUUAAG GCACGCAGUGAAUGCCAAAGUUUGGGGCAGCCUGGGCUG (SEQ ID NO:31)), gga-mir-124b-2 (MI0001253, AGCCCCAGCGUUUUGUGUUCACUGCAGACCUUGAUUUAAUGUCACACGAUUAAG GCACGCAGUGAAUGCCAAAGUUUGGGGCAGCCUGGGCUG (SEQ ID NO:32)), ggo-mir-124a (MI0002761, AUCAAGAUUAGAGGCUCUGCUCUCCGUGUUCACAGCGGACCUUGAUUUAAUGUC AUACAAUUAAGGCACGCGGUGAAUGCCAAGAGCGGAGCCUACGGCUGCACUUGA A (SEQ ID NO:33)), 11a-mir-124a (MI0002767, AUCAAGAUCAGAGGCUCUGCCCUCCGUGUUCACAGCGGACCUUGAUUUAAUGUCA UACAAUUAAGGCACGCGGUGAAUGCCAAGAGCGGAGCCUACGACUGCACUUG (SEQ ID NO:34)), mdo-mir-124a-1 (MI0005288, AGGCCUCUCUCUCCGUGUUCACAGCGGACCUUGAUUUAAAUGUCCAUACAAUUAA GGCACGCGGUGAAUGCCAAGAAUGGGGCUG (SEQ ID NO:35)), mdo-mir-124a-2 (MI0005289, AUCAGAGACUCUGUCUCUCCGUGUUCACAGCGGACCUUGAUUUAAUGUCAUACAA UUAAGGCACGCGGUGAAUGCCAAGAGCGGAGCCUGAAA (SEQ ID NO:36)), mdo-mir-124a-3 (MI0005290, CUCUGCGUGUUCACAGCGGACCUUGAUUUAAUGUCUAUACAAUUAAGGCACGCG GUGAAUGCCAAGAG (SEQ ID NO:37)), mml-mir-124a (MI0002766, AUCAAGAUCAGAGGCUCUGCCCUCCGUGUUCACAGCGGACCUUGAUUUAAUGUCA UACAAUUAAGGCACGCGGUGAAUGCCAAGAGCGGAGCCUACGGCUGCACUUGAA (SEQ ID NO:38)), mmu-mir-124-1 (MI0000716, AGGCCUCUCUCUCCGUGUUCACAGCGGACCUUGAUUUAAAUGUCCAUACAAUUAA GGCACGCGGUGAAUGCCAAGAAUGGGGCUG (SEQ ID NO:39)), mmu-mir-124-2 (MI0000717, AUCAAGAUCAGAGACUCUGCUCUCCGUGUUCACAGCGGACCUUGAUUUAAUGUCA UACAAUUAAGGCACGCGGUGAAUGCCAAGAGCGGAGCCUACGGCUGCACUUGAA (SEQ ID NO:40)), mmu-mir-124-3 (MI0000150, CUCUGCGUGUUCACAGCGGACCUUGAUUUAAUGUCUAUACAAUUAAGGCACGCG GUGAAUGCCAAGAG (SEQ ID NO:41)), ppa-mir-124a (MI0002763, AUCAAGAUUAGAGGCUCUGCUCUCCGUGUUCACAGCGGACCUUGAUUUAAUGUC AUACAAUUAAGGCACGCGGUGAAUGCCAAGAGCGGAGCCUACGGCUGCACUUGA A (SEQ ID NO:42)), ppy-mir-124a (MI0002764, AUCAAGAUUAGAGGCUCUGCCCUCCGUGUUCACAGCGGACCUUGAUUUAAUGUCA UACAAUUAAGGCACGCGGUGAAUGCCAAGAGCGGAGCCUACGGCUGCACUUGAA (SEQ ID NO:43)), ptr-mir-124a (MI0002765, AUCAAGAUUAGAGGCUCUGCUCUCCGUGUUCACAGCGGACCUUGAUUUAAUGUC AUACAAUUAAGGCACGCGGUGAAUGCCAAGAGCGGAGCCUACGGCUGCACUUGA A (SEQ ID NO:44)), rno-mir-124-1 (MI0000893, AGGCCUCUCUCUCCGUGUUCACAGCGGACCUUGAUUUAAAUGUCCAUACAAUUAA GGCACGCGGUGAAUGCCAAGAAUGGGGCUG (SEQ ID NO:45)), mo-mir-124-2 (MI0000894, AUCAAGAUCAGAGACUCUGCUCUCCGUGUUCACAGCGGACCUUGAUUUAAUGUCA UACAAUUAAGGCACGCGGUGAAUGCCAAGAGCGGAGCCUACGGCUGCACUUGAA (SEQ ID NO:46)), rno-mir-124-3 (MI0000892, UGAGGGCCCCUCUGCGUGUUCACAGCGGACCUUGAUUUAAUGUCUAUACAAUUA AGGCACGCGGUGAAUGCCAAGAGAGGCGCCUCC (SEQ ID NO:47)), ssc-mir-124a (MI0002450, AGGCCUCUCUCUCCGUGUUCACAGCGGACCUUGAGUUAAAUGUCCAUACAAUUAA GGCACGCGGUGAAUGCCAAGAAUGGGGCUG (SEQ ID NO:48)), tni-mir-124-1 (MI0003288, CUCUCCGUGUUCACAGCGGACCUUGAUUUAAUGUCUUACAAUUAAGGCACGCGGU GAAUGCCAAGAG (SEQ ID NO:49)), tni-mir-124-2 (MI0003355, GCCUCUCCUCGUGUUCACAGCGGACCUUGAUUUAAAUGUCCAUACAAUUAAGGCA CGCGGUGAAUGCCAAGAGAG (SEQ ID NO:50)), tni-mir-124-3 (MI0003212, GGUUUGAGCUCUUUGUGUUCACAGUGGACCUUGAUUUAAUUUCAAUACAAUUAA GGCACGCGGUGAAUGCCAAGAGAGAA (SEQ ID NO:51)), xtr-mir-124 (MI0004930, UAAGUCUCUGACUCUCCGUGUUCACAGCGGACCUUGAUUUAAUGUCAUACAAUU AAGGCACGCGGUGAAUGCCAAGAGUGGAGCCUAC (SEQ ID NO:52)), or a complement thereof.

In certain aspects, a miR-124 nucleic acid, or a segment or a mimetic thereof, will comprise 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or more nucleotides of the precursor miRNA or its processed sequence, including all ranges and integers there between. In certain embodiments, the miR-124 nucleic acid sequence contains the full-length processed miRNA sequence and is referred to as the “miR-124 full-length processed nucleic acid sequence.” In still further aspects, a miR-124 comprises at least one 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50 nucleotide (including all ranges and integers there between) segment of miR-124 that is at least 75, 80, 85, 90, 95, 98, 99 or 100% identical to SEQ ID NOs provided herein.

In specific embodiments, a miR-124 or miR-124 inhibitor containing nucleic acid is hsa-miR-124 or hsa-miR-124 inhibitor, or a variation thereof. In a further aspect, a miR-124 nucleic acid or miR-124 inhibitor can be administered with 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more miRNAs or miRNA inhibitors. miRNAs or their complements can be administered concurrently, in sequence, or in an ordered progression. In certain aspects, a miR-124 or miR-124 inhibitor can be administered in combination with one or more of let-7, miR-15, miR-16, miR-20, miR-21, miR-26a, miR-126, miR-143, miR-147, miR-188, miR-200, miR-215, miR-216, miR-292-3p, and/or miR-331. All or combinations of miRNAs or inhibitors thereof may be administered in a single formulation. Administration may be before, during or after a second therapy.

miR-124 nucleic acids or complements thereof may also include various heterologous nucleic acid sequences, i.e., those sequences not typically found operatively coupled with miR-124 in nature, such as promoters, enhancers, and the like. The miR-124 nucleic acid is a recombinant nucleic acid, and can be a ribonucleic acid and/or a deoxyribonucleic acid. The recombinant nucleic acid may comprise a miR-124 or miR-124 inhibitor expression cassette, i.e., a nucleic acid segment that expresses a nucleic acid when introduce into an environment containing components for nucleic acid synthesis. In a further aspect, the expression cassette is comprised in a viral vector, or plasmid DNA vector or other therapeutic nucleic acid vector or delivery vehicle, including liposomes and the like. In a particular aspect, the miR-124 nucleic acid is a synthetic nucleic acid. Moreover, nucleic acids of the invention may be fully or partially synthetic. In certain aspects, viral vectors can be administered at 1×10², 1×10³, 1×10⁴1×10⁵, 1×10⁶, 1×10⁷, 1×10⁸, 1×10⁹, 1×10¹⁰, 1×10¹¹, 1×10¹², 1×10¹³, 1×10¹⁴pfu or viral particle (vp).

In a particular aspect, the miR-124 nucleic acid or miR-124 inhibitor is a synthetic nucleic acid. Moreover, nucleic acids of the invention may be fully or partially synthetic. In still further aspects, a DNA encoding such a nucleic acid of the invention can be administered at 0.001, 0.01, 0.1, 1, 10, 20, 30, 40, 50, 100, 200, 400, 600, 800, 1000, 2000, to 4000 μg or mg, including all values and ranges there between. In yet a further aspect, nucleic acids of the invention, including synthetic nucleic acid, can be administered at 0.001, 0.01, 0.1, 1, 10, 20, 30, 40, 50, 100, to 200 μg or mg per kilogram (kg) of body weight. Each of the amounts described herein may be administered over a period of time, including 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, minutes, hours, days, weeks, months or years, including all values and ranges there between.

In certain embodiments, administration of the composition(s) can be enteral or parenteral. In certain aspects, enteral administration is oral. In further aspects, parenteral administration is intralesional, intravascular, intracranial, intrapleural, intratumoral, intraperitoneal, intramuscular, intralymphatic, intraglandular, subcutaneous, topical, intrabronchial, intratracheal, intranasal, inhaled, or instilled. Compositions of the invention may be administered regionally or locally and not necessarily directly into a lesion.

In certain aspects, the gene or genes modulated comprises 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 200 or more genes or combinations of genes identified in Tables 1, 3, 4, and/or 5. In still further aspects, the gene or genes modulated may exclude 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 100, 150, 175 or more genes or combinations of genes identified in Tables 1, 3, 4, and/or 5. Modulation includes modulating transcription, mRNA levels, mRNA translation, and/or protein levels in a cell, tissue, or organ. In certain aspects the expression of a gene or level of a gene product, such as mRNA or encoded protein, is down-regulated or up-regulated. In a particular aspect the gene modulated comprises or is selected from (and may even exclude) 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26. 27, 28, or all of the genes identified in Tables 1, 3, 4, and/or 5, or any combinations thereof. In certain embodiments a gene modulated or selected to be modulated is from Table 1. In further embodiments a gene modulated or selected to be modulated is from Table 3. In still further embodiments a gene modulated or selected to be modulated is from Table 4. In yet further embodiments a gene modulated or selected to be modulated is from Table 5.

Embodiments of the invention may also include obtaining or assessing a gene expression profile or miRNA profile of a target cell prior to selecting the mode of treatment, e.g., administration of a miR-124 nucleic acid, inhibitor of miR-124, or mimetics thereof. The database content related to all nucleic acids and genes designated by an accession number or a database submission are incorporated herein by reference as of the filing date of this application. In certain aspects of the invention one or more miRNA or miRNA inhibitor may modulate a single gene. In a further aspect, one or more genes in one or more genetic, cellular, or physiologic pathways can be modulated by one or more miRNAs or complements thereof, including miR-124 nucleic acids and miR-124 inhibitors in combination with other miRNAs.

miR-124 nucleic acids may also include various heterologous nucleic acid sequences, i.e., those sequences not typically found operatively coupled with miR-124 in nature, such as promoters, enhancers, and the like. The miR-124 nucleic acid is a recombinant nucleic acid, and can be a ribonucleic acid or a deoxyribonucleic acid. The recombinant nucleic acid may comprise a miR-124 expression cassette. In a further aspect, the expression cassette is comprised in a viral, or plasmid DNA vector or other therapeutic nucleic acid vector or delivery vehicle, including liposomes and the like. In a particular aspect, the miR-124 nucleic acid is a synthetic nucleic acid. Moreover, nucleic acids of the invention may be fully or partially synthetic.

A further embodiment of the invention is directed to methods of modulating a cellular pathway comprising administering to the cell an amount of an isolated nucleic acid comprising a miR-124 nucleic acid sequence in an amount sufficient to modulate the expression, function, status, or state of a cellular pathway, in particular those pathways described in Table 2 or the pathways known to include one or more genes from Table 1, 3, 4, and/or 5. Modulation of a cellular pathway includes, but is not limited to modulating the expression of one or more gene. Modulation of a gene can include inhibiting the function of an endogenous miRNA or providing a functional miRNA to a cell, tissue, or subject. Modulation refers to the expression levels or activities of a gene or its related gene product or protein, e.g., the mRNA levels may be modulated or the translation of an mRNA may be modulated, etc. Modulation may increase or up regulate a gene or gene product or it may decrease or down regulate a gene or gene product.

Still a further embodiment includes methods of treating a patient with a pathological condition comprising one or more of step of (a) administering to the patient an amount of an isolated nucleic acid comprising a miR-124 nucleic acid sequence in an amount sufficient to modulate the expression of a cellular pathway; and (b) administering a second therapy, wherein the modulation of the cellular pathway sensitizes the patient to the second therapy. A cellular pathway may include, but is not limited to one or more pathway described in Table 2 below or a pathway that is know to include one or more genes of Tables 1, 3, 4, and/or 5. A second therapy can include administration of a second miRNA or therapeutic nucleic acid, or may include various standard therapies, such as chemotherapy, radiation therapy, drug therapy, immunotherapy, and the like. Embodiments of the invention may also include the determination or assessment of a gene expression profile for the selection of an appropriate therapy.

Embodiments of the invention include methods of treating a subject with a pathological condition comprising one or more of the steps of (a) determining an expression profile of one or more genes selected from Table 1, 3, 4, and/or 5; (b) assessing the sensitivity of the subject to therapy based on the expression profile; (c) selecting a therapy based on the assessed sensitivity; and (d) treating the subject using selected therapy. Typically, the pathological condition will have as a component, indicator, or result the mis-regulation of one or more gene of Table 1, 3, 4, and/or 5.

Further embodiments include the identification and assessment of an expression profile indicative of miR-124 status in a cell or tissue comprising expression assessment of one or more gene from Table 1, 3, 4, and/or 5, or any combination thereof.

The term “miRNA” is used according to its ordinary and plain meaning and refers to a microRNA molecule found in eukaryotes that is involved in RNA-based gene regulation. See, e.g., Carrington et al., 2003, which is hereby incorporated by reference. The term can be used to refer to the single-stranded RNA molecule processed from a precursor or in certain instances the precursor itself.

In some embodiments, it may be useful to know whether a cell expresses a particular miRNA endogenously or whether such expression is affected under particular conditions or when it is in a particular disease state. Thus, in some embodiments of the invention, methods include assaying a cell or a sample containing a cell for the presence of one or more marker gene or mRNA or other analyte indicative of the expression level of a gene of interest. Consequently, in some embodiments, methods include a step of generating an RNA profile for a sample. The term “RNA profile” or “gene expression profile” refers to a set of data regarding the expression pattern for one or more gene or genetic marker in the sample (e.g., a plurality of nucleic acid probes that identify one or more markers from Tables 1, 3, 4, and/or 5); it is contemplated that the nucleic acid profile can be obtained using a set of RNAs, using for example nucleic acid amplification or hybridization techniques well know to one of ordinary skill in the art. The difference in the expression profile in the sample from the patient and a reference expression profile, such as an expression profile from a normal or non-pathologic sample, is indicative of a pathologic, disease, or cancerous condition. A nucleic acid or probe set comprising or identifying a segment of a corresponding mRNA can include all or part of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 100, 200, 500, or more nucleotides, including any integer or range derivable there between, of a gene, genetic marker, a nucleic acid, mRNA or a probe representative thereof that is listed in Tables 1, 3, 4, and/or 5 or identified by the methods described herein.

Certain embodiments of the invention are directed to compositions and methods for assessing, prognosing, or treating a pathological condition in a patient comprising measuring or determining an expression profile of one or more marker(s) in a sample from the patient, wherein a difference in the expression profile in the sample from the patient and an expression profile of a normal sample or reference expression profile is indicative of pathological condition and particularly cancer (e.g., In certain aspects of the invention, the cellular pathway, gene, or genetic marker is or is representative of one or more pathway or marker described in Table 1, 2, 3, 4, and/or 5, including any combination thereof.

Aspects of the invention include diagnosing, assessing, or treating a pathologic condition or preventing a pathologic condition from manifesting. For example, the methods can be used to screen for a pathological condition; assess prognosis of a pathological condition; stage a pathological condition; assess response of a pathological condition to therapy; or to modulate the expression of a gene, genes, or related pathway as a first therapy or to render a subject sensitive or more responsive to a second therapy. In particular aspects, assessing the pathological condition of the patient can be assessing prognosis of the patient. Prognosis may include, but is not limited to an estimation of the time or expected time of survival, assessment of response to a therapy, and the like. In certain aspects, the altered expression of one or more gene or marker is prognostic for a patient having a pathologic condition, wherein the marker is one or more of Table 1, 3, 4, and/or 5, including any combination thereof.

A further embodiment of the invention is directed to methods of modulating a cellular pathway comprising administering to the cell an amount of an isolated nucleic acid comprising a miR-124 nucleic acid sequence or a miR-124 inhibitor. A cell, tissue, or subject may be a cancer cell, a cancerous tissue or harbor cancerous tissue, or a cancer patient. The database content related to all nucleic acids and genes designated by an accession number or a database submission are incorporated herein by reference as of the filing date of this application.

A further embodiment of the invention is directed to methods of modulating a cellular pathway comprising administering to the cell an amount of an isolated nucleic acid comprising a miR-124 nucleic acid sequence in an amount sufficient to modulate the expression, function, status, or state of a cellular pathway, in particular those pathways described in Table 2 or the pathways known to include one or more genes from Table 1, 3, 4, and/or 5. Modulation of a cellular pathway includes, but is not limited to modulating the expression of one or more gene(s). Modulation of a gene can include inhibiting the function of an endogenous miRNA or providing a functional miRNA to a cell, tissue, or subject. Modulation refers to the expression levels or activities of a gene or its related gene product (e.g., mRNA) or protein, e.g., the mRNA levels may be modulated or the translation of an mRNA may be modulated. Modulation may increase or up regulate a gene or gene product or it may decrease or down regulate a gene or gene product (e.g., protein levels or activity).

Still a further embodiment includes methods of administering an miRNA or mimic thereof, and/or treating a subject or patient having, suspected of having, or at risk of developing a pathological condition comprising one or more of step (a) administering to a patient or subject an amount of an isolated nucleic acid comprising a miR-124 nucleic acid sequence or a miR-124 inhibitor in an amount sufficient to modulate expression of a cellular pathway; and (b) administering a second therapy, wherein the modulation of the cellular pathway sensitizes the patient or subject, or increases the efficacy of a second therapy. An increase in efficacy can include a reduction in toxicity, a reduced dosage or duration of the second therapy, or an additive or synergistic effect. A cellular pathway may include, but is not limited to one or more pathway described in Table 2 below or a pathway that is know to include one or more genes of Tables 1, 3, 4, and/or 5. The second therapy may be administered before, during, and/or after the isolated nucleic acid or miRNA or inhibitor is administered

A second therapy can include administration of a second miRNA or therapeutic nucleic acid such as a siRNA or antisense oligonucleotide, or may include various standard therapies, such as pharmaceuticals, chemotherapy, radiation therapy, drug therapy, immunotherapy, and the like. Embodiments of the invention may also include the determination or assessment of gene expression or gene expression profile for the selection of an appropriate therapy. In a particular aspect, a second therapy is a chemotherapy. A chemotherapy can include, but is not limited to paclitaxel, cisplatin, carboplatin, doxorubicin, oxaliplatin, larotaxel, taxol, lapatinib, docetaxel, methotrexate, capecitabine, vinorelbine, cyclophosphamide, gemcitabine, amrubicin, cytarabine, etoposide, camptothecin, dexamethasone, dasatinib, tipifarnib, bevacizumab, sirolimus, temsirolimus, everolimus, lonafamib, cetuximab, erlotinib, gefitinib, imatinib mesylate, rituximab, trastuzumab, nocodazole, sorafenib, sunitinib, bortezomib, alemtuzumab, gemtuzumab, tositumomab or ibritumomab.

Embodiments of the invention include methods of treating a subject with a disease or condition comprising one or more of the steps of (a) determining an expression profile of one or more genes selected from Table 1, 3, 4, and/or 5; (b) assessing the sensitivity of the subject to therapy based on the expression profile; (c) selecting a therapy based on the assessed sensitivity; and (d) treating the subject using a selected therapy. Typically, the disease or condition will have as a component, indicator, or resulting mis-regulation of one or more gene of Table 1, 3, 4, and/or 5.

In certain aspects, 2, 3, 4, 5, 6, 7, 8, 9, 10, or more miRNA may be used in sequence or in combination; for instance, any combination of miR-124 or a miR-124 inhibitor with another miRNA. Further embodiments include the identification and assessment of an expression profile indicative of miR-124 status in a cell or tissue comprising expression assessment of one or more gene from Table 1, 3, 4, and/or 5, or any combination thereof.

In certain aspects, miR-124 and let-7 can be administered to patients with acute lymphoblastic leukemia, acute myeloid leukemia, angiosarcoma, breast carcinoma, bladder carcinoma, cervical carcinoma, carcinoma of the head and neck, chronic lymphoblastic leukemia, chronic myeloid leukemia, colorectal carcinoma, endometrial carcinoma, glioma, glioblastoma, gastric carcinoma, hepatocellular carcinoma, Hodgkin lymphoma, Kaposi's sarcoma, leukemia, lung carcinoma, leiomyosarcoma, melanoma, medulloblastoma, myxofibrosarcoma, multiple myeloma, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung carcinoma, ovarian carcinoma, oesophageal carcinoma, pancreatic carcinoma, prostate carcinoma, squamous cell carcinoma of the head and neck, salivary gland tumor, thyroid carcinoma, or urothelial carcinoma.

Further aspects include administering miR-124 and miR-15 to patients with astrocytoma, acute myeloid leukemia, breast carcinoma, B-cell lymphoma, bladder carcinoma, cervical carcinoma, carcinoma of the head and neck, chronic myeloid leukemia, colorectal carcinoma, endometrial carcinoma, glioma, glioblastoma, gastric carcinoma, hepatoblastoma, hepatocellular carcinoma, Hodgkin lymphoma, lung carcinoma, laryngeal squamous cell carcinoma, melanoma, medulloblastoma, mantle cell lymphoma, myxofibrosarcoma, multiple myeloma, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung carcinoma, ovarian carcinoma, oesophageal carcinoma, pancreatic carcinoma, prostate carcinoma, renal cell carcinoma, rhabdomyosarcoma, squamous cell carcinoma of the head and neck, or thyroid carcinoma.

In still further aspects, miR-124 and miR-16 are administered to patients with astrocytoma, breast carcinoma, B-cell lymphoma, bladder carcinoma, colorectal carcinoma, endometrial carcinoma, glioblastoma, gastric carcinoma, hepatoblastoma, hepatocellular carcinoma, Hodgkin lymphoma, laryngeal squamous cell carcinoma, melanoma, medulloblastoma, mantle cell lymphoma, myxofibrosarcoma, multiple myeloma, non-small cell lung carcinoma, ovarian carcinoma, oesophageal carcinoma, pancreatic carcinoma, prostate carcinoma, renal cell carcinoma, rhabdomyosarcoma, squamous cell carcinoma of the head and neck, or thyroid carcinoma.

In certain aspects, miR-124 and miR-20 are administered to patients with astrocytoma, acute myeloid leukemia, breast carcinoma, bladder carcinoma, cervical carcinoma, colorectal carcinoma, endometrial carcinoma, glioma, glioblastoma, gastric carcinoma, hepatocellular carcinoma, Hodgkin lymphoma, leukemia, lipoma, melanoma, mantle cell lymphoma, myxofibrosarcoma, multiple myeloma, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung carcinoma, ovarian carcinoma, oesophageal carcinoma, osteosarcoma, pancreatic carcinoma, prostate carcinoma, squamous cell carcinoma of the head and neck, thyroid carcinoma, or urothelial carcinoma.

Aspects of the invention include methods where miR-124 and miR-21 are administered to patients with astrocytoma, acute lymphoblastic leukemia, acute myeloid leukemia, breast carcinoma, Burkitt's lymphoma, bladder carcinoma, colorectal carcinoma, endometrial carcinoma, glioma, glioblastoma, gastric carcinoma, hepatocellular carcinoma, melanoma, mantle cell lymphoma, neuroblastoma, non-small cell lung carcinoma, ovarian carcinoma, oesophageal carcinoma, pancreatic carcinoma, prostate carcinoma, renal cell carcinoma, rhabdomyosarcoma, or squamous cell carcinoma of the head and neck.

In still further aspects, miR-124 and miR-26a are administered to patients with anaplastic large cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, angiosarcoma, breast carcinoma, B-cell lymphoma, Burkitt's lymphoma, bladder carcinoma, cervical carcinoma, carcinoma of the head and neck, chronic lymphoblastic leukemia, chronic myeloid leukemia, colorectal carcinoma, glioma, glioblastoma, gastric carcinoma, hepatocellular carcinoma, Kaposi's sarcoma, leukemia, lung carcinoma, leiomyosarcoma, melanoma, multiple myeloma, neuroblastoma, non-Hodgkin lymphoma, non-small cell lung carcinoma, ovarian carcinoma, oesophageal carcinoma, osteosarcoma, pancreatic carcinoma, prostate carcinoma, renal cell carcinoma, rhabdomyosarcoma, small cell lung cancer, or testicular tumor.

In yet further aspects, miR-124 and miR-126 are administered to patients with astrocytoma, acute myeloid leukemia, breast carcinoma, Burkitt's lymphoma, bladder carcinoma, cervical carcinoma, colorectal carcinoma, endometrial carcinoma, Ewing's sarcoma, glioma, glioblastoma, gastric carcinoma, hepatoblastoma, hepatocellular carcinoma, Hodgkin lymphoma, leukemia, lung carcinoma, melanoma, mantle cell lymphoma, meningioma, non-Hodgkin lymphoma, non-small cell lung carcinoma, ovarian carcinoma, oesophageal carcinoma, oropharyngeal carcinoma, osteosarcoma, pancreatic carcinoma, papillary carcinoma, prostate carcinoma, renal cell carcinoma, rhabdomyosarcoma, squamous cell carcinoma of the head and neck, schwannoma, small cell lung cancer, or thyroid carcinoma

In a further aspect, miR-124 and miR-143 are administered to patients with astrocytoma, anaplastic large cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, breast carcinoma, B-cell lymphoma, bladder carcinoma, cervical carcinoma, chronic lymphoblastic leukemia, chronic myeloid leukemia, colorectal carcinoma, endometrial carcinoma, glioma, glioblastoma, gastric carcinoma, hepatocellular carcinoma, Hodgkin lymphoma, leukemia, lung carcinoma, melanoma, medulloblastoma, mantle cell lymphoma, multiple myeloma, non-Hodgkin lymphoma, non-small cell lung carcinoma, ovarian carcinoma, oesophageal carcinoma, osteosarcoma, pancreatic carcinoma, prostate carcinoma, renal cell carcinoma, squamous cell carcinoma of the head and neck, small cell lung cancer, thyroid carcinoma, or testicular tumor.

In still a further aspect, miR-124 and miR-147 are administered to patients with astrocytoma, breast carcinoma, bladder carcinoma, cervical carcinoma, colorectal carcinoma, endometrial carcinoma, glioma, glioblastoma, gastric carcinoma, hepatocellular carcinoma, Hodgkin lymphoma, leukemia, lipoma, melanoma, mantle cell lymphoma, myxofibrosarcoma, multiple myeloma, non-Hodgkin lymphoma, non-small cell lung carcinoma, ovarian carcinoma, oesophageal carcinoma, osteosarcoma, pancreatic carcinoma, prostate carcinoma, renal cell carcinoma, squamous cell carcinoma of the head and neck, or thyroid carcinoma.

In yet another aspect, miR-124 and miR-188 are administered to patients with astrocytoma, anaplastic large cell lymphoma, acute myeloid leukemia, breast carcinoma, B-cell lymphoma, Burkitt's lymphoma, bladder carcinoma, cervical carcinoma, chronic lymphoblastic leukemia, colorectal carcinoma, endometrial carcinoma, glioma, glioblastoma, gastric carcinoma, hepatocellular carcinoma, leukemia, lung carcinoma, melanoma, multiple myeloma, non-Hodgkin lymphoma, non-small cell lung carcinoma, ovarian carcinoma, oesophageal carcinoma, pancreatic carcinoma, prostate carcinoma, renal cell carcinoma, squamous cell carcinoma of the head and neck, thyroid carcinoma, or testicular tumor.

In yet a further aspect, miR-124 and miR-200b/c are administered to patients with anaplastic large cell lymphoma, breast carcinoma, B-cell lymphoma, cervical carcinoma, chronic lymphoblastic leukemia, colorectal carcinoma, glioma, glioblastoma, gastric carcinoma, hepatocellular carcinoma, leukemia, lung carcinoma, lipoma, multiple myeloma, non-small cell lung carcinoma, ovarian carcinoma, oesophageal carcinoma, osteosarcoma, pancreatic carcinoma, prostate carcinoma, rhabdomyosarcoma, squamous cell carcinoma of the head and neck, thyroid carcinoma, or testicular tumor.

In other aspects, miR-124 and miR-215 are administered to patients with astrocytoma, anaplastic large cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, angiosarcoma, breast carcinoma, B-cell lymphoma, bladder carcinoma, cervical carcinoma, chronic lymphoblastic leukemia, chronic myeloid leukemia, colorectal carcinoma, endometrial carcinoma, Ewing's sarcoma, glioma, glioblastoma, gastric carcinoma, hepatoblastoma, hepatocellular carcinoma, Hodgkin lymphoma, Kaposi's sarcoma, leukemia, lung carcinoma, lipoma, leiomyosarcoma, liposarcoma, melanoma, mucosa-associated lymphoid tissue B-cell lymphoma, mantle cell lymphoma, myxofibrosarcoma, multiple myeloma, neuroblastoma, non-Hodgkin lymphoma, nasopharyngeal carcinoma, non-small cell lung carcinoma, ovarian carcinoma, oesophageal carcinoma, osteosarcoma, pancreatic carcinoma, prostate carcinoma, retinoblastoma, renal cell carcinoma, rhabdomyosarcoma, squamous cell carcinoma of the head and neck, schwannoma, small cell lung cancer, salivary gland tumor, thyroid carcinoma, testicular tumor, urothelial carcinoma, or Wilm's tumor.

In certain aspects, miR-124 and miR-216 are administered to patients with astrocytoma, breast carcinoma, cervical carcinoma, carcinoma of the head and neck, colorectal carcinoma, endometrial carcinoma, glioma, glioblastoma, gastric carcinoma, hepatocellular carcinoma, Hodgkin lymphoma, leukemia, lung carcinoma, mucosa-associated lymphoid tissue B-cell lymphoma, non-Hodgkin lymphoma, non-small cell lung carcinoma, ovarian carcinoma, oesophageal carcinoma, osteosarcoma, prostate carcinoma, squamous cell carcinoma of the head and neck, or testicular tumor.

In a further aspect, miR-124 and miR-292-3p are administered to patients with astrocytoma, anaplastic large cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, angiosarcoma, breast carcinoma, B-cell lymphoma, bladder carcinoma, cervical carcinoma, chronic myeloid leukemia, colorectal carcinoma, endometrial carcinoma, Ewing's sarcoma, glioma, glioblastoma, gastric carcinoma, hepatoblastoma, hepatocellular carcinoma, Kaposi's sarcoma, leukemia, lung carcinoma, lipoma, leiomyosarcoma, liposarcoma, laryngeal squamous cell carcinoma, melanoma, myxofibrosarcoma, multiple myeloma, neuroblastoma, non-Hodgkin lymphoma, nasopharyngeal carcinoma, non-small cell lung carcinoma, ovarian carcinoma, oesophageal carcinoma, osteosarcoma, pancreatic carcinoma, prostate carcinoma, renal cell carcinoma, rhabdomyosarcoma, squamous cell carcinoma of the head and neck, schwannoma, small cell lung cancer, thyroid carcinoma, testicular tumor, urothelial carcinoma, or Wilm's tumor.

In still a further aspect, miR-124 and miR-331 are administered to patients with astrocytoma, anaplastic large cell lymphoma, acute lymphoblastic leukemia, acute myeloid leukemia, angiosarcoma, breast carcinoma, B-cell lymphoma, bladder carcinoma, cervical carcinoma, carcinoma of the head and neck, chronic lymphoblastic leukemia, colorectal carcinoma, endometrial carcinoma, glioma, glioblastoma, gastric carcinoma, hepatocellular carcinoma, Kaposi's sarcoma, leukemia, lung carcinoma, leiomyosarcoma, laryngeal squamous cell carcinoma, melanoma, myxofibrosarcoma, multiple myeloma, neuroblastoma, non-Hodgkin lymphoma, ovarian carcinoma, oesophageal carcinoma, osteosarcoma, pancreatic carcinoma, prostate carcinoma, renal cell carcinoma, rhabdomyosarcoma, squamous cell carcinoma of the head and neck, small cell lung cancer, thyroid carcinoma, or testicular tumor.

It is contemplated that when miR-124 or a miR-124 inhibitor is given in combination with one or more other miRNA molecules, the two different miRNAs or inhibitors may be given at the same time or sequentially. In some embodiments, therapy proceeds with one miRNA or inhibitor and that therapy is followed up with therapy with the other miRNA or inhibitor 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55 minutes, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 hours, 1, 2, 3, 4, 5, 6, 7 days, 1, 2, 3, 4, 5 weeks, or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months or any such combination later.

In some embodiments, it may be useful to know whether a cell expresses a particular miRNA endogenously or whether such expression is affected under particular conditions or when it is in a particular disease state. Thus, in some embodiments of the invention, methods include assaying a cell or a sample containing a cell for the presence of one or more miRNA marker gene or mRNA or other analyte indicative of the expression level of a gene of interest. Consequently, in some embodiments, methods include a step of generating an RNA profile for a sample. The term “RNA profile” or “gene expression profile” refers to a set of data regarding the expression pattern for one or more gene or genetic marker in the sample (e.g., a plurality of nucleic acid probes that identify one or more markers or genes from Tables 1, 3, 4, and/or 5); it is contemplated that the nucleic acid profile can be obtained using a set of RNAs, using for example nucleic acid amplification or hybridization techniques well know to one of ordinary skill in the art. The difference in the expression profile in the sample from a patient and a reference expression profile, such as an expression profile from a normal or non-pathologic sample, or a digitized reference, is indicative of a pathologic, disease, or cancerous condition. In certain aspects the expression profile is an indicator of a propensity to or probability of (i.e., risk factor for a disease or condition) developing such a condition(s). Such a risk or propensity may indicate a treatment, increased monitoring, prophylactic measures, and the like. A nucleic acid or probe set may comprise or identify a segment of a corresponding mRNA and may include all or part of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 100, 200, 500, or more segments, including any integer or range derivable there between, of a gene or genetic marker, or a nucleic acid, mRNA or a probe representative thereof that is listed in Tables 1, 3, 4, and/or 5 or identified by the methods described herein.

Certain embodiments of the invention are directed to compositions and methods for assessing, prognosing, or treating a pathological condition in a patient comprising measuring or determining an expression profile of one or more miRNA or marker(s) in a sample from the patient, wherein a difference in the expression profile in the sample from the patient and an expression profile of a normal sample or reference expression profile is indicative of pathological condition and particularly cancer (e.g., In certain aspects of the invention, the miRNAs, cellular pathway, gene, or genetic marker is or is representative of one or more pathway or marker described in Table 1, 2, 3, 4, and/or 5, including any combination thereof.

Predicted gene targets are shown in Table 3. Target genes whose mRNA expression levels are affected by hsa-miR-124 represent particularly useful candidates for cancer therapy and therapy of other diseases or conditions through manipulation of their expression levels.

Certain embodiments of the invention include determining expression of one or more marker, gene, or nucleic acid segment representative of one or more genes, by using an amplification assay, a hybridization assay, or protein assay, a variety of which are well known to one of ordinary skill in the art. In certain aspects, an amplification assay can be a quantitative amplification assay, such as quantitative RT-PCR or the like. In still further aspects, a hybridization assay can include array hybridization assays or solution hybridization assays. The nucleic acids from a sample may be labeled from the sample and/or hybridizing the labeled nucleic acid to one or more nucleic acid probes. Nucleic acids, mRNA, and/or nucleic acid probes may be coupled to a support. Such supports are well known to those of ordinary skill in the art and include, but are not limited to glass, plastic, metal, or latex. In particular aspects of the invention, the support can be planar or in the form of a bead or other geometric shapes or configurations known in the art. Proteins are typically assayed by immunoblotting, chromatography, or mass spectrometry or other methods known to those of ordinary skill in the art.

The present invention also concerns kits containing compositions of the invention or compositions to implement methods of the invention. In some embodiments, kits can be used to evaluate one or more marker molecules, and/or express one or more miRNA or miRNA inhibitor. In certain embodiments, a kit contains, contains at least or contains at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 100, 150, 200 or more probes, recombinant nucleic acid, or synthetic nucleic acid molecules related to the markers to be assessed or an miRNA or miRNA inhibitor to be expressed or modulated, and may include any range or combination derivable therein. Kits may comprise components, which may be individually packaged or placed in a container, such as a tube, bottle, vial, syringe, or other suitable container means. Individual components may also be provided in a kit in concentrated amounts; in some embodiments, a component is provided individually in the same concentration as it would be in a solution with other components. Concentrations of components may be provided as 1×, 2×, 5×, 10×, or 20× or more. Kits for using probes, synthetic nucleic acids, recombinant nucleic acids, or non-synthetic nucleic acids of the invention for therapeutic, prognostic, or diagnostic applications are included as part of the invention. Specifically contemplated are any such molecules corresponding to any miRNA reported to influence biological activity or expression of one or more marker gene or gene pathway described herein. In certain aspects, negative and/or positive controls are included in some kit embodiments. The control molecules can be used to verify transfection efficiency and/or control for transfection-induced changes in cells.

Certain embodiments are directed to a kit for assessment of a pathological condition or the risk of developing a pathological condition in a patient by nucleic acid profiling of a sample comprising, in suitable container means, two or more nucleic acid hybridization or amplification reagents. The kit can comprise reagents for labeling nucleic acids in a sample and/or nucleic acid hybridization reagents. The hybridization reagents typically comprise hybridization probes. Amplification reagents include, but are not limited to amplification primers, reagents, and enzymes.

In some embodiments of the invention, an expression profile is generated by steps that include: (a) labeling nucleic acid in the sample; (b) hybridizing the nucleic acid to a number of probes, or amplifying a number of nucleic acids, and (c) determining and/or quantitating nucleic acid hybridization to the probes or detecting and quantitating amplification products, wherein an expression profile is generated. See U.S. Provisional Patent Application 60/575,743 and the U.S. Provisional Patent Application 60/649,584, and U.S. patent application Ser. No. 11/141,707 and U.S. patent application Ser. No. 11/273,640, all of which are hereby incorporated by reference.

Methods of the invention involve diagnosing and/or assessing the prognosis of a patient based on a miRNA and/or a marker nucleic acid expression profile. In certain embodiments, the elevation or reduction in the level of expression of a particular gene or genetic pathway or set of nucleic acids in a cell is correlated with a disease state or pathological condition compared to the expression level of the same in a normal or non-pathologic cell or tissue sample. This correlation allows for diagnostic and/or prognostic methods to be carried out when the expression level of one or more nucleic acid is measured in a biological sample being assessed and then compared to the expression level of a normal or non-pathologic cell or tissue sample. It is specifically contemplated that expression profiles for patients, particularly those suspected of having or having a propensity for a particular disease or condition such as cancer, can be generated by evaluating any of or sets of the miRNAs and/or nucleic acids discussed in this application. The expression profile that is generated from the patient will be one that provides information regarding the particular disease or condition. In many embodiments, the profile is generated using nucleic acid hybridization or amplification, (e.g., array hybridization or RT-PCR). In certain aspects, an expression profile can be used in conjunction with other diagnostic and/or prognostic tests, such as histology, protein profiles in the serum and/or cytogenetic assessment.

The methods can further comprise one or more of the steps including: (a) obtaining a sample from the patient, (b) isolating nucleic acids from the sample, (c) labeling the nucleic acids isolated from the sample, and (d) hybridizing the labeled nucleic acids to one or more probes. Nucleic acids of the invention include one or more nucleic acid comprising at least one segment having a sequence or complementary sequence of to a nucleic acid representative of one or more of genes or markers in Table 1, 3, 4, and/or 5.

It is contemplated that any method or composition described herein can be implemented with respect to any other method or composition described herein and that different embodiments may be combined. It is specifically contemplated that any methods and compositions discussed herein with respect to miRNA molecules, miRNA, genes, and Certain embodiments of the invention include determining expression of one or more marker, gene, or nucleic acid representative thereof, by using an amplification assay, a hybridization assay, or protein assay, a variety of which are well known to one of ordinary skill in the art. In certain aspects, an amplification assay can be a quantitative amplification assay, such as quantitative RT-PCR or the like. In still further aspects, a hybridization assay can include array hybridization assays or solution hybridization assays. The nucleic acids from a sample may be labeled from the sample and/or hybridizing the labeled nucleic acid to one or more nucleic acid probes. Nucleic acids, mRNA, and/or nucleic acid probes may be coupled to a support. Such supports are well known to those of ordinary skill in the art and include, but are not limited to glass, plastic, metal, or latex. In particular aspects of the invention, the support can be planar or in the form of a bead or other geometric shapes or configurations known in the art. Protein are typically assayed by immunoblotting, chromatography, or mass spectrometry or other methods known to those of ordinary skill in the art.

The present invention also concerns kits containing compositions of the invention or compositions to implement methods of the invention. In some embodiments, kits can be used to evaluate one or more marker molecules, and/or express one or more miRNA. In certain embodiments, a kit contains, contains at least or contains at most 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 100, 150, 200 or more probes, recombinant nucleic acid, or synthetic nucleic acid molecules related to the markers to be assessed or an miRNA to be expressed or modulated, and may include any range or combination derivable therein. Kits may comprise components, which may be individually packaged or placed in a container, such as a tube, bottle, vial, syringe, or other suitable container means. Individual components may also be provided in a kit in concentrated amounts; in some embodiments, a component is provided individually in the same concentration as it would be in a solution with other components. Concentrations of components may be provided as 1×, 2×, 5×, 10×, or 20× or more. Kits for using probes, synthetic nucleic acids, recombinant nucleic acids, or non-synthetic nucleic acids of the invention for therapeutic, prognostic, or diagnostic applications are included as part of the invention. Specifically contemplated are any such molecules corresponding to any miRNA reported to influence biological activity or expression of one or more marker gene or gene pathway described herein. In certain aspects, negative and/or positive controls are included in some kit embodiments. The control molecules can be used to verify transfection efficiency and/or control for transfection-induced changes in cells.

Certain embodiments are directed to a kit for assessment of a pathological condition or the risk of developing a pathological condition in a patient by nucleic acid profiling of a sample comprising in suitable container means, two or more nucleic acid hybridization or amplification reagents. The kit can comprise reagents for labeling nucleic acids in a sample and/or nucleic acid hybridization reagents. The hybridization reagents typically comprise hybridization probes. Amplification reagents include, but are not limited to amplification primers, reagents, and enzymes.

Also, any embodiment of the invention involving specific genes (including representative fragments there of), mRNA, or miRNAs by name is contemplated also to cover embodiments involving miRNAs whose sequences are at least 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99% identical to the mature sequence of the specified miRNA.

It will be further understood that shorthand notations are employed such that a generic description of a gene or marker thereof, or of a miRNA refers to any of its gene family members (distinguished by a number) or representative fragments thereof, unless otherwise indicated. It is understood by those of skill in the art that a “gene family” refers to a group of genes having the same coding sequence or miRNA coding sequence. Typically, miRNA members of a gene family are identified by a number following the initial designation. For example, miR-16-1 and miR-16-2 are members of the miR-16 gene family and “mir-7” refers to miR-7-1, miR-7-2 and miR-7-3. Moreover, unless otherwise indicated, a shorthand notation refers to related miRNAs (distinguished by a letter). Exceptions to these shorthand notations will be otherwise identified.

Other embodiments of the invention are discussed throughout this application. Any embodiment discussed with respect to one aspect of the invention applies to other aspects of the invention as well and vice versa. The embodiments in the Example and Detailed Description section are understood to be embodiments of the invention that are applicable to all aspects of the invention.

The terms “inhibiting,” “reducing,” or “prevention,” or any variation of these terms, when used in the claims and/or the specification includes any measurable decrease or complete inhibition to achieve a desired result.

The use of the word “a” or “an” when used in conjunction with the term “comprising” in the claims and/or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.”

Throughout this application, the term “about” is used to indicate that a value includes the standard deviation of error for the device or method being employed to determine the value.

The use of the term “or” in the claims is used to mean “and/or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and/or.”

As used in this specification and claim(s), the words “comprising” (and any form of comprising, such as “comprise” and “comprises”), “having” (and any form of having, such as “have” and “has”), “including” (and any form of including, such as “includes” and “include”) or “containing” (and any form of containing, such as “contains” and “contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating specific embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description.

DESCRIPTION OF THE DRAWINGS

The following drawings form part of the present specification and are included to further demonstrate certain aspects of the present invention. The invention may be better understood by reference to one or more of these drawings in combination with the detailed description of specific embodiments presented herein.

FIG. 1. Genes affected by hsa-miR-124a that function in the regulation of the cell cycle. A description of the graph and the function of each molecule are presented in Table 9. Molecules in circles are differentially expressed upon transfection with hsa-miR-124a (see also Table 1). Solid lines represent direct interactions between molecules (e.g., phosphorylation); dotted lines indicate indirect interactions. Lines that end in arrows indicate an activating action; lines that end into circles denote an inhibitory action. G1, gap 1 phase; S, synthesis phase; G2, gap 2 phase; M, mitosis phase; R1, restriction point 1; R2, restriction point 2.

FIG. 2. Percent (%) proliferation of hsa-miR-124a-treated lung cancer cells relative to cells treated with negative control miRNA (100%). Abbreviations: miR-124a, hsa-miR-124a; siEg5, siRNA against the motor protein kinesin 11 (Eg5); Etopo, etoposide; NC, negative control miRNA. Standard deviations are indicated in the graph.

FIG. 3. Dose dependent inhibition of various lung cancer cell lines by hsa-miR-124a using Alamar Blue proliferation assays. Cell proliferation is reported as % proliferation relative to % proliferation of mock-transfected cells (0 pM=100% proliferation). Standard deviations are indicated in the graphs. Abbreviations: NC, negative control miRNA.

FIG. 4. Long-term effects of hsa-miR-124a on cultured human H226 lung cancer cells. Equal numbers of H226 cells were electroporated with 1.6 μM hsa-miR-124a or negative control miRNA (NC), seeded and propagated in regular growth medium. When the control cells reached confluence (days 6, and 17 and 25), cells were harvested, counted and electroporated again with the respective miRNAs. The population doubling and cumulative cell counts was calculated and plotted on a linear scale. Arrows represent electroporation days. Abbreviation: miR-124a, hsa-miR-124a; NC, negative control miRNA.

FIG. 5. Percent (%) proliferation of H460 lung cancer cells following administration of various combinations of microRNAs. A positive sign under each bar in the graph indicates that the miRNA was present in the administered combination. Standard deviations are shown in the graph. Abbreviations: Etopo, etoposide; NC, negative control miRNA.

FIG. 6. Average tumor volumes in mice harboring xenografts of A549 lung cancer cells treated with hsa-miR-124a or with a negative control miRNA (NC). Standard deviations are shown in the graph. The p value, indicating statistical significance, is shown for values obtained on day 16 (p=0.0036).

FIG. 7. Tumor volumes in mice harboring xenografts of H460 lung cancer cells treated with hsa-miR-124a or with a negative control miRNA (NC). Circles represent the presence of a tumor in a mouse on the indicated day. Numbers inside circles represent the tumor volume in mm³.

FIG. 8. Average tumor volumes in groups of six (n=6) mice carrying human H460 lung cancer xenografts. Palpable tumors were treated with hsa-miR-124a (white squares) or with a negative control miRNA (NC, black diamonds) on days 11, 14, and 17 (arrows). Standard deviations are shown in the graph. Data points with p values <0.05 and <0.01 are indicated by an asterisk or circles, respectively. Abbreviation: miR-124a, hsa-miR-124a; NC, negative control miRNA.

FIG. 9. Percent (%) proliferation of hsa-miR-124a treated human prostate cancer cells relative to cells treated with negative control miRNA (100%). Abbreviations: miR-124a, hsa-miR-124a; siEg5, siRNA against the motor protein kinesin 11 (Eg5); NC, negative control miRNA. Standard deviations are indicated in the graph.

FIG. 10. Long-term effects of hsa-miR-124a on cultured human PPC-1, PC3 and Du145 prostate cancer cells. Equal numbers of prostate cancer cells were electroporated with 1.6 μM hsa-miR-124a or negative control miRNA (NC), seeded and propagated in regular growth medium. When the control cells reached confluence (days 4 and 11 for PPC-1; days 7 and 14 for PC3 and Du145), cells were harvested, counted and electroporated again with the respective miRNAs. The population doubling and cumulative cell counts were calculated and plotted on a linear scale. Arrows represent electroporation days. Abbreviation: miR-124a, hsa-miR-124a; NC, negative control miRNA.

FIG. 11. Average tumor volumes in groups of four (n=4) mice carrying human PC3 prostate cancer xenografts. Palpable tumors were treated with hsa-miR-124a (black circles) or with a negative control miRNA (NC, white squares) on days 38 and 40 (arrows). Standard deviations are shown in the graph. The p value for data points obtained on day 41 is shown (p=0.0266). Abbreviation: miR-124a, hsa-miR-124a; NC, negative control miRNA.

FIG. 12. Percent (%) proliferation of hsa-miR-124a treated human liver cancer cells relative to cells treated with negative control miRNA (100%). Abbreviations: miR-124a, hsa-miR-124a; siEg5, siRNA against the motor protein kinesin 11 (Eg5); NC, negative control miRNA. Standard deviations are indicated in the graph.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to compositions and methods relating to the identification and characterization of genes and biological pathways related to these genes as represented by the expression of the identified genes, as well as use of miRNAs related to such, for therapeutic, prognostic, and diagnostic applications, particularly those methods and compositions related to assessing and/or identifying pathological conditions directly or indirectly related to miR-124 expression or the aberrant expression thereof.

In certain aspects, the invention is directed to methods for the assessment, analysis, and/or therapy of a cell or subject where certain genes have a reduced or increased expression (relative to normal) as a result of an increased or decreased expression of any one or a combination of miR-124 family members (including, but not limited to SEQ ID NO:1 to SEQ ID NO:52) and/or genes with an increased expression (relative to normal) as a result of an increased or decreased expression of one or a combination of miR-124 family members. The expression profile and/or response to miR-124 expression or inhibition may be indicative of a disease or an individual with a condition, e.g., cancer.

Prognostic assays featuring any one or combination of the miRNAs listed or the markers listed (including nucleic acids representative thereof) could be used in assessment of a patient to determine what if any treatment regimen is justified. As with the diagnostic assays mentioned above, the absolute values that define low expression will depend on the platform used to measure the miRNA(s). The same methods described for the diagnostic assays could be used for prognostic assays.

I. THERAPEUTIC METHODS

Embodiments of the invention concern nucleic acids that perform the activities of or inhibit endogenous miRNAs when introduced into cells. In certain aspects, nucleic acids are synthetic or non-synthetic miRNA. Sequence-specific miRNA inhibitors can be used to inhibit sequentially or in combination the activities of one or more endogenous miRNAs in cells, as well those genes and associated pathways modulated by the endogenous miRNA.

The present invention concerns, in some embodiments, short nucleic acid molecules that function as miRNAs or as inhibitors of miRNA in a cell. The term “short” refers to a length of a single polynucleotide that is 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 50, 100, or 150 nucleotides or fewer, including all integers or ranges derivable there between. The nucleic acid molecules are typically synthetic. The term “synthetic” refers to nucleic acid molecule that is isolated and not produced naturally in a cell. In certain aspects the sequence (the entire sequence) and/or chemical structure deviates from a naturally-occurring nucleic acid molecule, such as an endogenous precursor miRNA or miRNA molecule or complement thereof. While in some embodiments, nucleic acids of the invention do not have an entire sequence that is identical or complementary to a sequence of a naturally-occurring nucleic acid, such molecules may encompass all or part of a naturally-occurring sequence or a complement thereof. It is contemplated, however, that a synthetic nucleic acid administered to a cell may subsequently be modified or altered in the cell such that its structure or sequence is the same as non-synthetic or naturally occurring nucleic acid, such as a mature miRNA sequence. For example, a synthetic nucleic acid may have a sequence that differs from the sequence of a precursor miRNA, but that sequence may be altered once in a cell to be the same as an endogenous, processed miRNA or an inhibitor thereof. The term “isolated” means that the nucleic acid molecules of the invention are initially separated from different (in terms of sequence or structure) and unwanted nucleic acid molecules such that a population of isolated nucleic acids is at least about 90% homogenous, and may be at least about 95, 96, 97, 98, 99, or 100% homogenous with respect to other polynucleotide molecules. In many embodiments of the invention, a nucleic acid is isolated by virtue of it having been synthesized in vitro separate from endogenous nucleic acids in a cell. It will be understood, however, that isolated nucleic acids may be subsequently mixed or pooled together. In certain aspects, synthetic miRNA of the invention are RNA or RNA analogs. miRNA inhibitors may be DNA or RNA, or analogs thereof. miRNA and miRNA inhibitors of the invention are collectively referred to as “synthetic nucleic acids.”

In some embodiments, there is a miRNA or a synthetic miRNA having a length of between 17 and 130 residues. The present invention concerns miRNA or synthetic miRNA molecules that are, are at least, or are at most 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127, 128, 129, 130, 140, 145, 150, 160, 170, 180, 190, 200 or more residues in length, including any integer or any range there between.

In certain embodiments, synthetic miRNA have (a) a “miRNA region” whose sequence or binding region from 5′ to 3′ is identical or complementary to all or a segment of a mature miRNA sequence, and (b) a “complementary region” whose sequence from 5′ to 3′ is between 60% and 100% complementary to the miRNA sequence in (a). In certain embodiments, these synthetic miRNA are also isolated, as defined above. The term “miRNA region” refers to a region on the synthetic miRNA that is at least 75, 80, 85, 90, 95, or 100% identical, including all integers there between, to the entire sequence of a mature, naturally occurring miRNA sequence or a complement thereof. In certain embodiments, the miRNA region is or is at least 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 or 100% identical to the sequence of a naturally-occurring miRNA or complement thereof.

The term “complementary region” or “complement” refers to a region of a nucleic acid or mimetic that is or is at least 60% complementary to the mature, naturally occurring miRNA sequence. The complementary region is or is at least 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 or 100% complementary, or any range derivable therein. With single polynucleotide sequences, there may be a hairpin loop structure as a result of chemical bonding between the miRNA region and the complementary region. In other embodiments, the complementary region is on a different nucleic acid molecule than the miRNA region, in which case the complementary region is on the complementary strand and the miRNA region is on the active strand.

In other embodiments of the invention, there are synthetic nucleic acids that are miRNA inhibitors. A miRNA inhibitor is between about 17 to 25 nucleotides in length and comprises a 5′ to 3′ sequence that is at least 90% complementary to the 5′ to 3′ sequence of a mature miRNA. In certain embodiments, a miRNA inhibitor molecule is 17, 18, 19, 20, 21, 22, 23, 24, or 25 nucleotides in length, or any range derivable therein. Moreover, an miRNA inhibitor may have a sequence (from 5′ to 3′) that is or is at least 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 99.1, 99.2, 99.3, 99.4, 99.5, 99.6, 99.7, 99.8, 99.9 or 100% complementary, or any range derivable therein, to the 5′ to 3′ sequence of a mature miRNA, particularly a mature, naturally occurring miRNA. One of skill in the art could use a portion of the miRNA sequence that is complementary to the sequence of a mature miRNA as the sequence for a miRNA inhibitor. Moreover, that portion of the nucleic acid sequence can be altered so that it is still comprises the appropriate percentage of complementarity to the sequence of a mature miRNA.

In some embodiments, of the invention, a synthetic miRNA or inhibitor contains one or more design element(s). These design elements include, but are not limited to: (i) a replacement group for the phosphate or hydroxyl of the nucleotide at the 5′ terminus of the complementary region; (ii) one or more sugar modifications in the first or last 1 to 6 residues of the complementary region; or, (iii) noncomplementarity between one or more nucleotides in the last 1 to 5 residues at the 3′ end of the complementary region and the corresponding nucleotides of the miRNA region. A variety of design modifications are known in the art, see below.

In certain embodiments, a synthetic miRNA has a nucleotide at its 5′ end of the complementary region in which the phosphate and/or hydroxyl group has been replaced with another chemical group (referred to as the “replacement design”). In some cases, the phosphate group is replaced, while in others, the hydroxyl group has been replaced. In particular embodiments, the replacement group is biotin, an amine group, a lower alkylamine group, an aminohexyl phosphate group, an acetyl group, 2′O-Me (2′oxygen-methyl), DMTO (4,4′-dimethoxytrityl with oxygen), fluorescein, a thiol, or acridine, though other replacement groups are well known to those of skill in the art and can be used as well. This design element can also be used with a miRNA inhibitor.

Additional embodiments concern a synthetic miRNA having one or more sugar modifications in the first or last 1 to 6 residues of the complementary region (referred to as the “sugar replacement design”). In certain cases, there is one or more sugar modifications in the first 1, 2, 3, 4, 5, 6 or more residues of the complementary region, or any range derivable therein. In additional cases, there are one or more sugar modifications in the last 1, 2, 3, 4, 5, 6 or more residues of the complementary region, or any range derivable therein, have a sugar modification. It will be understood that the terms “first” and “last” are with respect to the order of residues from the 5′ end to the 3′ end of the region. In particular embodiments, the sugar modification is a 2′O-Me modification, a 2′F modification, a 2′H modification, a 2′amino modification, a 4′thioribose modification or a phosphorothioate modification on the carboxy group linked to the carbon at position 6′. In further embodiments, there are one or more sugar modifications in the first or last 2 to 4 residues of the complementary region or the first or last 4 to 6 residues of the complementary region. This design element can also be used with a miRNA inhibitor. Thus, a miRNA inhibitor can have this design element and/or a replacement group on the nucleotide at the 5′ terminus, as discussed above.

In other embodiments of the invention, there is a synthetic miRNA or inhibitor in which one or more nucleotides in the last 1 to 5 residues at the 3′ end of the complementary region are not complementary to the corresponding nucleotides of the miRNA region (“noncomplementarity”) (referred to as the “noncomplementarity design”). The noncomplementarity may be in the last 1, 2, 3, 4, and/or 5 residues of the complementary miRNA. In certain embodiments, there is noncomplementarity with at least 2 nucleotides in the complementary region.

It is contemplated that synthetic miRNA of the invention have one or more of the replacement, sugar modification, or noncomplementarity designs. In certain cases, synthetic RNA molecules have two of them, while in others these molecules have all three designs in place.

The miRNA region and the complementary region may be on the same or separate polynucleotides. In cases in which they are contained on or in the same polynucleotide, the miRNA molecule will be considered a single polynucleotide. In embodiments in which the different regions are on separate polynucleotides, the synthetic miRNA will be considered to be comprised of two polynucleotides.

When the RNA molecule is a single polynucleotide, there can be a linker region between the miRNA region and the complementary region. In some embodiments, the single polynucleotide is capable of forming a hairpin loop structure as a result of bonding between the miRNA region and the complementary region. The linker constitutes the hairpin loop. It is contemplated that in some embodiments, the linker region is, is at least, or is at most 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 residues in length, or any range derivable therein. In certain embodiments, the linker is between 3 and 30 residues (inclusive) in length.

In addition to having a miRNA or inhibitor region and a complementary region, there may be flanking sequences as well at either the 5′ or 3′ end of the region. In some embodiments, there is or is at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 nucleotides or more, or any range derivable therein, flanking one or both sides of these regions.

Methods of the invention include reducing or eliminating activity of one or more miRNAs in a cell comprising introducing into a cell a miRNA inhibitor (which may be described generally herein as an miRNA, so that a description of miRNA, where appropriate, also will refer to a miRNA inhibitor); or supplying or enhancing the activity of one or more miRNAs in a cell. The present invention also concerns inducing certain cellular characteristics by providing to a cell a particular nucleic acid, such as a specific synthetic miRNA molecule or a synthetic miRNA inhibitor molecule. However, in methods of the invention, the miRNA molecule or miRNA inhibitor need not be synthetic. They may have a sequence that is identical to a naturally occurring miRNA or they may not have any design modifications. In certain embodiments, the miRNA molecule and/or the miRNA inhibitor are synthetic, as discussed above.

The particular nucleic acid molecule provided to the cell is understood to correspond to a particular miRNA in the cell, and thus, the miRNA in the cell is referred to as the “corresponding miRNA.” In situations in which a named miRNA molecule is introduced into a cell, the corresponding miRNA will be understood to be the induced or inhibited miRNA function. It is contemplated, however, that the miRNA molecule introduced into a cell is not a mature miRNA but is capable of becoming or functioning as a mature miRNA under the appropriate physiological conditions. In cases in which a particular corresponding miRNA is being inhibited by a miRNA inhibitor, the particular miRNA will be referred to as the “targeted miRNA.” It is contemplated that multiple corresponding miRNAs may be involved. In particular embodiments, more than one miRNA molecule is introduced into a cell. Moreover, in other embodiments, more than one miRNA inhibitor is introduced into a cell. Furthermore, a combination of miRNA molecule(s) and miRNA inhibitor(s) may be introduced into a cell. The inventors contemplate that a combination of miRNA may act at one or more points in cellular pathways of cells with aberrant phenotypes and that such combination may have increased efficacy on the target cell while not adversely effecting normal cells. Thus, a combination of miRNA may have a minimal adverse effect on a subject or patient while supplying a sufficient therapeutic effect, such as amelioration of a condition, growth inhibition of a cell, death of a targeted cell, alteration of cell phenotype or physiology, slowing of cellular growth, sensitization to a second therapy, sensitization to a particular therapy, and the like.

Methods include identifying a cell or patient in need of inducing those cellular characteristics. Also, it will be understood that an amount of a synthetic nucleic acid that is provided to a cell or organism is an “effective amount,” which refers to an amount needed (or a sufficient amount) to achieve a desired goal, such as inducing a particular cellular characteristic(s).

In certain embodiments of the methods include providing or introducing to a cell a nucleic acid molecule corresponding to a mature miRNA in the cell in an amount effective to achieve a desired physiological result.

Moreover, methods can involve providing synthetic or nonsynthetic miRNA molecules. It is contemplated that in these embodiments, that methods may or may not be limited to providing only one or more synthetic miRNA molecules or only one or more nonsynthetic miRNA molecules. Thus, in certain embodiments, methods may involve providing both synthetic and nonsynthetic miRNA molecules. In this situation, a cell or cells are most likely provided a synthetic miRNA molecule corresponding to a particular miRNA and a nonsynthetic miRNA molecule corresponding to a different miRNA. Furthermore, any method articulated using a list of miRNAs using Markush group language may be articulated without the Markush group language and a disjunctive article (i.e., or) instead, and vice versa.

In some embodiments, there is a method for reducing or inhibiting cell proliferation in a cell comprising introducing into or providing to the cell an effective amount of (i) an miRNA inhibitor molecule or (ii) a synthetic or nonsynthetic miRNA molecule that corresponds to a miRNA sequence. In certain embodiments the methods involves introducing into the cell an effective amount of (i) a miRNA inhibitor molecule having a 5′ to 3′ sequence that is at least 90% complementary to the 5′ to 3′ sequence of one or more mature miRNA.

Certain embodiments of the invention include methods of treating a pathologic condition, in particular cancer, e.g., lung or liver cancer. In one aspect, the method comprises contacting a target cell with one or more nucleic acid, synthetic miRNA, or miRNA comprising at least one nucleic acid segment having all or a portion of a miRNA sequence. The segment may be 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30 or more nucleotides or nucleotide analog, including all integers there between. An aspect of the invention includes the modulation of gene expression, miRNA expression or function or mRNA expression or function within a target cell, such as a cancer cell.

Typically, an endogenous gene, miRNA or mRNA is modulated in the cell. In particular embodiments, the nucleic acid sequence comprises at least one segment that is at least 70, 75, 80, 85, 90, 95, or 100% identical in nucleic acid sequence to one or more miRNA or gene sequence. Modulation of the expression or processing of an endogenous gene, miRNA, or mRNA can be through modulation of the processing of a mRNA, such processing including transcription, transportation and/or translation with in a cell. Modulation may also be effected by the inhibition or enhancement of miRNA activity with a cell, tissue, or organ. Such processing may affect the expression of an encoded product or the stability of the mRNA. In still other embodiments, a nucleic acid sequence can comprise a modified nucleic acid sequence. In certain aspects, one or more miRNA sequence may include or comprise a modified nucleobase or nucleic acid sequence.

It will be understood in methods of the invention that a cell or other biological matter such as an organism (including patients) can be provided a miRNA or miRNA molecule corresponding to a particular miRNA by administering to the cell or organism a nucleic acid molecule that functions as the corresponding miRNA once inside the cell. The form of the molecule provided to the cell may not be the form that acts a miRNA once inside the cell. Thus, it is contemplated that in some embodiments, a synthetic miRNA or a nonsynthetic miRNA is provided such that it becomes processed into a mature and active miRNA once it has access to the cell's miRNA processing machinery. In certain embodiments, it is specifically contemplated that the miRNA molecule provided is not a mature miRNA molecule but a nucleic acid molecule that can be processed into the mature miRNA once it is accessible to miRNA processing machinery. The term “nonsynthetic” in the context of miRNA means that the miRNA is not “synthetic,” as defined herein. Furthermore, it is contemplated that in embodiments of the invention that concern the use of synthetic miRNAs, the use of corresponding nonsynthetic miRNAs is also considered an aspect of the invention, and vice versa. It will be understand that the term “providing” an agent is used to include “administering” the agent to a patient.

In certain embodiments, methods also include targeting a miRNA to modulate in a cell or organism. The term “targeting a miRNA to modulate” means a nucleic acid of the invention will be employed so as to modulate the selected miRNA. In some embodiments the modulation is achieved with a synthetic or non-synthetic miRNA that corresponds to the targeted miRNA, which effectively provides the targeted miRNA to the cell or organism (positive modulation). In other embodiments, the modulation is achieved with a miRNA inhibitor, which effectively inhibits the targeted miRNA in the cell or organism (negative modulation).

In some embodiments, the miRNA targeted to be modulated is a miRNA that affects a disease, condition, or pathway. In certain embodiments, the miRNA is targeted because a treatment can be provided by negative modulation of the targeted miRNA. In other embodiments, the miRNA is targeted because a treatment can be provided by positive modulation of the targeted miRNA or its targets.

In certain methods of the invention, there is a further step of administering the selected miRNA modulator to a cell, tissue, organ, or organism (collectively “biological matter”) in need of treatment related to modulation of the targeted miRNA or in need of the physiological or biological results discussed herein (such as with respect to a particular cellular pathway or result like decrease in cell viability). Consequently, in some methods of the invention there is a step of identifying a patient in need of treatment that can be provided by the miRNA modulator(s). It is contemplated that an effective amount of a miRNA modulator can be administered in some embodiments. In particular embodiments, there is a therapeutic benefit conferred on the biological matter, where a “therapeutic benefit” refers to an improvement in the one or more conditions or symptoms associated with a disease or condition or an improvement in the prognosis, duration, or status with respect to the disease. It is contemplated that a therapeutic benefit includes, but is not limited to, a decrease in pain, a decrease in morbidity, a decrease in a symptom. For example, with respect to cancer, it is contemplated that a therapeutic benefit can be inhibition of tumor growth, prevention of metastasis, reduction in number of metastases, inhibition of cancer cell proliferation, induction of cell death in cancer cells, inhibition of angiogenesis near cancer cells, induction of apoptosis of cancer cells, reduction in pain, reduction in risk of recurrence, induction of chemo- or radiosensitivity in cancer cells, prolongation of life, and/or delay of death directly or indirectly related to cancer.

Furthermore, it is contemplated that the miRNA compositions may be provided as part of a therapy to a patient, in conjunction with traditional therapies or preventative agents. Moreover, it is contemplated that any method discussed in the context of therapy may be applied as preventatively, particularly in a patient identified to be potentially in need of the therapy or at risk of the condition or disease for which a therapy is needed.

In addition, methods of the invention concern employing one or more nucleic acids corresponding to a miRNA and a therapeutic drug. The nucleic acid can enhance the effect or efficacy of the drug, reduce any side effects or toxicity, modify its bioavailability, and/or decrease the dosage or frequency needed. In certain embodiments, the therapeutic drug is a cancer therapeutic. Consequently, in some embodiments, there is a method of treating cancer in a patient comprising administering to the patient the cancer therapeutic and an effective amount of at least one miRNA molecule that improves the efficacy of the cancer therapeutic or protects non-cancer cells. Cancer therapies also include a variety of combination therapies with both chemical and radiation based treatments. Combination chemotherapies include but are not limited to, for example, 5-fluorouracil, alemtuzumab, amrubicin, bevacizumab, bleomycin, bortezomib, busulfan, camptothecin, capecitabine, cisplatin (CDDP), carboplatin, cetuximab, chlorambucil, cisplatin (CDDP), cyclophosphamide, camptothecin, COX-2 inhibitors (e.g., celecoxib), cyclophosphamide, cytarabine, dactinomycin, dasatinib, daunorubicin, dexamethasone, docetaxel, doxorubicin (adriamycin), EGFR inhibitors (gefitinib and cetuximab), erlotinib, estrogen receptor binding agents, etoposide (VP16), everolimus, farnesyl-protein transferase inhibitors, gefitinib, gemcitabine, gemtuzumab, ibritumomab, ifosfamide, imatinib mesylate, larotaxel, lapatinib, lonafarnib, mechlorethamine, melphalan, methotrexate, mitomycin, navelbine, nitrosurea, nocodazole, oxaliplatin, paclitaxel, plicomycin, procarbazine, raloxifene, rituximab, sirolimus, sorafenib, sunitinib, tamoxifen, taxol, taxotere, temsirolimus, tipifarnib, tositumomab, transplatinum, trastuzumab, vinblastin, vincristin, or vinorelbine or any analog or derivative variant of the foregoing.

Generally, inhibitors of miRNAs can be given to decrease the activity of an endogenous miRNA. Similarly, nucleic acid molecules corresponding to the mature miRNA can be given to achieve the opposite effect as compared to when inhibitors of the miRNA are given. For example, inhibitors of miRNA molecules that increase cell proliferation can be provided to cells to increase proliferation or decrease cell proliferation. The present invention contemplates these embodiments in the context of the different physiological effects observed with the different miRNA molecules and miRNA inhibitors disclosed herein. These include, but are not limited to, the following physiological effects: increase and decreasing cell proliferation, increasing or decreasing apoptosis, increasing transformation, increasing or decreasing cell viability, activating or inhibiting a kinase (e.g., Erk), activating/inducing or inhibiting hTert, inhibit stimulation of growth promoting pathway (e.g., Stat 3 signaling), reduce or increase viable cell number, and increase or decrease number of cells at a particular phase of the cell cycle. Methods of the invention are generally contemplated to include providing or introducing one or more different nucleic acid molecules corresponding to one or more different miRNA molecules. It is contemplated that the following, at least the following, or at most the following number of different nucleic acid or miRNA molecules may be provided or introduced: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, or any range derivable therein. This also applies to the number of different miRNA molecules that can be provided or introduced into a cell.

II. PHARMACEUTICAL FORMULATIONS AND DELIVERY

Methods of the present invention include the delivery of an effective amount of a miRNA or an expression construct encoding the same. An “effective amount” of the pharmaceutical composition, generally, is defined as that amount sufficient to detectably and repeatedly to achieve the stated desired result, for example, to ameliorate, reduce, minimize or limit the extent of the disease or its symptoms. Other more rigorous definitions may apply, including elimination, eradication or cure of disease.

A. Administration

In certain embodiments, it is desired to kill cells, inhibit cell growth, inhibit metastasis, decrease tumor or tissue size, and/or reverse or reduce the malignant or disease phenotype of cells. The routes of administration will vary, naturally, with the location and nature of the lesion or site to be targeted, and include, e.g., intradermal, subcutaneous, regional, parenteral, intravenous, intramuscular, intranasal, systemic, and oral administration and formulation. Direct injection, intratumoral injection, or injection into tumor vasculature is specifically contemplated for discrete, solid, accessible tumors, or other accessible target areas. Local, regional, or systemic administration also may be appropriate. For tumors of >4 cm, the volume to be administered will be about 4-10 ml (preferably 10 ml), while for tumors of <4 cm, a volume of about 1-3 ml will be used (preferably 3 ml).

Multiple injections delivered as a single dose comprise about 0.1 to about 0.5 ml volumes. Compositions of the invention may be administered in multiple injections to a tumor or a targeted site. In certain aspects, injections may be spaced at approximately 1 cm intervals.

In the case of surgical intervention, the present invention may be used preoperatively, to render an inoperable tumor subject to resection. Alternatively, the present invention may be used at the time of surgery, and/or thereafter, to treat residual or metastatic disease. For example, a resected tumor bed may be injected or perfused with a formulation comprising a miRNA or combinations thereof. Administration may be continued post-resection, for example, by leaving a catheter implanted at the site of the surgery. Periodic post-surgical treatment also is envisioned. Continuous perfusion of an expression construct or a viral construct also is contemplated.

Continuous administration also may be applied where appropriate, for example, where a tumor or other undesired affected area is excised and the tumor bed or targeted site is treated to eliminate residual, microscopic disease. Delivery via syringe or catherization is contemplated. Such continuous perfusion may take place for a period from about 1-2 hours, to about 2-6 hours, to about 6-12 hours, to about 12-24 hours, to about 1-2 days, to about 1-2 wk or longer following the initiation of treatment. Generally, the dose of the therapeutic composition via continuous perfusion will be equivalent to that given by a single or multiple injections, adjusted over a period of time during which the perfusion occurs.

Treatment regimens may vary as well and often depend on tumor type, tumor location, immune condition, target site, disease progression, and health and age of the patient. Certain tumor types will require more aggressive treatment. The clinician will be best suited to make such decisions based on the known efficacy and toxicity (if any) of the therapeutic formulations.

In certain embodiments, the tumor or affected area being treated may not, at least initially, be resectable. Treatments with compositions of the invention may increase the resectability of the tumor due to shrinkage at the margins or by elimination of certain particularly invasive portions. Following treatments, resection may be possible. Additional treatments subsequent to resection may serve to eliminate microscopic residual disease at the tumor or targeted site.

Treatments may include various “unit doses.” A unit dose is defined as containing a predetermined quantity of a therapeutic composition(s). The quantity to be administered, and the particular route and formulation, are within the skill of those in the clinical arts. A unit dose need not be administered as a single injection but may comprise continuous infusion over a set period of time. With respect to a viral component of the present invention, a unit dose may conveniently be described in terms of μg or mg of miRNA or miRNA mimetic. Alternatively, the amount specified may be the amount administered as the average daily, average weekly, or average monthly dose.

miRNA can be administered to the patient in a dose or doses of about or of at least about 0.5, 1, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, 1000 μg or mg, or more, or any range derivable therein. Alternatively, the amount specified may be the amount administered as the average daily, average weekly, or average monthly dose, or it may be expressed in terms of mg/kg, where kg refers to the weight of the patient and the mg is specified above. In other embodiments, the amount specified is any number discussed above but expressed as mg/m²(with respect to tumor size or patient surface area).

B. Injectable Compositions and Formulations

In some embodiments, the method for the delivery of a miRNA or an expression construct encoding such or combinations thereof is via systemic administration. However, the pharmaceutical compositions disclosed herein may also be administered parenterally, subcutaneously, directly, intratracheally, intravenously, intradermally, intramuscularly, or even intraperitoneally as described in U.S. Pat. Nos. 5,543,158; 5,641,515 and 5,399,363 (each specifically incorporated herein by reference in its entirety).

Injection of nucleic acids may be delivered by syringe or any other method used for injection of a solution, as long as the nucleic acid and any associated components can pass through the particular gauge of needle required for injection. A syringe system has also been described for use in gene therapy that permits multiple injections of predetermined quantities of a solution precisely at any depth (U.S. Pat. No. 5,846,225).

Solutions of the active compounds as free base or pharmacologically acceptable salts may be prepared in water suitably mixed with a surfactant, such as hydroxypropylcellulose. Dispersions may also be prepared in glycerol, liquid polyethylene glycols, mixtures thereof, and in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions (U.S. Pat. No. 5,466,468, specifically incorporated herein by reference in its entirety). In all cases the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms, such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol, and liquid polyethylene glycol, and the like), suitable mixtures thereof, and/or vegetable oils. Proper fluidity may be maintained, for example, by the use of a coating, such as lecithin, by the maintenance of the required particle size in the case of dispersion and by the use of surfactants. The prevention of the action of microorganisms can be brought about by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it will be preferable to include isotonic agents, for example, sugars or sodium chloride. Prolonged absorption of the injectable compositions can be brought about by the use in the compositions of agents delaying absorption, for example, aluminum monostearate and gelatin.

In certain formulations, a water-based formulation is employed while in others, it may be lipid-based. In particular embodiments of the invention, a composition comprising a tumor suppressor protein or a nucleic acid encoding the same is in a water-based formulation. In other embodiments, the formulation is lipid based.

For parenteral administration in an aqueous solution, for example, the solution should be suitably buffered if necessary and the liquid diluent first rendered isotonic with sufficient saline or glucose. These particular aqueous solutions are especially suitable for intravenous, intramuscular, subcutaneous, intratumoral, intralesional, and intraperitoneal administration. In this connection, sterile aqueous media which can be employed will be known to those of skill in the art in light of the present disclosure. For example, one dosage may be dissolved in 1 ml of isotonic NaCl solution and either added to 1000 ml of hypodermoclysis fluid or injected at the proposed site of infusion, (see for example, “Remington's Pharmaceutical Sciences” 15th Edition, pages 1035-1038 and 1570-1580). Some variation in dosage will necessarily occur depending on the condition of the subject being treated. The person responsible for administration will, in any event, determine the appropriate dose for the individual subject. Moreover, for human administration, preparations should meet sterility, pyrogenicity, general safety and purity standards as required by FDA Office of Biologics standards.

As used herein, a “carrier” includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.

The phrase “pharmaceutically acceptable” refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human.

The nucleic acid(s) are administered in a manner compatible with the dosage formulation, and in such amount as will be therapeutically effective. The quantity to be administered depends on the subject to be treated, including, e.g., the aggressiveness of the disease or cancer, the size of any tumor(s) or lesions, the previous or other courses of treatment. Precise amounts of active ingredient required to be administered depend on the judgment of the practitioner. Suitable regimes for initial administration and subsequent administration are also variable, but are typified by an initial administration followed by other administrations. Such administration may be systemic, as a single dose, continuous over a period of time spanning 10, 20, 30, 40, 50, 60 minutes, and/or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24 or more hours, and/or 1, 2, 3, 4, 5, 6, 7, days or more. Moreover, administration may be through a time release or sustained release mechanism, implemented by formulation and/or mode of administration.

C. Combination Treatments

In certain embodiments, the compositions and methods of the present invention involve a miRNA, or expression construct encoding such. These miRNA composition can be used in combination with a second therapy to enhance the effect of the miRNA therapy, or increase the therapeutic effect of another therapy being employed. These compositions would be provided in a combined amount effective to achieve the desired effect, such as the killing of a cancer cell and/or the inhibition of cellular hyperproliferation. This process may involve contacting the cells with the miRNA or second therapy at the same or different time. This may be achieved by contacting the cell with one or more compositions or pharmacological formulation that includes or more of the agents, or by contacting the cell with two or more distinct compositions or formulations, wherein one composition provides (1) miRNA; and/or (2) a second therapy. A second composition or method may be administered that includes a chemotherapy, radiotherapy, surgical therapy, immunotherapy or gene therapy.

It is contemplated that one may provide a patient with the miRNA therapy and the second therapy within about 12-24 h of each other and, more preferably, within about 6-12 h of each other. In some situations, it may be desirable to extend the time period for treatment significantly, however, where several days (2, 3, 4, 5, 6 or 7) to several weeks (1, 2, 3, 4, 5, 6, 7 or 8) lapse between the respective administrations.

In certain embodiments, a course of treatment will last 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90 days or more. It is contemplated that one agent may be given on day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, and/or 90, any combination thereof, and another agent is given on day 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, and/or 90, or any combination thereof. Within a single day (24-hour period), the patient may be given one or multiple administrations of the agent(s). Moreover, after a course of treatment, it is contemplated that there is a period of time at which no treatment is administered. This time period may last 1, 2, 3, 4, 5, 6, 7 days, and/or 1, 2, 3, 4, 5 weeks, and/or 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 months or more, depending on the condition of the patient, such as their prognosis, strength, health, etc.

Various combinations may be employed, for example miRNA therapy is “A” and a second therapy is “B”:

A/B/A B/A/B B/B/A A/A/B A/B/B B/A/A A/B/B/B

B/A/B/B B/B/B/A B/B/A/B A/A/B/B A/B/A/B A/B/B/A

B/B/A/A B/A/B/A B/A/A/B A/A/A/B B/A/A/A A/B/A/A

A/A/B/A

Administration of any compound or therapy of the present invention to a patient will follow general protocols for the administration of such compounds, taking into account the toxicity, if any, of the vector or any protein or other agent. Therefore, in some embodiments there is a step of monitoring toxicity that is attributable to combination therapy. It is expected that the treatment cycles would be repeated as necessary. It also is contemplated that various standard therapies, as well as surgical intervention, may be applied in combination with the described therapy.

In specific aspects, it is contemplated that a second therapy, such as chemotherapy, radiotherapy, immunotherapy, surgical therapy or other gene therapy, is employed in combination with the miRNA therapy, as described herein.

1. Chemotherapy

A wide variety of chemotherapeutic agents may be used in accordance with the present invention. The term “chemotherapy” refers to the use of drugs to treat cancer. A “chemotherapeutic agent” is used to connote a compound or composition that is administered in the treatment of cancer. These agents or drugs are categorized by their mode of activity within a cell, for example, whether and at what stage they affect the cell cycle. Alternatively, an agent may be characterized based on its ability to directly cross-link DNA, to intercalate into DNA, or to induce chromosomal and mitotic aberrations by affecting nucleic acid synthesis. Most chemotherapeutic agents fall into the following categories: alkylating agents, antimetabolites, antitumor antibiotics, mitotic inhibitors, and nitrosoureas.

a. Alkylating Agents

Alkylating agents are drugs that directly interact with genomic DNA to prevent the cancer cell from proliferating. This category of chemotherapeutic drugs represents agents that affect all phases of the cell cycle, that is, they are not phase-specific. Alkylating agents can be implemented to treat chronic leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, multiple myeloma, and particular cancers of the breast, lung, and ovary. They include: busulfan, chlorambucil, cisplatin, cyclophosphamide (cytoxan), dacarbazine, ifosfamide, mechlorethamine (mustargen), and melphalan. Troglitazaone can be used to treat cancer in combination with any one or more of these alkylating agents.

b. Antimetabolites

Antimetabolites disrupt DNA and RNA synthesis. Unlike alkylating agents, they specifically influence the cell cycle during S phase. They have been used to combat chronic leukemias in addition to tumors of breast, ovary and the gastrointestinal tract. Antimetabolites include 5-fluorouracil (5-FU), cytarabine (Ara-C), fludarabine, gemcitabine, and methotrexate.

5-Fluorouracil (5-FU) has the chemical name of 5-fluoro-2,4(1H,3H)-pyrimidinedione. Its mechanism of action is thought to be by blocking the methylation reaction of deoxyuridylic acid to thymidylic acid. Thus, 5-FU interferes with the synthesis of deoxyribonucleic acid (DNA) and to a lesser extent inhibits the formation of ribonucleic acid (RNA). Since DNA and RNA are essential for cell division and proliferation, it is thought that the effect of 5-FU is to create a thymidine deficiency leading to cell death. Thus, the effect of 5-FU is found in cells that rapidly divide, a characteristic of metastatic cancers.

c. Antitumor Antibiotics

Antitumor antibiotics have both antimicrobial and cytotoxic activity. These drugs also interfere with DNA by chemically inhibiting enzymes and mitosis or altering cellular membranes. These agents are not phase specific so they work in all phases of the cell cycle. Thus, they are widely used for a variety of cancers. Examples of antitumor antibiotics include bleomycin, dactinomycin, daunorubicin, doxorubicin (Adriamycin), and idarubicin, some of which are discussed in more detail below. Widely used in clinical setting for the treatment of neoplasms, these compounds are administered through bolus injections intravenously at doses ranging from 25-75 mg/m²at 21 day intervals for adriamycin, to 35-100 mg/m²for etoposide intravenously or orally.

d. Mitotic Inhibitors

Mitotic inhibitors include plant alkaloids and other natural agents that can inhibit either protein synthesis required for cell division or mitosis. They operate during a specific phase during the cell cycle. Mitotic inhibitors comprise docetaxel, etoposide (VP16), paclitaxel, taxol, taxotere, vinblastine, vincristine, and vinorelbine.

e. Nitrosureas

Nitrosureas, like alkylating agents, inhibit DNA repair proteins. They are used to treat non-Hodgkin's lymphomas, multiple myeloma, malignant melanoma, in addition to brain tumors. Examples include carmustine and lomustine.

2. Radiotherapy

Radiotherapy, also called radiation therapy, is the treatment of cancer and other diseases with ionizing radiation. Ionizing radiation deposits energy that injures or destroys cells in the area being treated by damaging their genetic material, making it impossible for these cells to continue to grow. Although radiation damages both cancer cells and normal cells, the latter are able to repair themselves and function properly. Radiotherapy may be used to treat localized solid tumors, such as cancers of the skin, tongue, larynx, brain, breast, or cervix. It can also be used to treat leukemia and lymphoma (cancers of the blood-forming cells and lymphatic system, respectively).

Radiation therapy used according to the present invention may include, but is not limited to, the use of γ-rays, X-rays, and/or the directed delivery of radioisotopes to tumor cells. Other forms of DNA damaging factors are also contemplated such as microwaves, proton beam irradiation (U.S. Pat. Nos. 5,760,395 and 4,870,287) and UV-irradiation. It is most likely that all of these factors effect a broad range of damage on DNA, on the precursors of DNA, on the replication and repair of DNA, and on the assembly and maintenance of chromosomes. Dosage ranges for X-rays range from daily doses of 50 to 200 roentgens for prolonged periods of time (3 to 4 wk), to single doses of 2000 to 6000 roentgens. Dosage ranges for radioisotopes vary widely, and depend on the half-life of the isotope, the strength and type of radiation emitted, and the uptake by the neoplastic cells. Radiotherapy may comprise the use of radiolabeled antibodies to deliver doses of radiation directly to the cancer site (radioimmunotherapy). Once injected into the body, the antibodies actively seek out the cancer cells, which are destroyed by the cell-killing (cytotoxic) action of the radiation. This approach can minimize the risk of radiation damage to healthy cells.

Stereotactic radio-surgery (gamma knife) for brain and other tumors does not use a knife, but very precisely targeted beams of gamma radiotherapy from hundreds of different angles. Only one session of radiotherapy, taking about four to five hours, is needed. For this treatment a specially made metal frame is attached to the head. Then, several scans and x-rays are carried out to find the precise area where the treatment is needed. During the radiotherapy for brain tumors, the patient lies with their head in a large helmet, which has hundreds of holes in it to allow the radiotherapy beams through. Related approaches permit positioning for the treatment of tumors in other areas of the body.

3. Immunotherapy

In the context of cancer treatment, immunotherapeutics, generally, rely on the use of immune effector cells and molecules to target and destroy cancer cells. Trastuzumab (Herceptin™) is such an example. The immune effector may be, for example, an antibody specific for some marker on the surface of a tumor cell. The antibody alone may serve as an effector of therapy or it may recruit other cells to actually affect cell killing. The antibody also may be conjugated to a drug or toxin (chemotherapeutic, radionuclide, ricin A chain, cholera toxin, pertussis toxin, etc.) and serve merely as a targeting agent. Alternatively, the effector may be a lymphocyte carrying a surface molecule that interacts, either directly or indirectly, with a tumor cell target. Various effector cells include cytotoxic T cells and NK cells. The combination of therapeutic modalities, i.e., direct cytotoxic activity and inhibition or reduction of ErbB2 would provide therapeutic benefit in the treatment of ErbB2 overexpressing cancers.

In one aspect of immunotherapy, the tumor or disease cell must bear some marker that is amenable to targeting, i.e., is not present on the majority of other cells. Many tumor markers exist and any of these may be suitable for targeting in the context of the present invention. Common tumor markers include carcinoembryonic antigen, prostate specific antigen, urinary tumor associated antigen, fetal antigen, tyrosinase (p97), gp68, TAG-72, HMFG, Sialyl Lewis Antigen, MucA, MucB, PLAP, estrogen receptor, laminin receptor, erb B and p155. An alternative aspect of immunotherapy is to combine anticancer effects with immune stimulatory effects. Immune stimulating molecules also exist including: cytokines such as IL-2, IL-4, IL-12, GM-CSF, gamma-IFN, chemokines such as MIP-1, MCP-1, IL-8 and growth factors such as FLT3 ligand. Combining immune stimulating molecules, either as proteins or using gene delivery in combination with a tumor suppressor such as MDA-7 has been shown to enhance anti-tumor effects (Ju et al., 2000). Moreover, antibodies against any of these compounds can be used to target the anti-cancer agents discussed herein.

Examples of immunotherapies currently under investigation or in use are immune adjuvants e.g., Mycobacterium bovis, Plasmodium falciparum, dinitrochlorobenzene and aromatic compounds (U.S. Pat. Nos. 5,801,005 and 5,739,169; Hui and Hashimoto, 1998; Christodoulides et al., 1998), cytokine therapy e.g., interferons α, β and γ; IL-1, GM-CSF and TNF (Bukowski et al., 1998; Davidson et al., 1998; Hellstrand et al., 1998) gene therapy e.g., TNF, IL-1, IL-2, p53 (Qin et al., 1998; Austin-Ward and Villaseca, 1998; U.S. Pat. Nos. 5,830,880 and 5,846,945) and monoclonal antibodies e.g., anti-ganglioside GM2, anti-HER-2, anti-p185; Pietras et al., 1998; Hanibuchi et al., 1998; U.S. Pat. No. 5,824,311). Herceptin (trastuzumab) is a chimeric (mouse-human) monoclonal antibody that blocks the HER2-neu receptor. It possesses anti-tumor activity and has been approved for use in the treatment of malignant tumors (Dillman, 1999). A non-limiting list of several known anti-cancer immunotherapeutic agents and their targets includes (Generic Name/Target) Cetuximab/EGFR, Panitumuma/EGFR, Trastuzumab/erbB2 receptor, Bevacizumab/VEGF, Alemtuzumab/CD52, Gemtuzumab ozogamicin/CD33, Rituximab/CD20, Tositumomab/CD20, Matuzumab/EGFR, Ibritumomab tiuxetan/CD20, Tositumomab/CD20, HuPAM4/MUC1, MORAb-009/Mesothelin, G250/carbonic anhydrase IX, mAb 8H9/8H9 antigen, M195/CD33, Ipilimumab/CTLA4, HuLuc63/CS1, Alemtuzumab/CD53, Epratuzumab/CD22, BC8/CD45, HuJ591/Prostate specific membrane antigen, hA20/CD20, Lexatumumab/TRAIL receptor-2, Pertuzumab/HER-2 receptor, Mik-beta-1/IL-2R, RAV12/RAAG12, SGN-30/CD30, AME-133v/CD20, HeFi-1/CD30, BMS-663513/CD137, Volociximab/anti-α5β1 integrin, GC1008/TGFβ, HCD122/CD40, Siplizumab/CD2, MORAb-003/Folate receptor alpha, CNTO 328/IL-6, MDX-060/CD30, Ofatumumab/CD20, and SGN-33/CD33. It is contemplated that one or more of these therapies may be employed with the miRNA therapies described herein.

A number of different approaches for passive immunotherapy of cancer exist. They may be broadly categorized into the following: injection of antibodies alone; injection of antibodies coupled to toxins or chemotherapeutic agents; injection of antibodies coupled to radioactive isotopes; injection of anti-idiotype antibodies; and finally, purging of tumor cells in bone marrow.

4. Gene Therapy

In yet another embodiment, a combination treatment involves gene therapy in which a therapeutic polynucleotide is administered before, after, or at the same time as one or more therapeutic miRNA. Delivery of a therapeutic polypeptide or encoding nucleic acid in conjunction with a miRNA may have a combined therapeutic effect on target tissues. A variety of proteins are encompassed within the invention, some of which are described below. Various genes that may be targeted for gene therapy of some form in combination with the present invention include, but are not limited to inducers of cellular proliferation, inhibitors of cellular proliferation, regulators of programmed cell death, cytokines and other therapeutic nucleic acids or nucleic acid that encode therapeutic proteins.

The tumor suppressor oncogenes function to inhibit excessive cellular proliferation. The inactivation of these genes destroys their inhibitory activity, resulting in unregulated proliferation. The tumor suppressors (e.g., therapeutic polypeptides) p53, FHIT, p16 and C-CAM can be employed.

In addition to p53, another inhibitor of cellular proliferation is p16. The major transitions of the eukaryotic cell cycle are triggered by cyclin-dependent kinases, or CDK's. One CDK, cyclin-dependent kinase 4 (CDK4), regulates progression through the G1. The activity of this enzyme may be to phosphorylate Rb at late G1. The activity of CDK4 is controlled by an activating subunit, D-type cyclin, and by an inhibitory subunit, the p16INK4 has been biochemically characterized as a protein that specifically binds to and inhibits CDK4, and thus may regulate Rb phosphorylation (Serrano et al., 1993; Serrano et al., 1995). Since the p16INK4 protein is a CDK4 inhibitor (Serrano, 1993), deletion of this gene may increase the activity of CDK4, resulting in hyperphosphorylation of the Rb protein. p16 also is known to regulate the function of CDK6.

p16INK4 belongs to a newly described class of CDK-inhibitory proteins that also includes p16B, p19, p21WAF1, and p27KIP1. The p16INK4 gene maps to 9p21, a chromosome region frequently deleted in many tumor types. Homozygous deletions and mutations of the p16INK4 gene are frequent in human tumor cell lines. This evidence suggests that the p16INK4 gene is a tumor suppressor gene. This interpretation has been challenged, however, by the observation that the frequency of the p16INK4 gene alterations is much lower in primary uncultured tumors than in cultured cell lines (Caldas et al., 1994; Cheng et al., 1994; Hussussian et al., 1994; Kamb et al., 1994; Mori et al., 1994; Okamoto et al., 1994; Nobori et al., 1995; Orlow et al., 1994; Arap et al., 1995). Restoration of wild-type p16INK4 function by transfection with a plasmid expression vector reduced colony formation by some human cancer cell lines (Okamoto, 1994; Arap, 1995).

Other genes that may be employed according to the present invention include Rb, APC, DCC, NF-1, NF-2, WT-1, MEN-I, MEN-II, zac1, p73, VHL, MMAC1/PTEN, DBCCR-1, FCC, rsk-3, p27, p27/p16 fusions, p21/p27 fusions, anti-thrombotic genes (e.g., COX-1, TFPI), PGS, Dp, E2F, ras, myc, neu, raf, erb, fms, trk, ret, gsp, hst, abl, E1A, p300, genes involved in angiogenesis (e.g., VEGF, FGF, thrombospondin, BAI-1, GDAIF, or their receptors) and MCC.

5. Surgery

Approximately 60% of persons with cancer will undergo surgery of some type, which includes preventative, diagnostic or staging, curative and palliative surgery. Curative surgery is a cancer treatment that may be used in conjunction with other therapies, such as the treatment of the present invention, chemotherapy, radiotherapy, hormonal therapy, gene therapy, immunotherapy and/or alternative therapies.

Curative surgery includes resection in which all or part of cancerous tissue is physically removed, excised, and/or destroyed. Tumor resection refers to physical removal of at least part of a tumor. In addition to tumor resection, treatment by surgery includes laser surgery, cryosurgery, electrosurgery, and microscopically controlled surgery (Mohs' surgery). It is further contemplated that the present invention may be used in conjunction with removal of superficial cancers, precancers, or incidental amounts of normal tissue.

Upon excision of part of all of cancerous cells, tissue, or tumor, a cavity may be formed in the body. Treatment may be accomplished by perfusion, direct injection or local application of the area with an additional anti-cancer therapy. Such treatment may be repeated, for example, every 1, 2, 3, 4, 5, 6, or 7 days, or every 1, 2, 3, 4, and 5 weeks or every 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, or 12 months. These treatments may be of varying dosages as well.

6. Other Agents

It is contemplated that other agents may be used in combination with the present invention to improve the therapeutic efficacy of treatment. These additional agents include immunomodulatory agents, agents that affect the upregulation of cell surface receptors and GAP junctions, cytostatic and differentiation agents, inhibitors of cell adhesion, agents that increase the sensitivity of the hyperproliferative cells to apoptotic inducers, or other biological agents. Immunomodulatory agents include tumor necrosis factor; interferon alpha, beta, and gamma; IL-2 and other cytokines; F42K and other cytokine analogs; or MIP-1, MIP-1beta, MCP-1, RANTES, and other chemokines. It is further contemplated that the upregulation of cell surface receptors or their ligands such as Fas/Fas ligand, DR4 or DR5/TRAIL (Apo-2 ligand) would potentiate the apoptotic inducing abilities of the present invention by establishment of an autocrine or paracrine effect on hyperproliferative cells. Increases intercellular signaling by elevating the number of GAP junctions would increase the anti-hyperproliferative effects on the neighboring hyperproliferative cell population. In other embodiments, cytostatic or differentiation agents can be used in combination with the present invention to improve the anti-hyperproliferative efficacy of the treatments. Inhibitors of cell adhesion are contemplated to improve the efficacy of the present invention. Examples of cell adhesion inhibitors are focal adhesion kinase (FAKs) inhibitors and Lovastatin. It is further contemplated that other agents that increase the sensitivity of a hyperproliferative cell to apoptosis, such as the antibody c225, could be used in combination with the present invention to improve the treatment efficacy.

Apo2 ligand (Apo2L, also called TRAIL) is a member of the tumor necrosis factor (TNF) cytokine family. TRAIL activates rapid apoptosis in many types of cancer cells, yet is not toxic to normal cells. TRAIL mRNA occurs in a wide variety of tissues. Most normal cells appear to be resistant to TRAIL's cytotoxic action, suggesting the existence of mechanisms that can protect against apoptosis induction by TRAIL. The first receptor described for TRAIL, called death receptor 4 (DR4), contains a cytoplasmic “death domain”; DR4 transmits the apoptosis signal carried by TRAIL. Additional receptors have been identified that bind to TRAIL. One receptor, called DR5, contains a cytoplasmic death domain and signals apoptosis much like DR4. The DR4 and DR5 mRNAs are expressed in many normal tissues and tumor cell lines. Recently, decoy receptors such as DcR1 and DcR2 have been identified that prevent TRAIL from inducing apoptosis through DR4 and DR5. These decoy receptors thus represent a novel mechanism for regulating sensitivity to a pro-apoptotic cytokine directly at the cell's surface. The preferential expression of these inhibitory receptors in normal tissues suggests that TRAIL may be useful as an anticancer agent that induces apoptosis in cancer cells while sparing normal cells. (Marsters et al., 1999).

There have been many advances in the therapy of cancer following the introduction of cytotoxic chemotherapeutic drugs. However, one of the consequences of chemotherapy is the development/acquisition of drug-resistant phenotypes and the development of multiple drug resistance. The development of drug resistance remains a major obstacle in the treatment of such tumors and therefore, there is an obvious need for alternative approaches such as gene therapy.

Another form of therapy for use in conjunction with chemotherapy, radiation therapy or biological therapy includes hyperthermia, which is a procedure in which a patient's tissue is exposed to high temperatures (up to 106° F.). External or internal heating devices may be involved in the application of local, regional, or whole-body hyperthermia. Local hyperthermia involves the application of heat to a small area, such as a tumor. Heat may be generated externally with high-frequency waves targeting a tumor from a device outside the body. Internal heat may involve a sterile probe, including thin, heated wires or hollow tubes filled with warm water, implanted microwave antennae, or radiofrequency electrodes.

A patient's organ or a limb is heated for regional therapy, which is accomplished using devices that produce high energy, such as magnets. Alternatively, some of the patient's blood may be removed and heated before being perfused into an area that will be internally heated. Whole-body heating may also be implemented in cases where cancer has spread throughout the body. Warm-water blankets, hot wax, inductive coils, and thermal chambers may be used for this purpose.

Hormonal therapy may also be used in conjunction with the present invention or in combination with any other cancer therapy previously described. The use of hormones may be employed in the treatment of certain cancers such as breast, prostate, ovarian, or cervical cancer to lower the level or block the effects of certain hormones such as testosterone or estrogen. This treatment is often used in combination with at least one other cancer therapy as a treatment option or to reduce the risk of metastases.

This application incorporates U.S. application Ser. No. 11/349,727 filed on Feb. 8, 2006 claiming priority to U.S. Provisional Application Ser. No. 60/650,807 filed Feb. 8, 2005 herein by references in its entirety.

III. miRNA Molecules

MicroRNA molecules (“miRNAs”) are generally 21 to 22 nucleotides in length, though lengths of 19 and up to 23 nucleotides have been reported. The miRNAs are each processed from a longer precursor RNA molecule (“precursor miRNA”). Precursor miRNAs are transcribed from non-protein-encoding genes. The precursor miRNAs have two regions of complementarity that enables them to form a stem-loop- or fold-back-like structure, which is cleaved in animals by a ribonuclease III-like nuclease enzyme called Dicer. The processed miRNA is typically a portion of the stem.

The processed miRNA (also referred to as “mature miRNA”) becomes part of a large complex to down-regulate a particular target gene or its gene product. Examples of animal miRNAs include those that imperfectly basepair with the target, which halts translation (Olsen et al., 1999; Seggerson et al., 2002). siRNA molecules also are processed by Dicer, but from a long, double-stranded RNA molecule. siRNAs are not naturally found in animal cells, but they can direct the sequence-specific cleavage of an mRNA target through a RNA-induced silencing complex (RISC) (Denli et al., 2003).

A. Array Preparation

Certain embodiments of the present invention concerns the preparation and use of mRNA or nucleic acid arrays, miRNA or nucleic acid arrays, and/or miRNA or nucleic acid probe arrays, which are macroarrays or microarrays of nucleic acid molecules (probes) that are fully or nearly complementary (over the length of the prove) or identical (over the length of the prove) to a plurality of nucleic acid, mRNA or miRNA molecules, precursor miRNA molecules, or nucleic acids derived from the various genes and gene pathways modulated by miR-124 miRNAs and that are positioned on a support or support material in a spatially separated organization. Macroarrays are typically sheets of nitrocellulose or nylon upon which probes have been spotted. Microarrays position the nucleic acid probes more densely such that up to 10,000 nucleic acid molecules can be fit into a region typically 1 to 4 square centimeters. Microarrays can be fabricated by spotting nucleic acid molecules, e.g., genes, oligonucleotides, etc., onto substrates or fabricating oligonucleotide sequences in situ on a substrate. Spotted or fabricated nucleic acid molecules can be applied in a high density matrix pattern of up to about 30 non-identical nucleic acid molecules per square centimeter or higher, e.g. up to about 100 or even 1000 per square centimeter. Microarrays typically use coated glass as the solid support, in contrast to the nitrocellulose-based material of filter arrays. By having an ordered array of marker RNA and/or miRNA-complementing nucleic acid samples, the position of each sample can be tracked and linked to the original sample.

A variety of different array devices in which a plurality of distinct nucleic acid probes are stably associated with the surface of a solid support are known to those of skill in the art. Useful substrates for arrays include nylon, glass, metal, plastic, latex, and silicon. Such arrays may vary in a number of different ways, including average probe length, sequence or types of probes, nature of bond between the probe and the array surface, e.g. covalent or non-covalent, and the like. The labeling and screening methods of the present invention and the arrays are not limited in its utility with respect to any parameter except that the probes detect miRNA, or genes or nucleic acid representative of genes; consequently, methods and compositions may be used with a variety of different types of nucleic acid arrays.

Representative methods and apparatus for preparing a microarray have been described, for example, in U.S. Pat. Nos. 5,143,854; 5,202,231; 5,242,974; 5,288,644; 5,324,633; 5,384,261; 5,405,783; 5,412,087; 5,424,186; 5,429,807; 5,432,049; 5,436,327; 5,445,934; 5,468,613; 5,470,710; 5,472,672; 5,492,806; 5,525,464; 5,503,980; 5,510,270; 5,525,464; 5,527,681; 5,529,756; 5,532,128; 5,545,531; 5,547,839; 5,554,501; 5,556,752; 5,561,071; 5,571,639; 5,580,726; 5,580,732; 5,593,839; 5,599,695; 5,599,672; 5,610,287; 5,624,711; 5,631,134; 5,639,603; 5,654,413; 5,658,734; 5,661,028; 5,665,547; 5,667,972; 5,695,940; 5,700,637; 5,744,305; 5,800,992; 5,807,522; 5,830,645; 5,837,196; 5,871,928; 5,847,219; 5,876,932; 5,919,626; 6,004,755; 6,087,102; 6,368,799; 6,383,749; 6,617,112; 6,638,717; 6,720,138, as well as WO 93/17126; WO 95/11995; WO 95/21265; WO 95/21944; WO 95/35505; WO 96/31622; WO 97/10365; WO 97/27317; WO 99/35505; WO 09923256; WO 09936760; WO0138580; WO 0168255; WO 03020898; WO 03040410; WO 03053586; WO 03087297; WO 03091426; WO03100012; WO 04020085; WO 04027093; EP 373 203; EP 785 280; EP 799 897 and UK 8 803 000; the disclosures of which are all herein incorporated by reference.

It is contemplated that the arrays can be high density arrays, such that they contain 2, 20, 25, 50, 80, 100 or more different probes. It is contemplated that they may contain 1000, 16,000, 65,000, 250,000 or 1,000,000 or more different probes. The probes can be directed to mRNA and/or miRNA targets in one or more different organisms or cell types. The oligonucleotide probes range from 5 to 50, 5 to 45, 10 to 40, 9 to 34, or 15 to 40 nucleotides in length in some embodiments. In certain embodiments, the oligonucleotide probes are 5, 10, 15, to 20, 25, 30, 35, 40 nucleotides in length including all integers and ranges there between.

The location and sequence of each different probe sequence in the array are generally known. Moreover, the large number of different probes can occupy a relatively small area providing a high density array having a probe density of generally greater than about 60, 100, 600, 1000, 5,000, 10,000, 40,000, 100,000, or 400,000 different oligonucleotide probes per cm². The surface area of the array can be about or less than about 1, 1.6, 2, 3, 4, 5, 6, 7, 8, 9, or 10 cm².

Moreover, a person of ordinary skill in the art could readily analyze data generated using an array. Such protocols are disclosed above, and include information found in WO 9743450; WO 03023058; WO 03022421; WO 03029485; WO 03067217; WO 03066906; WO 03076928; WO 03093810; WO 03100448A1, all of which are specifically incorporated by reference.

B. Sample Preparation

It is contemplated that the RNA and/or miRNA of a wide variety of samples can be analyzed using the arrays, index of probes, or array technology of the invention. While endogenous miRNA is contemplated for use with compositions and methods of the invention, recombinant miRNA—including nucleic acids that are complementary or identical to endogenous miRNA or precursor miRNA—can also be handled and analyzed as described herein. Samples may be biological samples, in which case, they can be from biopsy, fine needle aspirates, exfoliates, blood, tissue, organs, semen, saliva, tears, other bodily fluid, hair follicles, skin, or any sample containing or constituting biological cells, particularly cancer or hyperproliferative cells. In certain embodiments, samples may be, but are not limited to, biopsy, or cells purified or enriched to some extent from a biopsy or other bodily fluids or tissues. Alternatively, the sample may not be a biological sample, but be a chemical mixture, such as a cell-free reaction mixture (which may contain one or more biological enzymes).

C. Hybridization

After an array or a set of probes is prepared and/or the nucleic acid in the sample or probe is labeled, the population of target nucleic acids is contacted with the array or probes under hybridization conditions, where such conditions can be adjusted, as desired, to provide for an optimum level of specificity in view of the particular assay being performed. Suitable hybridization conditions are well known to those of skill in the art and reviewed in Sambrook et al. (2001) and WO 95/21944. Of particular interest in many embodiments is the use of stringent conditions during hybridization. Stringent conditions are known to those of skill in the art.

It is specifically contemplated that a single array or set of probes may be contacted with multiple samples. The samples may be labeled with different labels to distinguish the samples. For example, a single array can be contacted with a tumor tissue sample labeled with Cy3, and normal tissue sample labeled with Cy5. Differences between the samples for particular miRNAs corresponding to probes on the array can be readily ascertained and quantified.

The small surface area of the array permits uniform hybridization conditions, such as temperature regulation and salt content. Moreover, because of the small area occupied by the high density arrays, hybridization may be carried out in extremely small fluid volumes (e.g., about 250 μl or less, including volumes of about or less than about 5, 10, 25, 50, 60, 70, 80, 90, 100 μl, or any range derivable therein). In small volumes, hybridization may proceed very rapidly.

D. Differential Expression Analyses

Arrays of the invention can be used to detect differences between two samples. Specifically contemplated applications include identifying and/or quantifying differences between miRNA or gene expression from a sample that is normal and from a sample that is not normal, between a disease or condition and a cell not exhibiting such a disease or condition, or between two differently treated samples. Also, miRNA or gene expression may be compared between a sample believed to be susceptible to a particular disease or condition and one believed to be not susceptible or resistant to that disease or condition. A sample that is not normal is one exhibiting phenotypic or genotypic trait(s) of a disease or condition, or one believed to be not normal with respect to that disease or condition. It may be compared to a cell that is normal with respect to that disease or condition. Phenotypic traits include symptoms of, or susceptibility to, a disease or condition of which a component is or may or may not be genetic, or caused by a hyperproliferative or neoplastic cell or cells.

An array comprises a solid support with nucleic acid probes attached to the support. Arrays typically comprise a plurality of different nucleic acid probes that are coupled to a surface of a substrate in different, known locations. These arrays, also described as “microarrays” or colloquially “chips” have been generally described in the art, for example, U.S. Pat. Nos. 5,143,854, 5,445,934, 5,744,305, 5,677,195, 6,040,193, 5,424,186 and Fodor et al., (1991), each of which is incorporated by reference in its entirety for all purposes. Techniques for the synthesis of these arrays using mechanical synthesis methods are described in, e.g., U.S. Pat. No. 5,384,261, incorporated herein by reference in its entirety for all purposes. Although a planar array surface is used in certain aspects, the array may be fabricated on a surface of virtually any shape or even a multiplicity of surfaces. Arrays may be nucleic acids on beads, gels, polymeric surfaces, fibers such as fiber optics, glass or any other appropriate substrate, see U.S. Pat. Nos. 5,770,358, 5,789,162, 5,708,153, 6,040,193 and 5,800,992, which are hereby incorporated in their entirety for all purposes. Arrays may be packaged in such a manner as to allow for diagnostics or other manipulation of an all inclusive device, see for example, U.S. Pat. Nos. 5,856,174 and 5,922,591 incorporated in their entirety by reference for all purposes. See also U.S. patent application Ser. No. 09/545,207, filed Apr. 7, 2000 for additional information concerning arrays, their manufacture, and their characteristics, which is incorporated by reference in its entirety for all purposes.

Particularly, arrays can be used to evaluate samples with respect to pathological condition such as cancer and related conditions. It is specifically contemplated that the invention can be used to evaluate differences between stages or sub-classifications of disease, such as between benign, cancerous, and metastatic tissues or tumors.

Phenotypic traits to be assessed include characteristics such as longevity, morbidity, expected survival, susceptibility or receptivity to particular drugs or therapeutic treatments (drug efficacy), and risk of drug toxicity. Samples that differ in these phenotypic traits may also be evaluated using the compositions and methods described.

In certain embodiments, miRNA and/or expression profiles may be generated to evaluate and correlate those profiles with pharmacokinetics or therapies. For example, these profiles may be created and evaluated for patient tumor and blood samples prior to the patient's being treated or during treatment to determine if there are miRNA or genes whose expression correlates with the outcome of the patient's treatment. Identification of differential miRNAs or genes can lead to a diagnostic assay for evaluation of tumor and/or blood samples to determine what drug regimen the patient should be provided. In addition, it can be used to identify or select patients suitable for a particular clinical trial. If an expression profile is determined to be correlated with drug efficacy or drug toxicity, that profile is relevant to whether that patient is an appropriate patient for receiving a drug, for receiving a combination of drugs, or for a particular dosage of the drug.

In addition to the above prognostic assay, samples from patients with a variety of diseases can be evaluated to determine if different diseases can be identified based on miRNA and/or related gene expression levels. A diagnostic assay can be created based on the profiles that doctors can use to identify individuals with a disease or who are at risk to develop a disease. Alternatively, treatments can be designed based on miRNA profiling. Examples of such methods and compositions are described in the U.S. Provisional Patent Application entitled “Methods and Compositions Involving miRNA and miRNA Inhibitor Molecules” filed on May 23, 2005 in the names of David Brown, Lance Ford, Angie Cheng and Rich Jarvis, which is hereby incorporated by reference in its entirety.

E. Other Assays

In addition to the use of arrays and microarrays, it is contemplated that a number of different assays could be employed to analyze miRNAs or related genes, their activities, and their effects. Such assays include, but are not limited to, nucleic acid amplification, polymerase chain reaction, quantitative PCR, RT-PCR, in situ hybridization, Northern hybridization, hybridization protection assay (HPA) (GenProbe), branched DNA (bDNA) assay (Chiron), rolling circle amplification (RCA), single molecule hybridization detection (US Genomics), Invader assay (ThirdWave Technologies), and/or Bridge Litigation Assay (Genaco).

IV. NUCLEIC ACIDS

The present invention concerns nucleic acids, modified or mimetic nucleic acids, miRNAs, mRNAs, genes, and representative fragments thereof that can be labeled, used in array analysis, or employed in diagnostic, therapeutic, or prognostic applications, particularly those related to pathological conditions such as cancer. The molecules may have been endogenously produced by a cell, or been synthesized or produced chemically or recombinantly. They may be isolated and/or purified. Each of the miRNAs described herein and includes the corresponding SEQ ID NO and accession numbers for these miRNA sequences. The name of a miRNA is often abbreviated and referred to without a “hsa-” prefix and will be understood as such, depending on the context. Unless otherwise indicated, miRNAs referred to in the application are human sequences identified as miR-X or let-X, where X is a number and/or letter.

In certain aspects, a miRNA probe designated by a suffix “5P” or “3P” can be used. “5P” indicates that the mature miRNA derives from the 5′ end of the precursor and a corresponding “3P” indicates that it derives from the 3′ end of the precursor, as described on the world wide web at sanger.ac.uk. Moreover, in some embodiments, a miRNA probe is used that does not correspond to a known human miRNA. It is contemplated that these non-human miRNA probes may be used in embodiments of the invention or that there may exist a human miRNA that is homologous to the non-human miRNA. In other embodiments, any mammalian cell, biological sample, or preparation thereof may be employed.

In some embodiments of the invention, methods and compositions involving miRNA may concern miRNA, markers (mRNAs), and/or other nucleic acids. Nucleic acids may be, be at least, or be at most 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 nucleotides, or any range derivable therein, in length. Such lengths cover the lengths of processed miRNA, miRNA probes, precursor miRNA, miRNA containing vectors, mRNA, mRNA probes, control nucleic acids, and other probes and primers.

In many embodiments, miRNA are 19-24 nucleotides in length, while miRNA probes are 19-35 nucleotides in length, depending on the length of the processed miRNA and any flanking regions added. miRNA precursors are generally between 62 and 110 nucleotides in humans.

Nucleic acids of the invention may have regions of identity or complementarity to another nucleic acid. It is contemplated that the region of complementarity or identity can be at least 5 contiguous residues, though it is specifically contemplated that the region is, is at least, or is at most 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 100, 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 441, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800, 810, 820, 830, 840, 850, 860, 870, 880, 890, 900, 910, 920, 930, 940, 950, 960, 970, 980, 990, or 1000 contiguous nucleotides. It is further understood that the length of complementarity within a precursor miRNA or other nucleic acid or between a miRNA probe and a miRNA or a miRNA gene are such lengths. Moreover, the complementarity may be expressed as a percentage, meaning that the complementarity between a probe and its target is 90% or greater over the length of the probe. In some embodiments, complementarity is or is at least 90%, 95% or 100%. In particular, such lengths may be applied to any nucleic acid comprising a nucleic acid sequence identified in any of SEQ ID NOs described herein, accession number, or any other sequence disclosed herein. Typically, the commonly used name of the miRNA is given (with its identifying source in the prefix, for example, “hsa” for human sequences) and the processed miRNA sequence. Unless otherwise indicated, a miRNA without a prefix will be understood to refer to a human miRNA. Moreover, a lowercase letter in a miRNA name may or may not be lowercase; for example, hsa-mir-130b can also be referred to as miR-130B. The term “miRNA probe” refers to a nucleic acid probe that can identify a particular miRNA or structurally related miRNAs.

It is understood that some nucleic acids are derived from genomic sequences or a gene. In this respect, the term “gene” is used for simplicity to refer to the genomic sequence encoding the precursor nucleic acid or miRNA for a given miRNA or gene. However, embodiments of the invention may involve genomic sequences of a miRNA that are involved in its expression, such as a promoter or other regulatory sequences.

The term “recombinant” may be used and this generally refers to a molecule that has been manipulated in vitro or that is a replicated or expressed product of such a molecule.

The term “nucleic acid” is well known in the art. A “nucleic acid” as used herein will generally refer to a molecule (one or more strands) of DNA, RNA or a derivative or analog thereof, comprising a nucleobase. A nucleobase includes, for example, a naturally occurring purine or pyrimidine base found in DNA (e.g., an adenine “A,” a guanine “G,” a thymine “T” or a cytosine “C”) or RNA (e.g., an A, a G, an uracil “U” or a C). The term “nucleic acid” encompasses the terms “oligonucleotide” and “polynucleotide,” each as a subgenus of the term “nucleic acid.”

The term “miRNA” generally refers to a single-stranded molecule, but in specific embodiments, molecules implemented in the invention will also encompass a region or an additional strand that is partially (between 10 and 50% complementary across length of strand), substantially (greater than 50% but less than 100% complementary across length of strand) or fully complementary to another region of the same single-stranded molecule or to another nucleic acid. Thus, nucleic acids of the invention may encompass a molecule that comprises one or more complementary or self-complementary strand(s) or “complement(s)” of a particular sequence. For example, precursor miRNA may have a self-complementary region, which is up to 100% complementary. miRNA probes or nucleic acids of the invention can include, can be or can be at least 60, 65, 70, 75, 80, 85, 90, 95, 96, 97, 98, 99 or 100% complementary to their target.

It is understood that a “synthetic nucleic acid” of the invention means that the nucleic acid does not have all or part of a chemical structure or sequence of a naturally occurring nucleic acid. Consequently, it will be understood that the term “synthetic miRNA” refers to a “synthetic nucleic acid” that functions in a cell or under physiological conditions as a naturally occurring miRNA.

While embodiments of the invention may involve synthetic miRNAs or synthetic nucleic acids, in some embodiments of the invention, the nucleic acid molecule(s) need not be “synthetic.” In certain embodiments, a non-synthetic nucleic acid or miRNA employed in methods and compositions of the invention may have the entire sequence and structure of a naturally occurring mRNA or miRNA precursor or the mature mRNA or miRNA. For example, non-synthetic miRNAs used in methods and compositions of the invention may not have one or more modified nucleotides or nucleotide analogs. In these embodiments, the non-synthetic miRNA may or may not be recombinantly produced. In particular embodiments, the nucleic acid in methods and/or compositions of the invention is specifically a synthetic miRNA and not a non-synthetic miRNA (that is, not a miRNA that qualifies as “synthetic”); though in other embodiments, the invention specifically involves a non-synthetic miRNA and not a synthetic miRNA. Any embodiments discussed with respect to the use of synthetic miRNAs can be applied with respect to non-synthetic miRNAs, and vice versa.

It will be understood that the term “naturally occurring” refers to something found in an organism without any intervention by a person; it could refer to a naturally-occurring wildtype or mutant molecule. In some embodiments a synthetic miRNA molecule does not have the sequence of a naturally occurring miRNA molecule. In other embodiments, a synthetic miRNA molecule may have the sequence of a naturally occurring miRNA molecule, but the chemical structure of the molecule, particularly in the part unrelated specifically to the precise sequence (non-sequence chemical structure) differs from chemical structure of the naturally occurring miRNA molecule with that sequence. In some cases, the synthetic miRNA has both a sequence and non-sequence chemical structure that are not found in a naturally-occurring miRNA. Moreover, the sequence of the synthetic molecules will identify which miRNA is effectively being provided or inhibited; the endogenous miRNA will be referred to as the “corresponding miRNA.” Corresponding miRNA sequences that can be used in the context of the invention include, but are not limited to, all or a portion of those sequences in the SEQ IDs provided herein, as well as any other miRNA sequence, miRNA precursor sequence, or any sequence complementary thereof. In some embodiments, the sequence is or is derived from or contains all or part of a sequence identified herein to target a particular miRNA (or set of miRNAs) that can be used with that sequence. Any 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260 or any number or range of sequences there between may be selected to the exclusion of all non-selected sequences.

As used herein, “hybridization”, “hybridizes” or “capable of hybridizing” is understood to mean the forming of a double or triple stranded molecule or a molecule with partial double or triple stranded nature. The term “anneal” as used herein is synonymous with “hybridize.” The term “hybridization”, “hybridize(s)” or “capable of hybridizing” encompasses the terms “stringent condition(s)” or “high stringency” and the terms “low stringency” or “low stringency condition(s).”

As used herein “stringent condition(s)” or “high stringency” are those conditions that allow hybridization between or within one or more nucleic acid strand(s) containing complementary sequence(s), but preclude hybridization of random sequences. Stringent conditions tolerate little, if any, mismatch between a nucleic acid and a target strand. Such conditions are well known to those of ordinary skill in the art, and are preferred for applications requiring high selectivity. Non-limiting applications include isolating a nucleic acid, such as a gene or a nucleic acid segment thereof, or detecting at least one specific mRNA transcript or a nucleic acid segment thereof, and the like.

Stringent conditions may comprise low salt and/or high temperature conditions, such as provided by about 0.02 M to about 0.5 M NaCl at temperatures of about 42° C. to about 70° C. It is understood that the temperature and ionic strength of a desired stringency are determined in part by the length of the particular nucleic acid(s), the length and nucleobase content of the target sequence(s), the charge composition of the nucleic acid(s), and to the presence or concentration of formamide, tetramethylammonium chloride or other solvent(s) in a hybridization mixture.

It is also understood that these ranges, compositions and conditions for hybridization are mentioned by way of non-limiting examples only, and that the desired stringency for a particular hybridization reaction is often determined empirically by comparison to one or more positive or negative controls. Depending on the application envisioned it is preferred to employ varying conditions of hybridization to achieve varying degrees of selectivity of a nucleic acid towards a target sequence. In a non-limiting example, identification or isolation of a related target nucleic acid that does not hybridize to a nucleic acid under stringent conditions may be achieved by hybridization at low temperature and/or high ionic strength. Such conditions are termed “low stringency” or “low stringency conditions,” and non-limiting examples of low stringency include hybridization performed at about 0.15 M to about 0.9 M NaCl at a temperature range of about 20° C. to about 50° C. Of course, it is within the skill of one in the art to further modify the low or high stringency conditions to suite a particular application.

A. Nucleobase, Nucleoside, Nucleotide, and Modified Nucleotides

As used herein a “nucleobase” refers to a heterocyclic base, such as for example a naturally occurring nucleobase (i.e., an A, T, G, C or U) found in at least one naturally occurring nucleic acid (i.e., DNA and RNA), and naturally or non-naturally occurring derivative(s) and analogs of such a nucleobase. A nucleobase generally can form one or more hydrogen bonds (“anneal” or “hybridize”) with at least one naturally occurring nucleobase in a manner that may substitute for naturally occurring nucleobase pairing (e.g., the hydrogen bonding between A and T, Gand C, and Aand U).

“Purine” and/or “pyrimidine” nucleobase(s) encompass naturally occurring purine and/or pyrimidine nucleobases and also derivative(s) and analog(s) thereof, including but not limited to, those a purine or pyrimidine substituted by one or more of an alkyl, carboxyalkyl, amino, hydroxyl, halogen (i.e., fluoro, chloro, bromo, or iodo), thiol or alkylthiol moiety. Preferred alkyl (e.g., alkyl, carboxyalkyl, etc.) moieties comprise of from about 1, about 2, about 3, about 4, about 5, to about 6 carbon atoms. Other non-limiting examples of a purine or pyrimidine include a deazapurine, a 2,6-diaminopurine, a 5-fluorouracil, a xanthine, a hypoxanthine, a 8-bromoguanine, a 8-chloroguanine, a bromothymine, a 8-aminoguanine, a 8-hydroxyguanine, a 8-methylguanine, a 8-thioguanine, an azaguanine, a 2-aminopurine, a 5-ethylcytosine, a 5-methylcyosine, a 5-bromouracil, a 5-ethyluracil, a 5-iodouracil, a 5-chlorouracil, a 5-propyluracil, a thiouracil, a 2-methyladenine, a methylthioadenine, a N,N-dimethyladenine, an azaadenines, a 8-bromoadenine, a 8-hydroxyadenine, a 6-hydroxyaminopurine, a 6-thiopurine, a 4-(6-aminohexyl/cytosine), and the like. Other examples are well known to those of skill in the art.

As used herein, a “nucleoside” refers to an individual chemical unit comprising a nucleobase covalently attached to a nucleobase linker moiety. A non-limiting example of a “nucleobase linker moiety” is a sugar comprising 5-carbon atoms (i.e., a “5-carbon sugar”), including but not limited to a deoxyribose, a ribose, an arabinose, or a derivative or an analog of a 5-carbon sugar. Non-limiting examples of a derivative or an analog of a 5-carbon sugar include a 2′-fluoro-2′-deoxyribose or a carbocyclic sugar where a carbon is substituted for an oxygen atom in the sugar ring. Different types of covalent attachment(s) of a nucleobase to a nucleobase linker moiety are known in the art (Kornberg and Baker, 1992).

As used herein, a “nucleotide” refers to a nucleoside further comprising a “backbone moiety”. A backbone moiety generally covalently attaches a nucleotide to another molecule comprising a nucleotide, or to another nucleotide to form a nucleic acid. The “backbone moiety” in naturally occurring nucleotides typically comprises a phosphorus moiety, which is covalently attached to a 5-carbon sugar. The attachment of the backbone moiety typically occurs at either the 3′- or 5′-position of the 5-carbon sugar. However, other types of attachments are known in the art, particularly when a nucleotide comprises derivatives or analogs of a naturally occurring 5-carbon sugar or phosphorus moiety.

A nucleic acid may comprise, or be composed entirely of, a derivative or analog of a nucleobase, a nucleobase linker moiety and/or backbone moiety that may be present in a naturally occurring nucleic acid. RNA with nucleic acid analogs may also be labeled according to methods of the invention. As used herein a “derivative” refers to a chemically modified or altered form of a naturally occurring molecule, while the terms “mimic” or “analog” refer to a molecule that may or may not structurally resemble a naturally occurring molecule or moiety, but possesses similar functions. As used herein, a “moiety” generally refers to a smaller chemical or molecular component of a larger chemical or molecular structure. Nucleobase, nucleoside and nucleotide analogs or derivatives are well known in the art, and have been described (see for example, Scheit, 1980, incorporated herein by reference).

Additional non-limiting examples of nucleosides, nucleotides or nucleic acids include

those in: U.S. Pat. Nos. 5,681,947, 5,652,099 and 5,763,167, 5,614,617, 5,670,663, 5,872,232, 5,859,221, 5,446,137, 5,886,165, 5,714,606, 5,672,697, 5,466,786, 5,792,847, 5,223,618, 5,470,967, 5,378,825, 5,777,092, 5,623,070, 5,610,289, 5,602,240, 5,858,988, 5,214,136, 5,700,922, 5,708,154, 5,728,525, 5,637,683, 6,251,666, 5,480,980, and 5,728,525, each of which is incorporated herein by reference in its entirety.

Labeling methods and kits of the invention specifically contemplate the use of nucleotides that are both modified for attachment of a label and can be incorporated into a miRNA molecule. Such nucleotides include those that can be labeled with a dye, including a fluorescent dye, or with a molecule such as biotin. Labeled nucleotides are readily available; they can be acquired commercially or they can be synthesized by reactions known to those of skill in the art.

Modified nucleotides for use in the invention are not naturally occurring nucleotides, but instead, refer to prepared nucleotides that have a reactive moiety on them. Specific reactive functionalities of interest include: amino, sulfhydryl, sulfoxyl, aminosulfhydryl, azido, epoxide, isothiocyanate, isocyanate, anhydride, monochlorotriazine, dichlorotriazine, mono- or dihalogen substituted pyridine, mono- or disubstituted diazine, maleimide, epoxide, aziridine, sulfonyl halide, acid halide, alkyl halide, aryl halide, alkylsulfonate, N-hydroxysuccinimide ester, imido ester, hydrazine, azidonitrophenyl, azide, 3-(2-pyridyl dithio)-propionamide, glyoxal, aldehyde, iodoacetyl, cyanomethyl ester, p-nitrophenyl ester, o-nitrophenyl ester, hydroxypyridine ester, carbonyl imidazole, and the other such chemical groups. In some embodiments, the reactive functionality may be bonded directly to a nucleotide, or it may be bonded to the nucleotide through a linking group. The functional moiety and any linker cannot substantially impair the ability of the nucleotide to be added to the miRNA or to be labeled. Representative linking groups include carbon containing linking groups, typically ranging from about 2 to 18, usually from about 2 to 8 carbon atoms, where the carbon containing linking groups may or may not include one or more heteroatoms, e.g. S, O, N etc., and may or may not include one or more sites of unsaturation. Of particular interest in many embodiments is alkyl linking groups, typically lower alkyl linking groups of 1 to 16, usually 1 to 4 carbon atoms, where the linking groups may include one or more sites of unsaturation. The functionalized nucleotides (or primers) used in the above methods of functionalized target generation may be fabricated using known protocols or purchased from commercial vendors, e.g., Sigma, Roche, Ambion, Biosearch Technologies and NEN. Functional groups may be prepared according to ways known to those of skill in the art, including the representative information found in U.S. Pat. Nos. 4,404,289; 4,405,711; 4,337,063 and 5,268,486, and U.K. Patent 1,529,202, which are all incorporated by reference.

Amine-modified nucleotides are used in several embodiments of the invention. The amine-modified nucleotide is a nucleotide that has a reactive amine group for attachment of the label. It is contemplated that any ribonucleotide (G, A, U, or C) or deoxyribonucleotide (G, A, T, or C) can be modified for labeling. Examples include, but are not limited to, the following modified ribo- and deoxyribo-nucleotides: 5-(3-aminoallyl)-UTP; 8-[(4-amino)butyl]-amino-ATP and 8-[(6-amino)butyl]-amino-ATP; N6-(4-amino)butyl-ATP, N6-(6-amino)butyl-ATP, N4-[2,2-oxy-bis-(ethylamine)]-CTP; N6-(6-Amino)hexyl-ATP; 8-[(6-Amino)hexyl]-amino-ATP; 5-propargylamino-CTP, 5-propargylamino-UTP; 5-(3-aminoallyl)-dUTP; 8-[(4-amino)butyl]-amino-dATP and 8-[(6-amino)butyl]-amino-dATP; N6-(4-amino)butyl-dATP, N6-(6-amino)butyl-dATP, N4-[2,2-oxy-bis-(ethylamine)]-dCTP; N6-(6-Amino)hexyl-dATP; 8-[(6-Amino)hexyl]-amino-dATP; 5-propargylamino-dCTP, and 5-propargylamino-dUTP. Such nucleotides can be prepared according to methods known to those of skill in the art. Moreover, a person of ordinary skill in the art could prepare other nucleotide entities with the same amine-modification, such as a 5-(3-aminoallyl)-CTP, GTP, ATP, dCTP, dGTP, dTTP, or dUTP in place of a 5-(3-aminoallyl)-UTP.

B. Preparation of Nucleic Acids

A nucleic acid may be made by any technique known to one of ordinary skill in the art, such as for example, chemical synthesis, enzymatic production, or biological production. It is specifically contemplated that miRNA probes of the invention are chemically synthesized.

In some embodiments of the invention, miRNAs are recovered or isolated from a biological sample. The miRNA may be recombinant or it may be natural or endogenous to the cell (produced from the cell's genome). It is contemplated that a biological sample may be treated in a way so as to enhance the recovery of small RNA molecules such as miRNA. U.S. patent application Ser. No. 10/667,126 describes such methods and it is specifically incorporated by reference herein. Generally, methods involve lysing cells with a solution having guanidinium and a detergent.

Alternatively, nucleic acid synthesis is performed according to standard methods. See, for example, Itakura and Riggs (1980) and U.S. Pat. Nos. 4,704,362, 5,221,619, and 5,583,013, each of which is incorporated herein by reference. Non-limiting examples of a synthetic nucleic acid (e.g., a synthetic oligonucleotide), include a nucleic acid made by in vitro chemically synthesis using phosphotriester, phosphite, or phosphoramidite chemistry and solid phase techniques such as described in EP 266,032, incorporated herein by reference, or via deoxynucleoside H-phosphonate intermediates as described by Froehler et al., 1986 and U.S. Pat. No. 5,705,629, each incorporated herein by reference. Various different mechanisms of oligonucleotide synthesis have been disclosed in for example, U.S. Pat. Nos. 4,659,774, 4,816,571, 5,141,813, 5,264,566, 4,959,463, 5,428,148, 5,554,744, 5,574,146, 5,602,244, each of which is incorporated herein by reference.

A non-limiting example of an enzymatically produced nucleic acid include one produced by enzymes in amplification reactions such as PCR™ (see for example, U.S. Pat. Nos. 4,683,202 and 4,682,195, each incorporated herein by reference), or the synthesis of an oligonucleotide described in U.S. Pat. No. 5,645,897, incorporated herein by reference. See also Sambrook et al., 2001, incorporated herein by reference).

Oligonucleotide synthesis is well known to those of skill in the art. Various different mechanisms of oligonucleotide synthesis have been disclosed in for example, U.S. Pat. Nos. 4,659,774, 4,816,571, 5,141,813, 5,264,566, 4,959,463, 5,428,148, 5,554,744, 5,574,146, 5,602,244, each of which is incorporated herein by reference.

Recombinant methods for producing nucleic acids in a cell are well known to those of skill in the art. These include the use of vectors (viral and non-viral), plasmids, cosmids, and other vehicles for delivering a nucleic acid to a cell, which may be the target cell (e.g., a cancer cell) or simply a host cell (to produce large quantities of the desired RNA molecule). Alternatively, such vehicles can be used in the context of a cell free system so long as the reagents for generating the RNA molecule are present. Such methods include those described in Sambrook, 2003, Sambrook, 2001 and Sambrook, 1989, which are hereby incorporated by reference.

C. Isolation of Nucleic Acids

Nucleic acids may be isolated using techniques well known to those of skill in the art, though in particular embodiments, methods for isolating small nucleic acid molecules, and/or isolating RNA molecules can be employed. Chromatography is a process often used to separate or isolate nucleic acids from protein or from other nucleic acids. Such methods can involve electrophoresis with a gel matrix, filter columns, alcohol precipitation, and/or other chromatography. If miRNA from cells is to be used or evaluated, methods generally involve lysing the cells with a chaotropic (e.g., guanidinium isothiocyanate) and/or detergent (e.g., N-lauroyl sarcosine) prior to implementing processes for isolating particular populations of RNA.

In particular methods for separating miRNA from other nucleic acids, a gel matrix is prepared using polyacrylamide, though agarose can also be used. The gels may be graded by concentration or they may be uniform. Plates or tubing can be used to hold the gel matrix for electrophoresis. Usually one-dimensional electrophoresis is employed for the separation of nucleic acids. Plates are used to prepare a slab gel, while the tubing (glass or rubber, typically) can be used to prepare a tube gel. The phrase “tube electrophoresis” refers to the use of a tube or tubing, instead of plates, to form the gel. Materials for implementing tube electrophoresis can be readily prepared by a person of skill in the art or purchased, such as from C.B.S. Scientific Co., Inc. or Scie-Plas.

Methods may involve the use of organic solvents and/or alcohol to isolate nucleic acids, particularly miRNA used in methods and compositions of the invention. Some embodiments are described in U.S. patent application Ser. No. 10/667,126, which is hereby incorporated by reference. Generally, this disclosure provides methods for efficiently isolating small RNA molecules from cells comprising: adding an alcohol solution to a cell lysate and applying the alcohol/lysate mixture to a solid support before eluting the RNA molecules from the solid support. In some embodiments, the amount of alcohol added to a cell lysate achieves an alcohol concentration of about 55% to 60%. While different alcohols can be employed, ethanol works well. A solid support may be any structure, and it includes beads, filters, and columns, which may include a mineral or polymer support with electronegative groups. A glass fiber filter or column has worked particularly well for such isolation procedures.

In specific embodiments, miRNA isolation processes include: a) lysing cells in the sample with a lysing solution comprising guanidinium, wherein a lysate with a concentration of at least about 1 M guanidinium is produced; b) extracting miRNA molecules from the lysate with an extraction solution comprising phenol; c) adding to the lysate an alcohol solution for forming a lysate/alcohol mixture, wherein the concentration of alcohol in the mixture is between about 35% to about 70%; d) applying the lysate/alcohol mixture to a solid support; e) eluting the miRNA molecules from the solid support with an ionic solution; and, f) capturing the miRNA molecules. Typically the sample is dried and resuspended in a liquid and volume appropriate for subsequent manipulation.

V. Labels and Labeling Techniques

In some embodiments, the present invention concerns miRNA that are labeled. It is contemplated that miRNA may first be isolated and/or purified prior to labeling. This may achieve a reaction that more efficiently labels the miRNA, as opposed to other RNA in a sample in which the miRNA is not isolated or purified prior to labeling. In many embodiments of the invention, the label is non-radioactive. Generally, nucleic acids may be labeled by adding labeled nucleotides (one-step process) or adding nucleotides and labeling the added nucleotides (two-step process).

A. Labeling Techniques

In some embodiments, nucleic acids are labeled by catalytically adding to the nucleic acid an already labeled nucleotide or nucleotides. One or more labeled nucleotides can be added to miRNA molecules. See U.S. Pat. No. 6,723,509, which is hereby incorporated by reference.

In other embodiments, an unlabeled nucleotide or nucleotides is catalytically added to a miRNA, and the unlabeled nucleotide is modified with a chemical moiety that enables it to be subsequently labeled. In embodiments of the invention, the chemical moiety is a reactive amine such that the nucleotide is an amine-modified nucleotide. Examples of amine-modified nucleotides are well known to those of skill in the art, many being commercially available such as from Ambion, Sigma, Jena Bioscience, and TriLink.

In contrast to labeling of cDNA during its synthesis, the issue for labeling miRNA is how to label the already existing molecule. The present invention concerns the use of an enzyme capable of using a di- or tri-phosphate ribonucleotide or deoxyribonucleotide as a substrate for its addition to a miRNA. Moreover, in specific embodiments, it involves using a modified di- or tri-phosphate ribonucleotide, which is added to the 3′ end of a miRNA. Enzymes capable of adding such nucleotides include, but are not limited to, poly (A) polymerase, terminal transferase, and polynucleotide phosphorylase. In specific embodiments of the invention, a ligase is contemplated as not being the enzyme used to add the label, and instead, a non-ligase enzyme is employed. Terminal transferase catalyzes the addition of nucleotides to the 3′ terminus of a nucleic acid. Polynucleotide phosphorylase can polymerize nucleotide diphosphates without the need for a primer.

B. Labels

Labels on miRNA or miRNA probes may be colorimetric (includes visible and UV spectrum, including fluorescent), luminescent, enzymatic, or positron emitting (including radioactive). The label may be detected directly or indirectly. Radioactive labels include ¹²⁵I, ³²P, ³³P, and ³⁵S. Examples of enzymatic labels include alkaline phosphatase, luciferase, horseradish peroxidase, and β-galactosidase. Labels can also be proteins with luminescent properties, e.g., green fluorescent protein and phycoerythrin.

The colorimetric and fluorescent labels contemplated for use as conjugates include, but are not limited to, Alexa Fluor dyes, BODIPY dyes, such as BODIPY FL; Cascade Blue; Cascade Yellow; coumarin and its derivatives, such as 7-amino-4-methylcoumarin, aminocoumarin and hydroxycoumarin; cyanine dyes, such as Cy3 and Cy5; eosins and erythrosins; fluorescein and its derivatives, such as fluorescein isothiocyanate; macrocyclic chelates of lanthanide ions, such as Quantum Dye™; Marina Blue; Oregon Green; rhodamine dyes, such as rhodamine red, tetramethylrhodamine and rhodamine 6G; Texas Red; fluorescent energy transfer dyes, such as thiazole orange-ethidium heterodimer; and, TOTAB.

Specific examples of dyes include, but are not limited to, those identified above and the following: Alexa Fluor 350, Alexa Fluor 405, Alexa Fluor 430, Alexa Fluor 488, Alexa Fluor 500, Alexa Fluor 514, Alexa Fluor 532, Alexa Fluor 546, Alexa Fluor 555, Alexa Fluor 568, Alexa Fluor 594, Alexa Fluor 610, Alexa Fluor 633, Alexa Fluor 647, Alexa Fluor 660, Alexa Fluor 680, Alexa Fluor 700, and, Alexa Fluor 750; amine-reactive BODIPY dyes, such as BODIPY 493/503, BODIPY 530/550, BODIPY 558/568, BODIPY 564/570, BODIPY 576/589, BODIPY 581/591, BODIPY 630/650, BODIPY 650/655, BODIPY FL, BODIPY R6G, BODIPY TMR, and, BODIPY-TR; Cy3, Cy5,6-FAM, Fluorescein Isothiocyanate, HEX, 6-JOE, Oregon Green 488, Oregon Green 500, Oregon Green 514, Pacific Blue, REG, Rhodamine Green, Rhodamine Red, Renographin, ROX, SYPRO, TAMRA, 2′,4′,5′,7′-Tetrabromosulfonefluorescein, and TET.

Specific examples of fluorescently labeled ribonucleotides are available from Molecular Probes, and these include, Alexa Fluor 488-5-UTP, Fluorescein-12-UTP, BODIPY FL-14-UTP, BODIPY TMR-14-UTP, Tetramethylrhodamine-6-UTP, Alexa Fluor 546-14-UTP, Texas Red-5-UTP, and BODIPY TR-14-UTP. Other fluorescent ribonucleotides are available from Amersham Biosciences, such as Cy3-UTP and Cy5-UTP.

Examples of fluorescently labeled deoxyribonucleotides include Dinitrophenyl (DNP)-11-dUTP, Cascade Blue-7-dUTP, Alexa Fluor 488-5-dUTP, Fluorescein-12-dUTP, Oregon Green 488-5-dUTP, BODIPY FL-14-dUTP, Rhodamine Green-5-dUTP, Alexa Fluor 532-5-dUTP, BODIPY TMR-14-dUTP, Tetramethylrhodamine-6-dUTP, Alexa Fluor 546-14-dUTP, Alexa Fluor 568-5-dUTP, Texas Red-12-dUTP, Texas Red-5-dUTP, BODIPY TR-14-dUTP, Alexa Fluor 594-5-dUTP, BODIPY 630/650-14-dUTP, BODIPY 650/665-14-dUTP; Alexa Fluor 488-7-OBEA-dCTP, Alexa Fluor 546-16-OBEA-dCTP, Alexa Fluor 594-7-OBEA-dCTP, Alexa Fluor 647-12-OBEA-dCTP.

It is contemplated that nucleic acids may be labeled with two different labels. Furthermore, fluorescence resonance energy transfer (FRET) may be employed in methods of the invention (e.g., Klostermeier et al., 2002; Emptage, 2001; Didenko, 2001, each incorporated by reference).

Alternatively, the label may not be detectable per se, but indirectly detectable or allowing for the isolation or separation of the targeted nucleic acid. For example, the label could be biotin, digoxigenin, polyvalent cations, chelator groups and the other ligands, include ligands for an antibody.

C. Visualization Techniques

A number of techniques for visualizing or detecting labeled nucleic acids are readily available. Such techniques include, microscopy, arrays, Fluorometry, Light cyclers or other real time PCR machines, FACS analysis, scintillation counters, Phosphoimagers, Geiger counters, MRI, CAT, antibody-based detection methods (Westerns, immunofluorescence, immunohistochemistry), histochemical techniques, HPLC (Griffey et al., 1997), spectroscopy, capillary gel electrophoresis (Cummins et al., 1996), spectroscopy; mass spectroscopy; radiological techniques; and mass balance techniques.

When two or more differentially colored labels are employed, fluorescent resonance energy transfer (FRET) techniques may be employed to characterize association of one or more nucleic acid. Furthermore, a person of ordinary skill in the art is well aware of ways of visualizing, identifying, and characterizing labeled nucleic acids, and accordingly, such protocols may be used as part of the invention. Examples of tools that may be used also include fluorescent microscopy, a BioAnalyzer, a plate reader, Storm (Molecular Dynamics), Array Scanner, FACS (fluorescent activated cell sorter), or any instrument that has the ability to excite and detect a fluorescent molecule.

VI. KITS

Any of the compositions described herein may be comprised in a kit. In a non-limiting example, reagents for isolating miRNA, labeling miRNA, and/or evaluating a miRNA population using an array, nucleic acid amplification, and/or hybridization can be included in a kit, as well reagents for preparation of samples from blood samples. The kit may further include reagents for creating or synthesizing miRNA probes. The kits will thus comprise, in suitable container means, an enzyme for labeling the miRNA by incorporating labeled nucleotide or unlabeled nucleotides that are subsequently labeled. In certain aspects, the kit can include amplification reagents. In other aspects, the kit may include various supports, such as glass, nylon, polymeric beads, and the like, and/or reagents for coupling any probes and/or target nucleic acids. It may also include one or more buffers, such as reaction buffer, labeling buffer, washing buffer, or a hybridization buffer, compounds for preparing the miRNA probes, and components for isolating miRNA. Other kits of the invention may include components for making a nucleic acid array comprising miRNA, and thus, may include, for example, a solid support.

Kits for implementing methods of the invention described herein are specifically contemplated. In some embodiments, there are kits for preparing miRNA for multi-labeling and kits for preparing miRNA probes and/or miRNA arrays. In these embodiments, kit comprise, in suitable container means, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 or more of the following: (1) poly(A) polymerase; (2) unmodified nucleotides (G, A, T, C, and/or U); (3) a modified nucleotide (labeled or unlabeled); (4) poly(A) polymerase buffer; and, (5) at least one microfilter; (6) label that can be attached to a nucleotide; (7) at least one miRNA probe; (8) reaction buffer; (9) a miRNA array or components for making such an array; (10) acetic acid; (11) alcohol; (12) solutions for preparing, isolating, enriching, and purifying miRNAs or miRNA probes or arrays. Other reagents include those generally used for manipulating RNA, such as formamide, loading dye, ribonuclease inhibitors, and DNase.

In specific embodiments, kits of the invention include an array containing miRNA probes, as described in the application. An array may have probes corresponding to all known miRNAs of an organism or a particular tissue or organ in particular conditions, or to a subset of such probes. The subset of probes on arrays of the invention may be or include those identified as relevant to a particular diagnostic, therapeutic, or prognostic application. For example, the array may contain one or more probes that is indicative or suggestive of (1) a disease or condition (acute myeloid leukemia), (2) susceptibility or resistance to a particular drug or treatment; (3) susceptibility to toxicity from a drug or substance; (4) the stage of development or severity of a disease or condition (prognosis); and (5) genetic predisposition to a disease or condition.

For any kit embodiment, including an array, there can be nucleic acid molecules that contain or can be used to amplify a sequence that is a variant of, identical to or complementary to all or part of any of SEQ IDs described herein. In certain embodiments, a kit or array of the invention can contain one or more probes for the miRNAs identified by the SEQ IDs described herein. Any nucleic acid discussed above may be implemented as part of a kit.

The components of the kits may be packaged either in aqueous media or in lyophilized form. The container means of the kits will generally include at least one vial, test tube, flask, bottle, syringe or other container means, into which a component may be placed, and preferably, suitably aliquotted. Where there is more than one component in the kit (labeling reagent and label may be packaged together), the kit also will generally contain a second, third or other additional container into which the additional components may be separately placed. However, various combinations of components may be comprised in a vial. The kits of the present invention also will typically include a means for containing the nucleic acids, and any other reagent containers in close confinement for commercial sale. Such containers may include injection or blow molded plastic containers into which the desired vials are retained.

When the components of the kit are provided in one and/or more liquid solutions, the liquid solution is an aqueous solution, with a sterile aqueous solution being particularly preferred.

However, the components of the kit may be provided as dried powder(s). When reagents and/or components are provided as a dry powder, the powder can be reconstituted by the addition of a suitable solvent. It is envisioned that the solvent may also be provided in another container means. In some embodiments, labeling dyes are provided as a dried power. It is contemplated that 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 120, 120, 130, 140, 150, 160, 170, 180, 190, 200, 300, 400, 500, 600, 700, 800, 900, 1000 μg or at least or at most those amounts of dried dye are provided in kits of the invention. The dye may then be resuspended in any suitable solvent, such as DMSO.

Such kits may also include components that facilitate isolation of the labeled miRNA. It may also include components that preserve or maintain the miRNA or that protect against its degradation. Such components may be RNAse-free or protect against RNAses. Such kits generally will comprise, in suitable means, distinct containers for each individual reagent or solution.

A kit will also include instructions for employing the kit components as well the use of any other reagent not included in the kit. Instructions may include variations that can be implemented.

Kits of the invention may also include one or more of the following: Control RNA; nuclease-free water; RNase-free containers, such as 1.5 ml tubes; RNase-free elution tubes; PEG or dextran; ethanol; acetic acid; sodium acetate; ammonium acetate; guanidinium; detergent; nucleic acid size marker; RNase-free tube tips; and RNase or DNase inhibitors. It is contemplated that such reagents are embodiments of kits of the invention. Such kits, however, are not limited to the particular items identified above and may include any reagent used for the manipulation or characterization of miRNA.

VII. EXAMPLES

The following examples are included to demonstrate preferred embodiments of the invention. It should be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function well in the practice of the invention, and thus can be considered to constitute preferred modes for its practice. However, those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

Example 1
Gene Expression Analysis Following Transfection with Hsa-miR-124a

miRNAs are believed to regulate gene expression by binding to target mRNA transcripts and (1) initiating transcript degradation or (2) altering protein translation from the transcript. Translational regulation leading to an up or down change in protein expression may lead to changes in activity and expression of downstream gene products and genes that are in turn regulated by those proteins. These numerous regulatory effects may be revealed as changes in the global mRNA expression profile. Microarray gene expression analyses were performed to identify genes that are mis-regulated by hsa-miR-124a expression.

Synthetic Pre-miR™-hsa-miR-124a (Ambion; Austin, Tex., USA) or two negative control (NC) miRNAs (Pre-miR™ microRNA Precursor Molecule-Negative Control #1, Ambion, cat. no. AM17110 and Pre-miR™ microRNA Precursor Molecule-Negative Control #2, Ambion, cat. no. AM17111) were reverse transfected into quadruplicate samples of A549 cells for each of three time points. Cells were transfected using siPORT™ NeoFX™ (Ambion, cat. no. AM4511) according to the manufacturer's recommendations using the following parameters: 200,000 cells per well in a 6 well plate, 5.0 μl of NeoFX, 30 nM final concentration of miRNA in 2.5 ml. Cells were harvested at 4 h, 24 h, and 72 h post transfection. Total RNA was extracted using RNAqueous®-4PCR (Ambion) according to the manufacturer's recommended protocol.

mRNA array analyses were performed by Asuragen Services (Asuragen, Inc.; Austin, Tex., USA), according to the company's standard operating procedures. Using the MessageAmp™ II-96 aRNA Amplification Kit (Ambion, cat. no. 1819) 2 μg of total RNA were used for target preparation and labeling with biotin. cRNA yields were quantified using an Agilent Bioanalyzer 2100 (Agilent Technologies, Inc.; Santa Clara, Calif., USA) capillary electrophoresis protocol. Labeled target was hybridized to Affymetrix mRNA arrays (Human HG-U133A 2.0 arrays; Affymetrix, Inc.; Santa Clara, Calif., USA) using the manufacturer's recommendations and the following parameters. Hybridizations were carried out at 45° C. for 16 hr in an Affymetrix Model 640 hybridization oven. Arrays were washed and stained on an Affymetrix FS450 Fluidics station, running the wash script Midi_euk2v3_—450. The arrays were scanned on a Affymetrix GeneChip Scanner 3000. Summaries of the image signal data, group mean values, p-values with significance flags, log ratios and gene annotations for every gene on the array were generated using the Affymetrix Statistical Algorithm MAS 5.0 (GCOS v1.3). Data were reported in a file (cabinet) containing the Affymetrix data and result files and in files (.cel) containing the primary image and processed cell intensities of the arrays. Data were normalized for the effect observed by the average of two negative control microRNA sequences and then were averaged together for presentation. A list of genes whose expression levels varied by at least 0.7 log₂from the average negative control was assembled. Results of the microarray gene expression analysis are shown in Table 1.

TABLE 1

Genes with increased (positive values) or decreased (negative values) expression

following transfection of human cancer cells with pre-miR hsa-miR-124a.

Log2 (mir124 -

UniGene ID
Gene Title
Gene Symbol
NC #2)

Hs.445113
membrane-associated ring finger
MARCH2
1.44651

(C3HC4) 2

Hs.567284
membrane-associated ring finger
MARCH5
−1.1922

(C3HC4) 5

Hs.432862
membrane-associated ring finger
MARCH6
−1.44433

(C3HC4) 6

Hs.65377
membrane-associated ring finger
MARCH9
1.42294

(C3HC4) 9

Hs.469615
septin 10
SEPT10
−2.05922

Hs.469615
septin 10
SEPT10
−2.02304

Hs.128199
septin 11
SEPT11
−1.73143

Hs.128199
septin 11
SEPT11
−1.49535

Hs.510949
cDNA clone IMAGE: 5296106
—
−2.8575

—
—
—
−2.85197

Hs.128753
full-length cDNA clone
—
−2.72106

CS0DD009YB17 of Neuroblastoma Cot

50-normalized of Homo sapiens

(human)

Hs.560444
Transcribed locus
—
−2.57552

Hs.55028
cDNA clone IMAGE: 6043059
—
−2.42829

Hs.440492
cDNA FLJ43100 fis, clone
—
−2.32519

CTONG2003100

Hs.454036
cDNA clone IMAGE: 4814292
—
−2.18762

Hs.88045
cDNA FLJ45482 fis, clone
—
−2.14874

BRTHA2001953

—
—
—
−2.14729

—
—
—
−2.10765

Hs.383050
Similar to esterase/N-deacetylase (EC
—
−2.02776

3.5.1.—), 50K hepatic-rabbit

Hs.355655 ///
cDNA FLJ36584 fis, clone
—
−2.02022

Hs.547541
TRACH2013450 /// MRNA; cDNA

DKFZp564A222

Hs.562593
Transcribed locus
—
−1.96501

—
—
—
−1.82654

Hs.549889
cDNA FLJ12874 fis, clone
—
−1.79133

NT2RP2003769

Hs.561352
Transcribed locus
—
−1.78964

Hs.100261
cDNA FLJ26539 fis, clone KDN09310
—
−1.72363

Hs.44380
Transcribed locus, weakly similar to
—
−1.66449

NP_060312.1 hypothetical protein

FLJ20489

Hs.135904
cDNA FLJ26959 fis, clone SLV00568
—
−1.65519

Hs.191482
cDNA clone IMAGE: 4769453
—
−1.61616

Hs.372378
cDNA clone IMAGE: 4797099
—
−1.61128

Hs.406574
Transcribed locus
—
−1.59362

Hs.173030
cDNA FLJ34013 fis, clone
—
−1.59231

FCBBF2002111

Hs.9585
cDNA FLJ30010 fis, clone
—
−1.59113

3NB692000154

Hs.27463
Transcribed locus, weakly similar to
—
−1.58144

NP_055301.1 neuronal thread protein

AD7c-NT

Hs.547551
Transcribed locus
—
−1.56679

Hs.463677
cDNA FLJ11381 fis, clone
—
−1.56053

HEMBA1000501

Hs.491872
Transcribed locus, weakly similar to
—
−1.55238

NP_694983.1 hypothetical protein

FLJ25952

Hs.507978
cDNA FLJ34896 fis, clone
—
−1.53383

NT2NE2018180

Hs.560381
cDNA FLJ37777 fis, clone
—
−1.53149

BRHIP2026274

Hs.238996
Transcribed locus, weakly similar to
—
−1.51518

XP_510104.1

Hs.499682
Transcribed locus
—
−1.51318

—
—
—
−1.49041

Hs.29464
mRNA; cDNA DKFZp566C034 (from
—
−1.48947

clone DKFZp566C034)

Hs.550906
cDNA FLJ33653 fis, clone
—
−1.47234

BRAMY2024715

Hs.356530
Transcribed locus, strongly similar to
—
−1.45472

XP_421205.

—
—
—
−1.40051

Hs.212709
full-length cDNA clone CS0DJ013YE21
—
−1.39206

of T cells (Jurkat cell line) Cot 10-

normali

Hs.167371
LOC440702
—
−1.38094

Hs.102941
cDNA: FLJ21531 fis, clone COL06036
—
−1.36543

Hs.78050
Transcribed locus, weakly similar to
—
−1.36494

XP_510104.1

Hs.530328
Arsenic transactivated protein 1
—
−1.35564

Hs.530762
Transcribed locus
—
−1.3506

Hs.483955
Transcribed locus
—
−1.32209

Hs.254006
Transcribed locus
—
−1.30338

Hs.406574
Transcribed locus
—
−1.28178

Hs.547396
mRNA; cDNA DKFZp451K063 (from
—
−1.26815

clone DKFZp451K063)

—
—
—
−1.24766

Hs.69504
Hypothetical LOC133993
—
−1.20301

Hs.561587
cDNA: FLJ22100 fis, clone HEP17127
—
−1.19883

Hs.467411
Transcribed locus, moderately similar to
—
−1.19135

XP_512541.1

Hs.24359
cDNA FLJ11174 fis, clone
—
−1.1838

PLACE1007367

—
—
—
−1.17196

Hs.433345
Full-length cDNA clone
—
−1.16946

CL0BB014ZH04 of Neuroblastoma of

Homo sapiens (human)

—
—
—
−1.16405

—
—
—
−1.15814

—
—
—
−1.15514

Hs.63187
cDNA FLJ41910 fis, clone
—
−1.14991

PEBLM2007834

Hs.561587
cDNA: FLJ22100 fis, clone HEP17127
—
−1.14801

Hs.141003
cDNA: FLJ21691 fis, clone COL09555
—
−1.14667

Hs.5724
cDNA clone IMAGE: 5286019
—
−1.09054

Hs.96918
LOH11CR1J gene, loss of
—
−1.08984

heterozygosity, 11, chromosomal region

1 gene J product

Hs.516159
Hypothetical LOC388969
—
−1.04658

—
—
—
1.00113

Hs.432924
Full length insert cDNA YI37C01
—
1.01289

Hs.44698
cDNA FLJ42484 fis, clone
—
1.02778

BRACE2032182

—
—
—
1.04706

Hs.176376
Transcribed locus
—
1.048

Hs.30977
cDNA FLJ31513 fis, clone
—
1.05056

NT2RI1000127

Hs.143746
cDNA FLJ43450 fis, clone
—
1.06817

OCBBF2032968

Hs.561280
Transcribed locus
—
1.08508

Hs.518129
Transcribed locus, weakly similar to
—
1.10663

XP_510104.1

Hs.406990
Phosphodiesterase 4D interacting protein
—
1.10734

(myomegalin)

Hs.561676
Transcribed locus
—
1.13407

Hs.360028
Transcribed locus
—
1.14717

Hs.530168
Transcribed locus, weakly similar to
—
1.15046

NP_689672.2 hypothetical protein

MGC45438 [

Hs.34068

Homo sapiens, clone IMAGE: 3930408,
—
1.15922

mRNA

Hs.103159
Full length insert cDNA clone ZD51F08
—
1.16506

Hs.128076
Transcribed locus
—
1.17721

Hs.526422 ///
Similar to ankyrin repeat domain 20A ///
—
1.18723

Hs.567354
Hypothetical gene supported by

NM_03225

Hs.360028
Transcribed locus
—
1.19194

Hs.416155
Glioma amplified sequence 64
—
1.19709

—
—
—
1.20401

Hs.452398
cDNA FLJ30740 fis, clone
—
1.20445

FEBRA2000319

Hs.562715
Transcribed locus
—
1.21733

Hs.440643
mRNA; cDNA DKFZp779L1068 (from
—
1.21741

clone DKFZp779L1068)

Hs.370049
Hypothetical protein LOC157278
—
1.22335

Hs.113631
Transcribed locus, weakly similar to
—
1.22639

NP_062553.1 hypothetical protein

FLJ11267 [

Hs.44898
cDNA FLJ40901 fis, clone
—
1.23966

UTERU2003704

Hs.145804
cDNA clone IMAGE: 5312086
—
1.2741

Hs.87734

Homo sapiens, Similar to deafness,
—
1.27749

autosomal dominant 5 homolog

(human), clone I

Hs.200141
Transcribed locus
—
1.27791

Hs.387014
Hypothetical LOC219638
—
1.28599

Hs.446559
Full-length cDNA clone
—
1.29046

CS0DK010YA20 of HeLa cells Cot 25-

normalized of Homo sapiens (human)

Hs.14691
Transcribed locus
—
1.29222

Hs.408455
cDNA FLJ33993 fis, clone
—
1.31387

DFNES2007757

Hs.44698
cDNA FLJ42484 fis, clone
—
1.31419

BRACE2032182

Hs.22545
cDNA FLJ12935 fis, clone
—
1.31854

NT2RP2004982

Hs.322761
Hypothetical LOC497257
—
1.32524

—
—
—
1.32571

Hs.120170
Transcribed locus, moderately similar to
—
1.33979

XP_512541.1

Hs.374451

Homo sapiens, clone IMAGE: 4454331,
—
1.34083

mRNA

Hs.23606
Transcribed locus
—
1.34158

Hs.446446
Hypothetical LOC375010
—
1.34249

Hs.536567
cDNA FLJ37859 fis, clone
—
1.35057

BRSSN2015369

Hs.302631
cDNA clone IMAGE: 5286843
—
1.36052

Hs.174273
Transcribed locus
—
1.38715

Hs.371609
cDNA FLJ31683 fis, clone
—
1.39164

NT2RI2005353

Hs.527872
Transcribed locus
—
1.39529

Hs.371609
cDNA FLJ31683 fis, clone
—
1.40524

NT2RI2005353

Hs.5096

Homo sapiens, clone IMAGE: 3858719,
—
1.40929

mRNA

Hs.282800
Transcribed locus
—
1.41445

Hs.8379
Full-length cDNA clone CS0DJ001YJ05
—
1.41851

of T cells (Jurkat cell line) Cot 10-

normali

Hs.552018
Transcribed locus
—
1.42347

Hs.88156
Transcribed locus
—
1.42705

Hs.151334
Transcribed locus
—
1.42983

Hs.405427

Homo sapiens, clone IMAGE: 5175565,
—
1.43347

mRNA

Hs.13500
cDNA FLJ31593 fis, clone
—
1.44009

NT2RI2002481

Hs.535360
cDNA clone IMAGE: 6500775
—
1.45009

Hs.21423
cDNA FLJ30424 fis, clone
—
1.45296

BRACE2008881, weakly similar to

ZINC FINGER PROTEIN 195

Hs.21423
cDNA FLJ30424 fis, clone
—
1.46056

BRACE2008881, weakly similar to

ZINC FINGER PROTEIN 195

Hs.27688
Full-length cDNA clone
—
1.46675

CS0DF012YD09 of Fetal brain of Homo

sapiens (human)

Hs.536439
Transcribed locus
—
1.47116

—
—
—
1.49415

Hs.22380
Full length insert cDNA clone ZD79H10
—
1.49977

Hs.314414

Homo sapiens, clone IMAGE: 5743779,
—
1.56512

mRNA

Hs.234478
cDNA: FLJ22648 fis, clone HSI07329
—
1.57549

—
—
—
1.58385

Hs.178144

Homo sapiens, clone IMAGE: 5743799,
—
1.67264

mRNA

—
—
—
1.68495

Hs.548682
Full-length cDNA clone
—
1.68836

CS0DM011YC22 of Fetal liver of

Homo sapiens (human)

Hs.126893
Transcribed locus
—
1.69863

Hs.328236
cDNA clone IMAGE: 4806358
—
1.70004

Hs.88156
Transcribed locus
—
1.70768

—
—
—
1.70885

—
—
—
1.71742

Hs.440643
mRNA; cDNA DKFZp779L1068 (from
—
1.78147

clone DKFZp779L1068)

Hs.53126
Transcribed locus, moderately similar to
—
1.81242

XP_517655.1 PREDICTED: similar to

KIAA0

—
—
—
1.81859

Hs.444083
Transcribed locus
—
1.83349

—
—
—
1.83583

Hs.516367
mRNA; cDNA DKFZp686P18215
—
1.84302

(from clone DKFZp686P18215)

Hs.370049
Hypothetical protein LOC157278
—
1.91193

Hs.351126
Transcribed locus, moderately similar to
—
1.99147

XP_517655.1 PREDICTED: similar to

KIAA0

—
—
—
2.01427

Hs.446671
Transcribed locus, strongly similar to
—
2.04867

NP_003156.1 syntaxin binding protein

1; s

Hs.47208
cDNA FLJ45259 fis, clone
—
2.14126

BRHIP2020695

—
—
—
2.18694

Hs.160711
Transcribed locus
—
2.28638

Hs.436057
Transcribed locus
—
2.28848

Hs.418040
cDNA clone IMAGE: 30367357
—
2.41037

Hs.443798
Transcribed locus
—
2.48069

Hs.146317
Transcribed locus, weakly similar to
—
2.48636

XP_517655.1 PREDICTED: similar to

KIAA0825

Hs.308060
LOC440570
—
2.548

Hs.99785
cDNA: FLJ21245 fis, clone COL01184
—
2.69373

Hs.523897
cDNA FLJ38112 fis, clone
—
3.38473

D3OST2002272

—
—
—
3.49831

Hs.462598
82-kD FMRP Interacting Protein
182-FIP
−1.77251

Hs.462598
82-kD FMRP Interacting Protein
182-FIP
−1.34345

Hs.552584
AP2 associated kinase 1
AAK1
1.23153

Hs.336768
4-aminobutyrate aminotransferase
ABAT
1.20681

Hs.336768
4-aminobutyrate aminotransferase
ABAT
1.23674

Hs.429294
ATP-binding cassette, sub-family A
ABCA1
1.8146

(ABC1), member 1

Hs.429294
ATP-binding cassette, sub-family A
ABCA1
1.99636

(ABC1), member 1

Hs.134585
ATP-binding cassette, sub-family A
ABCA12
4.51284

(ABC1), member 12

Hs.124649
ATP-binding cassette, sub-family G
ABCG1
2.67865

(WHITE), member 1

Hs.508148
abl-interactor 1
ABI1
−1.1678

Hs.200136
acetyl-Coenzyme A acyltransferase 2
ACAA2
−3.11952

(mitochondrial 3-oxoacyl-Coenzyme A

thiolase

Hs.445040
acyl-Coenzyme A dehydrogenase, C-4
ACADM
−1.48728

to C-12 straight chain

Hs.81934
acyl-Coenzyme A dehydrogenase,
ACADSB
1.29385

short/branched chain

Hs.363137
acetyl-Coenzyme A acetyltransferase 2
ACAT2
−1.77551

(acetoacetyl Coenzyme A thiolase)

Hs.446685
acyl-CoA thioesterase 2
ACOT2
1.07252

Hs.464137
acyl-Coenzyme A oxidase 1, palmitoyl
ACOX1
−1.37507

Hs.444959
acyl-Coenzyme A oxidase 2, branched
ACOX2
−1.78602

chain

Hs.255491
acid phosphatase-like 2
ACPL2
2.42324

Hs.160976
acyl-CoA synthetase medium-chain
ACSM3
2.0203

family member 3

Hs.160976
acyl-CoA synthetase medium-chain
ACSM3
2.47004

family member 3

Hs.500483
actin, alpha 2, smooth muscle, aorta
ACTA2
1.81371

Hs.438918
activin A receptor, type IB
ACVR1B
1.13551

Hs.470174
activin A receptor, type IIA
ACVR2A
1.16595

Hs.356247
aminoacylase 1-like 2
ACY1L2
−1.22613

Hs.516173
acylphosphatase 2, muscle type
ACYP2
1.26039

Hs.522433
AD-003 protein
AD-003
−1.1865

Hs.483944
ADAM metallopeptidase domain 19
ADAM19
1.21804

(meltrin beta)

Hs.370287
ADAM metallopeptidase domain 23
ADAM23
1.03009

Hs.370287
ADAM metallopeptidase domain 23
ADAM23
1.14332

Hs.370287
ADAM metallopeptidase domain 23
ADAM23
1.64919

Hs.534221
ADAM metallopeptidase with
ADAMTS15
1.30093

thrombospondin type 1 motif, 15

Hs.192215
adenylate cyclase 1 (brain)
ADCY1
1.50926

Hs.518892
alcohol dehydrogenase 6 (class V)
ADH6
1.39262

Hs.518892
alcohol dehydrogenase 6 (class V)
ADH6
1.8487

Hs.375179
adenylosuccinate synthase like 1
ADSSL1
1.96783

Hs.248785
1-acylglycerol-3-phosphate O-
AGPAT3
1.18995

acyltransferase 3

Hs.516543
alkylglycerone phosphate synthase
AGPS
−2.01298

Hs.516543
alkylglycerone phosphate synthase
AGPS
−1.53364

Hs.530009
anterior gradient 2 homolog (Xenopus
AGR2
−1.93668

laevis)

Hs.530009
anterior gradient 2 homolog (Xenopus
AGR2
−1.11235

laevis)

Hs.19383
angiotensinogen (serpin peptidase
AGT
1.48949

inhibitor, clade A, member 8)

Hs.502756
AHNAK nucleoprotein (desmoyokin)
AHNAK
−1.17042

Hs.502756
AHNAK nucleoprotein (desmoyokin)
AHNAK
−1.02415

—
adenylate kinase 2
AK2
−2.11505

Hs.470907
adenylate kinase 2
AK2
−1.70834

Hs.493362
adenylate kinase 3
AK3
−2.67095

Hs.493362
adenylate kinase 3
AK3
−2.32644

Hs.10862
adenylate kinase 3-like 1
AK3L1
1.23455

Hs.10862
adenylate kinase 3-like 1
AK3L1
1.43994

Hs.510373
adenylate kinase 7
AK7
1.40726

Hs.371240
A kinase (PRKA) anchor protein
AKAP12
1.04634

(gravin) 12

Hs.371240
A kinase (PRKA) anchor protein
AKAP12
1.12727

(gravin) 12

Hs.371240
A kinase (PRKA) anchor protein
AKAP12
1.17874

(gravin) 12

Hs.527348
A kinase (PRKA) anchor protein
AKAP9
1.22674

(yotiao) 9

Hs.512807
aldo-keto reductase family 7, member
AKR7A2
−1.58112

A2 (aflatoxin aldehyde reductase)

Hs.512807
aldo-keto reductase family 7, member
AKR7A2
−1.47339

A2 (aflatoxin aldehyde reductase)

Hs.515542
AKT1 substrate 1 (proline-rich)
AKT1S1
−1.17537

Hs.150693
Activated leukocyte cell adhesion
ALCAM
1.01184

molecule

Hs.459538
aldehyde dehydrogenase 1 family,
ALDH1A3
1.34102

member A3

Hs.40919
asparagine-linked glycosylation 2
ALG2
−1.37104

homolog (yeast, alpha-1,3-

mannosyltransferase)

Hs.507769
asparagine-linked glycosylation 5
ALG5
−1.42868

homolog (yeast, dolichyl-phosphate

beta-glucose

Hs.184720
Alstrom syndrome 1
ALMS1
1.43349

Hs.184720
Alstrom syndrome 1
ALMS1
1.61137

Hs.471096
amyotrophic lateral sclerosis 2 (juvenile)
ALS2
1.11459

Hs.471130
amyotrophic lateral sclerosis 2 (juvenile)
ALS2CR13
2.32442

chromosome region, candidate 13

Hs.554880
amyotrophic lateral sclerosis 2 (juvenile)
ALS2CR15
2.14659

chromosome region, candidate 15

Hs.295137
autocrine motility factor receptor
AMFR
−1.01434

Hs.211021
Alport syndrome, mental retardation,
AMMECR1
−2.68372

midface hypoplasia and elliptocytosis

Hs.211021
Alport syndrome, mental retardation,
AMMECR1
−2.24775

midface hypoplasia and elliptocytosis

Hs.211021
Alport syndrome, mental retardation,
AMMECR1
−1.72189

midface hypoplasia and elliptocytosis

Hs.16229
associated molecule with the SH3
AMSH-LP
−1.2422

domain of STAM (AMSH) like protein

Hs.499725
ankyrin 3, node of Ranvier (ankyrin G)
ANK3
2.14295

Hs.513875
ankyrin repeat and FYVE domain
ANKFY1
−1.32868

containing 1

Hs.513875
ankyrin repeat and FYVE domain
ANKFY1
−1.2223

containing 1

Hs.156727
ankylosis, progressive homolog (mouse)
ANKH
1.09799

Hs.156727
ankylosis, progressive homolog (mouse)
ANKH
2.03558

Hs.239154
ankyrin repeat, family A (RFXANK-
ANKRA2
1.68394

like), 2

Hs.482853
ankyrin repeat domain 32
ANKRD32
−1.49302

Hs.463426
ankyrin repeat domain 40
ANKRD40
−1.31517

Hs.530199
ankyrin repeat domain 46
ANKRD46
2.45585

Hs.112909
ankyrin repeat domain 6
ANKRD6
1.07684

Hs.62180
anillin, actin binding protein (scraps
ANLN
−3.04043

homolog, Drosophila)

Hs.62180
anillin, actin binding protein (scraps
ANLN
−2.92708

homolog, Drosophila)

Hs.385913
acidic (leucine-rich) nuclear
ANP32E
−2.77779

phosphoprotein 32 family, member E

Hs.385913
Acidic (leucine-rich) nuclear
ANP32E
−2.07845

phosphoprotein 32 family, member E

Hs.385913
acidic (leucine-rich) nuclear
ANP32E
−1.72716

phosphoprotein 32 family, member E

Hs.165859
anthrax toxin receptor 1
ANTXR1
−2.06308

Hs.480653
annexin A5
ANXA5
−3.00322

Hs.386434
annexin A7
ANXA7
−2.1409

Hs.386434
annexin A7
ANXA7
−1.90276

Hs.430324
annexin A9
ANXA9
1.82787

Hs.430324
annexin A9 /// annexin A9
ANXA9
2.24924

Hs.406238
aldehyde oxidase 1
AOX1
−1.25234

Hs.101480
AP1 gamma subunit binding protein 1
AP1GBP1
2.66149

Hs.18894
adaptor-related protein complex 1, mu 2
AP1M2
−1.94622

subunit

Hs.18894
adaptor-related protein complex 1, mu 2
AP1M2
−1.93072

subunit

Hs.121592
adaptor-related protein complex 1, sigma
AP1S2
−1.41432

2 subunit

Hs.121592
adaptor-related protein complex 1, sigma
AP1S2
−1.24493

2 subunit

Hs.387648
adaptor-related protein complex 1, sigma
AP1S3
−1.04504

3 subunit

Hs.500104
adaptor-related protein complex 3, mu 1
AP3M1
−1.67829

subunit

Hs.555936
APEX nuclease (apurinic/apyrimidinic
APEX2
−1.17148

endonuclease) 2

Hs.74565
amyloid beta (A4) precursor-like protein 1
APLP1
1.97456

Hs.226307
apolipoprotein B mRNA editing
APOBEC3B
−1.93604

enzyme, catalytic polypeptide-like 3B

Hs.515465
apolipoprotein E
APOE
1.37948

Hs.434980
amyloid beta (A4) precursor protein
APP
1.20229

(peptidase nexin-II, Alzheimer disease)

Hs.434980
amyloid beta (A4) precursor protein
APP
1.36582

(peptidase nexin-II, Alzheimer disease)

Hs.84084
amyloid beta precursor protein
APPBP2
1.32834

(cytoplasmic tail) binding protein 2

Hs.446641
v-raf murine sarcoma 3611 viral
ARAF
−1.45485

oncogene homolog

Hs.416089
ADP-ribosylation factor interacting
ARFIP1
−2.66871

protein 1 (arfaptin 1)

Hs.416089
ADP-ribosylation factor interacting
ARFIP1
−1.78433

protein 1 (arfaptin 1)

Hs.138860
Rho GTPase activating protein 1
ARHGAP1
−1.51577

Hs.400818
Rho GTPase activating protein 11A
ARHGAP11A
−2.16059

Hs.159161
Rho GDP dissociation inhibitor (GDI)
ARHGDIA
−3.18235

alpha

Hs.159161
Rho GDP dissociation inhibitor (GDI)
ARHGDIA
−2.07826

alpha

Hs.159161
Rho GDP dissociation inhibitor (GDI)
ARHGDIA
−1.61522

alpha

Hs.159161
Rho GDP dissociation inhibitor (GDI)
ARHGDIA
−1.59814

alpha /// Rho GDP dissociation inhibitor

(G

Hs.443460
Rho guanine nucleotide exchange factor
ARHGEF10L
1.52476

(GEF) 10-like

Hs.250009
ADP-ribosylation factor-like 10C
ARL10C
−1.58997

Hs.182215
ADP-ribosylation factor-like 3
ARL3
1.42368

Hs.470233
ADP-ribosylation factor-like 5
ARL5
1.65731

Hs.190440
ADP-ribosylation factor-like 6
ARL6IP2
−1.13113

interacting protein 2

Hs.516468
ADP-ribosylation-like factor 6
ARL6IP6
−2.72541

interacting protein 6

Hs.516468
ADP-ribosylation-like factor 6
ARL6IP6
−1.20713

interacting protein 6

Hs.269542
armadillo repeat containing 1
ARMC1
−1.64954

Hs.269542
armadillo repeat containing 1
ARMC1
−1.45211

Hs.471610
armadillo repeat containing 9
ARMC9
1.5088

Hs.459070
aryl-hydrocarbon receptor nuclear
ARNT2
1.41846

translocator 2

Hs.512908
cyclic AMP phosphoprotein, 19 kD
ARPP-19
−2.21964

Hs.149103
arylsulfatase B
ARSB
−1.27475

Hs.528631
arylsulfatase D
ARSD
−1.14781

Hs.504187
Adipocyte-specific adhesion molecule
ASAM
−1.75017

Hs.16349
ATM/ATR-Substrate Chk2-Interacting
ASCIZ
−1.28851

Zn2+-finger protein

Hs.26516
ASF1 anti-silencing function 1 homolog
ASF1B
−1.90378

B (S. cerevisiae)

Hs.208414
activator of S phase kinase
ASK
−2.051

Hs.121028
asp (abnormal spindle)-like,
ASPM
−2.10725

microcephaly associated (Drosophila)

Hs.558301
argininosuccinate synthetase
ASS
1.30242

Hs.209217
astrotactin 2
ASTN2
2.09888

Hs.209217
astrotactin 2
ASTN2
2.13406

Hs.370834
ATPase family, AAA domain containing 2
ATAD2
−3.16311

Hs.370834
ATPase family, AAA domain containing 2
ATAD2
−3.10193

Hs.370834
ATPase family, AAA domain containing 2
ATAD2
−2.67001

Hs.370834
ATPase family, AAA domain containing 2
ATAD2
−1.42371

Hs.461285
AT-binding transcription factor 1
ATBF1
1.21411

Hs.461285
AT-binding transcription factor 1
ATBF1
1.3555

Hs.496487
activating transcription factor 4 (tax-
ATF4
−1.49983

responsive enhancer element B67)

Hs.492740
Activating transcription factor 6
ATF6
1.12993

Hs.477126
ATG3 autophagy related 3 homolog (S. cerevisiae)
ATG3
−1.69524

Hs.88252
ATPase, Class VI, type 11C
ATP11C
1.81479

Hs.506759
ATPase, Ca++ transporting, cardiac
ATP2A2
2.05217

muscle, slow twitch 2

Hs.438489
ATP synthase, H+ transporting,
ATP5S
1.2575

mitochondrial F0 complex, subunit s

(factor B)

Hs.484188
ATPase, H+ transporting, lysosomal
ATP6V0E
−3.94802

9 kDa, V0 subunit e

Hs.484188
ATPase, H+ transporting, lysosomal
ATP6V0E
−3.66723

9 kDa, V0 subunit e /// ATPase, H+

transportin

Hs.484188
ATPase, H+ transporting, lysosomal
ATP6V0E
−3.50595

9 kDa, V0 subunit e

Hs.484188
ATPase, H+ transporting, lysosomal
ATP6V0E
−3.35879

9 kDa, V0 subunit e

Hs.484188
ATPase, H+ transporting, lysosomal
ATP6V0E
−3.06293

9 kDa, V0 subunit e

Hs.484188
ATPase, H+ transporting, lysosomal
ATP6V0E
−2.27251

9 kDa, V0 subunit e

Hs.388654
ATPase, H+ transporting, lysosomal
ATP6V1G1
−1.21519

13 kDa, V1 subunit G isoform 1

Hs.491737
ATPase, H+ transporting, lysosomal
ATP6V1H
1.14584

50/57 kDa, V1 subunit H

Hs.368002
ATPase, Class II, type 9A
ATP9A
1.75501

Hs.465475
ATPase, Class II, type 9B
ATP9B
−1.27448

Hs.533526
alpha thalassemia/mental retardation
ATRX
1.21083

syndrome X-linked (RAD54 homolog,

S. cerevisiae)

Hs.434961
ataxin 1
ATXN1
1.78989

Hs.526425
ataxin 3
ATXN3
1.7092

Hs.442658
aurora kinase B
AURKB
−3.28843

Hs.272011
UDP-Gal:betaGlcNAc beta 1,4-
B4GALT1
−2.18016

galactosyltransferase, polypeptide 1

Hs.272011
UDP-Gal:betaGlcNAc beta 1,4-
B4GALT1
−1.68723

galactosyltransferase, polypeptide 1

Hs.272011
UDP-Gal:betaGlcNAc beta 1,4-
B4GALT1
−1.55955

galactosyltransferase, polypeptide 1

Hs.272011
UDP-Gal:betaGlcNAc beta 1,4-
B4GALT1
−1.30327

galactosyltransferase, polypeptide 1

Hs.464848
UDP-Gal:betaGlcNAc beta 1,4-
B4GALT6
−1.74964

galactosyltransferase, polypeptide 6

Hs.464848
UDP-Gal:betaGlcNAc beta 1,4-
B4GALT6
−1.58614

galactosyltransferase, polypeptide 6

Hs.464848
UDP-Gal:betaGlcNAc beta 1,4-
B4GALT6
−1.27649

galactosyltransferase, polypeptide 6

Hs.524138
brain-specific angiogenesis inhibitor 2
BAI2
2.82064

Hs.54089
BRCA1 associated RING domain 1
BARD1
−1.18684

Hs.509140
bromodomain adjacent to zinc finger
BAZ1A
−1.45554

domain, 1A

Hs.509140
bromodomain adjacent to zinc finger
BAZ1A
−1.30967

domain, 1A

Hs.502915
Bardet-Biedl syndrome 1
BBS1
1.92669

Hs.208681
Bardet-Biedl syndrome 4
BBS4
1.15935

Hs.438993
branched chain aminotransferase 1,
BCAT1
−2.45797

cytosolic

Hs.438993
branched chain aminotransferase 1,
BCAT1
−2.14227

cytosolic

Hs.438993
branched chain aminotransferase 1,
BCAT1
−2.04249

cytosolic

Hs.193516
B-cell CLL/lymphoma 10
BCL10
1.80226

Hs.469658
BCL2-like 11 (apoptosis facilitator)
BCL2L11
1.24619

Hs.469658
BCL2-like 11 (apoptosis facilitator)
BCL2L11
1.76976

Hs.478588
B-cell CLL/lymphoma 6 (zinc finger
BCL6
1.24494

protein 51)

Hs.486542
BCL2-associated transcription factor 1
BCLAF1
−1.2496

Hs.212172
beta-carotene 15,15′-monooxygenase 1
BCMO1
1.12146

Hs.525572
bradykinin receptor B2
BDKRB2
1.20304

Hs.502182
Brain-derived neurotrophic factor
BDNF
1.15806

opposite strand

Hs.502182
brain-derived neurotrophic factor
BDNF
1.16325

Hs.502182
brain-derived neurotrophic factor
BDNF
2.66234

Hs.184736
brain expressed X-linked-like 1
BEXL1
1.05078

Hs.514527
baculoviral IAP repeat-containing 5
BIRC5
−2.92443

(survivin)

Hs.514527
baculoviral IAP repeat-containing 5
BIRC5
−2.84713

(survivin)

Hs.514527
baculoviral IAP repeat-containing 5
BIRC5
−2.48729

(survivin)

Hs.514527
Effector cell peptidase receptor 1
BIRC5
−1.55356

Hs.288809
basic, immunoglobulin-like variable
BIVM
1.60758

motif containing

Hs.169348
Bloom syndrome
BLM
−1.56775

Hs.283532
uncharacterized bone marrow protein
BM039
−2.5703

BM039

Hs.283532
uncharacterized bone marrow protein
BM039
−1.57091

BM039

Hs.1274
bone morphogenetic protein 1
BMP1
1.07616

Hs.1274
bone morphogenetic protein 1
BMP1
1.22004

Hs.283454
BCL2/adenovirus E1B 19 kDa
BNIP2
1.35501

interacting protein 2

—
v-raf murine sarcoma viral oncogene
BRAF
1.03351

homolog B1

Hs.194143
breast cancer 1, early onset
BRCA1
−2.32949

Hs.194143
breast cancer 1, early onset
BRCA1
−1.40615

Hs.34012
breast cancer 2, early onset
BRCA2
−2.63976

Hs.532799
BRCA1 interacting protein C-terminal
BRIP1
−1.37567

helicase 1

Hs.532799
BRCA1 interacting protein C-terminal
BRIP1
−1.20299

helicase 1

Hs.525299
breast cancer metastasis-suppressor 1-
BRMS1L
1.34896

like

Hs.525299
breast cancer metastasis-suppressor 1-
BRMS1L
1.60725

like

Hs.308045
barren homolog (Drosophila)
BRRN1
−1.94109

Hs.244590
BTB (POZ) domain containing 3
BTBD3
1.56315

Hs.517830
biotinidase
BTD
−1.34728

Hs.519162
BTG family, member 2
BTG2
1.40327

Hs.469649
BUB1 budding uninhibited by
BUB1
−2.72123

benzimidazoles 1 homolog (yeast)

Hs.469649
BUB1 budding uninhibited by
BUB1
−2.66112

benzimidazoles 1 homolog (yeast)

Hs.36708
BUB1 budding uninhibited by
BUB1B
−2.4014

benzimidazoles 1 homolog beta (yeast)

Hs.418533
BUB3 budding uninhibited by
BUB3
−1.2881

benzimidazoles 3 homolog (yeast)

Hs.124246
chromosome 10 open reading frame 119
C10orf119
−1.09868

Hs.14559
chromosome 10 open reading frame 3
C10orf3
−2.96399

Hs.34492
chromosome 10 open reading frame 32
C10orf32
1.21753

Hs.446315
chromosome 10 open reading frame 45
C10orf45
−1.09303

Hs.446315
chromosome 10 open reading frame 45
C10orf45
−1.03421

Hs.446315
Chromosome 10 open reading frame 45
C10orf45
1.64975

Hs.420024
chromosome 10 open reading frame 46
C10orf46
−1.07798

Hs.499833
chromosome 10 open reading frame 74
C10orf74
−1.99852

Hs.499833
chromosome 10 open reading frame 74
C10orf74
−1.82678

Hs.93667
chromosome 10 open reading frame 78
C10orf78
−1.3269

Hs.93667
chromosome 10 open reading frame 78
C10orf78
−1.21737

Hs.14745
chromosome 10 open reading frame 9
C10orf9
1.04082

—
chromosome 11 open reading frame 32
C11orf32
1.80699

Hs.473109
chromosome 11 open reading frame 9
C11orf9
−1.0544

Hs.88523
chromosome 13 open reading frame 3
C13orf3
−1.60434

Hs.493062
chromosome 13 open reading frame 7
C13orf7
−1.19491

Hs.446850
chromosome 14 open reading frame 100
C14orf100
−1.37992

Hs.146040
chromosome 14 open reading frame 105
C14orf105
3.08437

Hs.437941
chromosome 14 open reading frame 106
C14orf106
−1.58434

Hs.437941
chromosome 14 open reading frame 106
C14orf106
−1.25714

Hs.343173
chromosome 14 open reading frame 111
C14orf111
−1.73122

Hs.437831
chromosome 14 open reading frame 111
C14orf111///
−2.07398

/// chromosome 14 open reading frame
C14orf32

32

Hs.137108
chromosome 14 open reading frame 112
C14orf112
−1.26989

Hs.9043
chromosome 14 open reading frame 120
C14orf120
−1.56964

Hs.370299
chromosome 14 open reading frame 125
C14orf125
−1.57587

Hs.20142
chromosome 14 open reading frame 142
C14orf142
−1.92889

Hs.123232
chromosome 14 open reading frame 143
C14orf143
−1.16551

Hs.162889
chromosome 14 open reading frame 145
C14orf145
−2.40228

Hs.162889
chromosome 14 open reading frame 145
C14orf145
−1.4913

Hs.29706
chromosome 14 open reading frame 149
C14orf149
−1.58168

Hs.510407
chromosome 14 open reading frame 154
C14orf154
1.44686

Hs.309849
chromosome 14 open reading frame 159
C14orf159
1.23828

Hs.446357
chromosome 14 open reading frame 24
C14orf24
−2.88651

Hs.82098
chromosome 14 open reading frame 28
C14orf28
1.05861

Hs.82098
chromosome 14 open reading frame 28
C14orf28
1.19184

Hs.179260
chromosome 14 open reading frame 4
C14orf4
1.52554

Hs.550547
Chromosome 14 open reading frame 44
C14orf44
1.12787

Hs.260555
chromosome 14 open reading frame 45
C14orf45
1.82442

Hs.513392
chromosome 14 open reading frame 46
C14orf46
−1.12219

Hs.441783
chromosome 14 open reading frame 78
C14orf78
1.29638

Hs.532683
chromosome 14 open reading frame 87
C14orf87
−1.69987

Hs.112160
chromosome 15 open reading frame 20
C15ort20
−1.06547

Hs.525796
chromosome 15 open reading frame 23
C15orf23
−2.21496

Hs.160565
chromosome 15 open reading frame 24
C15orf24
−1.14621

Hs.14347
chromosome 15 open reading frame 25
C15orf25
−1.39177

Hs.510938
Chromosome 15 open reading frame 29
C15orf29
1.33202

Hs.513261
chromosome 16 open reading frame 34
C16orf34
−2.53906

Hs.513261
chromosome 16 open reading frame 34
C16orf34
−1.74123

Hs.203594
chromosome 16 open reading frame 46
C16orf46
1.25378

Hs.498890
chromosome 16 open reading frame 52
C16orf52
1.44987

Hs.558473
Chromosome 18 open reading frame 10
C18orf10
−1.16121

Hs.134726
chromosome 18 open reading frame 24
C18orf24
−2.79183

Hs.208701
chromosome 18 open reading frame 54
C18orf54
−1.84765

Hs.532835
chromosome 18 open reading frame 55
C18orf55
−1.02679

—
chromosome 18 open reading frame 56
C18orf56
1.17245

Hs.76277
chromosome 19 open reading frame 32
C19orf32
1.16451

Hs.239666
core 1 synthase, glycoprotein-N-
C1GALT1
−1.34248

acetylgalactosamine 3-beta-

galactosyltransferase

Hs.202207
chromosome 1 open reading frame 102
C1orf102
1.34343

Hs.293563
chromosome 1 open reading frame 108
C1orf108
−1.35689

Hs.443551
chromosome 1 open reading frame 112
C1orf112
−3.33816

Hs.130746
chromosome 1 open reading frame 114
C1orf114
1.2474

Hs.498317
chromosome 1 open reading frame 121
C1orf121
−1.3606

Hs.498317
chromosome 1 open reading frame 121
C1orf121
−1.17342

Hs.554892
chromosome 1 open reading frame 124
C1orf124
−1.16234

Hs.556017
chromosome 1 open reading frame 131
C1orf131
−1.45997

Hs.252967
chromosome 1 open reading frame 144
C1orf144
−1.38903

Hs.252967
chromosome 1 open reading frame 144
C1orf144
−1.3514

Hs.434498
chromosome 1 open reading frame 155
C1orf155
−2.07

Hs.434498
chromosome 1 open reading frame 155
C1orf155
−1.66964

Hs.523811
chromosome 1 open reading frame 22
C1orf22
−1.69074

Hs.523811
chromosome 1 open reading frame 22
C1orf22
−1.32688

Hs.523811
chromosome 1 open reading frame 22
C1orf22
−1.2394

Hs.518662
chromosome 1 open reading frame 24
C1orf24
−1.7059

Hs.112949
chromosome 1 open reading frame 34
C1orf34
1.2974

Hs.520192
chromosome 1 open reading frame 55
C1orf55
−1.75702

Hs.520192
chromosome 1 open reading frame 55
C1orf55
−1.67518

Hs.528699
chromosome 1 open reading frame 79
C1orf79
−1.45216

Hs.528699
chromosome 1 open reading frame 79
C1orf79
−1.16355

Hs.156625
chromosome 1 open reading frame 80
C1orf80
−2.24918

Hs.156625
chromosome 1 open reading frame 80
C1orf80
−2.19773

Hs.172510
chromosome 1 open reading frame 88
C1orf88
1.64402

Hs.556016
chromosome 1 open reading frame 96
C1orf96
−1.98042

Hs.524224
complement component 1, r
C1R
1.2527

subcomponent

Hs.525264
complement component 1, r
C1RL
1.29964

subcomponent-like

Hs.458355
complement component 1, s
C1S
1.1701

subcomponent

Hs.143736
chromosome 20 open reading frame 108
C20orf108
1.30283

Hs.143736
chromosome 20 open reading frame 108
C20orf108
1.79836

Hs.516977
chromosome 20 open reading frame 112
C20orf112
1.32831

Hs.516977
chromosome 20 open reading frame 112
C20orf112
1.87434

Hs.283869
chromosome 20 open reading frame 121
C20orf121
−1.38738

Hs.283869
chromosome 20 open reading frame 121
C20orf121
−1.07381

Hs.472716
chromosome 20 open reading frame 129
C20orf129
−1.36816

Hs.266273
chromosome 20 open reading frame 172
C20orf172
−2.0766

Hs.274422
chromosome 20 open reading frame 27
C20orf27
−1.9419

Hs.274422
chromosome 20 open reading frame 27
C20orf27
−1.72317

Hs.320823
chromosome 20 open reading frame 72
C20orf72
−1.37017

Hs.190518
chromosome 21 open reading frame 45
C21orf45
−1.88741

Hs.190518
chromosome 21 open reading frame 45
C21orf45
−1.41595

Hs.208358
chromosome 21 open reading frame 63
C21orf63
−1.52188

Hs.208912
chromosome 22 open reading frame 18
C22orf18
−1.57651

Hs.516707
chromosome 2 open reading frame 17
C2orf17
1.51246

Hs.516707
chromosome 2 open reading frame 17
C2orf17
1.52854

Hs.553512
putative protein similar to nessy
C3F
−1.33476

(Drosophila)

Hs.55131
chromosome 3 open reading frame 23
C3orf23
1.68914

Hs.55131
chromosome 3 open reading frame 23
C3orf23
2.64324

Hs.478682
chromosome 3 open reading frame 6
C3orf6
−1.71881

Hs.368454
chromosome 4 open reading frame 15
C4orf15
−1.1094

Hs.435991
chromosome 4 open reading frame 16
C4orf16
−1.22157

Hs.166551
chromosome 5 open reading frame 3
C5orf3
−1.04141

Hs.483473
chromosome 5 open reading frame 5
C5orf5
1.22807

Hs.555954
chromosome 6 open reading frame 107
C6orf107
−1.69873

Hs.520287
chromosome 6 open reading frame 111
C6orf111
1.4713

Hs.88663
chromosome 6 open reading frame 139
C6orf139
−3.44482

Hs.485528
chromosome 6 open reading frame 141
C6orf141
1.13191

Hs.21945
chromosome 6 open reading frame 152
C6orf152
1.2155

Hs.21945
chromosome 6 open reading frame 152
C6orf152
1.46547

Hs.309231
chromosome 6 open reading frame 153
C6orf153
−1.31388

Hs.486401
chromosome 6 open reading frame 173
C6orf173
−2.22501

Hs.31917
chromosome 6 open reading frame 176
C6orf176
−3.52107

Hs.59554
chromosome 6 open reading frame 182
C6orf182
−1.30989

Hs.347144
chromosome 6 open reading frame 192
C6orf192
−1.57852

Hs.418520
chromosome 6 open reading frame 51
C6orf51
−1.14052

Hs.519930
Chromosome 6 open reading frame 62
C6orf62
−1.29276

Hs.214043
chromosome 6 open reading frame 79
C6orf79
−1.41464

Hs.283683
chromosome 8 open reading frame 4
C8orf4
1.39952

Hs.171455
chromosome 8 open reading frame 47
C8orf47
1.40888

Hs.368402
chromosome 8 open reading frame 55
C8orf55
−1.25513

—
chromosome 8 open reading frame 61
C8orf61
1.17136

Hs.414028
chromosome 9 open reading frame 116
C9orf116
1.54706

Hs.201258
chromosome 9 open reading frame 122
C9orf122
2.47079

Hs.388742
Chromosome 9 open reading frame 125
C9orf125
1.14297

Hs.493808
chromosome 9 open reading frame 127
C9orf127
1.13038

Hs.535972
chromosome 9 open reading frame 132
C9orf132
1.19294

Hs.522412
chromosome 9 open reading frame 16
C9orf16
1.32418

Hs.522412
chromosome 9 open reading frame 16
C9orf16
1.62565

Hs.435381
chromosome 9 open reading frame 39
C9orf39
1.54663

Hs.257556
chromosome 9 open reading frame 41
C9orf41
−1.70667

Hs.257556
chromosome 9 open reading frame 41
C9orf41
−1.50723

Hs.308074
Chromosome 9 open reading frame 5
C9orf5
−1.46697

Hs.208914
chromosome 9 open reading frame 64
C9orf64
−1.66481

Hs.530283
chromosome 9 open reading frame 80
C9orf80
−1.34228

Hs.374421
chromosome 9 open reading frame 81
C9orf81
−1.17057

Hs.428446
carbonic anhydrase XI
CA11
1.53318

Hs.155097
carbonic anhydrase II
CA2
−2.25715

Hs.63287
carbonic anhydrase IX
CA9
1.81937

Hs.443891
cache domain containing 1
CACHD1
1.4437

Hs.476358
Calcium channel, voltage-dependent, L
CACNA1D
1.34205

type, alpha 1D subunit

Hs.476358
calcium channel, voltage-dependent, L
CACNA1D
2.50302

type, alpha 1D subunit

Hs.194746
calcium channel, voltage-dependent,
CACNA1G
3.39333

alpha 1G subunit

Hs.194746
calcium channel, voltage-dependent,
CACNA1G
3.42834

alpha 1G subunit

Hs.490203
caldesmon 1
CALD1
1.86428

Hs.435457
calmodulin-like 4
CALML4
−1.15167

Hs.7753
calumenin
CALU
−1.7749

Hs.7753
calumenin
CALU
−1.32093

Hs.7753
calumenin
CALU
−1.27131

Hs.7753
calumenin
CALU
−1.13115

Hs.144114
Calcium/calmodulin-dependent protein
CAMK2D
1.05161

kinase (CaM kinase) II delta

Hs.144114
Calcium/calmodulin-dependent protein
CAMK2D
1.12993

kinase (CaM kinase) II delta

Hs.144114
calcium/calmodulin-dependent protein
CAMK2D
1.33867

kinase (CaM kinase) II delta

Hs.144114
calcium/calmodulin-dependent protein
CAMK2D
1.39652

kinase (CaM kinase) II delta

Hs.144114
calcium/calmodulin-dependent protein
CAMK2D
1.47631

kinase (CaM kinase) II delta

Hs.370581
CAP, adenylate cyclase-associated
CAP1
−1.13885

protein 1 (yeast)

Hs.370581
CAP, adenylate cyclase-associated
CAP1
−1.12518

protein 1 (yeast)

Hs.502842
calpain 1, (mu/I) large subunit
CAPN1
1.0046

Hs.350899
calpain 2, (m/II) large subunit
CAPN2
−2.05455

Hs.248153
calpain 5
CAPN5
1.24763

Hs.512867
cancer susceptibility candidate 4
CASC4
−1.44102

Hs.181855
cancer susceptibility candidate 5
CASC5
−2.52077

Hs.368982
caspase 2, apoptosis-related cysteine
CASP2
−1.37039

peptidase (neural precursor cell

expressed

Hs.368982
caspase 2, apoptosis-related cysteine
CASP2
−1.34704

peptidase (neural precursor cell

expressed

Hs.368982
caspase 2, apoptosis-related cysteine
CASP2
−1.30026

peptidase (neural precursor cell

expressed

Hs.368982
caspase 2, apoptosis-related cysteine
CASP2
−1.25427

peptidase (neural precursor cell

expressed

Hs.3280
caspase 6, apoptosis-related cysteine
CASP6
−1.39542

peptidase

Hs.9216
caspase 7, apoptosis-related cysteine
CASP7
−2.06042

peptidase

Hs.74034
caveolin 1, caveolae protein, 22 kDa
CAV1
−2.78632

Hs.74034
caveolin 1, caveolae protein, 22 kDa
CAV1
−2.1214

Hs.153934
core-binding factor, runt domain, alpha
CBFA2T2
1.20888

subunit 2; translocated to, 2

Hs.460988
core-binding factor, beta subunit
CBFB
−2.70489

Hs.460988
core-binding factor, beta subunit
CBFB
−1.58035

Hs.349283
Chromobox homolog 5 (HP1 alpha
CBX5
−1.99947

homolog, Drosophila)

Hs.55846
coiled-coil domain containing 10
CCDC10
1.33261

Hs.412019
coiled-coil domain containing 28A
CCDC28A
−1.23644

Hs.327068
coiled-coil domain containing 6
CCDC6
−2.15971

Hs.327068
coiled-coil domain containing 6
CCDC6
−2.01278

Hs.303649
chemokine (C-C motif) ligand 2
CCL2
−1.74877

Hs.85137
cyclin A2
CCNA2
−3.33175

Hs.85137
Cyclin A2
CCNA2
−2.60576

Hs.23960
cyclin B1
CCNB1
−2.80793

Hs.23960
cyclin B1
CCNB1
−2.64472

Hs.194698
cyclin B2
CCNB2
−2.2702

Hs.408658
cyclin E2
CCNE2
−2.27126

Hs.408658
cyclin E2
CCNE2
−1.71865

Hs.1600
chaperonin containing TCP1, subunit 5
CCT5
−1.5989

(epsilon)

Hs.520313
CD164 antigen, sialomucin
CD164
−3.41558

Hs.520313
CD164 antigen, sialomucin
CD164
−3.38079

Hs.520313
CD164 antigen, sialomucin
CD164
−3.25399

Hs.375108
CD24 antigen (small cell lung carcinoma
CD24
1.13881

cluster 4 antigen)

Hs.479214
CD38 antigen (p45)
CD38
−1.72773

Hs.374127
CDC16 cell division cycle 16 homolog
CDC16
−1.17129

(S. cerevisiae)

Hs.374127
CDC16 cell division cycle 16 homolog
CDC16
−1.02271

(S. cerevisiae)

Hs.334562
cell division cycle 2, G1 to S and G2 to M
CDC2
−2.74273

Hs.334562
cell division cycle 2, G1 to S and G2 to M
CDC2
−2.63937

Hs.334562
Cell division cycle 2, G1 to S and G2 to M
CDC2
−2.61709

Hs.334562
Cell division cycle 2, G1 to S and G2 to M
CDC2
−2.36056

Hs.524947
CDC20 cell division cycle 20 homolog
CDC20
−3.03263

(S. cerevisiae)

Hs.153546
CDC23 (cell division cycle 23, yeast,
CDC23
−1.77994

homolog)

Hs.1634
cell division cycle 25A
CDC25A
−2.82429

Hs.1634
cell division cycle 25A
CDC25A
−2.79743

Hs.656
cell division cycle 25C
CDC25C
−1.73437

Hs.656
cell division cycle 25C
CDC25C
−1.31429

Hs.463295
Cell division cycle 27
CDC27
−1.97837

Hs.463295
cell division cycle 27
CDC27
−1.41185

Hs.463295
cell division cycle 27
CDC27
−1.36668

Hs.463295
cell division cycle 27
CDC27
−1.34818

Hs.467637
cell division cycle 42 (GTP binding
CDC42
−1.17023

protein, 25 kDa)

Hs.467637
cell division cycle 42 (GTP binding
CDC42
2.53366

protein, 25 kDa)

Hs.467637
cell division cycle 42 (GTP binding
CDC42
3.27549

protein, 25 kDa)

Hs.369574
CDC42 effector protein (Rho GTPase
CDC42EP3
1.38367

binding) 3

Hs.369574
CDC42 effector protein (Rho GTPase
CDC42EP3
1.91269

binding) 3

Hs.369574
CDC42 effector protein (Rho GTPase
CDC42EP3
2.01896

binding) 3

Hs.508829
CDC42 small effector 2
CDC42SE2
−2.14599

Hs.508829
CDC42 small effector 2
CDC42SE2
−1.56215

Hs.508829
CDC42 small effector 2
CDC42SE2
−1.56059

Hs.474217
CDC45 cell division cycle 45-like (S. cerevisiae)
CDC45L
−1.66652

Hs.405958
CDC6 cell division cycle 6 homolog (S. cerevisiae)
CDC6
−3.94951

Hs.405958
CDC6 cell division cycle 6 homolog (S. cerevisiae)
CDC6
−3.29246

Hs.234545
cell division cycle associated 1
CDCA1
−3.47053

Hs.33366
cell division cycle associated 2
CDCA2
−1.49882

Hs.524216
cell division cycle associated 3 /// cell
CDCA3
−2.18457

division cycle associated 3

Hs.524216
cell division cycle associated 3
CDCA3
−2.12949

Hs.34045
cell division cycle associated 4
CDCA4
−1.40998

Hs.434886
cell division cycle associated 5
CDCA5
−2.09246

Hs.520245
cell division cycle associated 7-like
CDCA7L
−1.05903

Hs.524571
cell division cycle associated 8
CDCA8
−1.40849

Hs.461086
cadherin 1, type 1, E-cadherin
CDH1
1.70513

(epithelial)

Hs.89436
cadherin 17, LI cadherin (liver-intestine)
CDH17
1.63977

Hs.19192
cyclin-dependent kinase 2
CDK2
−2.72265

Hs.19192
cyclin-dependent kinase 2
CDK2
−2.43817

Hs.95577
cyclin-dependent kinase 4
CDK4
−2.95739

Hs.119882
cyclin-dependent kinase 6
CDK6
−2.36362

Hs.119882
cyclin-dependent kinase 6
CDK6
−2.00742

Hs.119882
cyclin-dependent kinase 6
CDK6
−1.82506

Hs.382306
Cyclin-dependent kinase 8
CDK8
−1.69632

Hs.382306
Cyclin-dependent kinase 8
CDK8
−1.56738

Hs.525324
cyclin-dependent kinase inhibitor 2C
CDKN2C
−1.37376

(p18, inhibits CDK4)

Hs.84113
cyclin-dependent kinase inhibitor 3
CDKN3
−2.65384

(CDK2-associated dual specificity

phosphatase

Hs.84113
cyclin-dependent kinase inhibitor 3
CDKN3
−2.56885

(CDK2-associated dual specificity

phosphatase

Hs.444924
CDP-diacylglycerol synthase
CDS1
1.66719

(phosphatidate cytidylyltransferase) 1

Hs.444924
CDP-diacylglycerol synthase
CDS1
1.84326

(phosphatidate cytidylyltransferase) 1

Hs.122908
DNA replication factor
CDT1
−2.04126

Hs.122908
DNA replication factor
CDT1
−1.77088

Hs.512682
carcinoembryonic antigen-related cell
CEACAM1
2.24852

adhesion molecule 1 (biliary

glycoprotein)

Hs.495230
cerebral endothelial cell adhesion
CEECAM1
1.25972

molecule 1

Hs.57652
cadherin, EGF LAG seven-pass G-type
CELSR2
1.76312

receptor 2 (flamingo homolog,

Drosophila)

Hs.57652
cadherin, EGF LAG seven-pass G-type
CELSR2
1.86204

receptor 2 (flamingo homolog,

Drosophila)

Hs.1594
centromere protein A, 17 kDa
CENPA
−3.18771

Hs.1594
centromere protein A, 17 kDa
CENPA
−1.7703

Hs.75573
centromere protein E, 312 kDa
CENPE
−2.09409

Hs.497741
centromere protein F, 350/400ka
CENPF
−2.37959

(mitosin)

Hs.497741
centromere protein F, 350/400ka
CENPF
−2.10529

(mitosin)

Hs.200395
centromere protein H
CENPH
−1.50918

Hs.533828
centromere protein J
CENPJ
−1.5592

Hs.503165
centaurin, delta 2
CENTD2
1.12553

Hs.504009
KIAA1052 protein
Cep164
−1.04867

Hs.363396
complement factor H
CFH
1.30117

Hs.363396
complement factor H
CFH
2.43226

Hs.154224
complement factor H /// complement
CFH /// CFHL1
2.13324

factor H-related 1

Hs.558457
complement factor H-related 4 ///
CFHL4 ///
1.98765

complement factor H-related 3
CFHL3

Hs.180141
cofilin 2 (muscle)
CFL2
−2.93902

Hs.180141
cofilin 2 (muscle) /// cofilin 2 (muscle)
CFL2
−2.85342

Hs.180141
cofilin 2 (muscle)
CFL2
−2.71961

Hs.444818
CGG triplet repeat binding protein 1
CGGBP1
−1.33141

Hs.501513
comparative gene identification
CGI-37
−1.26782

transcript 37

Hs.501513
comparative gene identification
CGI-37
−1.26573

transcript 37

Hs.463465
WD repeat domain 50
CGI-48
−1.64651

Hs.79018
chromatin assembly factor 1, subunit A
CHAF1A
−1.23151

(p150)

Hs.25601
chromodomain helicase DNA binding
CHD3
1.57624

protein 3

Hs.24529
CHK1 checkpoint homolog (S. pombe)
CHEK1
−2.28739

Hs.24529
CHK1 checkpoint homolog (S. pombe)
CHEK1
−2.22291

Hs.24529
CHK1 checkpoint homolog (S. pombe)
CHEK1
−2.18967

Hs.434286
checkpoint suppressor 1
CHES1
1.49966

Hs.434286
checkpoint suppressor 1
CHES1
1.57973

Hs.516874
chromogranin B (secretogranin 1)
CHGB
1.72318

Hs.496323
Cysteine-rich hydrophobic domain 1
CHIC1
−1.69798

Hs.476930
chromatin modifying protein 2B
CHMP2B
−1.27962

Hs.279704
chromatin accessibility complex 1
CHRAC1
−1.23092

Hs.534593
Similar to RIKEN cDNA 1700009P17
chromosome 1
−1.28965

open reading

frame 192

Hs.110488
carbohydrate (chondroitin) synthase 1
CHSY1
−1.31988

Hs.198998
conserved helix-loop-helix ubiquitous
CHUK
−1.98322

kinase

Hs.135471
calcium and integrin binding 1
CIB1
−1.05209

(calmyrin)

Hs.129634
Cyclin-dependent kinase 2-interacting
CINP
−1.32371

protein

Hs.119594
citron (rho-interacting, serine/threonine
CIT
−1.25598

kinase 21)

Hs.444028
cytoskeleton associated protein 2
CKAP2
−1.24034

Hs.173724
creatine kinase, brain
CKB
1.83826

Hs.298198
chemokine-like factor superfamily 3
CKLFSF3
−1.6061

Hs.298198
chemokine-like factor superfamily 3
CKLFSF3
−1.29543

Hs.380627
chemokine-like factor superfamily 6
CKLFSF6
−2.84068

Hs.380627
chemokine-like factor superfamily 6
CKLFSF6
−2.8031

Hs.440494
chemokine-like factor superfamily 7
CKLFSF7
−1.20631

Hs.374378
CDC28 protein kinase regulatory
CKS1B
−2.84574

subunit 1B

Hs.83758
CDC28 protein kinase regulatory
CKS2
−1.81245

subunit 2

Hs.554803
chloride channel CLIC-like 1
CLCC1
−1.23379

Hs.495674
Chloride channel 4
CLCN4
1.06607

Hs.439060
claudin 1
CLDN1
−2.15902

Hs.439060
claudin 1
CLDN1
−2.08021

Hs.86368
calmegin
CLGN
−1.01082

Hs.301478
calmin (calponin-like, transmembrane)
CLMN
1.92181

Hs.175613
claspin homolog (Xenopus laevis)
CLSPN
−1.23104

Hs.29665
calsyntenin 1
CLSTN1
1.45359

Hs.11463
cytidylate kinase
CMPK
−1.47314

Hs.5719
chromosome condensation-related SMC-
CNAP1
−1.45856

associated protein 1

Hs.148590
cornifelin /// cornifelin
CNFN
1.99736

Hs.483454
calponin 3, acidic
CNN3
−2.24638

Hs.483454
Calponin 3, acidic
CNN3
−1.66067

Hs.274579
cyclin M1
CNNM1
1.01851

Hs.460923
CCR4-NOT transcription complex,
CNOT1
−1.34874

subunit 1

Hs.157606
CCR4-NOT transcription complex,
CNOT6
1.39775

subunit 6

Hs.523446
collagen, type XI, alpha 1
COL11A1
1.36205

Hs.523446
collagen, type XI, alpha 1
COL11A1
1.66296

Hs.101302
collagen, type XII, alpha 1
COL12A1
−2.03051

Hs.172928
collagen, type I, alpha 1
COL1A1
1.45332

Hs.172928
collagen, type I, alpha 1
COL1A1
2.20304

Hs.172928
collagen, type I, alpha 1
COL1A1
2.80419

Hs.47629
collagen, type XXI, alpha 1 /// collagen,
COL21A1
1.21918

type XXI, alpha 1

Hs.17441
collagen, type IV, alpha 1
COL4A1
−1.71965

Hs.17441
collagen, type IV, alpha 1
COL4A1
−1.58672

Hs.471525
collagen, type IV, alpha 3 (Goodpasture
COL4A3
1.55068

antigen)

Hs.369089
collagen, type IV, alpha 5 (Alport
COL4A5
1.39226

syndrome)

Hs.145586
collagen, type IV, alpha 6
COL4A6
1.6256

Hs.145586
collagen, type IV, alpha 6
COL4A6
1.87491

Hs.210283
collagen, type V, alpha 1
COL5A1
1.36412

Hs.210283
collagen, type V, alpha 1
COL5A1
1.48443

Hs.476218
collagen, type VII, alpha 1
COL7A1
1.05271

Hs.476218
collagen, type VII, alpha 1
COL7A1
1.09717

Hs.2076
COMM domain containing 5 /// COMM
COMMD5
−1.18784

domain containing 5

Hs.532231
coatomer protein complex, subunit
COPG2
1.48591

gamma 2

Hs.505652
coatomer protein complex, subunit zeta 1
COPZ1
−1.9788

Hs.289092
coactosin-like 1 (Dictyostelium)
COTL1
−1.48488

Hs.289092
coactosin-like 1 (Dictyostelium)
COTL1
−1.32679

Hs.75360
carboxypeptidase E
CPE
1.19391

Hs.127126
cytoplasmic polyadenylation element
CPEB4
1.06491

binding protein 4

Hs.127126
cytoplasmic polyadenylation element
CPEB4
1.41208

binding protein 4

Hs.199877
copine IV
CPNE4
1.69765

Hs.476982
coproporphyrinogen oxidase
CPOX
−1.26337

Hs.149252
carbamoyl-phosphate synthetase 1,
CPS1
−1.69539

mitochondrial

Hs.149252
carbamoyl-phosphate synthetase 1,
CPS1
−1.44753

mitochondrial

Hs.503043
carnitine palmitoyltransferase 1A (liver)
CPT1A
−1.34021

Hs.150319
Crumbs homolog 3 (Drosophila)
CRB3
1.14995

Hs.924
crystallin, mu
CRYM
1.1329

Hs.474833
casein kinase 1, epsilon
CSNK1E
1.17153

Hs.443681
chondroitin sulfate proteoglycan 2
CSPG2
1.07451

(versican)

Hs.443681
chondroitin sulfate proteoglycan 2
CSPG2
1.08543

(versican)

Hs.443681
chondroitin sulfate proteoglycan 2
CSPG2
1.1818

(versican)

Hs.24485
chondroitin sulfate proteoglycan 6
CSPG6
−1.56026

(bamacan)

Hs.24485
chondroitin sulfate proteoglycan 6
CSPG6
−1.17463

(bamacan)

Hs.530904
cysteine and glycine-rich protein 2
CSRP2
−1.60358

Hs.444468
CTD (carboxy-terminal domain, RNA
CTDSP1
−1.09632

polymerase II, polypeptide A) small

phosphatas

Hs.445981
catenin (cadherin-associated protein),
CTNNA1
−1.94658

alpha 1, 102 kDa

Hs.58488
catenin (cadherin-associated protein),
CTNNAL1
−1.7894

alpha-like 1

Hs.166011
catenin (cadherin-associated protein),
CTNND1
−1.66793

delta 1

Hs.128065
cathepsin C
CTSC
−1.30469

Hs.128065
cathepsin C
CTSC
−1.25866

Hs.546248
cathepsin D (lysosomal aspartyl
CTSD
1.11754

peptidase)

Hs.181301
cathepsin S
CTSS
1.44435

Hs.789
chemokine (C—X—C motif) ligand 1
CXCL1
−2.7128

(melanoma growth stimulating activity,

alpha)

Hs.75765
chemokine (C—X—C motif) ligand 2
CXCL2
−2.68663

Hs.89714
chemokine (C—X—C motif) ligand 5
CXCL5
−2.89046

Hs.89714
chemokine (C—X—C motif) ligand 5
CXCL5
−1.6063

Hs.89714
chemokine (C—X—C motif) ligand 5
CXCL5
−1.55161

Hs.443061
Chromosome X open reading frame 45
CXorf45
1.47797

Hs.443061
chromosome X open reading frame 45
CXorf45
1.92828

Hs.443061
chromosome X open reading frame 45
CXorf45
2.97671

Hs.12248
CXXC finger 4
CXXC4
1.48583

Hs.189119
CXXC finger 5 /// CXXC finger 5
CXXC5
1.47101

Hs.465413
cytochrome b-5
CYB5
−1.22343

Hs.465413
cytochrome b-5
CYB5
−1.20915

Hs.465413
cytochrome b-5
CYB5
−1.18979

Hs.221941
cytochrome b reductase 1
CYBRD1
−1.71885

Hs.437060
cytochrome c, somatic
CYCS
−1.39544

Hs.26704
Cytoplasmic FMR1 interacting protein 1
CYFIP1
−1.23593

Hs.519702
cytoplasmic FMR1 interacting protein 2
CYFIP2
2.18417

Hs.519702
cytoplasmic FMR1 interacting protein 2
CYFIP2
2.55062

/// cytoplasmic FMR1 interacting protein

Hs.95120
cytoglobin
CYGB
1.41563

Hs.255664
cytoplasmic linker 2 /// cytoplasmic
CYLN2
1.21467

linker 2

Hs.522863
Chromosome Y open reading frame 15A
CYorf15A
−1.0077

Hs.154654
cytochrome P450, family 1, subfamily
CYP1B1
−2.16666

B, polypeptide 1

Hs.154654
cytochrome P450, family 1, subfamily
CYP1B1
−1.87882

B, polypeptide 1

Hs.154654
cytochrome P450, family 1, subfamily
CYP1B1
−1.62631

B, polypeptide 1

Hs.91546
cytochrome P450, family 26, subfamily
CYP26B1
−1.22772

B, polypeptide 1

Hs.150276
cytochrome P450, family 3, subfamily
CYP3A5
1.20104

A, polypeptide 5

Hs.150276
cytochrome P450, family 3, subfamily
CYP3A5
1.35169

A, polypeptide 5

Hs.150276
cytochrome P450, family 3, subfamily
CYP3A5
1.54568

A, polypeptide 5

Hs.417077
cytochrome P450, family 51, subfamily
CYP51A1
−1.4555

A, polypeptide 1

Hs.417077
cytochrome P450, family 51, subfamily
CYP51A1
−1.32422

A, polypeptide 1

Hs.371597
dynein 2 light intermediate chain
D2LIC
1.32776

Hs.371597
dynein 2 light intermediate chain
D2LIC
1.51611

Hs.75189
death-associated protein
DAP
−1.49054

Hs.270570
dihydrolipoamide branched chain
DBT
−1.2195

transacylase E2

Hs.458320
DC12 protein
DC12
−1.10743

Hs.507755
doublecortin and CaM kinase-like 1
DCAMKL1
−2.902

Hs.567333
discoidin, CUB and LCCL domain
DCBLD1
1.05197

containing 1

Hs.567333
discoidin, CUB and LCCL domain
DCBLD1
1.48436

containing 1

Hs.315167
defective in sister chromatid cohesion
DCC1
−2.34375

homolog 1 (S. cerevisiae)

Hs.443875
DCP2 decapping enzyme homolog (S. cerevisiae)
DCP2
−1.81125

Hs.328865
dynactin 4 (p62)
DCTN4
−2.02467

Hs.328865
dynactin4 (p62)
DCTN4
−1.31851

Hs.179852
Dendritic cell-derived ubiquitin-like
DC-UbP
1.32734

protein

Hs.446564
damage-specific DNA binding protein 2,
DDB2 /// LHX3
1.14095

48 kDa /// LIM homeobox 3

Hs.520004
discoidin domain receptor family,
DDR1
1.4327

member 1

Hs.520004
discoidin domain receptor family,
DDR1
1.68595

member 1

Hs.520004
discoidin domain receptor family,
DDR1
1.80256

member 1

Hs.520004
discoidin domain receptor family,
DDR1
1.89648

member 1

Hs.503794
DEAD (Asp-Glu-Ala-Asp) box
DDX10
−1.42152

polypeptide 10

Hs.363492
DEAD (Asp-Glu-Ala-Asp) box
DDX18
−1.05918

polypeptide 18

Hs.223141
DEAD (Asp-Glu-Ala-Asp) box
DDX21 ///
−1.30791

polypeptide 21 /// zinc finger protein 596
ZNF596

Hs.510328
DEAD (Asp-Glu-Ala-Asp) box
DDX24
−1.19965

polypeptide 24

Hs.311609
DEAD (Asp-Glu-Ala-Asp) box
DDX39
−1.08985

polypeptide 39

Hs.99120
DEAD (Asp-Glu-Ala-Asp) box
DDX3Y
1.50168

polypeptide 3, Y-linked

Hs.8765
DEAD (Asp-Glu-Ala-Asp) box
DDX42
−1.1377

polypeptide 42

Hs.190622
DEAD (Asp-Glu-Ala-Asp) box
DDX58
1.18939

polypeptide 58

Hs.190622
DEAD (Asp-Glu-Ala-Asp) box
DDX58
1.20084

polypeptide 58

Hs.299878
degenerative spermatocyte homolog 1,
DEGS1
−1.77701

lipid desaturase (Drosophila)

Hs.22393
density-regulated protein
DENR
−1.37677

Hs.22393
density-regulated protein
DENR
−1.25724

Hs.445098
DEP domain containing 1
DEPDC1
−3.6264

Hs.445098
DEP domain containing 1
DEPDC1
−3.46414

Hs.445098
DEP domain containing 1
DEPDC1
−2.92426

Hs.445098
DEP domain containing 1
DEPDC1
−2.39652

Hs.482233
DEP domain containing 1B
DEPDC1B
−3.43354

Hs.524488
diacylglycerol kinase, alpha 80 kDa
DGKA
1.2677

Hs.469022
deoxyguanosine kinase
DGUOK
1.04628

Hs.503134
7-dehydrocholesterol reductase
DHCR7
−1.80162

Hs.503134
7-dehydrocholesterol reductase
DHCR7
−1.72273

Hs.83765
dihydrofolate reductase
DHFR
−2.16081

Hs.83765
dihydrofolate reductase
DHFR
−2.0783

Hs.83765
dihydrofolate reductase
DHFR
−1.72997

Hs.83765
dihydrofolate reductase
DHFR
−1.7002

Hs.18788
dehydrogenase/reductase (SDR family)
DHRS10
1.23476

member 10

Hs.18788
dehydrogenase/reductase (SDR family)
DHRS10
1.55439

member 10

Hs.18788
dehydrogenase/reductase (SDR family)
DHRS10
1.66056

member 10

Hs.326950
dehydrogenase/reductase (SDR family)
DHRS4
−1.01155

member 4

Hs.29403
DEAH (Asp-Glu-Ala-His) box
DHX40
2.06771

polypeptide 40

Hs.191518
DEAH (Asp-Glu-Ala-His) box
DHX9
−1.59238

polypeptide 9

Hs.283127
Diaphanous homolog 3 (Drosophila)
DIAPH3
−2.38043

Hs.508141
diaphanous homolog 3 (Drosophila)
DIAPH3
−2.25026

Hs.87889
Dicer1, Dcr-1 homolog (Drosophila)
DICER1
−1.58904

Hs.87889
Dicer1, Dcr-1 homolog (Drosophila)
DICER1
−1.5863

Hs.506603
DIP13 beta
DIP13B
1.05222

Hs.177275
hypothetical protein dJ122O8.2
DJ122O8.2
−1.19499

Hs.177275
Hypothetical protein dJ122O8.2
DJ122O8.2
−1.04671

Hs.4747
dyskeratosis congenita 1, dyskerin
DKC1
−2.11937

Hs.4747
dyskeratosis congenita 1, dyskerin
DKC1
−2.05753

Hs.4747
dyskeratosis congenita 1, dyskerin
DKC1
−1.97153

Hs.511979
DKFZP434B0335 protein
DKFZP434B0335
1.06548

Hs.294103
LMBR1 domain containing 2
DKFZp434H2226
−1.03157

Hs.444668
hypothetical protein DKFZp434K2435
DKFZp434K2435
1.7496

Hs.485899
CTTNBP2 N-terminal like
DKFZp547A023
1.34904

Hs.491626
Ring finger protein 170
DKFZP564A022
1.75121

Hs.410889
putative ankyrin-repeat containing
DKFZP564D166
1.01131

protein

Hs.356719
DKFZP564J0863 protein
DKFZP564J0863
−3.57402

Hs.323562
implantation-associated protein
DKFZp564K142
−4.39045

Hs.323562
implantation-associated protein
DKFZp564K142
−3.5671

Hs.386989
DKFZP566O084 protein
DKFZp566O084
−1.01449

Hs.497518
hypothetical protein DKFZp761N1114
DKFZp761N1114
1.19395

Hs.497518
hypothetical protein DKFZp761N1114
DKFZp761N1114
1.89937

Hs.497518
hypothetical protein DKFZp761N1114
DKFZp761N1114
2.73396

Hs.532968
hypothetical protein DKFZp762E1312
DKFZp762E1312
−2.55383

Hs.292156
dickkopf homolog 3 (Xenopus laevis)
DKK3
1.1792

Hs.292156
Dickkopf homolog 3 (Xenopus laevis)
DKK3
1.19263

Hs.292156
dickkopf homolog 3 (Xenopus laevis)
DKK3
1.74194

Hs.134296
deleted in liver cancer 1
DLC1
−1.44525

Hs.527922
deleted in lymphocytic leukemia, 1
DLEU1
−1.40974

Hs.548247
deleted in lymphocytic leukemia, 2 ///
DLEU2 ///
−1.6719

BCMS upstream neighbor-like
BCMSUNL

Hs.548247
deleted in lymphocytic leukemia, 2 ///
DLEU2 ///
−1.31947

BCMS upstream neighbor-like
BCMSUNL

Hs.77695
discs, large homolog 7 (Drosophila)
DLG7
−2.90398

Hs.532446
DNA2 DNA replication helicase 2-like
DNA2L
−1.54051

(yeast)

Hs.490745
DnaJ (Hsp40) homolog, subfamily B,
DNAJB6
−1.41306

member 6

Hs.499000
DnaJ (Hsp40) homolog, subfamily C,
DNAJC1
−2.62796

member 1

Hs.499000
DnaJ (Hsp40) homolog, subfamily C,
DNAJC1
−2.54013

member 1

Hs.499000
DnaJ (Hsp40) homolog, subfamily C,
DNAJC1
−1.70042

member 1

Hs.521764
DnaJ (Hsp40) homolog, subfamily C,
DNAJC16
1.10086

member 16

Hs.536063
DnaJ (Hsp40) homolog, subfamily C,
DNAJC6
1.10817

member 6

Hs.59125
DnaJ (Hsp40) homolog, subfamily C,
DNAJC9
−1.32488

member 9

Hs.59125
DnaJ (Hsp40) homolog, subfamily C,
DNAJC9
−1.11517

member 9

Hs.529495
dynein, cytoplasmic, light intermediate
DNCLI1
−1.1779

polypeptide 1

Hs.159195
dedicator of cytokinesis 1
DOCK1
2.26656

Hs.476284
dedicator of cytokinesis 3
DOCK3
1.66379

Hs.406156
dedicator of cytokinesis 7
DOCK7
−1.19771

Hs.132599
dedicator of cytokinesis 8
DOCK8
1.50055

Hs.132599
dedicator of cytokinesis 8
DOCK8
2.35211

Hs.279832
docking protein 4
DOK4
1.3361

Hs.279832
docking protein 4
DOK4
1.37223

Hs.502914
dipeptidylpeptidase 3
DPP3
1.01747

Hs.502914
dipeptidylpeptidase 3
DPP3
1.07768

Hs.533644
dpy-19-like 2 (C. elegans)
DPY19L2
1.1825

Hs.335034
dihydropyrimidine dehydrogenase
DPYD
−1.98042

Hs.519659
dihydropyrimidinase-like 3
DPYSL3
−1.73075

Hs.519659
dihydropyrimidinase-like 3
DPYSL3
−1.50947

Hs.100058
dihydropyrimidinase-like 4
DPYSL4
1.09712

Hs.100058
dihydropyrimidinase-like 4
DPYSL4
2.60688

Hs.191705
DEAQ box polypeptide 1 (RNA-
DQX1
1.27392

dependent ATPase)

Hs.148680
dopamine receptor D1 interacting
DRD1IP
1.07102

protein

Hs.279583
DORA reverse strand protein 1
DREV1
1.06286

Hs.369998
Dbf4-related factor 1
DRF1
−1.17251

Hs.412597
desmoglein 2
DSG2
−1.9102

Hs.412597
Desmoglein 2
DSG2
−1.34315

Hs.126774
denticleless homolog (Drosophila)
DTL
−4.10861

Hs.126774
denticleless homolog (Drosophila)
DTL
−3.43887

Hs.471873
deoxythymidylate kinase (thymidylate
DTYMK
−1.86636

kinase)

Hs.471873
deoxythymidylate kinase (thymidylate
DTYMK
−1.71737

kinase)

Hs.171695
dual specificity phosphatase 1
DUSP1
−1.50727

Hs.130988
dual-specificity tyrosine-(Y)-
DYRK1B
1.35198

phosphorylation regulated kinase 1B

Hs.126403
dyslexia susceptibility 1 candidate 1
DYX1C1
1.7048

Hs.409210
zinc finger DAZ interacting protein 3
DZIP3
1.07621

Hs.409210
zinc finger DAZ interacting protein 3
DZIP3
1.2468

Hs.523526
E2F transcription factor 8
E2F8
−3.18656

Hs.474479
ELL associated factor 1
EAF1
−2.10197

Hs.522636
emopamil binding protein (sterol
EBP
−1.26922

isomerase)

Hs.522636
emopamil binding protein (sterol
EBP
−1.25848

isomerase)

Hs.196176
enoyl Coenzyme A hydratase 1,
ECH1
−1.42239

peroxisomal

Hs.518299
epithelial cell transforming sequence 2
ECT2
−2.10847

oncogene

Hs.518299
epithelial cell transforming sequence 2
ECT2
−1.73218

oncogene

Hs.492445
E3 ubiquitin protein ligase, HECT
EDD
2.022

domain containing, 1

Hs.482730
EGF-like repeats and discoidin I-like
EDIL3
2.8031

domains 3

Hs.134857
EF-hand calcium binding domain 2
EFCAB2
−1.71885

Hs.134857
EF-hand calcium binding domain 2
EFCAB2
−1.01445

Hs.76224
EGF-containing fibulin-like extracellular
EFEMP1
−1.83654

matrix protein 1

Hs.76224
EGF-containing fibulin-like extracellular
EFEMP1
−1.31285

matrix protein 1

Hs.403594
EF-hand domain family, member A2
EFHA2
1.31663

Hs.257224
EF-hand domain family, member B
EFHB
1.00964

Hs.465374
EF-hand domain family, member D2
EFHD2
−2.46123

Hs.132483
EGF-like-domain, multiple 4
EGFL4
1.87874

Hs.494977
EGF-like-domain, multiple 5
EGFL5
1.80931

Hs.368808
EH-domain containing 3
EHD3
1.71415

Hs.461178
eukaryotic translation initiation factor
EIF1AY
−1.10984

1A, Y-linked

Hs.449415
Eukaryotic translation initiation factor
EIF2C2
−1.12295

2C, 2

Hs.471492
Eukaryotic translation initiation factor
EIF2C4
1.80642

2C, 4

Hs.151777
eukaryotic translation initiation factor 2,
EIF2S1
−2.73226

subunit 1 alpha, 35 kDa

Hs.151777
eukaryotic translation initiation factor 2,
EIF2S1
−2.09459

subunit 1 alpha, 35 kDa

Hs.404056
eukaryotic translation initiation factor 3,
EIF3S1
−2.28229

subunit 1 alpha, 35 kDa

Hs.404056
eukaryotic translation initiation factor 3,
EIF3S1
−1.79959

subunit 1 alpha, 35 kDa

Hs.404056
eukaryotic translation initiation factor 3,
EIF3S1
−1.4991

subunit 1 alpha, 35 kDa

Hs.129673
Eukaryotic translation initiation factor
EIF4A1
−1.15915

4A, isoform 1

Hs.476782
eukaryotic translation initiation factor
EIF4E3
1.41972

4E member 3

Hs.476782
eukaryotic translation initiation factor
EIF4E3
1.5781

4E member 3

Hs.411641
eukaryotic translation initiation factor
EIF4EBP1
−1.39677

4E binding protein 1

Hs.433750
eukaryotic translation initiation factor 4
EIF4G1
−1.03814

gamma, 1

Hs.467084
eukaryotic translation initiation factor 4
EIF4G3
1.26523

gamma, 3

Hs.558325
eukaryotic translation initiation factor 5
EIF5
−1.93228

Hs.558325
eukaryotic translation initiation factor 5
EIF5
−1.86911

Hs.46523
ELK3, ETS-domain protein (SRF
ELK3
−2.45655

accessory protein 2)

Hs.46523
ELK3, ETS-domain protein (SRF
ELK3
−1.25066

accessory protein 2)

Hs.192221
elongation factor, RNA polymerase II, 2
ELL2
−1.91899

Hs.192221
elongation factor, RNA polymerase II, 2
ELL2
−1.62813

Hs.192221
elongation factor, RNA polymerase II, 2
ELL2
−1.57786

Hs.558550
elongation factor RNA polymerase II-
ELL3
1.13084

like 3

Hs.558550
elongation factor RNA polymerase II-
ELL3
1.71885

like 3

Hs.200100
hypothetical protein Ells1
Ells1
1.24292

Hs.304578
engulfment and cell motility 1 (ced-12
ELMO1
1.22869

homolog, C. elegans)

Hs.25597
elongation of very long chain fatty acids
ELOVL1
−2.76914

(FEN1/Elo2, SUR4/Elo3, yeast)-like 1

Hs.25597
elongation of very long chain fatty acids
ELOVL1
−2.59687

(FEN1/Elo2, SUR4/Elo3, yeast)-like 1

Hs.101915
elongation of very long chain fatty acids
ELOVL4
1.71465

(FEN1/Elo2, SUR4/Elo3, yeast)-like 4

Hs.520189
ELOVL family member 5, elongation of
ELOVL5
−2.45897

long chain fatty acids

Hs.511915
enolase 2 (gamma, neuronal)
ENO2
1.49254

Hs.224171
enolase 3 (beta, muscle)
ENO3
1.13782

Hs.511916
endosulfine alpha
ENSA
−1.27401

Hs.511916
endosulfine alpha
ENSA
−1.25068

Hs.511916
endosulfine alpha
ENSA
1.18864

Hs.444389
ectonucleoside triphosphate
ENTPD4
1.05884

diphosphohydrolase 4

Hs.437422
erythrocyte membrane protein band 4.1-
EPB41L1
1.95706

like 1

Hs.371218
EPH receptor A4
EPHA4
1.1881

Hs.462445
B9 protein
EPPB9
1.47687

Hs.200412
epiplakin 1
EPPK1
1.15271

Hs.200412
epiplakin 1
EPPK1
1.31746

Hs.497788
glutamyl-prolyl-tRNA synthetase
EPRS
−1.02469

Hs.3426
Era G-protein-like 1 (E. coli)
ERAL1
−1.06767

Hs.558519
ERO1-like beta (S. cerevisiae)
ERO1LB
1.04461

Hs.99480
establishment of cohesion 1 homolog 2
ESCO2
−2.44684

(S. cerevisiae)

Hs.99480
establishment of cohesion 1 homolog 2
ESCO2
−1.78936

(S. cerevisiae)

Hs.153479
extra spindle poles like 1 (S. cerevisiae)
ESPL1
−1.91154

Hs.153479
extra spindle poles like 1 (S. cerevisiae)
ESPL1
−1.82069

Hs.369438
v-ets erythroblastosis virus E26
ETS1
−1.6735

oncogene homolog 1 (avian)

Hs.22634
ets variant gene 1
ETV1
−1.88347

Hs.125867
Enah/Vasp-like
EVL
1.13764

Hs.498248
exonuclease 1
EXO1
−2.25023

Hs.546354
exosome component 2
EXOSC2
−1.3212

Hs.493887
exosome component 3
EXOSC3
−1.11772

Hs.294041
exosome component 8
EXOSC8
−1.5286

Hs.357637
exostoses (multiple)-like 2
EXTL2
−1.22071

Hs.102408
Eyes absent homolog 4 (Drosophila)
EYA4
−1.19608

Hs.194669
enhancer of zeste homolog 1
EZH1
1.20347

(Drosophila)

Hs.444082
enhancer of zeste homolog 2
EZH2
−1.78348

(Drosophila)

Hs.517293
F11 receptor
F11R
−1.8927

Hs.517293
F11 receptor
F11R
−1.85886

Hs.435782
coagulation factor XIII, B polypeptide
F13B
1.78363

Hs.482562
coagulation factor II (thrombin) receptor
F2R
2.34626

Hs.42502
coagulation factor II (thrombin)
F2RL2
−2.82395

receptor-like 2

Hs.30054
coagulation factor V (proaccelerin, labile
F5
1.78664

factor)

Hs.413083
coagulation factor VIII, procoagulant
F8
1.97013

component (hemophilia A)

Hs.503546
fatty acid desaturase 1
FADS1
−1.6424

Hs.444200
fetal Alzheimer antigen
FALZ
1.07428

Hs.567322
family with sequence similarity 13,
FAM13C1
1.79836

member C1

Hs.436854
family with sequence similarity 19
FAM19A5
1.40543

(chemokine (C-C motif)-like), member

A5

Hs.548148
family with sequence similarity 29,
FAM29A
−1.93931

member A

Hs.548148
family with sequence similarity 29,
FAM29A
−1.82376

member A

Hs.533468
family with sequence similarity 29,
FAM29A
−1.3457

member A

Hs.121536
family with sequence similarity 54,
FAM54A
−2.61482

member A

Hs.121536
family with sequence similarity 54,
FAM54A
−1.11101

member A

Hs.404323
family with sequence similarity 64,
FAM64A
−1.37793

member A

Hs.495480
family with sequence similarity 69,
FAM69B
2.2303

member B

Hs.339665
family with sequence similarity 72,
FAM72A
−2.16905

member A

—
family with sequence similarity 73,
FAM73A
−2.3104

member A

—
family with sequence similarity 73,
FAM73A
−2.1617

member A

Hs.124951
family with sequence similarity 84,
FAM84B
2.32367

member B

Hs.38516
family with sequence similarity 89,
FAM89A
−2.11277

member A

Hs.284153
Fanconi anemia, complementation group A
FANCA
−1.32474

Hs.554740
Fanconi anemia, complementation group B
FANCB
−1.13523

Hs.208388
Fanconi anemia, complementation group
FANCD2
−2.84826

D2

Hs.208388
Fanconi anemia, complementation group
FANCD2
−1.60374

D2

Hs.434873
Fanconi anemia, complementation group G
FANCG
−1.5852

Hs.244139
Fas (TNF receptor superfamily, member
FAS
1.17228

6)

Hs.244139
Fas (TNF receptor superfamily, member
FAS
1.24654

6)

Hs.244139
Fas (TNF receptor superfamily, member
FAS
1.31565

6)

Hs.244139
Fas (TNF receptor superfamily, member
FAS
1.4722

6)

Hs.475872
F-box and leucine-rich repeat protein 2
FBXL2
1.17038

Hs.558474
F-box and leucine-rich repeat protein 21
FBXL21
1.27072

Hs.558474
F-box and leucine-rich repeat protein 21
FBXL21
2.34014

Hs.558475
F-box and leucine-rich repeat protein 4
FBXL4
−1.08835

Hs.458959
F-box protein 22
FBXO22
1.33276

Hs.64691
F-box protein 28
FBXO28
−1.7029

Hs.406787
F-box protein 3
FBXO3
1.62174

Hs.421095
F-box protein 30
FBXO30
−1.01912

Hs.23158
F-box protein 41
FBXO41
1.55528

Hs.339577
F-box protein 43
FBXO43
−1.14098

Hs.520506
F-box protein 5
FBXO5
−1.48612

Hs.520506
F-box protein 5
FBXO5
−1.26949

Hs.494985
F-box and WD-40 domain protein 2
FBXW2
1.58044

Hs.519029
F-box and WD-40 domain protein 7
FBXW7
1.64939

(archipelago homolog, Drosophila)

Hs.445748
FCH and double SH3 domains 2
FCHSD2
1.02896

Hs.335918
farnesyl diphosphate synthase (farnesyl
FDPS
−1.10151

pyrophosphate synthetase, dimethylallylt

Hs.69745
ferredoxin reductase
FDXR
2.8746

Hs.409065
flap structure-specific endonuclease 1
FEN1
−2.23817

Hs.409065
flap structure-specific endonuclease 1
FEN1
−2.1121

Hs.351593
fibrinogen alpha chain
FGA
−2.37948

Hs.351593
fibrinogen alpha chain
FGA
−2.28712

Hs.117835
FYVE, RhoGEF and PH domain
FGD4
1.13339

containing 4

Hs.284244
fibroblast growth factor 2 (basic)
FGF2
−1.70317

Hs.1420
fibroblast growth factor receptor 3
FGFR3
2.07112

(achondroplasia, thanatophoric

dwarfism)

Hs.436636
formin homology 2 domain containing 3
FHOD3
2.33086

Hs.137516
fidgetin-like 1
FIGNL1
−2.0818

Hs.137516
fidgetin-like 1
FIGNL1
−1.68787

Hs.526972
filamin A interacting protein 1
FILIP1
1.55547

Hs.529778
leucine zipper protein FKSG14
FKSG14
−2.8554

Hs.104650
mago-nashi homolog
FLJ10292
−1.21858

Hs.513126
hypothetical protein FLJ10719
FLJ10719
−2.38659

Hs.513126
hypothetical protein FLJ10719
FLJ10719
−2.04896

Hs.513126
hypothetical protein FLJ10719
FLJ10719
−1.25703

Hs.8395
hypothetical protein FLJ10781
FLJ10781
1.22672

Hs.212774
hypothetical protein FLJ10808
FLJ10808
−1.39867

Hs.212774
hypothetical protein FLJ10808
FLJ10808
−1.34747

Hs.212774
hypothetical protein FLJ10808
FLJ10808
−1.06753

Hs.556432
Hypothetical protein FLJ10979
FLJ10979
1.12946

Hs.152385
hypothetical protein FLJ10980
FLJ10980
1.58824

Hs.567288
hypothetical protein FLJ11000
FLJ11000
1.06971

Hs.274448
Hypothetical protein FLJ11029
FLJ11029
−2.28046

Hs.368853
hypothetical protein FLJ12443
FLJ12443
1.3187

Hs.482301
Hypothetical protein FLJ13611
FLJ13611
1.09987

Hs.387057
hypothetical protein FLJ13710
FLJ13710
1.27871

Hs.47125
hypothetical protein FLJ13912
FLJ13912
−1.42993

Hs.47125
hypothetical protein FLJ13912
FLJ13912
−1.27517

Hs.55148
hypothetical protein FLJ14466
FLJ14466
−2.34469

Hs.190983
hypothetical protein FLJ14624
FLJ14624
1.19615

Hs.190983
hypothetical protein FLJ14624
FLJ14624
1.24685

Hs.190983
hypothetical protein FLJ14624
FLJ14624
1.8325

Hs.437195
hypothetical protein FLJ14627
FLJ14627
1.50921

Hs.321689
hypothetical protein FLJ14981
FLJ14981
1.46622

Hs.518926
hypothetical protein FLJ20054
FLJ20054
−1.24644

Hs.47558
FLJ20105 protein
FLJ20105
−1.64963

Hs.418581
FLJ20160 protein
FLJ20160
2.47673

Hs.418581
FLJ20160 protein
FLJ20160
2.48305

Hs.148677
hypothetical protein FLJ20232
FLJ20232
−1.17884

Hs.518727
RNA-binding protein
FLJ20273
−1.65332

Hs.518727
RNA-binding protein
FLJ20273
−1.61792

Hs.518727
RNA-binding protein
FLJ20273
−1.37823

Hs.351798
FLJ20298 protein
FLJ20298
1.66429

Hs.368710
hypothetical protein FLJ20364
FLJ20364
−2.39146

Hs.426696
timeless-interacting protein
FLJ20516
−1.487

Hs.330663
hypothetical protein FLJ20641
FLJ20641
−2.81289

Hs.330663
hypothetical protein FLJ20641
FLJ20641
−2.77079

Hs.96852
hypothetical protein FLJ21128
FLJ21128
−1.36176

Hs.549331
ASAP
FLJ21159
1.52083

Hs.369368
Hypothetical protein FLJ21924
FLJ21924
−1.52374

Hs.187505
hypothetical protein FLJ22222
FLJ22222
−1.25193

Hs.424711
hypothetical protein FLJ22313
FLJ22313
1.5447

Hs.424711
hypothetical protein FLJ22313
FLJ22313
1.66334

Hs.424711
hypothetical protein FLJ22313
FLJ22313
1.80024

Hs.459795
leucine zipper domain protein
FLJ22386
1.25305

Hs.114111
limkain beta 2
FLJ22471
1.06387

Hs.209715
FLJ22624 protein
FLJ22624
−1.46878

Hs.351173
hypothetical protein FLJ25006
FLJ25006
1.62739

Hs.529340
hypothetical protein FLJ25067
FLJ25067
1.25011

Hs.165607
hypothetical protein FLJ25416
FLJ25416
−2.27211

Hs.404000
hypothetical protein FLJ30655
FLJ30655
−1.23773

Hs.404000
Hypothetical protein FLJ30655
FLJ30655
−1.19698

Hs.556067
hypothetical protein FLJ31306
FLJ31306
1.20769

Hs.349306
Hypothetical protein FLJ31951
FLJ31951
−1.0858

Hs.448041
FLJ32363 protein
FLJ32363
−1.56733

Hs.362702
hypothetical protein FLJ32745
FLJ32745
−1.55915

Hs.406460
hypothetical protein FLJ33814
FLJ33814
−2.20913

Hs.462829
likely ortholog of mouse schlafen 8/9
FLJ34922
−1.52667

Hs.556039
FLJ35348
FLJ35348
1.84642

Hs.400698
hypothetical protein FLJ35630
FLJ35630
1.73821

Hs.91930
hypothetical protein FLJ35808
FLJ35808
1.96306

Hs.29692
Hypothetical protein FLJ36031
FLJ36031
1.72685

Hs.148768
Hypothetical protein FLJ36166
FLJ36166
2.08619

Hs.234681
hypothetical protein FLJ36812
FLJ36812
−1.32073

Hs.289044
CDC20-like protein
FLJ37927
−2.39272

Hs.210586
hypothetical protein FLJ38725
FLJ38725
2.06097

Hs.210586
hypothetical protein FLJ38725
FLJ38725
2.57804

Hs.44817
FLJ40142 protein
FLJ40142
1.4769

Hs.434250
hypothetical protein FLJ40629
FLJ40629
−2.3014

Hs.467793
hypothetical protein FLJ40869
FLJ40869
−1.42174

Hs.530438
FLJ46154 protein
FLJ46154
3.28063

Hs.506309
FLJ46688 protein
FLJ46688
−2.05925

Hs.448889
FLJ90757 protein
FLJ90757
1.22948

Hs.448889
FLJ90757 protein
FLJ90757
1.66574

Hs.476448
filamin B, beta (actin binding protein
FLNB
−1.30095

278)

Hs.41296
fibronectin leucine rich transmembrane
FLRT3
1.50282

protein 3

Hs.459715
FLYWCH-type zinc finger 1
FLYWCH1
1.03851

Hs.24889
formin 2
FMN2
1.35305

Hs.303476
flavin containing monooxygenase 5
FMO5
1.72565

Hs.203717
fibronectin 1
FN1
1.09597

Hs.438064
FN5 protein
FN5
−1.39882

Hs.189409
formin binding protein 1
FNBP1
1.32566

Hs.298735
formin binding protein 3
FNBP3
−2.29703

Hs.298735
formin binding protein 3
FNBP3
−2.23899

Hs.298735
formin binding protein 3
FNBP3
−1.95234

Hs.239
forkhead box M1
FOXM1
−1.63511

Hs.370666
forkhead box O1A (rhabdomyosarcoma)
FOXO1A
1.16937

Hs.297452
forkhead box Q1
FOXQ1
−1.20527

Hs.369448
Fraser syndrome 1
FRAS1
1.36333

Hs.369448
Fraser syndrome 1
FRAS1
2.70237

Hs.127535
FERM domain containing 3
FRMD3
−1.75635

Hs.127535
FERM domain containing 3
FRMD3
−1.04118

Hs.369384
FERM domain containing 4A
FRMD4A
1.28615

Hs.30561
fibrinogen silencer binding protein ///
FSBP ///
1.35416

RAD54 homolog B (S. cerevisiae)
RAD54B

Hs.348920
FSH primary response (LRPR1
FSHPRH1
−2.69849

homolog, rat) 1

Hs.348920
FSH primary response (LRPR1
FSHPRH1
−1.74732

homolog, rat) 1

Hs.513522
fusion (involved in t(12; 16) in malignant
FUS
−1.08667

liposarcoma)

Hs.29978
frataxin
FXN
−1.70992

Hs.413137
FXYD domain containing ion transport
FXYD2
1.14961

regulator 2

Hs.413137
FXYD domain containing ion transport
FXYD2
1.31436

regulator 2

Hs.173859
frizzled homolog 7 (Drosophila)
FZD7
1.05336

Hs.3353
Ras-GTPase-activating protein SH3-
G3BP
−3.2146

domain-binding protein

Hs.3353
Ras-GTPase-activating protein SH3-
G3BP
−2.67307

domain-binding protein

Hs.3353
Ras-GTPase-activating protein SH3-
G3BP
−1.7465

domain-binding protein

Hs.3353
Ras-GTPase-activating protein SH3-
G3BP
−1.16863

domain-binding protein

Hs.167017
gamma-aminobutyric acid (GABA) B
GABBR1
1.64427

receptor, 1

Hs.511316
GA binding protein transcription factor,
GABPB2
−1.67162

beta subunit 2

Hs.24969
gamma-aminobutyric acid (GABA) A
GABRA5
−1.70953

receptor, alpha 5

Hs.24969
gamma-aminobutyric acid (GABA) A
GABRA5
−1.38757

receptor, alpha 5

Hs.302352
gamma-aminobutyric acid (GABA) A
GABRB3
−1.59092

receptor, beta 3

Hs.80409
growth arrest and DNA-damage-
GADD45A
1.88766

inducible, alpha

Hs.294088
GAJ protein
GAJ
−2.79177

Hs.278959
galanin
GAL
−1.213

Hs.329978
UDP-N-acetyl-alpha-D-
GALNT11
1.28416

galactosamine:polypeptide N-

acetylgalactosaminyltransferase

Hs.534374
UDP-N-acetyl-alpha-D-
GALNT4
−1.82726

galactosamine:polypeptide N-

acetylgalactosaminyltransferase

Hs.501911
UDP-N-acetyl-alpha-D-
GALNTL4
1.52977

galactosamine:polypeptide N-

acetylgalactosaminyltransferase

Hs.499659
GTPase activating Rap/RanGAP
GARNL4
1.92745

domain-like 4

Hs.322852
growth arrest-specific 2 like 1
GAS2L1
−1.61419

Hs.20575
Growth arrest-specific 2 like 3
GAS2L3
−1.9064

Hs.75335
glycine amidinotransferase (L-
GATM
1.22063

arginine:glycine amidinotransferase)

Hs.556063
opposite strand transcription unit to
GATS
1.20979

STAG3

Hs.62661
guanylate binding protein 1, interferon-
GBP1
1.12929

inducible, 67 kDa /// guanylate binding p

Hs.62661
guanylate binding protein 1, interferon-
GBP1
1.54182

inducible, 67 kDa

Hs.62661
guanylate binding protein 1, interferon-
GBP1
1.67365

inducible, 67 kDa /// guanylate binding p

Hs.386567
guanylate binding protein 2, interferon-
GBP2
1.66864

inducible

Hs.386567
guanylate binding protein 2, interferon-
GBP2
1.99681

inducible /// guanylate binding protein

Hs.86724
GTP cyclohydrolase 1 (dopa-responsive
GCH1
−1.99276

dystonia)

Hs.293971
germ cell-less homolog 1 (Drosophila)
GCL
−1.14224

Hs.484313
germ cell-less homolog 1 (Drosophila)
GCL ///
−1.17319

GMCL1L

Hs.315562
glutamate-cysteine ligase, modifier
GCLM
−2.78511

subunit

Hs.315562
Glutamate-cysteine ligase, modifier
GCLM
−2.45471

subunit

Hs.315562
glutamate-cysteine ligase, modifier
GCLM
−1.26658

subunit

Hs.435741
glycine cleavage system protein H
GCSH
−2.04979

(aminomethyl carrier)

Hs.435741
glycine cleavage system protein H
GCSH
−1.18143

(aminomethyl carrier)

Hs.515258
growth differentiation factor 15
GDF15
2.31472

Hs.499620
gem (nuclear organelle) associated
GEMIN4
−1.21779

protein 4

Hs.483921
gem (nuclear organelle) associated
GEMIN5
−1.77235

protein 5

Hs.277154
G elongation factor, mitochondrial 2
GFM2
−1.19729

Hs.460336
golgi associated, gamma adaptin ear
GGA2
−1.2013

containing, ARF binding protein 2

Hs.78619
gamma-glutamyl hydrolase (conjugase,
GGH
−1.93222

folylpolygammaglutamyl hydrolase)

Hs.55498
geranylgeranyl diphosphate synthase 1
GGPS1
−1.2686

Hs.532593
gap junction protein, alpha 7, 45 kDa
GJA7
−1.94477

(connexin 45)

Hs.202011
GK001 protein
GK001
−1.11277

Hs.522255
G kinase anchoring protein 1
GKAP1
1.27201

Hs.69089
galactosidase, alpha
GLA
−1.15553

Hs.443031
Galactosidase, beta 1
GLB1
−1.59027

Hs.131673
glucocorticoid induced transcript 1
GLCCI1
1.00364

Hs.111867
GLI-Kruppel family member GLI2
GLI2
1.25283

Hs.116448
glutaminase
GLS
−1.24749

Hs.212606
glutaminase 2 (liver, mitochondrial)
GLS2
1.14395

Hs.381256
glycolipid transfer protein
GLTP
−1.99754

Hs.381256
glycolipid transfer protein
GLTP
−1.21499

Hs.368538
glutamate dehydrogenase 2
GLUD2
−1.0293

Hs.149585
glutamate-ammonia ligase (glutamine
GLULD1
1.08826

synthetase) domain containing 1

Hs.415312
CG9886-like
GLYCTK
1.20524

Hs.551552
KIAA1196 protein
GM632
1.03667

Hs.551552
KIAA1196 protein
GM632
1.05692

Hs.234896
geminin, DNA replication inhibitor
GMNN
−1.47841

Hs.515018
guanine nucleotide binding protein (G
GNA13
−2.47089

protein), alpha 13

Hs.515018
Guanine nucleotide binding protein (G
GNA13
−1.58408

protein), alpha 13

Hs.515018
guanine nucleotide binding protein (G
GNA13
−1.51352

protein), alpha 13

Hs.134587
guanine nucleotide binding protein (G
GNAI1
1.21805

protein), alpha inhibiting activity polype

Hs.269782
Guanine nucleotide binding protein (G
GNAQ
1.11832

protein), q polypeptide

Hs.125898
GNAS complex locus
GNAS
1.0648

Hs.125898
GNAS complex locus
GNAS
2.00192

Hs.430425
guanine nucleotide binding protein (G
GNB1
1.83826

protein), beta polypeptide 1

Hs.430425
guanine nucleotide binding protein (G
GNB1
2.00349

protein), beta polypeptide 1

Hs.155090
guanine nucleotide binding protein (G
GNB5
1.1154

protein), beta 5

Hs.431101
guanine nucleotide binding protein (G
GNG12
−1.91611

protein), gamma 12

Hs.431101
guanine nucleotide binding protein (G
GNG12
−1.1241

protein), gamma 12

Hs.431101
guanine nucleotide binding protein (G
GNG12
−1.03355

protein), gamma 12

Hs.532401
golgi transport 1 homolog A (S. cerevisiae)
GOLT1A
2.60705

Hs.62275
golgi transport 1 homolog B (S. cerevisiae)
GOLT1B
−1.40902

Hs.62275
golgi transport 1 homolog B (S. cerevisiae)
GOLT1B
−1.23646

Hs.191539
golgi associated PDZ and coiled-coil
GOPC
1.20331

motif containing

Hs.191539
golgi associated PDZ and coiled-coil
GOPC
1.41408

motif containing

Hs.194691
G protein-coupled receptor, family C,
GPCR5A
−1.40268

group 5, member A

Hs.148266
glycerol-3-phosphate dehydrogenase 2
GPD2
−2.27771

(mitochondrial)

Hs.148266
glycerol-3-phosphate dehydrogenase 2
GPD2
−1.85335

(mitochondrial)

Hs.190495
glycoprotein (transmembrane) nmb
GPNMB
1.60921

Hs.558674
G protein-coupled receptor 113
GPR113
1.8613

Hs.150131
G protein-coupled receptor 115
GPR115
1.31636

Hs.516604
G protein-coupled receptor 155
GPR155
1.60148

Hs.231320
G protein-coupled receptor 160
GPR160
1.34179

Hs.194691
G protein-coupled receptor, family C,
GPRC5A
−1.34424

group 5, member A

Hs.489353
G-protein signalling modulator 2
GPSM2
−1.66056

(AGS3-like, C. elegans)

Hs.489353
G-protein signalling modulator 2
GPSM2
−1.49301

(AGS3-like, C. elegans)

Hs.76686
glutathione peroxidase 1
GPX1
1.45177

Hs.467733
GREB1 protein
GREB1
4.41713

Hs.369825
grainyhead-like 3 (Drosophila)
GRHL3
2.39619

Hs.514220
granulin
GRN
1.30359

Hs.514220
granulin
GRN
1.37371

Hs.514220
granulin
GRN
1.46186

Hs.309763
G-rich RNA sequence binding factor 1
GRSF1
−2.59626

Hs.309763
G-rich RNA sequence binding factor 1
GRSF1
−2.11956

Hs.309763
G-rich RNA sequence binding factor 1
GRSF1
−1.69432

Hs.170904
Growth hormone regulated TBC protein 1
GRTP1
1.45126

Hs.445733
Glycogen synthase kinase 3 beta
GSK3B
1.38957

Hs.203634
glutathione S-transferase omega 2
GSTO2
1.52027

Hs.520459
general transcription factor II, i
GTF2I
−1.8785

Hs.276925
GTP binding protein 1
GTPBP1
1.03123

Hs.386189
G-2 and S-phase expressed 1
GTSE1
−2.42102

Hs.386189
G-2 and S-phase expressed 1
GTSE1
−1.73016

Hs.386189
G-2 and S-phase expressed 1
GTSE1
−1.59681

Hs.386189
G-2 and S-phase expressed 1 ///
GTSE1 ///
−2.397

hypothetical gene supported by
LOC440834

BC069212

Hs.477879
H2A histone family, member X
H2AFX
−2.1569

Hs.119192
H2A histone family, member Z
H2AFZ
−1.62167

Hs.119192
H2A histone family, member Z
H2AFZ
−1.4254

Hs.518265
hypothetical protein H41
H41
−1.78639

Hs.518265
Hypothetical protein H41
H41
−1.29288

Hs.470611
histone acetyltransferase 1
HAT1
−1.32684

Hs.291079
HESB like domain containing 1
HBLD1
−1.59109

Hs.378532
HBS1-like (S. cerevisiae)
HBS1L
−1.2303

Hs.438550
KIAA0056 protein
hCAP-D3
−1.35079

Hs.567295
chromosome condensation protein G
HCAP-G
−3.46013

Hs.567295
chromosome condensation protein G
HCAP-G
−3.2148

Hs.20516
histone deacetylase 4
HDAC4
−1.3466

Hs.438782
histone deacetylase 5
HDAC5
1.39836

Hs.209958
HEAT repeat containing 1
HEATR1
−1.25984

Hs.546260
Helicase, lymphoid-specific
HELLS
−1.8674

Hs.546260
helicase, lymphoid-specific
HELLS
−1.5462

Hs.546260
helicase, lymphoid-specific
HELLS
−1.50163

Hs.529317
hect domain and RLD 6
HERC6
1.39401

Hs.513008
hexosaminidase A (alpha polypeptide)
HEXA
1.52815

Hs.58650
hedgehog acyltransferase
HHAT
1.6184

Hs.142245
HERV-H LTR-associating 3
HHLA3
−1.32593

Hs.124156
hippocampus abundant transcript 1
HIAT1
−1.36064

Hs.555996
hippocampus abundant transcript-like 1
HIATL1
−1.1823

Hs.521171
hypoxia-inducible protein 2
HIG2
1.70536

Hs.521171
hypoxia-inducible protein 2
HIG2
1.7415

Hs.72325
histidine triad nucleotide binding protein 3
HINT3
−1.84562

Hs.397465
Homeodomain interacting protein kinase 2
HIPK2
−1.15842

Hs.7644
histone 1, H1c
HIST1H1C
4.14109

Hs.484950
histone 1, H2ac
HIST1H2AC
1.91071

Hs.51011
histone 1, H2ag
HIST1H2AG
2.46271

Hs.546314
histone 1, H2bc
HIST1H2BC
1.72508

Hs.546314
histone 1, H2bc
HIST1H2BC
2.80658

Hs.130853
histone 1, H2bd
HIST1H2BD
1.39519

Hs.130853
histone 1, H2bd
HIST1H2BD
1.72945

Hs.130853
Histone 1, H2bd
HIST1H2BD
2.74242

Hs.130853
Histone 1, H2bd
HIST1H2BD
3.31633

Hs.70937
histone 1, H3h
HIST1H3H
2.30897

Hs.46423
histone 1, H4c
HIST1H4C
−1.98509

Hs.421737
histone 1, H4h
HIST1H4H
3.01933

Hs.421737
histone 1, H4h
HIST1H4H
3.29807

Hs.530461
Histone 2, H2aa
HIST2H2AA
2.12275

Hs.530461
histone 2, H2aa
HIST2H2AA
2.84316

Hs.530461
histone 2, H2aa
HIST2H2AA
3.20575

Hs.2178
histone 2, H2be
HIST2H2BE
3.2941

Hs.55468
Histone 2, H4
HIST2H4
1.5663

Hs.371350
Holocarboxylase synthetase (biotin-
HLCS
2.21798

(proprionyl-Coenzyme A-carboxylase

(ATP-hydrolysing)) ligase)

Hs.196952
hepatic leukemia factor
HLF
1.04531

Hs.197086
high-mobility group protein 2-like 1
HMG2L1
−1.35713

Hs.434953
high-mobility group box 2
HMGB2
−2.03362

Hs.72550
hyaluronan-mediated motility receptor
HMMR
−3.1347

(RHAMM)

Hs.72550
hyaluronan-mediated motility receptor
HMMR
−2.73338

(RHAMM)

Hs.42151
histamine N-methyltransferase
HNMT
1.19206

Hs.42151
histamine N-methyltransferase
HNMT
1.93024

Hs.202166
heterogeneous nuclear ribonucleoprotein
HNRPH1
−1.6109

H1 (H)

Hs.202166
heterogeneous nuclear ribonucleoprotein
HNRPH1
−1.08502

H1 (H)

Hs.129051
homer homolog 1 (Drosophila)
HOMER1
1.80166

Hs.378836
Hook homolog 1 (Drosophila)
HOOK1
1.71795

Hs.77348
hydroxyprostaglandin dehydrogenase
HPGD
1.061

15-(NAD)

Hs.534169
heat shock 70 kDa protein 14
HSPA14
−1.39294

Hs.90093
heat shock 70 kDa protein 4
HSPA4
−1.29062

Hs.11614
HSPC065 protein
HSPC065
2.57539

Hs.529475
hypothetical protein HSPC111
HSPC111
−1.27724

Hs.372208
HSPC159 protein
HSPC159
1.81017

Hs.90753
HIV-1 Tat interactive protein 2, 30 kDa
HTATIP2
2.35107

Hs.421649
5-hydroxytryptamine (serotonin)
HTR2B
1.42638

receptor 2B

Hs.546478
IBR domain containing 3
IBRDC3
1.01982

Hs.353214
intercellular adhesion molecule 3
ICAM3
−2.31627

Hs.417022
intestinal cell (MAK-like) kinase
ICK
1.46572

Hs.504609
inhibitor of DNA binding 1, dominant
ID1
−1.64509

negative helix-loop-helix protein

Hs.567240
iduronate 2-sulfatase (Hunter syndrome)
IDS
1.19532

Hs.567240
iduronate 2-sulfatase (Hunter syndrome)
IDS
1.20866

Hs.567240
iduronate 2-sulfatase (Hunter syndrome)
IDS
1.33917

Hs.567240
iduronate 2-sulfatase (Hunter syndrome)
IDS
1.36826

Hs.315177
interferon-related developmental
IFRD2
−1.2166

regulator 2

Hs.401316
insulin-like growth factor binding
IGFBP1
−1.64161

protein 1

Hs.450230
insulin-like growth factor binding
IGFBP3
−2.6144

protein 3

Hs.450230
insulin-like growth factor binding
IGFBP3
−2.4886

protein 3

Hs.252543
IKK interacting protein
IKIP
−2.22335

Hs.252543
IKK interacting protein
IKIP
−2.14205

Hs.467304
interleukin 11
IL11
−3.67212

Hs.130652
Interleukin 17D
IL17D
1.63864

Hs.532082
Interleukin 6 signal transducer (gp130,
IL6ST
1.73339

oncostatin M receptor)

Hs.532082
Interleukin 6 signal transducer (gp130,
IL6ST
1.94406

oncostatin M receptor)

Hs.624
interleukin 8
IL8
−2.07134

Hs.465885
interleukin enhancer binding factor 3,
ILF3
−1.36934

90 kDa

Hs.144936
IGF-II mRNA-binding protein 1
IMP-1
−1.58159

Hs.367992
inositol(myo)-1(or 4)-monophosphatase 2
IMPA2
−1.00389

Hs.438689
inositol monophosphatase domain
IMPAD1
−1.2956

containing 1

Hs.438689
inositol monophosphatase domain
IMPAD1
−1.22495

containing 1

Hs.369755
inositol polyphosphate-5-phosphatase F
INPP5F
1.23448

Hs.465744
Insulin receptor
INSR
1.06549

Hs.465744
insulin receptor
INSR
1.1958

Hs.465744
Insulin receptor
INSR
1.46677

Hs.482269
importin 11
IPO11
−1.07067

Hs.411865
importin 4
IPO4
−1.92311

Hs.430551
IQ motif containing GTPase activating
IQGAP1
−2.71932

protein 1

Hs.430551
IQ motif containing GTPase activating
IQGAP1
−2.36104

protein 1

Hs.133294
IQ motif containing GTPase activating
IQGAP3
−2.14329

protein 3

Hs.133294
IQ motif containing GTPase activating
IQGAP3
−1.93274

protein 3

Hs.301904
interferon stimulated exonuclease gene
ISG20L2
−1.20778

20 kDa-like 2

Hs.301904
interferon stimulated exonuclease gene
ISG20L2
−1.05117

20 kDa-like 2

Hs.429052
integrin, beta 1
ITGB1
−3.02802

Hs.429052
integrin, beta 1
ITGB1
−2.91707

Hs.429052
integrin, beta 1
ITGB1
−2.17534

Hs.166539
integrin beta 3 binding protein (beta3-
ITGB3BP
−2.02551

endonexin)

Hs.443650
Jumonji, AT rich interactive domain 1B
JARID1B
1.15969

(RBP2-like)

Hs.443650
Jumonji, AT rich interactive domain 1B
JARID1B
1.23534

(RBP2-like)

Hs.443650
Jumonji, AT rich interactive domain 1B
JARID1B
1.37239

(RBP2-like)

Hs.368944
juxtaposed with another zinc finger gene 1
JAZF1
−2.16226

Hs.531819
jumonji domain containing 1A
JMJD1A
1.01766

Hs.371013
jumonji domain containing 2B
JMJD2B
1.6286

Hs.371013
jumonji domain containing 2B
JMJD2B
1.95999

Hs.334017
tubulin, alpha, ubiquitous
K-ALPHA-1
−1.35471

Hs.334017
tubulin, alpha, ubiquitous /// tubulin,
K-ALPHA-1
−1.29311

alpha, ubiquitous

Hs.334017
tubulin, alpha, ubiquitous
K-ALPHA-1
−1.29099

Hs.524390
tubulin, alpha, ubiquitous /// tubulin,
K-ALPHA-1
−1.25129

alpha, ubiquitous

Hs.524390
tubulin, alpha, ubiquitous
K-ALPHA-1
−1.13449

Hs.131838
katanin p60 (ATPase-containing)
KATNA1
−1.22168

subunit A 1

Hs.243596
katanin p60 subunit A-like 1
KATNAL1
−1.21293

Hs.153521
potassium voltage-gated channel, Shaw-
KCNC4
1.19395

related subfamily, member 4

Hs.463985
potassium inwardly-rectifying channel,
KCNJ16
3.12427

subfamily J, member 16

Hs.420016
potassium channel, subfamily T,
KCNT2
1.42217

member 2

Hs.520210
KDEL (Lys-Asp-Glu-Leu) endoplasmic
KDELR2
−1.19309

reticulum protein retention receptor 2

Hs.520210
KDEL (Lys-Asp-Glu-Leu) endoplasmic
KDELR2
−1.18837

reticulum protein retention receptor 2

Hs.554798
KDEL (Lys-Asp-Glu-Leu) endoplasmic
KDELR3
−2.2101

reticulum protein retention receptor 3

Hs.554798
KDEL (Lys-Asp-Glu-Leu) endoplasmic
KDELR3
−1.50849

reticulum protein retention receptor 3

Hs.151761
KIAA0100 gene product
KIAA0100
1.84019

Hs.81892
KIAA0101 /// KIAA0101
KIAA0101
−2.32423

Hs.81892
KIAA0101
KIAA0101
−1.43559

Hs.9997
KIAA0256 gene product
KIAA0256
1.18229

Hs.520710
KIAA0265 protein
KIAA0265
−1.95842

Hs.520710
KIAA0265 protein
KIAA0265
−1.51772

Hs.520710
KIAA0265 protein
KIAA0265
−1.42047

Hs.529959
KIAA0274
KIAA0274
1.24735

Hs.475334
KIAA0280 protein
KIAA0280
1.31133

Hs.475334
KIAA0280 protein
KIAA0280
1.74146

Hs.533787
KIAA0286 protein
KIAA0286
−1.98542

Hs.533787
KIAA0286 protein
KIAA0286
−1.74506

Hs.456507
KIAA0319-like
KIAA0319L
1.02549

Hs.558466
KIAA0323
KIAA0323
−1.02258

Hs.195667
KIAA0329
KIAA0329
1.14037

Hs.35490
KIAA0350 protein
KIAA0350
1.08686

Hs.100874
KIAA0494
KIAA0494
−2.58555

Hs.100874
KIAA0494
KIAA0494
−2.2072

Hs.100874
KIAA0494
KIAA0494
−1.27129

—
KIAA0500 protein
KIAA0500
2.05514

Hs.552801
KIAA0507
KIAA0507
−1.97595

Hs.301658
KIAA0513
KIAA0513
1.31685

Hs.495349
KIAA0515
KIAA0515
1.31926

Hs.7426
KIAA0841
KIAA0841
−1.49066

Hs.480819
KIAA0882 protein
KIAA0882
1.28729

Hs.91662
KIAA0888 protein
KIAA0888
1.18916

Hs.91662
KIAA0888 protein
KIAA0888
1.31162

Hs.65135
KIAA0913
KIAA0913
1.2604

Hs.432397
KIAA0934
KIAA0934
1.32651

Hs.120855
KIAA0960 protein
KIAA0960
1.28359

Hs.120855
KIAA0960 protein
KIAA0960
1.37374

Hs.151220
palladin
KIAA0992
−1.22682

Hs.151220
palladin
KIAA0992
−1.17649

Hs.151220
palladin
KIAA0992
−1.1354

Hs.443673
KIAA1002 protein
KIAA1002
1.44265

Hs.387856
KIAA1043 protein
KIAA1043
1.18433

Hs.21554
KIAA1107
KIAA1107
1.08839

Hs.408142
KIAA1109
KIAA1109
1.41971

Hs.368548
Family with sequence similarity 63,
KIAA1164
−1.2885

member B

Hs.368548
Family with sequence similarity 63,
KIAA1164
−1.09906

member B

Hs.292925
KIAA1212
KIAA1212
−1.35975

Hs.527524
KIAA1280 protein
KIAA1280
1.76698

Hs.509008
KIAA1333
KIAA1333
−1.36628

Hs.509008
KIAA1333
KIAA1333
−1.315

Hs.509008
KIAA1333
KIAA1333
−1.11062

Hs.509008
KIAA1333
KIAA1333
−1.04474

Hs.211700
KIAA1411
KIAA1411
1.91421

Hs.472044
hypothetical protein KIAA1434
KIAA1434
1.36436

Hs.472044
hypothetical protein KIAA1434
KIAA1434
1.49113

Hs.472044
hypothetical protein KIAA1434
KIAA1434
2.22034

Hs.479677
KIAA1458 protein
KIAA1458
−1.55098

Hs.479677
KIAA1458 protein
KIAA1458
−1.37582

Hs.130435
KIAA1524
KIAA1524
−1.40287

Hs.130435
KIAA1524
KIAA1524
−1.23312

Hs.515351
KIAA1533
KIAA1533
1.74878

Hs.514554
KIAA1618
KIAA1618
1.51785

Hs.419171
KIAA1671 protein
KIAA1671
−1.06096

—
KIAA1702 protein
KIAA1702
−1.75231

Hs.507922
KIAA1704
KIAA1704
−1.27003

Hs.209561
KIAA1715
KIAA1715
−1.85742

Hs.87128
KIAA1815
KIAA1815
−1.48463

Hs.117136
KIAA1912 protein
KIAA1912
1.4711

Hs.28872
KIAA1946
KIAA1946
3.24543

Hs.483329
KIAA1961 gene
KIAA1961
−1.48319

Hs.8878
kinesin family member 11
KIF11
−1.49293

Hs.3104
kinesin family member 14
KIF14
−2.89786

Hs.3104
kinesin family member 14
KIF14
−2.75907

Hs.307529
kinesin family member 15
KIF15
−2.88846

Hs.301052
kinesin family member 18A /// kinesin
KIF18A
−1.84792

family member 18A

Hs.97858
Kinesin family member 1B
KIF1B
−1.82461

Hs.97858
kinesin family member 1B
KIF1B
−1.35829

Hs.73625
kinesin family member 20A
KIF20A
−2.08686

Hs.119324
kinesin family member 22
KIF22
−1.93115

Hs.119324
kinesin family member 22
KIF22
−1.11284

Hs.270845
kinesin family member 23
KIF23
−2.90771

Hs.69360
kinesin family member 2C
KIF2C
−2.06125

Hs.69360
kinesin family member 2C
KIF2C
−1.71731

Hs.369670
kinesin family member 3B
KIF3B
1.14989

Hs.369670
kinesin family member 3B
KIF3B
1.37049

Hs.21611
kinesin family member 3C
KIF3C
1.31582

Hs.279766
kinesin family member 4A
KIF4A
−2.29215

Hs.435557
kinesin family member 5C
KIF5C
1.39683

Hs.376206
Kruppel-like factor 4 (gut)
KLF4
−1.78421

Hs.4055
Kruppel-like factor 6
KLF6
−1.66734

Hs.4055
Kruppel-like factor 6
KLF6
−1.54399

Hs.4055
Kruppel-like factor 6
KLF6
−1.46888

Hs.150557
Kruppel-like factor 9
KLF9
2.20737

Hs.495854
kelch-like 15 (Drosophila)
KLHL15
−1.79347

Hs.512576
killer cell lectin-like receptor subfamily
KLRC1 ///
1.01631

C, member
KLRC2

Hs.20107
kinesin 2
KNS2
1.38069

Hs.300559
kinetochore associated 1
KNTC1
−1.56558

Hs.414407
kinetochore associated 2
KNTC2
−2.76939

Hs.159557
karyopherin alpha 2 (RAG cohort 1,
KPNA2
−1.44524

importin alpha 1)

Hs.229335
Kringle containing transmembrane
KREMEN1
1.35716

protein 1

—
ubiquitin-conjugating enzyme variant
Kua
−1.46174

Kua

Hs.118554
lactamase, beta 2
LACTB2
1.44974

Hs.118554
lactamase, beta 2
LACTB2
2.12263

Hs.497039
laminin, gamma 1 (formerly LAMB2)
LAMC1
−2.45129

Hs.496684
lysosomal-associated membrane protein 2
LAMP2
−1.48459

Hs.496684
lysosomal-associated membrane protein 2
LAMP2
−1.2167

Hs.496684
lysosomal-associated membrane protein 2
LAMP2
1.60281

Hs.467807
lysosomal-associated protein
LAPTM4A
−1.10012

transmembrane 4 alpha

Hs.292078
La ribonucleoprotein domain family,
LARP1
−1.35604

member 1

Hs.416755
La ribonucleoprotein domain family,
LARP6
1.19353

member 6

Hs.285976
LAG1 longevity assurance homolog 2
LASS2
−2.73956

(S. cerevisiae)

Hs.270525
LAG1 longevity assurance homolog 5
LASS5
1.62465

(S. cerevisiae)

Hs.468044
likely ortholog of mouse limb-bud and
LBH
2.98095

heart gene /// likely ortholog of mouse li

Hs.435166
lamin B receptor
LBR
−2.36514

Hs.213289
low density lipoprotein receptor
LDLR
−2.03319

(familial hypercholesterolemia)

Hs.213289
low density lipoprotein receptor
LDLR
−1.55439

(familial hypercholesterolemia)

Hs.23581
Leptin receptor
LEPR
−2.49346

Hs.23581
leptin receptor
LEPR
−2.30081

Hs.374191
leprecan-like 1
LEPREL1
1.18867

—
leptin receptor overlapping transcript
LEPROT
−1.25243

Hs.531776
lectin, galactoside-binding, soluble, 2
LGALS2
1.68289

(galectin 2)

Hs.4082
lectin, galactoside-binding, soluble, 8
LGALS8
−1.56978

(galectin 8)

Hs.507798
lipoma HMGIC fusion partner
LHFP
−1.77146

Hs.445265
LIM homeobox 2
LHX2
−1.72893

Hs.496545
LIM homeobox 4
LHX4
1.20242

Hs.469593
LIM and senescent cell antigen-like
LIMS1
−2.74954

domains 1

Hs.469593
LIM and senescent cell antigen-like
LIMS1
−1.51863

domains 1

Hs.23616
lin-28 homolog B (C. elegans)
LIN28B
−2.56884

Hs.91393
lin-7 homolog C (C. elegans)
LIN7C
−2.25246

Hs.91393
lin-7 homolog C (C. elegans)
LIN7C
−2.20511

Hs.91393
lin-7 homolog C (C. elegans)
LIN7C
−1.44311

Hs.120817
lin-9 homolog (C. elegans)
LIN9
−1.3572

Hs.127445
lipase A, lysosomal acid, cholesterol
LIPA
−1.87712

esterase (Wolman disease)

Hs.459940
lipopolysaccharide-induced TNF factor
LITAF
−2.92415

Hs.459940
lipopolysaccharide-induced TNF factor
LITAF
−2.49069

Hs.465295
lectin, mannose-binding, 1
LMAN1
−1.26264

Hs.158852
lectin, mannose-binding 2-like /// lectin,
LMAN2L
−1.3844

mannose-binding 2-like

Hs.491359
lamin A/C
LMNA
−1.33749

Hs.89497
lamin B1
LMNB1
−3.36368

Hs.518084
Hypothetical protein LOC116064
LOC116064
−2.41821

Hs.518084
hypothetical protein LOC116064
LOC116064
−1.46921

Hs.106510
hypothetical protein LOC116236
LOC116236
1.35506

Hs.31409
hypothetical protein LOC120376
LOC120376
1.76479

Hs.74655
Hypothetical protein LOC124512
LOC124512
−1.33014

Hs.171130
hypothetical protein BC014608
LOC128153
1.1545

Hs.171130
hypothetical protein BC014608
LOC128153
2.01562

Hs.474210
hypothetical protein LOC128977
LOC128977
1.37265

Hs.100743
hypothetical protein BC015395
LOC130940
1.18246

Hs.483259
hypothetical protein MGC12103
LOC133619
−1.40895

Hs.481569
hypothetical protein LOC134145
LOC134145
−1.22968

Hs.192586
similar to mouse 2310016A09Rik gene
LOC134147
1.83777

—
hypothetical protein LOC144871
LOC144871
−1.47892

Hs.410126
hypothetical protein LOC145837
LOC145837
1.14848

Hs.135094
hypothetical protein LOC146909
LOC146909
−2.72781

Hs.336588
hypothetical protein LOC147670
LOC147670
1.07518

Hs.355162
hypothetical protein LOC147965
LOC147965
1.33707

Hs.531822
hypothetical protein LOC150759
LOC150759
1.23594

Hs.4988
hypothetical protein LOC151162
LOC151162
1.00691

Hs.558655
similar to hepatocellular carcinoma-
LOC151194
1.48618

associated antigen HCA557b

Hs.259046
hypothetical protein BC010062
LOC152078
1.92028

Hs.153799
hypothetical protein LOC158402
LOC158402
1.10633

Hs.192877
hypothetical protein LOC169834
LOC169834
1.19901

Hs.380920
hypothetical protein LOC201725
LOC201725
−2.62

Hs.380920
hypothetical protein LOC201725
LOC201725
−2.60329

Hs.205952
Hypothetical protein LOC201895
LOC201895
−1.5966

Hs.205952
Hypothetical protein LOC201895
LOC201895
−1.24914

Hs.175563
hypothetical protein LOC203274
LOC203274
2.18005

Hs.496658
similar to solute carrier family 25,
LOC203427
−1.26066

member 16

Hs.7626
hypothetical protein LOC219854
LOC219854
−1.0769

Hs.131417
Hypothetical protein LOC253039
LOC253039
1.53062

Hs.12326
hypothetical protein LOC257396
LOC257396
1.51933

Hs.376041
hypothetical protein LOC283070
LOC283070
1.23583

Hs.558716
hypothetical protein LOC283130
LOC283130
1.73938

Hs.436276
hypothetical protein LOC283400
LOC283400
1.51226

Hs.259347
hypothetical protein LOC283464
LOC283464
−2.24686

Hs.259347
hypothetical protein LOC283464
LOC283464
−2.17741

—
hypothetical protein LOC283481
LOC283481
1.49339

Hs.117167
hypothetical protein LOC283537
LOC283537
1.13913

Hs.561967
hypothetical protein LOC283788
LOC283788
1.16912

Hs.406976
hypothetical protein LOC283874
LOC283874
1.18679

—
hypothetical protein LOC285943
LOC285943
−1.62171

Hs.558072
hypothetical protein LOC338620
LOC338620
−2.30874

Hs.103939
hypothetical protein LOC339448
LOC339448
−1.58204

Hs.103939
hypothetical protein LOC339448
LOC339448
−1.35804

Hs.533212
hypothetical protein LOC340109
LOC340109
3.23497

Hs.450057
hypothetical LOC344595
LOC344595
1.30361

Hs.351582
similar to hypothetical testis protein
LOC352909
1.3257

from macaque

Hs.458285
hypothetical LOC375010 /// hypothetical
LOC375010 ///
2.00067

LOC401131
LOC401131

Hs.23459
hypothetical LOC388727
LOC388727
1.85395

Hs.5215
hypothetical LOC400843
LOC400843
1.27083

Hs.517791
hypothetical LOC401052
LOC401052
1.60118

Hs.385650
hypothetical gene supported by
LOC401068
1.22439

BC028186

Hs.534807
hypothetical LOC401394 /// hypothetical
LOC401394 ///
1.07536

LOC402578
LOC402578

Hs.534807
hypothetical LOC401394 /// hypothetical
LOC401394 ///
1.57808

LOC402578
LOC402578

Hs.512257
hypothetical LOC401449 /// family with
LOC401449 ///
1.15272

sequence similarity 66, member C
FAM66C ///

FAM66E

—
LOC401629 /// LOC401630
LOC401629 ///
1.72622

LOC401630

Hs.474095
hypothetical gene supported by
LOC440160
1.24066

AK022914; AK095211; BC016035;

BC041856; BX248778

Hs.192643
LOC440173
LOC440173
1.20596

Hs.549433
LOC440667 /// LOC440669 ///
LOC440667 ///
1.34729

LOC440688
LOC440669 ///

LOC440688

Hs.474401
hypothetical gene supported by
LOC441130
−1.13484

AK026843; BX640678

Hs.559431
similar to RIKEN cDNA 2310016C16
LOC493869
−1.22366

Hs.556510
similar to RIKEN cDNA 2510006C20
LOC494143
−2.71573

gene

Hs.559276
putative NFkB activating protein
LOC497661
1.26885

Hs.469254
hypothetical protein LOC51315
LOC51315
1.39745

Hs.469254
hypothetical protein LOC51315
LOC51315
1.52108

Hs.469254
hypothetical protein LOC51315
LOC51315
1.96249

Hs.549342
hypothetical protein LOC54103
LOC54103
1.16933

Hs.355559
hypothetical protein LOC550643
LOC550643
2.54798

Hs.185489
hypothetical protein A-211C6.1
LOC57149
−1.90502

Hs.350700
hypothetical protein LOC90288
LOC90288
1.01511

Hs.351461
hypothetical protein BC016861 ///
LOC90557 ///
2.33225

hypothetical protein DKFZp434E2321
DKFZp434E2321

Hs.444338
prematurely terminated mRNA decay
LOC91431
−1.04871

factor-like

Hs.280990
novel 58.3 KDA protein
LOC91614
1.8188

Hs.190394
Hypothetical protein BC001610
LOC91661
−1.07787

Hs.369763
hypothetical protein LOC92558
LOC92558
1.37412

Hs.398111
hypothetical protein BC015148
LOC93081
−1.42127

Hs.152944
loss of heterozygosity, 11, chromosomal
LOH11CR2A
1.3699

region 2, gene A

Hs.180178
LON peptidase N-terminal domain and
LONRF1
−1.85202

ring finger 1

Hs.143792
leucine rich repeat and fibronectin type
LRFN3
1.44215

III domain containing 3

Hs.408355
low density lipoprotein receptor-related
LRP11
−1.43395

protein 11

Hs.128071
leucine rich repeat containing 19
LRRC19
1.61682

Hs.12692
leucine rich repeat containing 49
LRRC49
1.65546

Hs.471779
leucine rich repeat (in FLII) interacting
LRRFIP1
1.55611

protein 1

Hs.103106
LSM2 homolog, U6 small nuclear RNA
LSM2
−1.19716

associated (S. cerevisiae)

Hs.515255
LSM4 homolog, U6 small nuclear RNA
LSM4
−1.10515

associated (S. cerevisiae)

Hs.515255
LSM4 homolog, U6 small nuclear RNA
LSM4
−1.0212

associated (S. cerevisiae)

Hs.524648
leukotriene A4 hydrolase
LTA4H
−1.22343

Hs.289019
latent transforming growth factor beta
LTBP3
1.8186

binding protein 3

Hs.155048
Lutheran blood group (Auberger b
LU
1.24443

antigen included)

Hs.18616
leucine zipper protein 5
LUZP5
−1.84564

Hs.425427
hypothetical protein FLJ20425
LYAR
−1.61007

Hs.468048
lysocardiolipin acyltransferase
LYCAT
−2.35965

Hs.158665
Ly6/neurotoxin 1
LYNX1
1.29112

Hs.432395
LY6/PLAUR domain containing 1
LYPD1
1.18646

Hs.125291
Lysophospholipase-like 1
LYPLAL1
1.89692

Hs.136235
LysM, putative peptidoglycan-binding,
LYSMD3
−1.1191

domain containing 3

Hs.523221
leucine zipper, putative tumor
LZTS2
1.23552

suppressor 2

Hs.140452
mannose-6-phosphate receptor binding
M6PRBP1
−1.94943

protein 1

Hs.28312
MAD2 mitotic arrest deficient-like 1
MAD2L1
−2.51145

(yeast)

Hs.567455
MAD2 mitotic arrest deficient-like 1
MAD2L1
−2.48232

(yeast)

Hs.517617
v-maf musculoaponeurotic fibrosarcoma
MAFF
−1.66059

oncogene homolog F (avian)

Hs.269528
Mak3 homolog (S. cerevisiae)
MAK3
−2.16189

Hs.269528
Mak3 homolog (S. cerevisiae)
MAK3
−1.75418

Hs.185055
mal, T-cell differentiation protein-like
MALL
−1.19366

Hs.444627
mastermind-like 3 (Drosophila)
MAML3
1.03755

Hs.188464
mannosidase, alpha, class 2B, member 2
MAN2B2
1.19584

Hs.368281
Microtubule-associated protein 2
MAP2
3.27489

Hs.433332
Mitogen-activated protein kinase kinase
MAP2K1IP1
1.70622

1 interacting protein 1

Hs.211601
mitogen-activated protein kinase kinase
MAP3K12
1.21363

kinase 12

Hs.211601
mitogen-activated protein kinase kinase
MAP3K12
1.75107

kinase 12

Hs.145605
mitogen-activated protein kinase kinase
MAP3K2
−1.30602

kinase 2

Hs.145605
Mitogen-activated protein kinase kinase
MAP3K2
−1.24925

kinase 2

Hs.269775
mitogen-activated protein kinase kinase
MAP3K7IP2
−1.58644

kinase 7 interacting protein 2

Hs.269775
mitogen-activated protein kinase kinase
MAP3K7IP2
−1.36177

kinase 7 interacting protein 2

Hs.517949
microtubule-associated protein 4
MAP4
1.34906

Hs.431550
mitogen-activated protein kinase kinase
MAP4K4
1.10562

kinase kinase 4

Hs.431550
mitogen-activated protein kinase kinase
MAP4K4
1.21588

kinase kinase 4

Hs.485233
mitogen-activated protein kinase 14
MAPK14
−1.17889

Hs.513661
mitogen activated protein kinase binding
MAPKBP1
1.11226

protein 1

Hs.515860
microtubule-associated protein, RP/EB
MAPRE3
1.64105

family, member 3

Hs.515860
microtubule-associated protein, RP/EB
MAPRE3
1.7594

family, member 3

Hs.519909
myristoylated alanine-rich protein kinase
MARCKS
−1.59242

C substrate

Hs.209614
MARVEL domain containing 1
MARVELD1
−1.30457

Hs.513706
MARVEL domain containing 3
MARVELD3
1.08477

Hs.276905
microtubule associated serine/threonine
MASTL
−2.62644

kinase-like

Hs.189445
matrilin 2
MATN2
−1.2392

Hs.198158
MAWD binding protein
MAWBP
2.064

Hs.517586
myoglobin
MB
1.82459

Hs.458312
methyl-CpG binding domain protein 5
MBD5
1.24077

Hs.478000
muscleblind-like (Drosophila)
MBNL1
−1.92316

Hs.478000
muscleblind-like (Drosophila)
MBNL1
−1.41977

Hs.478000
muscleblind-like (Drosophila)
MBNL1
−1.28311

Hs.478000
Muscleblind-like (Drosophila)
MBNL1
1.17164

Hs.511397
melanoma cell adhesion molecule ///
MCAM
−2.21725

melanoma cell adhesion molecule

Hs.483104
mutated in colorectal cancers
MCC
1.6236

Hs.167531
methylcrotonoyl-Coenzyme A
MCCC2
−1.16197

carboxylase 2 (beta)

Hs.170422
MCF.2 cell line derived transforming
MCF2L
1.07163

sequence-like

Hs.170422
MCF.2 cell line derived transforming
MCF2L
1.21451

sequence-like

Hs.532826
myeloid cell leukemia sequence 1
MCL1
−2.38298

(BCL2-related)

Hs.198363
MCM10 minichromosome maintenance
MCM10
−3.67476

deficient 10 (S. cerevisiae)

Hs.198363
MCM10 minichromosome maintenance
MCM10
−3.14371

deficient 10 (S. cerevisiae)

Hs.198363
MCM10 minichromosome maintenance
MCM10
−2.6166

deficient 10 (S. cerevisiae)

Hs.477481
MCM2 minichromosome maintenance
MCM2
−1.64223

deficient 2, mitotin (S. cerevisiae)

Hs.179565
MCM3 minichromosome maintenance
MCM3
−1.45867

deficient 3 (S. cerevisiae)

Hs.460184
MCM4 minichromosome maintenance
MCM4
−2.80012

deficient 4 (S. cerevisiae)

Hs.460184
MCM4 minichromosome maintenance
MCM4
−2.40207

deficient 4 (S. cerevisiae)

Hs.460184
MCM4 minichromosome maintenance
MCM4
−2.0644

deficient 4 (S. cerevisiae)

Hs.460184
MCM4 minichromosome maintenance
MCM4
−1.90396

deficient 4 (S. cerevisiae)

Hs.517582
MCM5 minichromosome maintenance
MCM5
−2.28141

deficient 5, cell division cycle 46 (S. cerevisiae)

Hs.517582
MCM5 minichromosome maintenance
MCM5
−1.64733

deficient 5, cell division cycle 46 (S. cerevisiae)

Hs.444118
MCM6 minichromosome maintenance
MCM6
−1.3262

deficient 6 (MIS5 homolog, S. pombe)

(S. cerevisae)

Hs.438720
MCM7 minichromosome maintenance
MCM7
−2.11744

deficient 7 (S. cerevisiae)

Hs.438720
MCM7 minichromosome maintenance
MCM7
−1.98814

deficient 7 (S. cerevisiae)

Hs.437582
MCM8 minichromosome maintenance
MCM8
−1.58228

deficient 8 (S. cerevisiae)

Hs.535239
mucolipin 3
MCOLN3
1.33364

Hs.427236
MyoD family inhibitor domain
MDFIC
−2.25427

containing /// MyoD family inhibitor

domain contain

Hs.427236
MyoD family inhibitor domain
MDFIC
−1.44874

containing

Hs.427236
MyoD family inhibitor domain
MDFIC
1.77906

containing

Hs.369849
Mdm2, transformed 3T3 cell double
MDM2
1.14346

minute 2, p53 binding protein (mouse)

Hs.368866
hypothetical protein MDS025
MDS025
1.15319

Hs.233119
malic enzyme 2, NAD(+)-dependent,
ME2
−1.34462

mitochondrial

Hs.233119
malic enzyme 2, NAD(+)-dependent,
ME2
−1.17652

mitochondrial

Hs.33032
Mediator of RNA polymerase II
MED28
−1.06214

transcription, subunit 28 homolog

(yeast)

Hs.268675
MADS box transcription enhancer factor
MEF2A
1.71546

2, polypeptide A (myocyte enhancer

factor

Hs.184339
maternal embryonic leucine zipper
MELK
−3.00861

kinase

Hs.433213
methyltransferase like 2 /// hypothetical
METTL2 ///
−1.08206

protein FLJ12760
FLJ12760

Hs.432818
Microfibrillar-associated protein 3
MFAP3
−1.33928

Hs.7678
major facilitator superfamily domain
MFSD3
1.40961

containing 3

Hs.130692
Hypothetical protein MGC10946
MGC10946
−1.08651

Hs.425178
hypothetical protein MGC11102
MGC11102
−1.22482

Hs.546428
hypothetical protein MGC11266
MGC11266
−1.6299

Hs.99196
hypothetical protein MGC11324 ///
MGC11324
−2.27527

hypothetical protein MGC11324

Hs.460617
hypothetical protein MGC13024
MGC13024
1.79446

Hs.347408
Hypothetical protein MGC13102
MGC13102
1.17064

Hs.256301
multidrug resistance-related protein ///
MGC13170
−1.23603

multidrug resistance-related protein

Hs.533747
hypothetical protein MGC13183 ///
MGC13183
−1.58484

hypothetical protein MGC13183

Hs.368399
FERM domain containing 5
MGC14161
1.72705

Hs.558588
similar to RIKEN cDNA 1200014N16
MGC14289
−1.89713

gene

Hs.30323
hypothetical protein MGC15634
MGC15634
−1.62444

Hs.373941 ///
Hypothetical gene MGC16733 similar to
MGC16733
1.49468

Hs.533723
CG12113

Hs.380228
hypothetical protein MGC17839
MGC17839
1.29437

Hs.257664
hypothetical protein MGC17943
MGC17943
−1.34111

Hs.314261
Hypothetical protein MGC21644
MGC21644
1.2091

Hs.347524
hypothetical protein MGC24665
MGC24665
−1.9388

Hs.4253
hypothetical protein MGC2574
MGC2574
−1.70946

Hs.48343
hypothetical protein MGC26963
MGC26963
−3.61698

Hs.356467
Hypothetical protein MGC2747
MGC2747
1.34962

Hs.483796
hypothetical protein MGC3265
MGC3265
1.8559

Hs.40808
hypothetical protein MGC33926
MGC33926
1.14901

Hs.413457 ///
Chromosome 11 open reading frame 35
MGC35138
1.95509

Hs.559182
/// CDNA clone IMAGE: 4837775

Hs.351133
hypothetical protein MGC35558
MGC35558
1.17753

Hs.374414
hypothetical protein MGC39606
MGC39606
1.2437

Hs.6920
Hypothetical protein MGC45562
MGC45562
1.56375

Hs.6920
hypothetical protein MGC45562
MGC45562
2.51953

Hs.441708
leucine-rich repeat kinase 1
MGC45866
−1.20743

Hs.345588
hypothetical protein MGC45871
MGC45871
−1.5647

Hs.345588
hypothetical protein MGC45871
MGC45871
−1.35041

Hs.560915
hypothetical protein MGC4677 ///
MGC4677 ///
−1.56693

hypothetical LOC541471
LOC541471

—
hypothetical protein MGC5370
MGC5370
1.06303

Hs.13662
hypothetical protein MGC5508
MGC5508
−2.29289

Hs.507584
hypothetical protein MGC9850
MGC9850
1.28469

Hs.526494
mahogunin, ring finger 1
MGRN1
1.12992

Hs.501928
microtubule associated monoxygenase,
MICAL2
2.27797

calponin and LIM domain containing 2

Hs.80976
antigen identified by monoclonal
MKI67
−2.89189

antibody Ki-67

Hs.80976
antigen identified by monoclonal
MKI67
−2.41542

antibody Ki-67

Hs.80976
antigen identified by monoclonal
MKI67
−2.12196

antibody Ki-67

Hs.80976
antigen identified by monoclonal
MKI67
−1.7532

antibody Ki-67

Hs.481307
MLF1 interacting protein
MLF1IP
−3.50592

Hs.493585
myeloid/lymphoid or mixed-lineage
MLLT3
−1.31182

leukemia (trithorax homolog,

Drosophila)

Hs.487188
Myeloid/lymphoid or mixed-lineage
MLLT4
1.94359

leukemia (trithorax homolog,

Drosophila)

Hs.533499
Membrane associated DNA binding
MNAB
1.68856

protein

Hs.253552
MAX binding protein
MNT
1.32128

Hs.196437
MOB1, Mps One Binder kinase
MOBK1B
−3.20419

activator-like 1B (yeast)

Hs.196437
MOB1, Mps One Binder kinase
MOBK1B
−2.19267

activator-like 1B (yeast)

Hs.196437
MOB1, Mps One Binder kinase
MOBK1B
−2.06639

activator-like 1B (yeast)

Hs.196437
MOB1, Mps One Binder kinase
MOBK1B
−1.35494

activator-like 1B (yeast)

Hs.437153
MondoA
MONDOA
1.03873

Hs.521086
motile sperm domain containing 3
MOSPD3
1.15951

Hs.240
M-phase phosphoprotein 1
MPHOSPH1
−1.04733

Hs.344400
M-phase phosphoprotein 6
MPHOSPH6
−1.6802

Hs.507175
M-phase phosphoprotein 9
MPHOSPH9
−1.33309

Hs.507175
M-phase phosphoprotein 9
MPHOSPH9
−1.27568

Hs.493919
myelin protein zero-like 1
MPZL1
−1.58706

Hs.493919
myelin protein zero-like 1
MPZL1
−1.21636

Hs.493919
myelin protein zero-like 1
MPZL1
−1.20361

Hs.101840
major histocompatibility complex, class
MR1
1.13452

I-related

Hs.279652
mitochondrial ribosomal protein L4
MRPL4
−1.2165

Hs.75859
mitochondrial ribosomal protein L49
MRPL49
−1.25511

Hs.411125
mitochondrial ribosomal protein S12
MRPS12
−1.24674

Hs.533291
MRS2-like, magnesium homeostasis
MRS2L
1.05364

factor (S. cerevisiae)

Hs.156519
mutS homolog 2, colon cancer,
MSH2
−1.27183

nonpolyposis type 1 (E. coli)

Hs.134470
Musashi homolog 2 (Drosophila)
MSI2
1.34406

Hs.87752
moesin
MSN
−1.35017

Hs.339024
methionine sulfoxide reductase B3
MSRB3
−1.05195

Hs.89404
msh homeo box homolog 2 (Drosophila)
MSX2
1.11101

Hs.513626
metallothionein 1F (functional)
MT1F
1.18931

Hs.513626
metallothionein 1F (functional)
MT1F
1.49789

Hs.193268
methylthioadenosine phosphorylase
MTAP
−1.25422

Hs.502773
membrane-type 1 matrix
MTCBP-1
−3.68512

metalloproteinase cytoplasmic tail

binding protein-1

Hs.502773
membrane-type 1 matrix
MTCBP-1
−2.92784

metalloproteinase cytoplasmic tail

binding protein-1

Hs.269944
mitochondrial carrier homolog 2 (C. elegans)
MTCH2
1.12443

Hs.377155
metadherin
MTDH
−1.96269

Hs.377155
metadherin
MTDH
−1.93929

Hs.31016
metal response element binding
MTF2
−1.04464

transcription factor 2

Hs.435974
methylenetetrahydrofolate
MTHFD1
−1.69882

dehydrogenase (NADP+ dependent) 1

Hs.479954
methylenetetrahydrofolate
MTHFD2L
−1.4306

dehydrogenase (NADP+ dependent) 2-

like

Hs.507536
myotubularin related protein 6
MTMR6
−1.77082

Hs.498187
5-methyltetrahydrofolate-homocysteine
MTR
−1.323

methyltransferase

Hs.485527
methylmalonyl Coenzyme A mutase
MUT
1.10356

Hs.501023
MAX interactor 1
MXI1
1.95993

Hs.380906
myeloid-associated differentiation
MYADM
−1.43997

marker

Hs.380906
myeloid-associated differentiation
MYADM
−1.38718

marker

Hs.445898
v-myb myeloblastosis viral oncogene
MYBL1
−3.26889

homolog (avian)-like 1

Hs.179718
v-myb myeloblastosis viral oncogene
MYBL2
−1.32601

homolog (avian)-like 2

Hs.370040
c-myc binding protein
MYCBP
−3.2538

Hs.370040
c-myc binding protein
MYCBP
−1.34931

Hs.82116
myeloid differentiation primary response
MYD88
−1.09524

gene (88)

Hs.460109
Myosin, heavy polypeptide 11, smooth
MYH11
−1.90836

muscle

Hs.504687
myosin, light polypeptide 9, regulatory
MYL9
1.26146

Hs.481720
myosin X
MYO10
−1.67665

Hs.481720
Myosin X
MYO10
−1.15977

Hs.462777
myosin ID
MYO1D
1.68759

Hs.21213
myosin VA (heavy polypeptide 12,
MYO5A
1.45005

myoxin)

Hs.21213
myosin VA (heavy polypeptide 12,
MYO5A
1.62243

myoxin)

Hs.503137
NAD synthetase 1
NADSYN1
1.44189

Hs.503137
NAD synthetase 1
NADSYN1
1.49212

Hs.50727
N-acetylglucosaminidase, alpha-
NAGLU
1.17799

(Sanfilippo disease IIIB)

Hs.104305
NACHT, leucine rich repeat and PYD
NALP1
1.82885

(pyrin domain) containing 1

Hs.351851
nanos homolog 1 (Drosophila)
NANOS1
2.72079

Hs.524599
nucleosome assembly protein 1-like 1
NAP1L1
−1.66365

Hs.524599
nucleosome assembly protein 1-like 1
NAP1L1
−1.49322

Hs.524599
60S ribosomal protein L6 (RPL6A)
NAP1L1
−1.12756

Hs.66180
nucleosome assembly protein 1-like 2
NAP1L2
1.1834

Hs.21365
nucleosome assembly protein 1-like 3
NAP1L3
1.42937

Hs.516471
Nck-associated protein 5
NAP5
1.57263

Hs.324271
N-acyl-phosphatidylethanolamine-
NAPE-PLD
−1.63822

hydrolyzing phospholipase D

Hs.324271
N-acyl-phosphatidylethanolamine-
NAPE-PLD
−1.59187

hydrolyzing phospholipase D

Hs.324271
N-acyl-phosphatidylethanolamine-
NAPE-PLD
−1.52464

hydrolyzing phospholipase D

Hs.555985
NMDA receptor regulated 1
NARG1
−1.17163

Hs.200943
NMDA receptor regulated 2
NARG2
−1.66609

Hs.200943
NMDA receptor regulated 2
NARG2
−1.4174

Hs.200943
NMDA receptor regulated 2
NARG2
−1.2328

Hs.319334
nuclear autoantigenic sperm protein
NASP
−1.02505

(histone-binding)

Hs.491172
neurobeachin
NBEA
1.65917

Hs.491172
neurobeachin
NBEA
1.92913

Hs.412293
nuclear receptor coactivator 1
NCOA1
1.21726

Hs.322430
NDRG family member 4
NDRG4
2.21026

Hs.502528
NADH dehydrogenase (ubiquinone) Fe—S
NDUFS3
−1.31414

protein 3, 30 kDa (NADH-coenzyme Q

reductase

Hs.555882
nebulin
NEB
4.13713

Hs.437385
NECAP endocytosis associated 2
NECAP2
−1.60539

Hs.1565
neural precursor cell expressed,
NEDD4
−2.34889

developmentally down-regulated 4

Hs.521461
neurofilament, light polypeptide 68 kDa
NEFL
1.63415

Hs.521461
Neurofilament, light polypeptide 68 kDa
NEFL
1.63614

Hs.521461
neurofilament, light polypeptide 68 kDa
NEFL
1.73377

Hs.405467
nei endonuclease VIII-like 3 (E. coli)
NEIL3
−2.42887

Hs.153704
NIMA (never in mitosis gene a)-related
NEK2
−2.69612

kinase 2 /// NIMA (never in mitosis gene

Hs.153704
NIMA (never in mitosis gene a)-related
NEK2
−2.33339

kinase 2

Hs.129550
NIMA (never in mitosis gene a)-related
NEK4
−1.31387

kinase 4

Hs.197071
NIMA (never in mitosis gene a)-related
NEK6
−2.53692

kinase 6

Hs.197071
NIMA (never in mitosis gene a)-related
NEK6
−1.8551

kinase 6

Hs.24119
NIMA (never in mitosis gene a)-related
NEK7
1.53595

kinase 7

Hs.455336
nasal embryonic LHRH factor
NELF
1.48971

Hs.370359
Nuclear factor I/B
NFIB
−1.06797

Hs.73090
nuclear factor of kappa light polypeptide
NFKB2
−1.93871

gene enhancer in B-cells 2 (p49/p100)

Hs.448588
nerve growth factor receptor
NGFRAP1
−1.52893

(TNFRSF16) associated protein 1

Hs.369924
NHL repeat containing 2
NHLRC2
−1.39749

Hs.494457
ninjurin 1
NINJ1
1.05039

Hs.370367
non imprinted in Prader-Willi/Angelman
NIPA2
−1.36816

syndrome 2

Hs.567289
nipsnap homolog 3B (C. elegans)
NIPSNAP3B
1.26388

Hs.567289
nipsnap homolog 3B (C. elegans)
NIPSNAP3B
2.15883

Hs.54473
NK2 transcription factor related, locus 5
NKX2-5
1.60664

(Drosophila)

Hs.208759
nemo like kinase
NLK
1.22495

Hs.208759
nemo like kinase
NLK
1.23634

Hs.112242
normal mucosa of esophagus specific 1
NMES1
−3.76104

Hs.418367
neuromedin U
NMU
−1.35758

Hs.503911
nicotinamide N-methyltransferase
NNMT
−2.5314

Hs.503911
nicotinamide N-methyltransferase
NNMT
−2.32083

Hs.376064
nucleolar protein 5A (56 kDa with
NOL5A
−1.26261

KKE/D repeat)

Hs.69851
nucleolar protein family A, member 1
NOLA1
−1.33268

(H/ACA small nucleolar RNPs)

Hs.523238
nucleolar and coiled-body
NOLC1
−1.13473

phosphoprotein 1

Hs.458607
likely ortholog of mouse neighbor of
NOPE
1.01313

Punc E11

Hs.189780
nitric oxide synthase trafficker
NOSTRIN
−1.25711

Hs.132370
NADPH oxidase 1
NOX1
−1.8453

Hs.75514
nucleoside phosphorylase
NP
−1.87778

Hs.237028
natriuretic peptide receptor C/guanylate
NPR3
−1.67883

cyclase C

Hs.91622
neuronal pentraxin receptor
NPTXR
1.65391

Hs.37125
neuropeptide Y receptor Y2
NPY2R
2.87693

Hs.521926
nuclear receptor binding protein 2
NRBP2
1.53575

Hs.453951
neuregulin 1
NRG1
1.77579

Hs.471200
Neuropilin 2
NRP2
−2.51084

Hs.363558
HCV NS3-transactivated protein 2
NS3TP2
1.62867

Hs.372000
neutral sphingomyelinase (N-SMase)
NSMAF
−1.01183

activation associated factor

Hs.153952
5′-nucleotidase, ecto (CD73)
NT5E
−2.25153

Hs.213061
Nuclear casein kinase and cyclin-
NUCKS
−1.83593

dependent kinase substrate 1

Hs.213061
Nuclear casein kinase and cyclin-
NUCKS
−1.41169

dependent kinase substrate 1

Hs.213061
Nuclear casein kinase and cyclin-
NUCKS
−1.25709

dependent kinase substrate 1

Hs.213061
nuclear casein kinase and cyclin-
NUCKS1
−1.43043

dependent kinase substrate 1

Hs.203961
nudix (nucleoside diphosphate linked
NUDT19
−1.85138

moiety X)-type motif 19

Hs.188882
Nudix (nucleoside diphosphate linked
NUDT3
−1.45819

moiety X)-type motif 3

Hs.506325
nudix (nucleoside diphosphate linked
NUDT4
−1.22772

moiety X)-type motif 4

Hs.356699
nudix (nucleoside diphosphate linked
NUDT4 ///
−2.53923

moiety X)-type motif 4
NUDT4P1

Hs.356699
nudix (nucleoside diphosphate linked
NUDT4 ///
−1.60875

moiety X)-type motif 4
NUDT4P1

Hs.525006
nuclear fragile X mental retardation
NUFIP1
−1.34278

protein interacting protein 1

Hs.525006
nuclear fragile X mental retardation
NUFIP1
−1.27415

protein interacting protein 1

Hs.524574
nucleoporin 107 kDa
NUP107
−1.26355

Hs.372099
nucleoporin 160 kDa
NUP160
−1.63572

Hs.444276
nucleoporin 37 kDa
NUP37
−1.28191

Hs.475103
nucleoporin 50 kDa
NUP50
−1.45184

Hs.475103
nucleoporin 50 kDa
NUP50
−1.39414

Hs.430435
nucleoporin 54 kDa
NUP54
−1.59421

Hs.511093
nucleolar and spindle associated protein 1
NUSAP1
−2.3605

Hs.511093
nucleolar and spindle associated protein 1
NUSAP1
−2.33333

Hs.25010
nuclear transport factor 2-like export
NXT2
−2.04794

factor 2

Hs.25010
nuclear transport factor 2-like export
NXT2
−1.87275

factor 2

Hs.404088
sarcoma antigen NY-SAR-48
NY-SAR-48
−1.26639

Hs.467634
O-acyltransferase (membrane bound)
OACT2
−1.4826

domain containing 2

Hs.549512
Opa interacting protein 5
OIP5
−3.00223

Hs.357004
olfactomedin-like 2A
OLFML2A
1.49582

Hs.478708
optic atrophy 1 (autosomal dominant)
OPA1
−1.17613

Hs.478708
optic atrophy 1 (autosomal dominant)
OPA1
−1.10312

Hs.409081
opsin 3 (encephalopsin, panopsin)
OPN3
−1.32804

Hs.522087
opioid receptor, sigma 1
OPRS1
−1.90353

Hs.522087
opioid receptor, sigma 1
OPRS1
−1.62272

Hs.17908
origin recognition complex, subunit 1-
ORC1L
−1.60903

like (yeast)

Hs.49760
origin recognition complex, subunit 6
ORC6L
−2.38188

homolog-like (yeast)

Hs.502688
oxysterol binding protein
OSBP
−1.10455

Hs.520259
oxysterol binding protein-like 3
OSBPL3
−1.52275

Hs.520259
oxysterol binding protein-like 3
OSBPL3
−1.14884

Hs.270851
OTU domain containing 4
OTUD4
−1.59582

Hs.30532
OTU domain containing 6B
OTUD6B
−2.29222

Hs.524331
ovostatin 2
OVOS2
−1.68574

Hs.148778
oxidation resistance 1
OXR1
1.3573

Hs.148778
oxidation resistance 1
OXR1
1.41333

Hs.475970
oxidative-stress responsive 1
OXSR1
−1.4717

Hs.321709
purinergic receptor P2X, ligand-gated
P2RX4
1.34502

ion channel, 4

Hs.500047
procollagen-proline, 2-oxoglutarate 4-
P4HA1
−2.25798

dioxygenase (proline 4-hydroxylase),

alpha

Hs.118964
GATA zinc finger domain containing
p66alpha
−1.18512

2A

Hs.525626
phosphofurin acidic cluster sorting
PACS2
1.41153

protein 2

Hs.525626
phosphofurin acidic cluster sorting
PACS2
1.99778

protein 2

Hs.435714
p21/Cdc42/Rac1-activated kinase 1
PAK1
1.78254

(STE20 homolog, yeast)

Hs.310231
PAK1 interacting protein 1
PAK1IP1
−1.49793

Hs.465933
pantothenate kinase 1
PANK1
1.5753

Hs.253726
poly(A) polymerase alpha
PAPOLA
1.49923

Hs.524491
3′-phosphoadenosine 5′-phosphosulfate
PAPSS2
−4.30952

synthase 2

Hs.524491
3′-phosphoadenosine 5′-phosphosulfate
PAPSS2
−2.91296

synthase 2

Hs.147229
progestin and adipoQ receptor family
PAQR5
−1.38694

member V

Hs.391828
par-6 partitioning defective 6 homolog
PARD6B
1.31316

beta (C. elegans)

Hs.504538
poly (ADP-ribose) polymerase family,
PARP11
1.27914

member 11

Hs.409412
poly (ADP-ribose) polymerase family,
PARP2
−1.66216

member 2

Hs.409412
poly (ADP-ribose) polymerase family,
PARP2
−1.28179

member 2

Hs.409412
poly (ADP-ribose) polymerase family,
PARP2
−1.26004

member 2

Hs.436319
parvin, alpha
PARVA
−1.20289

Hs.104741
PDZ binding kinase
PBK
−3.13144

Hs.493096
Pre-B-cell leukemia transcription factor 1
PBX1
1.47769

Hs.533055
p300/CBP-associated factor
PCAF
2.20792

Hs.199343
protocadherin alpha 9 /// protocadherin
PCDHA9 ///
1.39255

alpha subfamily C, 2 /// protocadherin a
PCDHAC2 ///

PCDHAC1 ///

PCDHA13 ///

PCDHA12 ///

PCDHA11 ///

PCDHA10 /

Hs.199343
protocadherin alpha 9 /// protocadherin
PCDHA9 ///
1.42632

alpha subfamily C, 2 /// protocadherin a
PCDHAC2 ///

PCDHAC1 ///

PCDHA13 ///

PCDHA12 ///

PCDHA11 ///

PCDHA10 /

Hs.500512
polycomb group ring finger 5
PCGF5
−1.49539

Hs.500512
polycomb group ring finger 5
PCGF5
−1.46584

Hs.500512
polycomb group ring finger 5
PCGF5
−1.38566

Hs.308480
protein-L-isoaspartate (D-aspartate) O-
PCMTD1
1.08009

methyltransferase domain containing 1

Hs.308480
protein-L-isoaspartate (D-aspartate) O-
PCMTD1
1.22917

methyltransferase domain containing 1

Hs.362817
pericentrin 1
PCNT1
−1.42821

Hs.370605
pecanex-like 2 (Drosophila)
PCNXL2
1.45518

Hs.370605
pecanex-like 2 (Drosophila)
PCNXL2
1.52687

Hs.370605
Pecanex-like 2 (Drosophila)
PCNXL2
1.68659

Hs.8944
procollagen C-endopeptidase enhancer 2
PCOLCE2
−2.65874

Hs.522640
proprotein convertase subtilisin/kexin
PCSK1N
1.85419

type 1 inhibitor

Hs.368542
proprotein convertase subtilisin/kexin
PCSK5
1.01193

type 5

Hs.368542
proprotein convertase subtilisin/kexin
PCSK5
1.05504

type 5

Hs.368542
Proprotein convertase subtilisin/kexin
PCSK5
1.65711

type 5

Hs.478150
programmed cell death 10
PDCD10
−2.03829

Hs.352298
platelet derived growth factor D
PDGFD
1.29642

Hs.458573
platelet-derived growth factor receptor-
PDGFRL
1.46289

like

Hs.468801
PDLIM1 interacting kinase 1 like
PDIK1L
1.19335

Hs.470633
pyruvate dehydrogenase kinase,
PDK1
1.61172

isoenzyme 1

Hs.8364
pyruvate dehydrogenase kinase,
PDK4
1.19434

isoenzyme 4

Hs.480311
PDZ and LIM domain 5
PDLIM5
−1.48602

Hs.480311
PDZ and LIM domain 5 /// PDZ and
PDLIM5
−1.43123

LIM domain 5

Hs.480311
PDZ and LIM domain 5
PDLIM5
−1.23481

Hs.480311
PDZ and LIM domain 5
PDLIM5
−1.09421

Hs.480311
PDZ and LIM domain 5
PDLIM5
−1.00615

Hs.533040
PDZ and LIM domain 7 (enigma)
PDLIM7
1.55311

Hs.533040
PDZ and LIM domain 7 (enigma)
PDLIM7
2.36693

Hs.444751
PDZ domain containing 1
PDZK1
3.06013

Hs.391481
PDZ domain containing 6
PDZK6
1.52836

Hs.517216
phosphoprotein enriched in astrocytes 15
PEA15
−1.6779

Hs.517216
phosphoprotein enriched in astrocytes 15
PEA15
−1.17028

Hs.7886
pellino homolog 1 (Drosophila)
PELI1
1.53945

Hs.105103
pellino homolog 2 (Drosophila)
PELI2
1.52135

Hs.523816
pellino homolog 3 (Drosophila)
PELI3
1.23966

Hs.164682
peroxisome biogenesis factor 1
PEX1
1.24024

Hs.507680
phosphonoformate immuno-associated
PFAAP5
1.29441

protein 5

Hs.282702
6-phosphofructo-2-kinase/fructose-2,6-
PFKFB2
1.44929

biphosphatase 2

Hs.433180
DNA replication complex GINS protein
Pfs2
−2.90308

PSF2

Hs.229988
GPI deacylase
PGAP1
1.44515

Hs.156178
plasma glutamate carboxypeptidase
PGCP
1.23044

Hs.23363
phosphoglucomutase 2
PGM2
−2.32892

Hs.23363
phosphoglucomutase 2
PGM2
−1.77539

Hs.23363
phosphoglucomutase 2
PGM2
−1.3856

Hs.26612
phosphoglucomutase 2-like 1
PGM2L1
1.25726

Hs.553496
phosphoglucomutase 3
PGM3
−1.05073

Hs.126706
1-aminocyclopropane-1-carboxylate
PHACS
1.50676

synthase

Hs.514303
prohibitin
PHB
−1.00059

Hs.23862
phytoceramidase, alkaline
PHCA
−1.70081

Hs.23862
phytoceramidase, alkaline
PHCA
−1.47105

Hs.23862
phytoceramidase, alkaline
PHCA
−1.3924

Hs.435933
PHD finger protein 10
PHF10
−1.55222

Hs.159918
PHD finger protein 14
PHF14
1.2242

Hs.371977
PHD finger protein 16
PHF16
−1.42662

Hs.460124
PHD finger protein 19
PHF19
−1.56515

Hs.460124
PHD finger protein 19
PHF19
−1.32722

Hs.304362
PHD finger protein 20-like 1
PHF20L1
1.30542

Hs.502458
PHD finger protein 21A
PHF21A
1.25549

Hs.356501
PHD finger protein 6
PHF6
−1.44838

Hs.154036
pleckstrin homology-like domain, family
PHLDA2
−2.7486

A, member 2

Hs.477114
pleckstrin homology-like domain, family
PHLDB2
−1.38182

B, member 2

Hs.558732
pleckstrin homology-like domain, family
PHLDB3
1.33169

B, member 3

Hs.499704
phytanoyl-CoA hydroxylase interacting
PHYHIPL
1.59009

protein-like

Hs.443733
phosphatidylinositol 4-kinase type 2 beta
PI4K2B
−1.62981

Hs.514846
protein inhibitor of activated STAT, 2
PIAS2
1.67722

Hs.514846
Protein inhibitor of activated STAT, 2
PIAS2
1.76893

Hs.137154
phosphatidylinositol glycan, class A
PIGA
−1.64119

(paroxysmal nocturnal hemoglobinuria)

Hs.175343
phosphoinositide-3-kinase, class 2, alpha
PIK3C2A
−1.77584

polypeptide

Hs.175343
Phosphoinositide-3-kinase, class 2, alpha
PIK3C2A
−1.30933

polypeptide

Hs.175343
Phosphoinositide-3-kinase, class 2, alpha
PIK3C2A
−1.07223

polypeptide

Hs.553498
phosphoinositide-3-kinase, catalytic,
PIK3CA
−1.33909

alpha polypeptide

Hs.132225
phosphoinositide-3-kinase, regulatory
PIK3R1
1.13739

subunit 1 (p85 alpha)

Hs.371344
phosphoinositide-3-kinase, regulatory
PIK3R2
1.06086

subunit 2 (p85 beta)

Hs.170510
phosphoinositide-3-kinase, regulatory
PIK3R3
1.48927

subunit 3 (p55, gamma)

Hs.149032
phosphoinositide-3-kinase, regulatory
PIK3R4
−1.13893

subunit 4, p150

Hs.556578
phosphatidylinositol 4-kinase, catalytic,
PIK4CA
1.21523

alpha polypeptide

Hs.529438
phosphatidylinositol 4-kinase, catalytic,
PIK4CA ///
1.17674

alpha polypeptide
LOC220686

Hs.260603
Phosphatidylinositol-4-phosphate 5-
PIP5K2B
1.14329

kinase, type II, beta

Hs.413525
polycystic kidney disease 1-like 2
PKD1L2
1.15593

Hs.181272
polycystic kidney disease 2 (autosomal
PKD2
1.35233

dominant)

Hs.407580
plakophilin 4
PKP4
3.46089

Hs.437451
phospholipase A1 member A
PLA1A
1.13547

Hs.154104
pleiomorphic adenoma gene-like 2
PLAGL2
−1.55709

Hs.431173
phospholipase C, beta 1
PLCB1
1.7594

(phosphoinositide-specific)

Hs.202010
phospholipase C-like 2
PLCL2
1.94862

Hs.202010
phospholipase C-like 2
PLCL2
2.32691

Hs.128933
phospholipase C-like 3
PLCL3
1.01731

Hs.292419
Phosphatidylinositol-specific
PLCXD2
1.61892

phospholipase C, X domain containing 2

Hs.478230
phospholipase D1, phophatidylcholine-
PLD1
1.00323

specific

Hs.478230
phospholipase D1, phophatidylcholine-
PLD1
1.05373

specific

Hs.498252
phospholipase D family, member 5
PLD5
1.95598

Hs.7037
pallidin homolog (mouse)
PLDN
−1.80514

Hs.7037
pallidin homolog (mouse)
PLDN
−1.18319

Hs.445489
pleckstrin homology domain containing,
PLEKHB1
1.01316

family B (evectins) member 1

Hs.509343
pleckstrin homology domain containing,
PLEKHC1
−2.61276

family C (with FERM domain) member 1

Hs.509343
pleckstrin homology domain containing,
PLEKHC1
−2.25718

family C (with FERM domain) member 1

Hs.509343
pleckstrin homology domain containing,
PLEKHC1
−1.88276

family C (with FERM domain) member 1

Hs.189781
pleckstrin homology domain containing,
PLEKHG1
1.05708

family G (with RhoGef domain) member 1

Hs.164162
pleckstrin homology domain containing,
PLEKHH2
2.40781

family H (with MyTH4 domain)

member 2

Hs.514242
pleckstrin homology domain containing,
PLEKHM1
1.30239

family M (with RUN domain) member 1

Hs.329989
polo-like kinase 1 (Drosophila)
PLK1
−2.07924

Hs.172052
polo-like kinase 4 (Drosophila)
PLK4
−2.32191

Hs.172052
polo-like kinase 4 (Drosophila)
PLK4
−2.27272

Hs.172052
polo-like kinase 4 (Drosophila) /// polo-
PLK4
−1.92856

like kinase 4 (Drosophila)

Hs.477866
procollagen-lysine, 2-oxoglutarate 5-
PLOD2
−2.13748

dioxygenase 2

Hs.477866
procollagen-lysine, 2-oxoglutarate 5-
PLOD2
−2.11609

dioxygenase 2

Hs.77422
proteolipid protein 2 (colonic
PLP2
−1.22623

epithelium-enriched)

Hs.477869
phospholipid scramblase 4
PLSCR4
−2.80174

Hs.476209
plexin B1
PLXNB1
1.62737

Hs.2182
pro-melanin-concentrating hormone
PMCH
−1.86413

Hs.372031
peripheral myelin protein 22
PMP22
−2.63762

Hs.558367
postmeiotic segregation increased 2-like 5
PMS2L5
1.26411

Hs.264
patatin-like phospholipase domain
PNPLA4
1.06474

containing 4

Hs.16426
podocalyxin-like
PODXL
−1.32073

Hs.421608
polymerase (DNA directed), alpha
POLA
−1.32853

Hs.201897
polymerase (DNA directed), alpha 2
POLA2
−1.80002

(70 kD subunit)

Hs.279413
polymerase (DNA directed), delta 1,
POLD1
−1.03211

catalytic subunit 125 kDa

Hs.162777
polymerase (DNA directed), epsilon 2
POLE2
−2.7769

(p59 subunit)

Hs.108112
polymerase (DNA directed), epsilon 3
POLE3
−1.60352

(p17 subunit)

Hs.135756
polymerase (DNA directed) kappa
POLK
−1.0252

Hs.241517
polymerase (DNA directed), theta
POLQ
−1.61821

Hs.460298
polymerase (RNA) III (DNA directed)
POLR3E
1.55522

polypeptide E (80 kD)

Hs.282387
Polymerase (RNA) III (DNA directed)
POLR3G
−2.46957

polypeptide G (32 kD)

Hs.530077
paraoxonase 2
PON2
−1.13258

Hs.331420
phosphoribosyl pyrophosphate
PPAT
−1.93237

amidotransferase

Hs.331420
phosphoribosyl pyrophosphate
PPAT
−1.71664

amidotransferase

Hs.530749
protein tyrosine phosphatase, receptor
PPFIA1
−1.12563

type, f polypeptide (PTPRF), interacting

Hs.517076
protective protein for beta-galactosidase
PPGB
1.11581

(galactosialidosis)

Hs.381072
peptidylprolyl isomerase F (cyclophilin
PPIF
−2.05479

F)

Hs.381072
peptidylprolyl isomerase F (cyclophilin
PPIF
−1.80713

F)

Hs.256639
peptidyl prolyl isomerase H (cyclophilin
PPIH
−1.00601

H)

Hs.451090
peptidylprolyl isomerase (cyclophilin)-
PPIL5
−1.93631

like 5

Hs.192233
periplakin
PPL
1.74529

Hs.286073
protein phosphatase 1D magnesium-
PPM1D
1.31417

dependent, delta isoform

Hs.444403
protein phosphatase 1, regulatory
PPP1R12B
1.36524

(inhibitor) subunit 12B

Hs.521937
protein phosphatase 1, regulatory
PPP1R16A
1.49094

(inhibitor) subunit 16A

Hs.518155
protein phosphatase 2 (formerly 2A),
PPP2R3A
1.04353

regulatory subunit B″, alpha

Hs.334868
protein phosphatase 2, regulatory
PPP2R5E
−1.31338

subunit B (B56), epsilon isoform

Hs.495128
Protein phosphatase 6, catalytic subunit
PPP6C
−1.37405

Hs.366401
protein regulator of cytokinesis 1
PRC1
−1.61069

Hs.523302
peroxiredoxin 3
PRDX3
−1.58887

Hs.148105
prickle-like 2 (Drosophila)
PRICKLE2
1.18704

Hs.534339
primase, polypeptide 1, 49 kDa
PRIM1
−1.46383

Hs.485640
primase, polypeptide 2A, 58 kDa
PRIM2A
−1.50349

Hs.485640
primase, polypeptide 2A, 58 kDa
PRIM2A
−1.38518

Hs.485640
primase, polypeptide 2A, 58 kDa
PRIM2A
−1.33074

Hs.433068
protein kinase, cAMP-dependent,
PRKAR2B
1.35769

regulatory, type II, beta

Hs.531704
protein kinase C, alpha
PRKCA
1.2181

Hs.221497
PRO0149 protein
PRO0149
−1.03492

Hs.304792
proline synthetase co-transcribed
PROSC
−2.37988

homolog (bacterial)

Hs.304792
proline synthetase co-transcribed
PROSC
−1.92295

homolog (bacterial)

Hs.304792
proline synthetase co-transcribed
PROSC
−1.65093

homolog (bacterial)

Hs.374973
PRP4 pre-mRNA processing factor 4
PRPF4
−1.69717

homolog (yeast)

Hs.374973
PRP4 pre-mRNA processing factor 4
PRPF4
−1.60194

homolog (yeast)

Hs.77498
phosphoribosyl pyrophosphate
PRPSAP1
−1.18715

synthetase-associated protein 1

Hs.534492
proline rich 7 (synaptic)
PRR7
1.16679

Hs.435699
protease, serine, 3 (mesotrypsin)
PRSS3
1.19249

Hs.191215
pleckstrin homology, Sec7 and coiled-
PSCD1
1.169

coil domains 1(cytohesin 1)

Hs.360033
DNA replication complex GINS protein
PSF1
−2.78898

PSF1

Hs.193725
proteasome (prosome, macropain) 26S
PSMD5
−1.61581

subunit, non-ATPase, 5

Hs.413801
proteasome (prosome, macropain)
PSME4
−2.00632

activator subunit 4

Hs.413801
proteasome (prosome, macropain)
PSME4
1.61373

activator subunit 4

Hs.471917
proteasome (prosome, macropain)
PSMF1
−1.21949

inhibitor subunit 1 (PI31)

Hs.172550
polypyrimidine tract binding protein 1
PTBP1
−2.78375

Hs.172550
polypyrimidine tract binding protein 1
PTBP1
−2.65173

Hs.172550
polypyrimidine tract binding protein 1
PTBP1
−2.63976

Hs.172550
polypyrimidine tract binding protein 1
PTBP1
−2.63633

Hs.172550
polypyrimidine tract binding protein 1
PTBP1
−2.61287

Hs.172550
polypyrimidine tract binding protein 1
PTBP1
−2.48951

Hs.269895
polypyrimidine tract binding protein 2
PTBP2
1.81453

Hs.269895
polypyrimidine tract binding protein 2
PTBP2
2.00615

Hs.494538
patched homolog (Drosophila)
PTCH
1.9786

Hs.491322
PTK2B protein tyrosine kinase 2 beta
PTK2B
1.23034

Hs.227777
protein tyrosine phosphatase type IVA,
PTP4A1
−1.88222

member 1

Hs.227777
protein tyrosine phosphatase type IVA,
PTP4A1
−1.72964

member 1

Hs.227777
protein tyrosine phosphatase type IVA,
PTP4A1
−1.59097

member 1

Hs.227777
protein tyrosine phosphatase type IVA,
PTP4A1
−1.35933

member 1

Hs.227777
Protein tyrosine phosphatase type IVA,
PTP4A1
1.98833

member 1

Hs.470477
protein tyrosine phosphatase type IVA,
PTP4A2
−1.26364

member 2

Hs.470477
protein tyrosine phosphatase type IVA,
PTP4A2
−1.25613

member 2

Hs.61812
protein tyrosine phosphatase, non-
PTPN12
−2.50939

receptor type 12

Hs.63489
protein tyrosine phosphatase, non-
PTPN6
1.87317

receptor type 6

Hs.558433
pituitary tumor-transforming 1
PTTG1
−2.20164

Hs.474010
pituitary tumor-transforming 1
PTTG1IP
−1.55298

interacting protein

Hs.521097
pituitary tumor-transforming 3
PTTG3
−1.58106

Hs.506652
PWP1 homolog (S. cerevisiae)
PWP1
−1.09208

Hs.332197
peroxidasin homolog (Drosophila)
PXDN
1.14244

Hs.332197
peroxidasin homolog (Drosophila)
PXDN
1.29412

Hs.75438
quinoid dihydropteridine reductase
QDPR
−1.4076

Hs.510324
quaking homolog, KH domain RNA
QKI
−1.11137

binding (mouse)

Hs.513484
quinolinate phosphoribosyltransferase
QPRT
1.1253

Hs.191179
RAB11 family interacting protein 1
RAB11FIP1
−1.32558

(class I)

Hs.406788
RAB11 family interacting protein 4
RAB11FIP4
1.39055

(class II)

Hs.512492
RAB15, member RAS onocogene family
RAB15
1.56277

Hs.512492
RAB15, member RAS onocogene family
RAB15
1.62729

Hs.369017
RAB2, member RAS oncogene family
RAB2
−1.03651

Hs.369017
RAB2, member RAS oncogene family
RAB2
−1.01457

Hs.524590
RAB21, member RAS oncogene family
RAB21
−1.58636

Hs.524590
RAB21, member RAS oncogene family
RAB21
−1.44147

Hs.524590
RAB21, member RAS oncogene family
RAB21
−1.13511

Hs.3797
RAB26, member RAS oncogene family
RAB26
1.9821

Hs.3797
RAB26, member RAS oncogene family
RAB26
2.55672

Hs.298651
RAB27A, member RAS oncogene
RAB27A
−1.60256

family

Hs.301853
RAB34, member RAS oncogene family
RAB34
−2.03641

Hs.301853
RAB34, member RAS oncogene family
RAB34
−1.96036

Hs.24970
RAB39B, member RAS oncogene
RAB39B
2.42681

family

Hs.24970
RAB39B, member RAS oncogene
RAB39B
2.93719

family

Hs.25367
RAB4B, member RAS oncogene family
RAB4B
1.41231

Hs.25367
RAB4B, member RAS oncogene family
RAB4B
1.55256

Hs.25367
RAB4B, member RAS oncogene family
RAB4B
1.57251

Hs.503222
RAB6A, member RAS oncogene family
RAB6A
−1.91365

Hs.503222
RAB6A, member RAS oncogene family
RAB6A
−1.42256

Hs.554921
RAB6A, member RAS oncogene family
RAB6A ///
−1.9879

/// RAB6C, member RAS oncogene
RAB6C

family

Hs.5947
RAB8A, member RAS oncogene family
RAB8A
−1.41121

Hs.389733
RAB8B, member RAS oncogene family
RAB8B
−1.4505

Hs.551518
rabaptin, RAB GTPase binding effector
RABEP1
1.11893

protein 1

Hs.555978
rabaptin, RAB GTPase binding effector
RABEP2
1.09546

protein 2

Hs.446425
RAB, member of RAS oncogene family-
RABL2B ///
1.16822

like 2B /// RAB, member of RAS
RABL2A

oncogene family-like 2A

Hs.446425
RAB, member of RAS oncogene family-
RABL2B ///
1.72341

like 2B /// RAB, member of RAS
RABL2A

oncogene family-like 2A

Hs.444360
RAB, member of RAS oncogene family-
RABL3
−1.81614

like 3

Hs.558376
ras-related C3 botulinum toxin substrate
RAC1
−1.28282

1 (rho family, small GTP binding protei

Hs.558376
ras-related C3 botulinum toxin substrate 1
RAC1
−1.1215

Hs.505469
Rac GTPase activating protein 1
RACGAP1
−2.95039

Hs.375684
RAD18 homolog (S. cerevisiae)
RAD18
−1.67716

Hs.81848
RAD21 homolog (S. pombe)
RAD21
−1.22098

Hs.446554
RAD51 homolog (RecA homolog, E. coli)
RAD51
−2.27717

(S. cerevisiae)

Hs.504550
RAD51 associated protein 1
RAD51AP1
−3.55496

Hs.30561
RAD54 homolog B (S. cerevisiae)
RAD54B
−1.08081

Hs.292154
recombination activating gene 1
RAG1AP1
−1.13271

activating protein 1

Hs.431400
retinoic acid induced 14
RAI14
−2.11871

Hs.6906
v-ral simian leukemia viral oncogene
RALA
−1.57377

homolog A (ras related)

Hs.106185
ral guanine nucleotide dissociation
RALGDS
1.33841

stimulator

Hs.106185
ral guanine nucleotide dissociation
RALGDS
1.86441

stimulator

Hs.432842
Ral GEF with PH domain and SH3
RALGPS1
1.16611

binding motif 1

Hs.24763
RAN binding protein 1
RANBP1
−1.53333

Hs.183800
Ran GTPase activating protein 1
RANGAP1
−1.70082

Hs.183800
Ran GTPase activating protein 1
RANGAP1
−1.58115

Hs.369920
RAP1B, member of RAS oncogene
RAP1B
−2.23787

family

Hs.148178
RAP1, GTPase activating protein 1
RAP1GA1
1.27096

Hs.508480
RAP2A, member of RAS oncogene
RAP2A
−1.91799

family

Hs.119889
RAP2C, member of RAS oncogene
RAP2C
−1.58749

family

Hs.119889
RAP2C, member of RAS oncogene
RAP2C
−1.47988

family

Hs.119889
RAP2C, member of RAS oncogene
RAP2C
−1.41492

family

Hs.113912
Rap guanine nucleotide exchange factor
RAPGEF2
−1.46202

(GEF) 2

Hs.558443
RAS p21 protein activator 4 ///
RASA4 ///
1.5824

hypothetical protein FLJ21767
FLJ21767

Hs.558443
RAS p21 protein activator 4 ///
RASA4 ///
3.61211

hypothetical protein FLJ21767
FLJ21767

Hs.129136
RAS and EF-hand domain containing
RASEF
−2.3736

Hs.125293
RasGEF domain family, member 1A
RASGEF1A
2.00713

Hs.379970
Ras association (RalGDS/AF-6) domain
RASSF2
1.94318

family 2

Hs.346527
Ras association (RalGDS/AF-6) domain
RASSF3
−1.16186

family 3

Hs.529677
Ras association (RalGDS/AF-6) domain
RASSF6
1.62967

family 6

Hs.269941
Ras association (RalGDS/AF-6) domain
RASSF8
−1.32982

family 8

Hs.408528
retinoblastoma 1 (including
RB1
−1.20143

osteosarcoma)

Hs.188553
retinoblastoma binding protein 6
RBBP6
1.11464

Hs.434993
Ras-associated protein Rap1
RBJ
1.18327

Hs.207745
retinoblastoma-like 1 (p107)
RBL1
−2.00961

Hs.11170
RNA binding motif protein 14
RBM14
−1.53215

Hs.116630
RNA binding motif protein 20
RBM20
1.14796

Hs.470412
RNA binding motif, single stranded
RBMS1
−1.99679

interacting protein 1

Hs.470412
RNA binding motif, single stranded
RBMS1
−1.59702

interacting protein 1

Hs.470412
RNA binding motif, single stranded
RBMS1
−1.51043

interacting protein 1

Hs.470412
RNA binding motif, single stranded
RBMS1
−1.47133

interacting protein 1

Hs.263671
radixin
RDX
1.39089

Hs.263671
radixin
RDX
1.80454

Hs.235069
RecQ protein-like (DNA helicase Q1-
RECQL
−2.28531

like)

Hs.235069
RecQ protein-like (DNA helicase Q1-
RECQL
−2.07482

like)

Hs.235069
RecQ protein-like (DNA helicase Q1-
RECQL
−2.03886

like)

Hs.235069
RecQ protein-like (DNA helicase Q1-
RECQL
−1.87239

like)

Hs.463041
arginine-glutamic acid dipeptide (RE)
RERE
1.30624

repeats

Hs.440401
all-trans-13,14-dihydroretinol saturase
RetSat
1.02155

Hs.440401
all-trans-13,14-dihydroretinol saturase
RetSat
1.25994

Hs.232021
REV3-like, catalytic subunit of DNA
REV3L
1.37671

polymerase zeta (yeast)

Hs.139226
replication factor C (activator 1) 2,
RFC2
−1.48632

40 kDa

Hs.139226
replication factor C (activator 1) 2,
RFC2
−1.4243

40 kDa

Hs.115474
replication factor C (activator 1) 3,
RFC3
−2.31176

38 kDa

Hs.115474
replication factor C (activator 1) 3,
RFC3
−2.01625

38 kDa

Hs.518475
replication factor C (activator 1) 4,
RFC4
−1.99843

37 kDa

Hs.506989
replication factor C (activator 1) 5,
RFC5
−2.93661

36.5 kDa

Hs.506989
replication factor C (activator 1) 5,
RFC5
−2.69851

36.5 kDa

Hs.13680
ring finger and FYVE-like domain
RFFL
−1.73088

containing 1

Hs.444899
RFT1 homolog (S. cerevisiae)
RFT1
−1.35848

Hs.77510
ring finger and WD repeat domain 3
RFWD3
−1.7061

Hs.509622
ral guanine nucleotide dissociation
RGL2
1.30131

stimulator-like 2

Hs.501728
ras homolog gene family, member G
RHOG
−1.27666

(rho G)

Hs.552455
RAP1 interacting factor homolog (yeast)
RIF1
−1.0823

Hs.552455
RAP1 interacting factor homolog (yeast)
RIF1
−1.00523

—
regulated in glioma
RIG
1.09335

Hs.434924
regulating synaptic membrane
RIMS3
2.15065

exocytosis 3

Hs.491234
Ras-like without CAAX 1
RIT1
1.46481

Hs.491234
Ras-like without CAAX 1
RIT1
1.53593

Hs.491234
Ras-like without CAAX 1
RIT1
1.57192

Hs.491234
Ras-like without CAAX 1
RIT1
1.70037

Hs.491234
Ras-like without CAAX 1
RIT1
2.22167

Hs.127032
relaxin 2
RLN2
1.58052

Hs.532851
ribonuclease H2, large subunit
RNASEH2A
−1.70633

Hs.518545
ribonuclease L (2′,5′-oligoisoadenylate
RNASEL
1.12248

synthetase-dependent)

Hs.469199
ring finger protein 103
RNF103
1.35088

Hs.44685
ring finger protein 141
RNF141
−1.35539

Hs.17820
Rho-associated, coiled-coil containing
ROCK1
−1.22899

protein kinase 1

Hs.306307
Rho-associated, coiled-coil containing
ROCK1
−1.0587

protein kinase 1

Hs.269988
ROD1 regulator of differentiation 1 (S. pombe)
ROD1
−1.18649

Hs.469264
ribose 5-phosphate isomerase A (ribose
RPIA
−1.78744

5-phosphate epimerase)

Hs.558384
ribosomal protein L19 /// ribosomal
RPL19
−1.30271

protein L19

Hs.380933
ribosomal protein L22-like 1
RPL22L1
−2.32985

Hs.356371
ribosomal protein L28
RPL28
−1.05916

Hs.478582
ribosomal protein L39-like
RPL39L
−1.07522

Hs.518244
ribophorin I
RPN1
−2.13441

Hs.408073
Ribosomal protein S6
RPS6
−1.78218

Hs.148767
RCD1 required for cell differentiation1
RQCD1
−1.50748

homolog (S. pombe)

Hs.532461
Ras-related GTP binding C
RRAGC
1.22188

Hs.515536
related RAS viral (r-ras) oncogene
RRAS
−1.08608

homolog

Hs.502004
related RAS viral (r-ras) oncogene
RRAS2
−3.41426

homolog 2

Hs.502004
related RAS viral (r-ras) oncogene
RRAS2
−2.95738

homolog 2

Hs.472213
Ribosome binding protein 1 homolog
RRBP1
−1.64308

180 kDa (dog)

Hs.472213
ribosome binding protein 1 homolog
RRBP1
−1.57318

180 kDa (dog)

Hs.472213
ribosome binding protein 1 homolog
RRBP1
−1.49967

180 kDa (dog)

Hs.558393
ribonucleotide reductase M1 polypeptide
RRM1
−1.73693

Hs.558393
ribonucleotide reductase M1 polypeptide
RRM1
−1.57029

Hs.226390
ribonucleotide reductase M2 polypeptide
RRM2
−3.67646

Hs.226390
ribonucleotide reductase M2 polypeptide
RRM2
−3.3362

Hs.524809
restin (Reed-Steinberg cell-expressed
RSN
−1.23138

intermediate filament-associated protein)

Hs.524809
restin (Reed-Steinberg cell-expressed
RSN
−1.07857

intermediate filament-associated protein)

Hs.526920
rhabdoid tumor deletion region gene 1
RTDR1
1.66682

Hs.511096
Rtf1, Paf1/RNA polymerase II complex
RTF1
1.40165

component, homolog (S. cerevisiae)

Hs.47517
reticulon 2
RTN2
1.66199

Hs.47517
reticulon 2
RTN2
1.7177

Hs.133337
RWD domain containing 4A
RWDD4A
−2.37591

Hs.54649
putative nucleic acid binding protein
RY1
1.79623

RY-1

Hs.54649
putative nucleic acid binding protein
RY1
2.02502

RY-1

Hs.65641
sterile alpha motif domain containing 9
SAMD9
1.2507

Hs.413835
sin3-associated polypeptide, 30 kDa
SAP30
−1.53811

Hs.499960
SAR1 gene homolog A (S. cerevisiae)
SAR1A
−1.19671

Hs.486292
squamous cell carcinoma antigen
SART2
1.55722

recognized by T cells 2

Hs.506663
squamous cell carcinoma antigen
SART3
−1.73216

recognised by T cells 3

Hs.145497
spindle assembly 6 homolog (C. elegans)
SASS6
−1.14581

Hs.28491
spermidine/spermine N1-
SAT
1.16964

acetyltransferase

Hs.10846
spermidine/spermine N1-
SAT2
1.62909

acetyltransferase 2

Hs.110445
Shwachman-Bodian-Diamond syndrome
SBDS
−1.08895

Hs.110445
Shwachman-Bodian-Diamond syndrome
SBDS /// SBDSP
−1.20921

/// Shwachman-Bodian-Diamond

syndrome pseudoge

Hs.438794
SET binding factor 2
SBF2
1.09612

Hs.482587
Secretory carrier membrane protein 1
SCAMP1
1.45542

Hs.482587
secretory carrier membrane protein 1
SCAMP1
1.78245

Hs.482587
secretory carrier membrane protein 1
SCAMP1
2.06156

Hs.482587
secretory carrier membrane protein 1
SCAMP1
2.48393

Hs.482587
secretory carrier membrane protein 1
SCAMP1
2.54707

Hs.482587
secretory carrier membrane protein 1
SCAMP1
3.02503

Hs.558396
stearoyl-CoA desaturase (delta-9-
SCD
−1.46391

desaturase)

Hs.558396
stearoyl-CoA desaturase (delta-9-
SCD
−1.37392

desaturase)

Hs.379191
stearoyl-CoA desaturase 5
SCD5
1.21783

Hs.492938
sciellin
SCEL
−1.42502

Hs.93485
Sodium channel, voltage-gated, type II,
SCN2A2
1.55241

alpha 2

Hs.435274
sodium channel, voltage-gated, type III,
SCN3A
2.49334

alpha

Hs.130989
sodium channel, nonvoltage-gated 1
SCNN1A
1.22373

alpha

Hs.480815
short coiled-coil protein
SCOC
1.06333

Hs.476365
Sterol carrier protein 2
SCP2
−2.09018

Hs.270107
SDA1 domain containing 1
SDAD1
−1.55494

Hs.200804
syndecan binding protein (syntenin)
SDCBP
−3.15907

Hs.356270
succinate dehydrogenase complex,
SDHD
−1.33721

subunit D, integral membrane protein

Hs.435719
sidekick homolog 2 (chicken)
SDK2
1.60915

Hs.120790
CTCL tumor antigen se57-1
SE57-1
−2.09234

Hs.166924
SEC13-like 1 (S. cerevisiae)
SEC13L1
−1.34897

Hs.211612
SEC24 related gene family, member A
SEC24A
−1.35121

(S. cerevisiae)

Hs.59804
SECIS binding protein 2
SECISBP2
1.3938

Hs.301048
SEH1-like (S. cerevisiae)
SEH1L
−2.38946

Hs.301048
SEH1-like (S. cerevisiae)
SEH1L
−1.54378

Hs.528721
sema domain, immunoglobulin domain
SEMA3E
2.03993

(Ig), short basic domain, secreted,

(semaphor

Hs.550526
sema domain, immunoglobulin domain
SEMA4G
1.66918

(Ig), transmembrane domain (TM) and

short cyt

Hs.371957
SUMO1/sentrin specific peptidase 1
SENP1
−1.21968

Hs.275775
selenoprotein P, plasma, 1
SEPP1
3.35585

Hs.518326
stress-associated endoplasmic reticulum
SERP1
−2.55068

protein 1

Hs.518326
stress-associated endoplasmic reticulum
SERP1
−2.29199

protein 1

Hs.518326
stress-associated endoplasmic reticulum
SERP1
−1.55424

protein 1

Hs.525557
serpin peptidase inhibitor, clade A
SERPINA1
1.93719

(alpha-1 antiproteinase, antitrypsin),

membe

Hs.525557
serpin peptidase inhibitor, clade A
SERPINA1
2.69097

(alpha-1 antiproteinase, antitrypsin),

membe

Hs.104879
serpin peptidase inhibitor, clade B
SERPINB9
−2.06905

(ovalbumin), member 9

Hs.104879
serpin peptidase inhibitor, clade B
SERPINB9
−1.83307

(ovalbumin), member 9

Hs.478153
serpin peptidase inhibitor, clade I
SERPINI1
1.54454

(neuroserpin), member 1

Hs.548672
sestrin 1
SESN1
1.99351

Hs.469543
sestrin 2
SESN2
1.31211

Hs.120633
Sestrin 3
SESN3
1.00409

Hs.480792
SET domain-containing protein 7
SET7
−1.09659

Hs.443735
PR/SET domain containing protein 8
SET8
−1.61495

Hs.471011
splicing factor 3b, subunit 1, 155 kDa
SF3B1
−1.24028

Hs.471011
splicing factor 3b, subunit 1, 155 kDa
SF3B1
−1.1432

Hs.68714
Splicing factor, arginine/serine-rich 1
SFRS1
−1.17971

(splicing factor 2, alternate splicing f

Hs.533122
splicing factor, arginine/serine-rich 10
SFRS10
−1.38503

(transformer 2 homolog, Drosophila)

Hs.479693
splicing factor, arginine/serine-rich 11
SFRS11
1.00768

Hs.6891
splicing factor, arginine/serine-rich 6
SFRS6
−1.5006

Hs.44269
shugoshin-like 2 (S. pombe)
SGOL2
−2.66873

Hs.44269
shugoshin-like 2 (S. pombe)
SGOL2
−2.56864

Hs.499984
sphingosine-1-phosphate lyase 1
SGPL1
−1.67514

Hs.499984
sphingosine-1-phosphate lyase 1
SGPL1
−1.38589

Hs.159368
SH3 multiple domains 1
SH3MD1
1.72135

Hs.301804
SH3 multiple domains 2
SH3MD2
1.13498

Hs.556866
SH3 domain containing, Ysc84-like 1
SH3YL1
1.48937

(S. cerevisiae)

Hs.123253
SHC SH2-domain binding protein 1
SHCBP1
−3.50024

Hs.75069
serine hydroxymethyltransferase 2
SHMT2
−1.38347

(mitochondrial)

Hs.75069
serine hydroxymethyltransferase 2
SHMT2
−1.16072

(mitochondrial)

Hs.410977
SID1 transmembrane family, member 2
SIDT2
1.38653

Hs.525198
TAL1 (SCL) interrupting locus
SIL
−2.38936

Hs.146186
single-minded homolog 2 (Drosophila)
SIM2
1.60666

Hs.268774
signal-induced proliferation-associated 1
SIPA1L2
1.15833

like 2

Hs.112058
CD27-binding (Siva) protein
SIVA
−1.2054

Hs.112058
CD27-binding (Siva) protein
SIVA
−1.06964

Hs.23348
S-phase kinase-associated protein 2
SKP2
−3.35993

(p45)

Hs.23348
S-phase kinase-associated protein 2
SKP2
−3.20865

(p45)

Hs.23348
S-phase kinase-associated protein 2
SKP2
−2.68355

(p45)

Hs.298345
stem-loop (histone) binding protein
SLBP
−2.63949

Hs.505545
solute carrier family 11 (proton-coupled
SLC11A2
1.70586

divalent metal ion transporters), membe

Hs.505545
solute carrier family 11 (proton-coupled
SLC11A2
1.9944

divalent metal ion transporters), membe

Hs.75231
solute carrier family 16 (monocarboxylic
SLC16A1
−2.33265

acid transporters), member 1

Hs.75231
solute carrier family 16 (monocarboxylic
SLC16A1
−2.31664

acid transporters), member 1

Hs.75231
solute carrier family 16 (monocarboxylic
SLC16A1
−2.08744

acid transporters), member 1

Hs.75231
solute carrier family 16 (monocarboxylic
SLC16A1
−1.72763

acid transporters), member 1

Hs.504317
solute carrier family 16 (monocarboxylic
SLC16A14
1.97925

acid transporters), member 14

Hs.75317
solute carrier family 16 (monocarboxylic
SLC16A2
1.11369

acid transporters), member 2

Hs.485760
solute carrier family 17 (anion/sugar
SLC17A5
−1.39441

transporter), member 5

Hs.30246
solute carrier family 19 (thiamine
SLC19A2
−1.6085

transporter), member 2

Hs.125482
solute carrier family 22 (organic cation
SLC22A15
1.10374

transporter), member 15

Hs.143436
solute carrier family 22 (extraneuronal
SLC22A3
1.12722

monoamine transporter), member 3

Hs.443572
solute carrier family 22 (organic cation
SLC22A5
−1.54401

transporter), member 5

Hs.310449
solute carrier family 23 (nucleobase
SLC23A1
1.73231

transporters), member 1

Hs.111024
solute carrier family 25 (mitochondrial
SLC25A1
−1.43875

carrier; citrate transporter), member 1

Hs.4866
solute carrier family 26, member 11
SLC26A11
1.03764

Hs.302738
solute carrier family 26 (sulfate
SLC26A2
−2.88899

transporter), member 2

Hs.302738
solute carrier family 26 (sulfate
SLC26A2
−1.91058

transporter), member 2

Hs.302738
solute carrier family 26 (sulfate
SLC26A2
−1.61653

transporter), member 2

Hs.419240
solute carrier family 2 (facilitated
SLC2A3
1.10459

glucose transporter), member 3

Hs.419240
solute carrier family 2 (facilitated
SLC2A3
1.70527

glucose transporter), member 3

Hs.419240
solute carrier family 2 (facilitated
SLC2A3
1.90675

glucose transporter), member 3

Hs.419240
solute carrier family 2 (facilitated
SLC2A3 ///
1.90763

glucose transporter), member 3
SLC2A14

Hs.542233
solute carrier family 30 (zinc
SLC30A6
−2.09805

transporter), member 6

Hs.542233
solute carrier family 30 (zinc
SLC30A6
−1.31222

transporter), member 6

Hs.533903
solute carrier family 30 (zinc
SLC30A7
−1.2746

transporter), member 7

Hs.533903
Solute carrier family 30 (zinc
SLC30A7
−1.24817

transporter), member 7

Hs.532315
solute carrier family 31 (copper
SLC31A1
−2.29064

transporters), member 1

Hs.532315
solute carrier family 31 (copper
SLC31A1
−1.41874

transporters), member 1

Hs.154073
solute carrier family 35, member B1
SLC35B1
−1.19479

Hs.182885
solute carrier family 35, member B2
SLC35B2
−1.0296

Hs.158748
solute carrier family 35, member F3
SLC35F3
−1.66741

Hs.292509
solute carrier family 35, member F5
SLC35F5
−2.13878

Hs.413434
solute carrier family 39 (zinc
SLC39A10
−1.46413

transporter), member 10

Hs.491232
solute carrier family 39 (zinc
SLC39A14
−1.3285

transporter), member 14

Hs.432690
solute carrier family 39 (zinc
SLC39A9
−1.52698

transporter), member 9

Hs.306448
solute carrier family 41, member 2
SLC41A2
−1.13911

Hs.306448
solute carrier family 41, member 2
SLC41A2
−1.0582

Hs.518220
solute carrier family 41, member 3
SLC41A3
1.3

Hs.518220
solute carrier family 41, member 3
SLC41A3
1.4211

Hs.494700
solute carrier family 44, member 1
SLC44A1
−1.91768

Hs.494700
solute carrier family 44, member 1
SLC44A1
−1.63703

Hs.494700
solute carrier family 44, member 1
SLC44A1
−1.30969

Hs.480188
solute carrier family 44, member 5
SLC44A5
1.38426

Hs.105607
solute carrier family 4, sodium
SLC4A11
1.54877

bicarbonate transporter-like, member 11

Hs.560907
Solute carrier family 4, sodium
SLC4A5
−1.36366

bicarbonate cotransporter, member 5

Hs.370636
solute carrier family 4, sodium
SLC4A8
1.17528

bicarbonate cotransporter, member 8

Hs.44424
solute carrier family 6, member 15
SLC6A15
1.39234

Hs.14846
solute carrier family 7 (cationic amino
SLC7A1
−1.52518

acid transporter, y+ system), member 1

Hs.504966
solute carrier organic anion transporter
SLCO1B3
−1.67878

family, member 1B3

Hs.521557
SLD5 homolog /// SLD5 homolog
SLD5
−1.51953

Hs.500972
STE20-like kinase (yeast)
SLK
−1.80416

Hs.517070
secretory leukocyte peptidase inhibitor
SLPI
−1.00064

Hs.167700
SMAD, mothers against DPP homolog 5
SMAD5
−1.17949

(Drosophila)

Hs.167700
SMAD, mothers against DPP homolog 5
SMAD5
−1.11905

(Drosophila)

Hs.546339
small acidic protein
SMAP
−1.48376

Hs.546339
small acidic protein /// small acidic
SMAP
−1.18439

protein

Hs.476179
SWI/SNF related, matrix associated,
SMARCC1
−1.55548

actin dependent regulator of chromatin,

subf

Hs.476179
SWI/SNF related, matrix associated,
SMARCC1
−1.54247

actin dependent regulator of chromatin,

subf

Hs.476179
SWI/SNF related, matrix associated,
SMARCC1
−1.26259

actin dependent regulator of chromatin,

subf

Hs.119023
SMC2 structural maintenance of
SMC2L1
−2.39835

chromosomes 2-like 1 (yeast)

Hs.119023
SMC2 structural maintenance of
SMC2L1
−2.21741

chromosomes 2-like 1 (yeast)

Hs.58992
SMC4 structural maintenance of
SMC4L1
−2.23418

chromosomes 4-like 1 (yeast)

Hs.58992
SMC4 structural maintenance of
SMC4L1
−1.88314

chromosomes 4-like 1 (yeast)

Hs.8118
structural maintenance of chromosomes
SMCHD1
−1.55959

flexible hinge domain containing 1

Hs.8118
structural maintenance of chromosomes
SMCHD1
−1.28447

flexible hinge domain containing 1

Hs.8118
structural maintenance of chromosomes
SMCHD1
−1.24675

flexible hinge domain containing 1

Hs.331268
SMILE protein
SMILE
−1.49332

Hs.202179
survival of motor neuron 1, telomeric ///
SMN1 /// SMN2
−1.14845

survival of motor neuron 2, centromeric

Hs.433337
spermine oxidase
SMOX
−1.28388

Hs.433337
spermine oxidase
SMOX
−1.03309

Hs.486357
sphingomyelin phosphodiesterase, acid-
SMPDL3A
−1.62965

like 3A

Hs.5212
single-strand selective monofunctional
SMUG1
1.1219

uracil DNA glycosylase

Hs.515011
SMAD specific E3 ubiquitin protein
SMURF2
1.60074

ligase 2

Hs.515011
SMAD specific E3 ubiquitin protein
SMURF2
1.71702

ligase 2

Hs.127406
SET and MYND domain containing 3
SMYD3
−1.81401

Hs.432755
Sorting nexin associated golgi protein 1
SNAG1
−1.35123

Hs.167317
synaptosomal-associated protein, 25 kDa
SNAP25
2.2641

Hs.167317
synaptosomal-associated protein, 25 kDa
SNAP25
2.37493

Hs.459952
stannin
SNN
2.44046

Hs.280378
small nuclear ribonucleoprotein
SNRPB2
−2.39942

polypeptide B″

Hs.464734
small nuclear ribonucleoprotein D1
SNRPD1
−1.8753

polypeptide 16 kDa

Hs.192326
sorting nexin family member 27
SNX27
1.1421

Hs.316890
sorting nexin 5
SNX5
−1.14759

Hs.316890
sorting nexin 5
SNX5
−1.03699

Hs.356647
sorting nexin 6
SNX6
−2.19379

Hs.356647
sorting nexin 6
SNX6
−2.05642

Hs.496383
Sterol O-acyltransferase (acyl-
SOAT1
1.19849

Coenzyme A: cholesterol

acyltransferase) 1

Hs.517262
SON DNA binding protein
SON
−1.22097

Hs.517262
SON DNA binding protein
SON
−1.09787

Hs.558450
sorbin and SH3 domain containing 1
SORBS1
1.13729

Hs.878
sorbitol dehydrogenase
SORD
−1.48759

Hs.485195
sortilin 1
SORT1
1.01531

Hs.518438
SRY (sex determining region Y)-box 2
SOX2
1.51679

Hs.357901
SRY (sex determining region Y)-box 4
SOX4
1.25978

Hs.357901
SRY (sex determining region Y)-box 4
SOX4
1.47878

Hs.2316
SRY (sex determining region Y)-box 9
SOX9
−1.89741

(campomelic dysplasia, autosomal sex-

revers

Hs.2316
SRY (sex determining region Y)-box 9
SOX9
−1.50674

(campomelic dysplasia, autosomal sex-

revers

Hs.524461
Sp1 transcription factor
SP1
−1.25481

Hs.524461
Sp1 transcription factor
SP1
−1.2495

Hs.524461
Sp1 transcription factor
SP1
−1.2019

Hs.514033
sperm associated antigen 5
SPAG5
−2.08749

Hs.527090
spermatogenesis associated 18 homolog
SPATA18
2.13251

(rat)

Hs.103147
spermatogenesis associated 20
SPATA20
1.74075

Hs.408467
Spermatogenesis associated 6
SPATA6
1.08874

Hs.525518
spermatogenesis associated 7
SPATA7
1.16118

Hs.525518
spermatogenesis associated 7
SPATA7
1.60602

Hs.381225
spindle pole body component 24
SPBC24
−1.29212

homolog (S. cerevisiae)

Hs.421956
spindle pole body component 25
SPBC25
−3.85245

homolog (S. cerevisiae)

Hs.42194
signal peptidase complex subunit 3
SPCS3
−1.17448

homolog (S. cerevisiae)

Hs.431045
spectrin domain with coiled-coils 1
SPECC1
1.41964

Hs.150087
SPFH domain family, member 1
SPFH1
−1.7124

Hs.150087
SPFH domain family, member 1
SPFH1
−1.22728

Hs.440414
spastic paraplegia 20, spartin (Troyer
SPG20
−2.13037

syndrome)

Hs.241503
spastic paraplegia 3A (autosomal
SPG3A
1.06782

dominant)

Hs.522672
spindlin family, member 3
SPIN3
1.74925

Hs.62604
SPOC domain containing 1
SPOCD1
1.34155

Hs.401537
signal peptide peptidase-like 2A
SPPL2A
−1.25698

Hs.301540
sepiapterin reductase (7,8-
SPR
−1.82932

dihydrobiopterin:NADP+

oxidoreductase)

Hs.503178
Spectrin, beta, non-erythrocytic 1
SPTBN1
−1.2976

Hs.529892
sequestosome 1
SQSTM1
−1.42587

Hs.195659
v-src sarcoma (Schmidt-Ruppin A-2)
SRC
−1.32887

viral oncogene homolog (avian)

Hs.489040
sorcin
SRI
−1.34605

Hs.76244
spermidine synthase
SRM
−1.60483

Hs.237825
signal recognition particle 72 kDa
SRP72
−1.17216

Hs.15154
sushi-repeat-containing protein, X-
SRPX
−2.07806

linked

Hs.288178
TROVE domain family, member 2
SSA2
−1.73081

Hs.102735
single-stranded DNA binding protein 2
SSBP2
1.464

Hs.102735
single-stranded DNA binding protein 2
SSBP2
2.06512

Hs.196983
sperm specific antigen 2
SSFA2
−1.13277

Hs.207459
ST6 beta-galactosamide alpha-2,6-
ST6GAL1
1.21227

sialyltranferase 1

Hs.98265
ST6 beta-galactosamide alpha-2,6-
ST6GAL2
1.84133

sialyltranferase 2

Hs.308628
ST8 alpha-N-acetyl-neuraminide alpha-
ST8SIA4
1.38116

2,8-sialyltransferase 4

Hs.308628
ST8 alpha-N-acetyl-neuraminide alpha-
ST8SIA4
1.6526

2,8-sialyltransferase 4

Hs.188606
START domain containing 10
STARD10
1.06176

Hs.470943
signal transducer and activator of
STAT1
−1.11395

transcription 1, 91 kDa

Hs.80642
signal transducer and activator of
STAT4
1.32949

transcription 4

Hs.25590
Stanniocalcin 1
STC1
−1.96514

Hs.25590
stanniocalcin 1
STC1
−1.29341

Hs.352341
stress 70 protein chaperone, microsome-
STCH
−1.11468

associated, 60 kDa

Hs.20805
STEAP family member 3
STEAP3
1.60471

Hs.337295
stress-induced-phosphoprotein 1
STIP1
−1.31807

(Hsp70/Hsp90-organizing protein)

Hs.250822
serine/threonine kinase 6
STK6
−3.40582

Hs.250822
serine/threonine kinase 6
STK6
−2.83369

Hs.250822
serine/threonine kinase 6
STK6
−2.22636

Hs.348326
stathmin-like 3
STMN3
1.61593

Hs.253903
stomatin
STOM
−1.52633

Hs.253903
stomatin
STOM
−1.0987

Hs.21958
storkhead box 2
STOX2
1.05666

Hs.522578
steroid sulfatase (microsomal),
STS
1.62674

arylsulfatase C, isozyme S

Hs.43812
syntaxin 10
STX10
−1.05792

Hs.523855
syntaxin 12
STX12
1.01497

Hs.130643
Syntaxin 17
STX17
−1.77384

Hs.288229
syntaxin binding protein 1
STXBP1
1.43683

Hs.508958
syntaxin binding protein 6 (amisyn)
STXBP6
2.67956

Hs.24979
serine/threonine/tyrosine kinase 1
STYK1
1.07694

Hs.448070
SUB1 homolog (S. cerevisiae) /// SUB1
SUB1 ///
1.22735

homolog (S. cerevisiae) pseudogene 1
SUB1P1

Hs.186512
succinate-CoA ligase, GDP-forming,
SUCLG2
−3.47892

beta subunit

Hs.186512
succinate-CoA ligase, GDP-forming,
SUCLG2
−3.2152

beta subunit

Hs.186512
succinate-CoA ligase, GDP-forming,
SUCLG2
−2.98048

beta subunit

Hs.281902
SGT1, suppressor of G2 allele of SKP1
SUGT1
−1.31

(S. cerevisiae)

Hs.162016
sulfatase 2
SULF2
2.66907

Hs.162016
sulfatase 2
SULF2
2.73783

Hs.436123
sulfotransferase family, cytosolic, 1C,
SULT1C1
2.01252

member 1

Hs.436123
sulfotransferase family, cytosolic, 1C,
SULT1C1
2.12614

member 1

Hs.213724
suppressor of Ty 16 homolog (S. cerevisiae)
SUPT16H
−1.4652

Hs.286145
SRB7 suppressor of RNA polymerase B
SURB7
−2.06851

homolog (yeast)

Hs.286145
SRB7 suppressor of RNA polymerase B
SURB7
−1.74676

homolog (yeast)

Hs.512465
surfeit 4
SURF4
−1.57149

Hs.512465
surfeit 4
SURF4
−1.42496

Hs.494827
sushi domain containing 1
SUSD1
1.21596

Hs.435277
synaptogyrin 3
SYNGR3
1.93769

Hs.480615
synaptopodin 2
SYNPO2
−1.95139

Hs.480615
synaptopodin 2
SYNPO2
1.12017

Hs.80919
synaptophysin-like 1
SYPL1
−3.38439

Hs.80919
synaptophysin-like 1
SYPL1
−1.95282

Hs.310545
synaptotagmin I
SYT1
1.60701

Hs.310545
synaptotagmin I
SYT1
1.81623

Hs.32984
synaptotagmin XI
SYT11
1.33604

Hs.188256
TAK1-binding protein 3
TAB3
1.25396

Hs.279245
transforming, acidic coiled-coil
TACC1
−1.23007

containing protein 1

Hs.104019
transforming, acidic coiled-coil
TACC3
−1.58666

containing protein 3

Hs.692
tumor-associated calcium signal
TACSTD1
2.30134

transducer 1

Hs.503998
transgelin
TAGLN
1.91915

Hs.503998
transgelin
TAGLN
2.56072

Hs.61590
TPR domain, ankyrin-repeat and coiled-
TANC
1.28123

coil-containing

Hs.13854
T-cell activation protein phosphatase 2C
TA-PP2C
−1.13956

Hs.6918
threonyl-tRNA synthetase-like 2
TARSL2
1.19846

Hs.12956
Tax1 (human T-cell leukemia virus type
TAX1BP3
−1.43209

I) binding protein 3

Hs.12956
Tax1 (human T-cell leukemia virus type
TAX1BP3
−1.34309

I) binding protein 3

Hs.558562
TBC1 domain family, member 10A
TBC1D10A
−1.75425

Hs.369819
TBC1 domain family, member 16
TBC1D16
1.20748

Hs.105891
TBC1 domain family, member 3 ///
TBC1D3 ///
1.08387

TBC1 domain family, member 3C
TBC1D3C

Hs.475629
TBC1 domain family, member 5
TBC1D5
−1.45511

Hs.475629
TBC1 domain family, member 5
TBC1D5
−1.32512

Hs.484678
TBC1 domain family, member 7
TBC1D7
1.5709

Hs.442657
TBC1 domain family, member 8 (with
TBC1D8
1.73295

GRAM domain)

Hs.495656
transducin (beta)-like 1X-linked
TBL1X
−1.47039

Hs.251830
T-box 18
TBX18
−1.22633

Hs.505004
transcription elongation factor A (SII), 2
TCEA2
1.31996

Hs.511504
Transcription factor 12 (HTF4, helix-
TCF12
−1.53336

loop-helix transcription factors 4)

Hs.555894
transcription factor 19 (SC1)
TCF19
−1.5746

Hs.371282
transcription factor 3 (E2A
TCF3
−1.2752

immunoglobulin enhancer binding

factors E12/E47)

Hs.446392
t-complex-associated-testis-expressed 1-
TCTE1L
−2.58705

like

Hs.516087
testis expressed sequence 261
TEX261
−1.21638

Hs.511476
testis expressed sequence 9
TEX9
2.01224

Hs.473152
transcription factor AP-2 gamma
TFAP2C
1.19787

(activating enhancer binding protein 2

gamma)

Hs.473152
transcription factor AP-2 gamma
TFAP2C
1.25248

(activating enhancer binding protein 2

gamma)

Hs.79353
transcription factor Dp-1
TFDP1
−2.62562

Hs.79353
transcription factor Dp-1
TFDP1
−2.29669

Hs.79353
transcription factor Dp-1
TFDP1
−2.19872

Hs.79353
Transcription factor Dp-1
TFDP1
−1.42905

Hs.516578
tissue factor pathway inhibitor
TFPI
−2.02628

(lipoprotein-associated coagulation

inhibitor)

Hs.516578
Tissue factor pathway inhibitor
TFPI
−1.98713

(lipoprotein-associated coagulation

inhibitor)

Hs.516578
tissue factor pathway inhibitor
TFPI
−1.40011

(lipoprotein-associated coagulation

inhibitor)

Hs.529618
transferrin receptor (p90, CD71)
TFRC
−2.06349

Hs.12393
TDP-glucose 4,6-dehydratase
TGDS
−1.09049

Hs.513530
transforming growth factor beta 1
TGFB1I1
1.38866

induced transcript 1

Hs.133379
Transforming growth factor, beta 2
TGFB2
1.93103

Hs.82028
transforming growth factor, beta
TGFBR2
−1.94501

receptor II (70/80 kDa)

Hs.482390
transforming growth factor, beta
TGFBR3
−2.12203

receptor III (betaglycan, 300 kDa)

Hs.482390
Transforming growth factor, beta
TGFBR3
−2.10583

receptor III (betaglycan, 300 kDa)

Hs.517033
transglutaminase 2 (C polypeptide,
TGM2
−3.20595

protein-glutamine-gamma-

glutamyltransferase)

Hs.517033
transglutaminase 2 (C polypeptide,
TGM2
−2.04406

protein-glutamine-gamma-

glutamyltransferase)

Hs.517033
transglutaminase 2 (C polypeptide,
TGM2
−1.78471

protein-glutamine-gamma-

glutamyltransferase)

Hs.14894
trans-golgi network protein 2
TGOLN2
−1.12887

Hs.479971
THAP domain containing 6
THAP6
1.40583

Hs.2030
thrombomodulin
THBD
−2.01692

Hs.2030
thrombomodulin
THBD
−1.01679

Hs.164226
thrombospondin 1
THBS1
1.46471

Hs.164226
thrombospondin 1
THBS1
1.76749

Hs.20000
three prime histone mRNA exonuclease 1
THEX1
−1.69473

Hs.553878
thrombospondin, type I, domain
THSD1 ///
1.0871

containing 1 /// thrombospondin, type I,
THSD1P

domain c

Hs.443081
THUMP domain containing 3
THUMPD3
−1.19184

Hs.278391
toll-like receptor adaptor molecule 2
TICAM2
−1.80389

Hs.118631
timeless homolog (Drosophila)
TIMELESS
−1.03072

Hs.104839
TIMP metallopeptidase inhibitor 2
TIMP2
1.09933

Hs.209431
TIP41, TOR signalling pathway
TIPRL
−1.93302

regulator-like (S. cerevisiae)

Hs.209431
TIP41, TOR signalling pathway
TIPRL
−1.4105

regulator-like (S. cerevisiae)

Hs.515122
thymidine kinase 1, soluble
TK1
−2.489

Hs.515122
thymidine kinase 1, soluble
TK1
−2.3099

Hs.512619
thymidine kinase 2, mitochondrial
TK2
2.00304

Hs.375001
talin 1
TLN1
1.27688

Hs.529591
translocation protein 1
TLOC1
−1.45673

Hs.529591
translocation protein 1
TLOC1
−1.32688

Hs.351316
transmembrane 4 L six family member 1
TM4SF1
−1.24857

Hs.31130
transmembrane 7 superfamily member 2
TM7SF2
1.45683

Hs.555971
transmembrane BAX inhibitor motif
TMBIM1
−1.25666

containing 1

Hs.510745
transmembrane emp24 protein transport
TMED4
1.71641

domain containing 4

Hs.482873
transmembrane emp24 protein transport
TMED5
−1.33367

domain containing 5

Hs.144513
transmembrane protein with EGF-like
TMEFF2
1.41511

and two follistatin-like domains 2

Hs.437409
Transmembrane protein 20
TMEM20
−1.87807

Hs.129614
transmembrane protein 27
TMEM27
1.13364

Hs.8769
transmembrane protein 47
TMEM47
1.42559

Hs.476525
transmembrane protein 48
TMEM48
−1.34569

Hs.433668
transmembrane protein 50B
TMEM50B
1.98389

Hs.202517
transmembrane protein 55A
TMEM55A
1.14151

Hs.523262
transmembrane protein 59
TMEM59
−1.06308

Hs.116240
transmembrane protein 67
TMEM67
1.06596

Hs.420076
transmembrane protein 68
TMEM68
1.67253

Hs.485606
transmembrane protein 77
TMEM77
−1.5814

Hs.513734
Tropomodulin 2 (neuronal)
TMOD2
2.41916

Hs.11355
thymopoietin
TMPO
−2.65071

Hs.11355
thymopoietin
TMPO
−2.6112

Hs.11355
Thymopoietin
TMPO
−1.85058

Hs.11355
thymopoietin
TMPO
−1.70745

Hs.556258
trophoblast-derived noncoding RNA
TncRNA
−1.56784

Hs.523789
Trophoblast-derived noncoding RNA
TncRNA
1.83062

Hs.443577
tumor necrosis factor receptor
TNFRSF21
−1.99853

superfamily, member 21

Hs.443577
tumor necrosis factor receptor
TNFRSF21
−1.83323

superfamily, member 21

Hs.482497
Transportin 1
TNPO1
−2.38902

Hs.193613
transportin 3
TNPO3
−1.26913

Hs.193613
transportin 3
TNPO3
−1.21284

Hs.407740
trinucleotide repeat containing 6A
TNRC6A
1.53347

Hs.80618
trinucleotide repeat containing 6C
TNRC6C
1.41076

Hs.471381
tensin 1 /// tensin 1
TNS1
2.23004

Hs.528574
topoisomerase (DNA) I, mitochondrial
TOP1MT
1.61288

Hs.156346
topoisomerase (DNA) II alpha 170 kDa
TOP2A
−3.45121

Hs.156346
topoisomerase (DNA) II alpha 170 kDa
TOP2A
−2.71292

Hs.53454
topoisomerase (DNA) II binding protein 1
TOPBP1
−1.48618

Hs.496459
torsin A interacting protein 1
TOR1AIP1
−1.34467

Hs.496459
torsin A interacting protein 1
TOR1AIP1
−1.14929

Hs.496459
torsin A interacting protein 1
TOR1AIP1
−1.14894

Hs.252682
torsin family 1, member B (torsin B)
TOR1B
−1.50129

Hs.554791
tumor protein p53 inducible protein 11
TP53I11
1.18773

Hs.50649
tumor protein p53 inducible protein 3
TP53I3
1.8759

Hs.492261
tumor protein p53 inducible nuclear
TP53INP1
2.56175

protein 1

Hs.516994
tumor protein p53 inducible nuclear
TP53INP2
1.22242

protein 2

Hs.473296
tumor protein D52-like 2
TPD52L2
−1.90007

Hs.133892
tropomyosin 1 (alpha)
TPM1
3.2798

Hs.300772
Tropomyosin 2 (beta)
TPM2
1.24243

Hs.300772
tropomyosin 2 (beta)
TPM2
2.25258

Hs.466088
Tropomyosin 4
TPM4
1.19271

Hs.432424
tripeptidyl peptidase II
TPP2
−1.06767

Hs.279640
translocated promoter region (to
TPR
−1.18552

activated MET oncogene)

Hs.558468
trans-prenyltransferase
TPRT
−1.32401

Hs.244580
TPX2, microtubule-associated, homolog
TPX2
−2.48558

(Xenopus laevis)

Hs.524078
trafficking protein particle complex 4
TRAPPC4
−1.63407

Hs.524078
trafficking protein particle complex 4
TRAPPC4
−1.6043

Hs.466929
trafficking protein particle complex 6A
TRAPPC6A
1.6066

Hs.278434
Trf (TATA binding protein-related
TRFP
−1.26727

factor)-proximal homolog (Drosophila)

Hs.516826
tribbles homolog 3 (Drosophila)
TRIB3
−1.01059

Hs.555909
tripartite motif-containing 14
TRIM14
−2.18727

Hs.490287
tripartite motif-containing 24
TRIM24
1.38135

Hs.490287
tripartite motif-containing 24
TRIM24
1.38717

Hs.159408
tripartite motif-containing 3
TRIM3
1.20424

Hs.159408
tripartite motif-containing 3
TRIM3
1.89824

Hs.212957
tripartite motif-containing 59
TRIM59
−1.54122

Hs.368928
tripartite motif-containing 9
TRIM9
1.89995

Hs.368985
Thyroid hormone receptor interactor 12
TRIP12
−2.16301

Hs.436187
thyroid hormone receptor interactor 13
TRIP13
−1.08916

Hs.524399
trophinin associated protein (tastin)
TROAP
−1.31723

Hs.288178
TROVE domain family, member 2
TROVE2
−1.47133

Hs.288178
TROVE domain family, member 2
TROVE2
−1.34204

Hs.250687
transient receptor potential cation
TRPC1
1.51598

channel, subfamily C, member 1

Hs.250687
transient receptor potential cation
TRPC1
1.6526

channel, subfamily C, member 1

Hs.250687
transient receptor potential cation
TRPC1
1.73898

channel, subfamily C, member 1

Hs.21187
TruB pseudouridine (psi) synthase
TRUB1
−2.42347

homolog 1 (E. coli)

Hs.21187
TruB pseudouridine (psi) synthase
TRUB1
−2.25384

homolog 1 (E. coli)

Hs.21187
TruB pseudouridine (psi) synthase
TRUB1
−1.03454

homolog 1 (E. coli)

Hs.145925
testis specific A2 homolog (mouse)
TSGA2
1.33296

Hs.75066
translin
TSN
−2.38669

Hs.75066
translin
TSN
−2.17376

Hs.75066
translin
TSN
−1.94214

Hs.16529
tetraspanin 12
TSPAN12
−1.5222

Hs.310453
tetraspanin 14 /// tetraspanin 14
TSPAN14
−1.36207

Hs.310458
tetraspanin 2
TSPAN2
1.13685

Hs.441664
tetraspanin 7
TSPAN7
1.74728

Hs.284141
TSPY-like 4
TSPYL4
1.16724

Hs.513195
tetratricopeptide repeat domain 23
TTC23
2.04805

Hs.510213
tetratricopeptide repeat domain 7B
TTC7B
1.52316

Hs.79170
tetratricopeptide repeat domain 9
TTC9
1.26096

Hs.169840
TTK protein kinase
TTK
−2.80142

Hs.358997
tubulin tyrosine ligase
TTL
−1.38282

Hs.358997
tubulin tyrosine ligase
TTL
−1.21128

Hs.440899
tweety homolog 3 (Drosophila)
TTYH3
1.55269

Hs.75318
tubulin, alpha 1 (testis specific)
TUBA1
−1.08001

Hs.436035
tubulin alpha 6 /// tubulin alpha 6
TUBA6
−1.19356

Hs.436035
tubulin alpha 6
TUBA6
−1.14334

Hs.533059
tubulin, beta polypeptide
TUBB
−1.47079

Hs.533059
tubulin, beta polypeptide
TUBB
−1.15728

Hs.533059
tubulin, beta polypeptide /// tubulin, beta
TUBB
−1.14511

polypeptide

Hs.433615
tubulin, beta, 2
TUBB2
−1.61272

Hs.433615
tubulin, beta, 2
TUBB2
−1.52911

Hs.512712
tubulin, beta 2 /// tubulin, beta
TUBB2 ///
−1.06679

polypeptide paralog
TUBB-

PARALOG

Hs.511743
tubulin, beta 3
TUBB3
−1.24198

Hs.511743
tubulin, beta 3
TUBB3
−1.10955

Hs.193491
tubulin, beta 6
TUBB6
−1.91894

Hs.279669
tubulin, gamma 1
TUBG1
−2.30037

Hs.426324
tumor suppressor candidate 3
TUSC3
1.22834

Hs.353035
TWIST neighbor
TWISTNB
−2.4257

Hs.353035
TWIST neighbor
TWISTNB
−1.67295

Hs.514685
twisted gastrulation homolog 1
TWSG1
−1.05709

(Drosophila)

Hs.17987
taxilin alpha
TXLNA
−1.48329

Hs.125221
thioredoxin domain containing
TXNDC
−2.39992

Hs.125221
thioredoxin domain containing
TXNDC
−2.29287

Hs.385986
ubiquitin-conjugating enzyme E2B
UBE2B
−1.21338

(RAD6 homolog)

Hs.93002
ubiquitin-conjugating enzyme E2C
UBE2C
−2.75961

Hs.344165
Ubiquitin-conjugating enzyme E2H
UBE2H
1.1387

(UBC8 homolog, yeast)

Hs.163776
ubiquitin-conjugating enzyme E2, J1
UBE2J1
−1.21165

(UBC6 homolog, yeast)

Hs.406068
ubiquitin-conjugating enzyme E2M
UBE2M
−1.13928

(UBC12 homolog, yeast)

Hs.462306
ubiquitin-conjugating enzyme E2S
UBE2S
−1.70792

Hs.5199
ubiquitin-conjugating enzyme E2T
UBE2T
−1.45046

(putative)

Hs.491695
Ubiquitin-conjugating enzyme E2
UBE2V2
−1.45046

variant 2

Hs.491695
Ubiquitin-conjugating enzyme E2
UBE2V2
−1.28108

variant 2

Hs.118351
ubiquitin protein ligase E3C
UBE3C
−1.91103

Hs.153678
UBX domain containing 6
UBXD6
−1.03407

Hs.145469
ubiquitin carboxyl-terminal hydrolase
UCHL5
−1.36253

L5

Hs.145469
ubiquitin carboxyl-terminal hydrolase
UCHL5
−1.26492

L5

Hs.144197
UDP glycosyltransferase 8 (UDP-
UGT8
−1.20054

galactose ceramide

galactosyltransferase)

Hs.127310
U2AF homology motif (UHM) kinase 1
UHMK1
−1.46655

Hs.108106
ubiquitin-like, containing PHD and
UHRF1
−2.73893

RING finger domains, 1

Hs.2057
uridine monophosphate synthetase
UMPS
−1.26768

(orotate phosphoribosyl transferase and

orotidi

Hs.2057
uridine monophosphate synthetase
UMPS
−1.21064

(orotate phosphoribosyl transferase and

orotidi

Hs.158357
Unc-5 homolog C (C. elegans)-like
UNC5CL
1.93767

Hs.438072
unc-84 homolog A (C. elegans)
UNC84A
1.25936

Hs.438072
unc-84 homolog A (C. elegans)
UNC84A
1.37302

Hs.191334
uracil-DNA glycosylase
UNG
−1.12501

Hs.159309
uroplakin 1A
UPK1A
1.25889

Hs.136778
ubiquitin specific peptidase 10
USP10
−1.06342

Hs.464416
ubiquitin specific peptidase 14 (tRNA-
USP14
−1.40594

guanine transglycosylase)

Hs.166068
ubiquitin specific peptidase 37
USP37
−1.17024

Hs.96513
Ubiquitin specific peptidase 40
USP40
−1.12769

Hs.467524
Ubiquitin specific peptidase 48
USP48
−1.06636

Hs.406703
UTP15, U3 small nucleolar
UTP15
−1.13351

ribonucleoprotein, homolog (yeast)

Hs.20021
vesicle-associated membrane protein 1
VAMP1
1.83895

(synaptobrevin 1)

Hs.25348
vesicle-associated membrane protein 2
VAMP2
1.0336

(synaptobrevin 2)

Hs.25348
vesicle-associated membrane protein 2
VAMP2
1.25148

(synaptobrevin 2)

Hs.66708
vesicle-associated membrane protein 3
VAMP3
−3.43922

(cellubrevin)

Hs.66708
vesicle-associated membrane protein 3
VAMP3
−3.00517

(cellubrevin)

Hs.66708
vesicle-associated membrane protein 3
VAMP3
−2.95829

(cellubrevin)

Hs.515130
vang-like 1 (van gogh, Drosophila)
VANGL1
−2.38658

Hs.515130
Vang-like 1 (van gogh, Drosophila)
VANGL1
−1.63434

Hs.515130
vang-like 1 (van gogh, Drosophila)
VANGL1
−1.58932

Hs.99477
vang-like 2 (van gogh, Drosophila)
VANGL2
1.90408

Hs.165195
VAMP (vesicle-associated membrane
VAPA
−1.27708

protein)-associated protein A, 33 kDa

Hs.514199
vesicle amine transport protein 1
VAT1
1.10246

homolog (T californica)

Hs.267659
vav 3 oncogene
VAV3
1.18062

Hs.249170
ventral anterior homeobox 2
VAX2
1.05896

Hs.355927
voltage-dependent anion channel 2
VDAC2
−1.37345

Hs.491597
voltage-dependent anion channel 3
VDAC3
−1.29732

Hs.491597
voltage-dependent anion channel 3
VDAC3
−1.04455

Hs.24135
transmembrane protein vezatin
VEZATIN
1.62615

Hs.534364
villin 1
VIL1
3.89723

Hs.487027
villin 2 (ezrin)
VIL2
−2.02301

Hs.511668
vacuolar protein sorting 13C (yeast)
VPS13C
1.0261

Hs.511668
Vacuolar protein sorting 13C (yeast)
VPS13C
1.65247

Hs.255015
vacuolar protein sorting 24 (yeast)
VPS24
1.14503

Hs.255015
vacuolar protein sorting 24 (yeast)
VPS24
1.2101

Hs.255015
vacuolar protein sorting 24 (yeast)
VPS24
1.32152

Hs.447547
vacuolar protein sorting 35 (yeast)
VPS35
−1.05515

Hs.148721
vacuolar protein sorting 41 (yeast)
VPS41
1.34209

Hs.148721
vacuolar protein sorting 41 (yeast)
VPS41
1.5398

Hs.422662
vaccinia related kinase 1
VRK1
−1.36691

Hs.443330
vaccinia related kinase 3
VRK3
1.624

Hs.516114
WW domain binding protein 1
WBP1
1.31978

Hs.385998
WD repeat and HMG-box DNA binding
WDHD1
−2.67897

protein 1

Hs.385998
WD repeat and HMG-box DNA binding
WDHD1
−1.92371

protein 1

Hs.385998
WD repeat and HMG-box DNA binding
WDHD1
−1.85968

protein 1

Hs.128548
WD repeat domain 1
WDR1
1.02563

Hs.128548
WD repeat domain 1
WDR1
1.07342

Hs.532056
WD repeat domain 17
WDR17
1.98877

Hs.133331
WD repeat domain 31
WDR31
1.39708

Hs.493750
WD repeat domain 40A
WDR40A
−1.37629

Hs.463465
WD repeat domain 50
WDR50
−1.78047

Hs.478095
WD repeat domain 56
WDR56
1.44822

Hs.478095
WD repeat domain 56
WDR56
1.46879

Hs.97933
WD repeat domain 63
WDR63
2.30932

Hs.250154
WD repeat domain 76
WDR76
−1.28428

Hs.389438
WD and tetratricopeptide repeats 2
WDTC2
1.35418

Hs.113876
Wolf-Hirschhorn syndrome candidate 1
WHSC1
−1.10369

Hs.113876
Wolf-Hirschhorn syndrome candidate 1
WHSC1
1.21057

Hs.32099
Wolf-Hirschhorn syndrome candidate 1-
WHSC1L1
−1.01105

like 1

Hs.386299
p53 target zinc finger protein
WIG1
1.21836

Hs.506985
WD repeat and SOCS box-containing 2
WSB2
−2.6357

Hs.506985
WD repeat and SOCS box-containing 2
WSB2
−2.55938

Hs.477921
WW domain containing transcription
WWTR1
−1.51793

regulator 1

Hs.475538
xeroderma pigmentosum,
XPC
1.44

complementation group C

Hs.370770
Exportin 1 (CRM1 homolog, yeast)
XPO1
1.25975

Hs.85951
exportin, tRNA (nuclear export receptor
XPOT
−1.11526

for tRNAs)

Hs.227656
Xenotropic and polytropic retrovirus
XPR1
2.88274

receptor

Hs.503692
Yes-associated protein 1, 65 kDa
YAP1
−1.70202

Hs.503692
Yes-associated protein 1, 65 kDa
YAP1
−1.66827

Hs.82719
Yip1 domain family, member 6
YIPF6
−2.06789

Hs.82719
Yip1 domain family, member 6
YIPF6
−1.39079

Hs.82719
Yip1 domain family, member 6
YIPF6
−1.31724

Hs.391944
YOD1 OTU deubiquinating enzyme 1
YOD1
−2.26119

homolog (yeast)

Hs.391944
YOD1 OTU deubiquinating enzyme 1
YOD1
−2.10226

homolog (yeast)

Hs.517436
yippee-like 1 (Drosophila)
YPEL1
1.19587

Hs.463613
yippee-like 2 (Drosophila)
YPEL2
1.94554

Hs.513491
yippee-like 3 (Drosophila)
YPEL3
2.75211

Hs.10056
Ysg2 homolog (mouse) /// Ysg2
YSG2
1.12171

homolog (mouse)

Hs.11747
YTH domain family, member 1
YTHDF1
−1.17086

Hs.98365
zinc binding alcohol dehydrogenase,
ZADH1
1.55913

domain containing 1

Hs.444451
sterile alpha motif and leucine zipper
ZAK
−1.37311

containing kinase AZK

Hs.444451
sterile alpha motif and leucine zipper
ZAK
−1.10919

containing kinase AZK

Hs.444451
sterile alpha motif and leucine zipper
ZAK
1.2113

containing kinase AZK

Hs.444451
sterile alpha motif and leucine zipper
ZAK
1.34285

containing kinase AZK

Hs.518301
zinc finger and BTB domain containing
ZBTB38
−1.21687

38

Hs.190477
Zinc finger CCCH-type containing 6
ZC3HDC6
1.09859

Hs.370424
zinc finger protein, X-linked
ZFX
1.14659

Hs.482660
zinc finger, FYVE domain containing 16
ZFYVE16
1.09813

Hs.533986
zinc finger, MYM-type 6
ZMYM6
−1.61165

Hs.499453
zinc finger protein 11B
ZNF11B
1.50934

Hs.181552
zinc finger protein 140 (clone pHZ-39)
ZNF140
−1.04575

Hs.145956
zinc finger protein 226
ZNF226
1.75717

Hs.499429
zinc finger protein 25 (KOX 19)
ZNF25
1.27101

Hs.314246
zinc finger protein 271
ZNF271
−1.41129

Hs.489722
zinc finger protein 277
ZNF277
1.11347

Hs.458986
zinc finger protein 291
ZNF291
1.33906

Hs.458986
zinc finger protein 291
ZNF291
1.39406

Hs.288773
zinc finger protein 294
ZNF294
−1.61094

Hs.436350
zinc finger protein 302
ZNF302
1.55881

Hs.435774
zinc finger protein 33A
ZNF33A
1.69754

Hs.494557
zinc finger protein 367
ZNF367
−3.04638

Hs.530930
zinc finger protein 423
ZNF423
1.90391

Hs.529178
zinc finger protein 512
ZNF512
1.33088

Hs.529178
zinc finger protein 512
ZNF512
1.35578

Hs.349444
zinc finger protein 558
ZNF558
1.48459

Hs.511848
zinc finger protein 569
ZNF569
−1.11338

Hs.522147
zinc finger protein 658
ZNF658
1.21013

Hs.427284
zinc and ring finger 1
ZNRF1
1.25766

Hs.21331
Zwilch, kinetochore associated, homolog
ZWILCH
−2.23041

(Drosophila)

Hs.42650
ZW10 interactor
ZWINT
−2.92582

Manipulation of the expression levels of the genes listed in Table 1 represents a potentially useful therapy for cancer and other diseases in which increased or reduced expression of hsa-miR-124a has a role in the disease.

Example 2
Cellular Pathways Affected by Hsa-miR-124a

The mis-regulation of gene expression by hsa-miR-124a (Table 1) affects many cellular pathways that represent potential therapeutic targets for the control of cancer and other diseases and disorders. The inventors determined the identity and nature of the cellular genetic pathways affected by the regulatory cascade induced by hsa-miR-124a expression. Cellular pathway analyses were performed using Ingenuity Pathways Analysis (Version 4.0, Ingenuity® Systems; Redwood City, Calif., USA). Alteration of a given pathway was determined by Fisher's Exact test (Fisher, 1922). The most significantly affected pathways following over-expression of hsa-miR-124a in A549 cells are shown in Table 2.

TABLE 2

Significantly affected functional cellular pathways following hsa-miR-124a

overexpression in human cancer cells.

Number

of Genes
Pathway Functions

33
Cell Cycle, Gene Expression, Cancer

33
Cell Cycle, Cell Death, Gene Expression

32
Cellular Function and Maintenance, Cell Signaling, Molecular Transport

32
Cancer, Reproductive System Disease, DNA Replication, Recombination, and Repair

32
Nucleic Acid Metabolism, Cellular Assembly and Organization, DNA Replication,

Recombination, and Repair

32
RNA Post-Transcriptional Modification, Gene Expression, Connective Tissue Development and

Function

30
Cell Death, Embryonic Development, Dermatological Diseases and Conditions

29
Cell Signaling, Cancer, Cell Morphology

29
Cell Cycle, Cell Morphology, Connective Tissue Development and Function

29
Cellular Development, Hematological System Development and Function, Immune and

Lymphatic System Development and Function

29
DNA Replication, Recombination, and Repair, Cellular Assembly and Organization, Cell Cycle

29
Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry

29
Cell Cycle, Cellular Assembly and Organization, DNA Replication, Recombination, and Repair

28
Cell Cycle, Cellular Movement, Cardiovascular System Development and Function

28
Tissue Development, Genetic Disorder, Immunological Disease

27
Cell Cycle, Cell Signaling, Embryonic Development

25
Cell Signaling, Cell Cycle, Hair and Skin Development and Function

24
Cellular Movement, Connective Tissue Development and Function, Cellular Assembly and

Organization

24
Cell Signaling, Neurological Disease, Nervous System Development and Function

23
Cell Morphology, Connective Tissue Development and Function, Cell Signaling

22
Cellular Assembly and Organization, Tissue Morphology, Cellular Function and Maintenance

22
DNA Replication, Recombination, and Repair, Cancer, Cell Cycle

22
Hematological Disease, Drug Metabolism, Lipid Metabolism

21
Cellular Assembly and Organization, Cell-To-Cell Signaling and Interaction, Cellular Function

and Maintenance

16
Gene Expression, Cancer, Cell-To-Cell Signaling and Interaction

20
Cell Cycle, Connective Tissue Development and Function, Reproductive System Development

and Function

20
Cancer, Reproductive System Disease, Protein Synthesis

20
DNA Replication, Recombination, and Repair, Cell Death, Cancer

20
Cancer, Cardiovascular System Development and Function, Cell Cycle

17
Gene Expression, Cell Cycle, Reproductive System Development and Function

19
Cell Cycle, Gene Expression, Connective Tissue Development and Function

19
Cell Cycle, DNA Replication, Recombination, and Repair, Cancer

19
Organismal Functions, Digestive System Development and Function, Cell Morphology

19
Cell Signaling, Hair and Skin Development and Function, Cell Morphology

19
Drug Metabolism, Nucleic Acid Metabolism, Small Molecule Biochemistry

19
Cell Signaling, Cellular Assembly and Organization, Cellular Function and Maintenance

19
Post-Translational Modification, Gene Expression, Skeletal and Muscular System Development

and Function

18
Cell-To-Cell Signaling and Interaction, Tissue Development, Dermatological Diseases and

Conditions

18
Endocrine System Disorders, Metabolic Disease, Cell Cycle

18
Cancer, Cellular Response to Therapeutics, Reproductive System Disease

17
Cancer, Cell Cycle, Reproductive System Disease

17
Cell Cycle, Cell Death, Cancer

17
Cell-To-Cell Signalin and Interaction, Cellular Compromise, Amino Acid Metabolism

17
Cell Morphology, Cell-To-Cell Signaling and Interaction, Hematological System Development

and Function

17
Cell-To-Cell Signaling and Interaction, Cellular Growth and Proliferation, Hematological System

Development and Function

17
Cardiovascular System Development and Function, Cardiovascular Disease, Organismal Injury

and Abnormalities

15
Gene Expression, Organ Development, Organ Morphology

16
Gastrointestinal Disease, Hepatic System Disease, Cell Death

16
Cell Cycel, Post-Translational Modification, Neurological Disease

16
Cell Death, Hematological Disease, Immunological Disease

16
Cancer, Immune Response, Hematological Disease

16
Amino Acid Metabolism, Post-Translational Modification, Small Molecule Biochemistry

15
Cell Cycle, Cellular Movement, Connective Tissue Development and Function

15
Embryonic Development, Tissue Development, Cellular Development

15
Cell Death, Hematological Disease, Immunological Disease

15
Amino Acid Metabolism, Hematological Disease, Cellular Assembly and Organization

15
RNA Post-Transcriptional Modification, Cellular Assembly and Organization, Cell Cycle

14
Cell Cycle, DNA Replication, Recombination, and Repair, Cellular Assembly and Organization

14
Cell Signaling, Gene Expression, Cancer

13
Cancer, Dermatological Diseases and Conditions, Carbohydrate Metabolism

13
Protein Synthesis, Nucleic Acid Metabolism, Protein Degradation

9
Lipid Metabolism, Molecular Transport, Small Molecule Biochemistry

These data demonstrate that hsa-miR-124a directly or indirectly affects the expression of numerous cancer-, cellular proliferation-, cellular development-, cell signaling-, and cell cycle-related genes and thus primarily affects functional pathways related to cancer, cellular growth, development, and proliferation. Those cellular processes all have integral roles in the development and progression of various cancers. Manipulation of the expression levels of genes in the cellular pathways shown in Table 2 represents a potentially useful therapy for cancer and other diseases in which increased or reduced expression of hsa-miR-124a has a role in the disease.

Example 3
Predicted Gene Targets of Hsa-miR-124a

Gene targets for binding of and regulation by hsa-miR-124a were predicted using the proprietary algorithm miRNATarget™ (Asuragen), which is an implementation of the method proposed by Krek et al. (Krek et al., 2005). Predicted target genes are shown in Table 3.

TABLE 3

Predicted target genes of hsa-miR-124a.

RefSeq

Transcript ID

Gene Symbol
(Pruitt et al., 2005)
Description

ABCA2
NM_001606
ATP-binding cassette, sub-family A, member 2

ABCA2
NM_212533
ATP-binding cassette, sub-family A, member 2

ABCC4
NM_005845
ATP-binding cassette, sub-family C, member 4

ABHD3
NM_138340
alpha/beta hydrolase domain containing protein

ABHD7
NM_173567
abhydrolase domain containing 7

ABR
NM_001092
active breakpoint cluster region-related

ABR
NM_021962
active breakpoint cluster region-related

ACACA
NM_198834
acetyl-Coenzyme A carboxylase alpha isoform 1

ACACA
NM_198836
acetyl-Coenzyme A carboxylase alpha isoform 2

ACACA
NM_198837
acetyl-Coenzyme A carboxylase alpha isoform 3

ACACA
NM_198838
acetyl-Coenzyme A carboxylase alpha isoform 4

ACACA
NM_198839
acetyl-Coenzyme A carboxylase alpha isoform 2

ACCN2
NM_001095
amiloride-sensitive cation channel 2, neuronal

ACCN2
NM_020039
amiloride-sensitive cation channel 2, neuronal

ACSL1
NM_001995
acyl-CoA synthetase long-chain family member 1

ACVR2A
NM_001616
activin A receptor, type IIA precursor

ADCY1
NM_021116
brain adenylate cyclase 1

ADIPOR2
NM_024551
adiponectin receptor 2

AFF3
NM_001025108
AF4/FMR2 family, member 3 isoform 2

AFF3
NM_002285
AF4/FMR2 family, member 3 isoform 1

AFF4
NM_014423
ALL1 fused gene from 5q31

AHCYL1
NM_006621
S-adenosylhomocysteine hydrolase-like 1

AHR
NM_001621
aryl hydrocarbon receptor

AKAP1
NM_139275
A-kinase anchor protein 1 isoform 2 precursor

AKT3
NM_005465
v-akt murine thymoma viral oncogene homolog 3

ALCAM
NM_001627
activated leukocyte cell adhesion molecule

ALG2
NM_033087
alpha-1,3-mannosyltransferase ALG2 isoform 1

ALG2
NM_197973
alpha-1,3-mannosyltransferase ALG2 isoform 2

ANGEL1
NM_015305
angel homolog 1

ANK1
NM_000037
ankyrin 1 isoform 3

ANK1
NM_020475
ankyrin 1 isoform 4

ANK1
NM_020476
ankyrin 1 isoform 1

ANK1
NM_020477
ankyrin 1 isoform 2

ANK1
NM_020478
ankyrin 1 isoform 5

ANK1
NM_020479
ankyrin 1 isoform 6

ANK1
NM_020480
ankyrin 1 isoform 7

ANK1
NM_020481
ankyrin 1 isoform 8

ANKFY1
NM_016376
ankyrin repeat and FYVE domain containing 1

ANKRD13
NM_033121
ankyrin repeat domain 13

ANKRD15
NM_015158
ankyrin repeat domain protein 15 isoform a

ANKRD15
NM_153186
ankyrin repeat domain protein 15 isoform b

ANTXR2
NM_058172
anthrax toxin receptor 2

ANXA11
NM_001157
annexin A11

ANXA11
NM_145868
annexin A11

ANXA11
NM_145869
annexin A11

ANXA5
NM_001154
annexin 5

ANXA7
NM_001156
annexin VII isoform 1

ANXA7
NM_004034
annexin VII isoform 2

AOF1
NM_153042
amine oxidase (flavin containing) domain 1

AP1G1
NM_001030007
adaptor-related protein complex 1, gamma 1

AP1G1
NM_001128
adaptor-related protein complex 1, gamma 1

AP3M1
NM_012095
adaptor-related protein complex 3, mu 1 subunit

AP3M1
NM_207012
adaptor-related protein complex 3, mu 1 subunit

ARFIP1
NM_001025593
ADP-ribosylation factor interacting protein 1

ARFIP1
NM_001025595
ADP-ribosylation factor interacting protein 1

ARFIP1
NM_014447
ADP-ribosylation factor interacting protein 1

ARG2
NM_001172
arginase, type II precursor

ARHGDIA
NM_004309
Rho GDP dissociation inhibitor (GDI) alpha

ARHGEF4
NM_032995
Rho guanine nucleotide exchange factor 4 isoform

ARHGEF4
NM_015320
Rho guanine nucleotide exchange factor 4 isoform

ARHGEF7
NM_003899
Rho guanine nucleotide exchange factor 7 isoform

ARL8B
NM_018184
ADP-ribosylation factor-like 10C

ARPC5
NM_005717
actin related protein 2/3 complex subunit 5

ARPP-19
NM_006628
cyclic AMP phosphoprotein, 19 kD

ASB1
NM_016114
ankyrin repeat and SOCS box-containing protein

ASCC2
NM_032204
activating signal cointegrator 1 complex subunit

ASCIZ
NM_015251
ATM/ATR-Substrate Chk2-Interacting Zn2+-finger

ATF7IP
NM_018179
activating transcription factor 7 interacting

ATP11A
NM_032189
ATPase, Class VI, type 11A isoform b

ATP11A
NM_015205
ATPase, Class VI, type 11A isoform a

ATP6V0A2
NM_012463
ATPase, H+ transporting, lysosomal V0 subunit a

ATP6V0E
NM_003945
ATPase, H+ transporting, lysosomal, V0 subunit

ATP7A
NM_000052
ATPase, Cu++ transporting, alpha polypeptide

ATRX
NM_000489
transcriptional regulator ATRX isoform 1

ATRX
NM_138270
transcriptional regulator ATRX isoform 2

ATRX
NM_138271
transcriptional regulator ATRX isoform 3

B4GALT1
NM_001497
UDP-Gal:betaGlcNAc beta 1,4-

BACE1
NM_012104
beta-site APP-cleaving enzyme 1 isoform A

BACE1
NM_138971
beta-site APP-cleaving enzyme 1 isoform C

BACE1
NM_138972
beta-site APP-cleaving enzyme 1 isoform B

BACE1
NM_138973
beta-site APP-cleaving enzyme 1 isoform D

BACH2
NM_021813
BTB and CNC homology 1, basic leucine zipper

BAHD1
NM_014952
bromo adjacent homology domain containing 1

BAZ2B
NM_013450
bromodomain adjacent to zinc finger domain, 2B

BC002942
NM_033200
hypothetical protein LOC91289

BCL2L11
NM_006538
BCL2-like 11 isoform 6

BCL2L11
NM_138621
BCL2-like 11 isoform 1

BCL2L11
NM_138622
BCL2-like 11 isoform 2

BCL2L11
NM_138623
BCL2-like 11 isoform 3

BCL2L11
NM_138624
BCL2-like 11 isoform 4

BCL2L11
NM_138626
BCL2-like 11 isoform 7

BCL2L11
NM_138627
BCL2-like 11 isoform 8

BCL2L11
NM_207003
BCL2-like 11 isoform 10

BRP44L
NM_016098
brain protein 44-like

BRWD1
NM_033656
bromodomain and WD repeat domain containing 1

BRWD3
NM_153252
bromo domain-containing protein disrupted in

BTBD14B
NM_052876
transcriptional repressor NAC1

C10orf12
NM_015652
hypothetical protein LOC26148

C10orf39
NM_194303
hypothetical protein LOC282973

C10orf56
NM_153367
hypothetical protein LOC219654

C11orf9
NM_013279
hypothetical protein LOC745

C13orf23
NM_025138
hypothetical protein LOC80209

C13orf23
NM_170719
hypothetical protein LOC80209

C14orf162
NM_020181
chromosome 14 open reading frame 162

C15orf29
NM_024713
hypothetical protein LOC79768

C17orf63
NM_018182
hypothetical protein LOC55731

C1orf108
NM_024595
hypothetical protein LOC79647

C1orf121
NM_016076
hypothetical protein LOC51029

C1orf198
NM_032800
hypothetical protein LOC84886

C1orf21
NM_030806
chromosome 1 open reading frame 21

C1QL3
NM_001010908
complement component 1, q subcomponent-like 3

C20orf133
NM_001033086
hypothetical protein LOC140733 isoform 1

C20orf133
NM_001033087
hypothetical protein LOC140733 isoform 2

C4orf13
NM_001029998
hypothetical protein LOC84068 isoform b

C9orf25
NM_147202
hypothetical protein LOC203259

CACNA2D2
NM_001005505
calcium channel, voltage-dependent, alpha

CACNA2D2
NM_006030
calcium channel, voltage-dependent, alpha

CACNB3
NM_000725
calcium channel, voltage-dependent, beta 3

CADPS
NM_003716
Ca2+-dependent secretion activator isoform 1

CADPS
NM_183393
Ca2+-dependent secretion activator isoform 3

CADPS
NM_183394
Ca2+-dependent secretion activator isoform 2

CAPN2
NM_001748
calpain 2, large subunit

CAPN6
NM_014289
calpain 6

CASC3
NM_007359
cancer susceptibility candidate 3

CASC4
NM_138423
cancer susceptibility candidate 4 isoform a

CASC4
NM_177974
cancer susceptibility candidate 4 isoform b

CAST1
NM_015576
cytomatrix protein p110

CBFB
NM_022845
core-binding factor, beta subunit isoform 1

CBFB
NM_001755
core-binding factor, beta subunit isoform 2

CBLN2
NM_182511
cerebellin 2 precursor

CCDC28A
NM_015439
hypothetical protein LOC25901

CCL2
NM_002982
small inducible cytokine A2 precursor

CCND2
NM_001759
cyclin D2

CCNL2
NM_030937
cyclin L2 isoform A

CD164
NM_006016
CD164 antigen, sialomucin

CD276
NM_001024736
CD276 antigen isoform a

CD276
NM_025240
CD276 antigen isoform b

CDH11
NM_001797
cadherin 11, type 2 preproprotein

CDK4
NM_000075
cyclin-dependent kinase 4

CDK6
NM_001259
cyclin-dependent kinase 6

CEACAM1
NM_001024912
carcinoembryonic antigen-related cell adhesion

CEACAM1
NM_001712
carcinoembryonic antigen-related cell adhesion

CEBPG
NM_001806
CCAAT/enhancer binding protein gamma

CELSR3
NM_001407
cadherin EGF LAG seven-pass G-type receptor 3

CEP350
NM_014810
centrosome-associated protein 350

CFL2
NM_021914
cofilin 2

CFL2
NM_138638
cofilin 2

CGN
NM_020770
Cingulin

CHMP2B
NM_014043
chromatin modifying protein 2B

CHP
NM_007236
calcium binding protein P22

CHST1
NM_003654
carbohydrate (keratan sulfate Gal-6)

CHSY1
NM_014918
carbohydrate (chondroitin) synthase 1

CLDN11
NM_005602
claudin 11

CNOT7
NM_013354
CCR4-NOT transcription complex, subunit 7

CNTN3
NM_020872
contactin 3

COL12A1
NM_004370
alpha 1 type XII collagen long isoform

COL12A1
NM_080645
alpha 1 type XII collagen short isoform

COL4A1
NM_001845
alpha 1 type IV collagen preproprotein

CPNE5
NM_020939
copine V

CPNE8
NM_153634
copine VIII

CREB1
NM_004379
cAMP responsive element binding protein 1

CREB1
NM_134442
cAMP responsive element binding protein 1

CRSP7
NM_004831
cofactor required for Sp1 transcriptional

CSNK1G1
NM_001011664
casein kinase 1, gamma 1 isoform L

CSNK1G1
NM_022048
casein kinase 1, gamma 1 isoform S

CSTF3
NM_001326
cleavage stimulation factor subunit 3 isoform 1

CTDSP2
NM_005730
nuclear LIM interactor-interacting factor 2

CTDSPL
NM_001008392
small CTD phosphatase 3 isoform 1

CTDSPL
NM_005808
small CTD phosphatase 3 isoform 2

CTNS
NM_001031681
cystinosis, nephropathic isoform 1

CTNS
NM_004937
cystinosis, nephropathic isoform 2

CUL5
NM_003478
Vasopressin-activated calcium-mobilizing

DCHS1
NM_003737
dachsous 1 precursor

DDX6
NM_004397
DEAD (Asp-Glu-Ala-Asp) box polypeptide 6

DHX40
NM_024612
DEAH (Asp-Glu-Ala-His) box polypeptide 40

DIAPH1
NM_005219
diaphanous 1

DIXDC1
NM_033425
DIX domain containing 1 isoform b

DKFZp564K142
NM_032121
implantation-associated protein

DKFZP686A01247
NM_014988
hypothetical protein LOC22998

DKFZp686K16132
NM_001012987
hypothetical protein LOC388957

DLGAP2
NM_004745
discs large-associated protein 2

DMD
NM_000109
dystrophin Dp427c isoform

DMD
NM_004006
dystrophin Dp427m isoform

DMD
NM_004007
dystrophin Dp427l isoform

DMD
NM_004009
dystrophin Dp427p1 isoform

DMD
NM_004010
dystrophin Dp427p2 isoform

DMD
NM_004011
dystrophin Dp260-1 isoform

DMD
NM_004012
dystrophin Dp260-2 isoform

DMD
NM_004013
dystrophin Dp140 isoform

DMD
NM_004014
dystrophin Dp116 isoform

DMD
NM_004015
dystrophin Dp71 isoform

DMD
NM_004016
dystrophin Dp71b isoform

DMD
NM_004017
dystrophin Dp71a isoform

DMD
NM_004018
dystrophin Dp71ab isoform

DMD
NM_004020
dystrophin Dp140c isoform

DMD
NM_004021
dystrophin Dp140b isoform

DMD
NM_004022
dystrophin Dp140ab isoform

DMD
NM_004023
dystrophin Dp140bc isoform

DMXL1
NM_005509
Dmx-like 1

DNAJB12
NM_001002762
DnaJ (Hsp40) homolog, subfamily B, member 12

DNAJB12
NM_017626
DnaJ (Hsp40) homolog, subfamily B, member 12

DUSP15
NM_001012644
dual specificity phosphatase 15 isoform b

DUSP15
NM_080611
dual specificity phosphatase 15 isoform a

DUSP15
NM_177991
dual specificity phosphatase 15 isoform b

DYNC1LI2
NM_006141
dynein, cytoplasmic, light intermediate

DYNLT3
NM_006520
t-complex-associated-testis-expressed 1-like

E2F6
NM_001952
E2F transcription factor 6 isoform 1

E2F6
NM_198256
E2F transcription factor 6 isoform 2

E2F6
NM_198257
E2F transcription factor 6 isoform 3

E2F6
NM_198258
E2F transcription factor 6 isoform 3

E2F6
NM_198325
E2F transcription factor 6 isoform 3

E2F6
NM_212540
E2F transcription factor 6 isoform 4

EBF
NM_024007
early B-cell factor

EBF3
NM_001005463
early B-cell factor 3

EDEM1
NM_014674
ER degradation enhancer, mannosidase alpha-like

EDNRB
NM_000115
endothelin receptor type B isoform 1

EFNB2
NM_004093
ephrin B2

EGR1
NM_001964
early growth response 1

EIF2C1
NM_012199
eukaryotic translation initiation factor 2C, 1

EIF3S1
NM_003758
eukaryotic translation initiation factor 3,

ELAVL1
NM_001419
ELAV-like 1

ELK3
NM_005230
ELK3 protein

ELL2
NM_012081
elongation factor, RNA polymerase II, 2

ELOVL2
NM_017770
elongation of very long chain fatty acids

ELOVL5
NM_021814
homolog of yeast long chain polyunsaturated

EMD
NM_000117
Emerin

EMP2
NM_001424
epithelial membrane protein 2

EN2
NM_001427
engrailed homolog 2

EPB41L3
NM_012307
erythrocyte membrane protein band 4.1-like 3

EPHA3
NM_005233
ephrin receptor EphA3 isoform a precursor

ERF
NM_006494
Ets2 repressor factor

ETF1
NM_004730
eukaryotic translation termination factor 1

ETS1
NM_005238
v-ets erythroblastosis virus E26 oncogene

ETV1
NM_004956
ets variant gene 1

EVI1
NM_005241
ecotropic viral integration site 1

EXTL3
NM_001440
Reg receptor

EYA1
NM_000503
eyes absent 1 isoform b

EYA1
NM_172058
eyes absent 1 isoform b

EYA1
NM_172059
eyes absent 1 isoform c

EYA1
NM_172060
eyes absent 1 isoform a

EYA2
NM_005244
eyes absent 2 isoform a

EYA2
NM_172110
eyes absent 2 isoform c

EYA2
NM_172111
eyes absent 2 isoform a

EYA2
NM_172112
eyes absent 2 isoform a

EYA2
NM_172113
eyes absent 2 isoform b

EYA4
NM_004100
eyes absent 4 isoform a

EYA4
NM_172103
eyes absent 4 isoform b

EYA4
NM_172104
eyes absent 4 isoform c

EYA4
NM_172105
eyes absent 4 isoform d

F11R
NM_016946
F11 receptor isoform a precursor

F11R
NM_144501
F11 receptor isoform a precursor

F11R
NM_144502
F11 receptor isoform b

F11R
NM_144503
F11 receptor isoform a precursor

F11R
NM_144504
F11 receptor isoform a precursor

FAM107B
NM_031453
hypothetical protein LOC83641

FAM38B
NM_022068
hypothetical protein LOC63895

FAM53B
NM_014661
hypothetical protein LOC9679

FAM78A
NM_033387
hypothetical protein LOC286336

FARP1
NM_005766
FERM, RhoGEF, and pleckstrin domain protein 1

FBXL7
NM_012304
F-box and leucine-rich repeat protein 7

FGFR2
NM_023028
fibroblast growth factor receptor 2 isoform 10

FGFR2
NM_000141
fibroblast growth factor receptor 2 isoform 1

FGFR2
NM_022969
fibroblast growth factor receptor 2 isoform 2

FGFR2
NM_022970
fibroblast growth factor receptor 2 isoform 3

FGFR2
NM_022972
fibroblast growth factor receptor 2 isoform 5

FGFR2
NM_022975
fibroblast growth factor receptor 2 isoform 8

FGFR2
NM_023029
fibroblast growth factor receptor 2 isoform 11

FGFR2
NM_023030
fibroblast growth factor receptor 2 isoform 12

FGFR2
NM_023031
fibroblast growth factor receptor 2 isoform 13

FLJ10154
NM_018011
hypothetical protein LOC55082

FLJ11021
NM_023012
hypothetical protein LOC65117 isoform a

FLJ11021
NM_198261
hypothetical protein LOC65117 isoform b

FLJ11021
NM_198262
hypothetical protein LOC65117 isoform c

FLJ13576
NM_022484
hypothetical protein LOC64418

FLJ20054
NM_019049
hypothetical protein LOC54530

FLJ20489
NM_017842
hypothetical protein LOC55652

FLJ20701
NM_017933
hypothetical protein LOC55022

FLJ22222
NM_175902
hypothetical protein LOC79701 isoform 2

FLJ22222
NM_024648
hypothetical protein LOC79701 isoform 1

FLJ25476
NM_152493
hypothetical protein LOC149076

FLJ25530
NM_152722
hepatocyte cell adhesion molecule

FLJ33814
NM_173510
hypothetical protein LOC150275

FLJ34931
NM_001029883
hypothetical protein LOC388939

FLOT2
NM_004475
flotillin 2

FNBP1L
NM_001024948
formin binding protein 1-like isoform 1

FNBP1L
NM_017737
formin binding protein 1-like isoform 2

FOXQ1
NM_033260
forkhead box Q1

GAS2
NM_005256
growth arrest-specific 2

GAS2
NM_177553
growth arrest-specific 2

GAS2L1
NM_006478
growth arrest-specific 2 like 1 isoform a

GAS2L1
NM_152236
growth arrest-specific 2 like 1 isoform a

GAS2L1
NM_152237
growth arrest-specific 2 like 1 isoform b

GCN1L1
NM_006836
GCN1 general control of amino-acid synthesis

Gcom1
NM_001018100
GRINL1A upstream protein isoform 7

Gcom1
NM_001018101
GRINL1A upstream protein isoform 8

GLCE
NM_015554
D-glucuronyl C5-epimerase

GLRB
NM_000824
glycine receptor, beta

GLT8D1
NM_001010983
glycosyltransferase 8 domain containing 1

GLT8D1
NM_018446
glycosyltransferase 8 domain containing 1

GLT8D1
NM_152932
glycosyltransferase 8 domain containing 1

GLTP
NM_016433
glycolipid transfer protein

GNA13
NM_006572
guanine nucleotide binding protein (G protein),

GNPDA2
NM_138335
glucosamine-6-phosphate deaminase 2

GOLT1B
NM_016072
golgi transport 1 homolog B

GPR85
NM_018970
G protein-coupled receptor 85

GRIA2
NM_000826
glutamate receptor, ionotropic, AMPA 2

GRID1
NM_017551
glutamate receptor, ionotropic, delta 1

GRM1
NM_000838
glutamate receptor, metabotropic 1

HDAC4
NM_006037
histone deacetylase 4

HDAC5
NM_001015053
histone deacetylase 5 isoform 3

HDAC5
NM_005474
histone deacetylase 5 isoform 1

HIAT1
NM_033055
hippocampus abundant transcript 1

HIATL1
NM_032558
hypothetical protein LOC84641

HIC1
NM_006497
hypermethylated in cancer 1

HIPK1
NM_181358
homeodomain-interacting protein kinase 1 isoform

HIPK1
NM_198268
homeodomain-interacting protein kinase 1 isoform

HIPK1
NM_198269
homeodomain-interacting protein kinase 1 isoform

HMFN0839
NM_032717
hypothetical protein LOC84803

HMG2L1
NM_001003681
high-mobility group protein 2-like 1 isoform b

HMG2L1
NM_005487
high-mobility group protein 2-like 1 isoform a

HMG2L1
NM_014250
high-mobility group protein 2-like 1 isoform a

HMGA1
NM_002131
high mobility group AT-hook 1 isoform b

HMGA1
NM_145899
high mobility group AT-hook 1 isoform a

HMGA1
NM_145901
high mobility group AT-hook 1 isoform a

HMGA1
NM_145902
high mobility group AT-hook 1 isoform b

HMGA1
NM_145903
high mobility group AT-hook 1 isoform b

HMGA1
NM_145904
high mobility group AT-hook 1 isoform a

HMGA1
NM_145905
high mobility group AT-hook 1 isoform b

ICMT
NM_012405
isoprenylcysteine carboxyl methyltransferase

IGSF4
NM_014333
immunoglobulin superfamily, member 4

ILKAP
NM_176799
integrin-linked kinase-associated protein

IQGAP1
NM_003870
IQ motif containing GTPase activating protein 1

ITGA11
NM_001004439
integrin, alpha 11 precursor

ITGA11
NM_012211
integrin, alpha 11 precursor

ITPR3
NM_002224
inositol 1,4,5-triphosphate receptor, type 3

JAG1
NM_000214
jagged 1 precursor

JAKMIP1
NM_144720
multiple coiled-coil GABABR1-binding protein

JPH1
NM_020647
junctophilin 1

KCNK10
NM_138317
potassium channel, subfamily K, member 10

KCNK10
NM_138318
potassium channel, subfamily K, member 10

KCNK10
NM_021161
potassium channel, subfamily K, member 10

KCNK2
NM_001017424
potassium channel, subfamily K, member 2 isoform

KCNK2
NM_001017425
potassium channel, subfamily K, member 2 isoform

KCNK2
NM_014217
potassium channel, subfamily K, member 2 isoform

KCNQ2
NM_004518
potassium voltage-gated channel KQT-like protein

KCTD12
NM_138444
potassium channel tetramerisation domain

KIAA0174
NM_014761
putative MAPK activating protein PM28

KIAA0376
NM_015330
cytospin A

KIAA0408
NM_014702
hypothetical protein LOC9729

KIAA0494
NM_014774
hypothetical protein LOC9813

KIAA0564
NM_015058
hypothetical protein LOC23078 isoform a

KIAA0676
NM_015043
hypothetical protein LOC23061 isoform b

KIAA0676
NM_198868
hypothetical protein LOC23061 isoform a

KIAA1024
NM_015206
hypothetical protein LOC23251

KIAA1161
NM_020702
hypothetical protein LOC57462

KIAA1244
NM_020340
hypothetical protein LOC57221

KIAA1324L
NM_152748
hypothetical protein LOC222223

KIAA1522
NM_020888
hypothetical protein LOC57648

KIAA1576
NM_020927
hypothetical protein LOC57687

KIAA1815
NM_024896
hypothetical protein LOC79956

KIAA2022
NM_001008537
hypothetical protein LOC340533

KIF5A
NM_004984
kinesin family member 5A

KLC2
NM_022822
likely ortholog of kinesin light chain 2

KLF12
NM_007249
Kruppel-like factor 12 isoform a

KLF13
NM_015995
Kruppel-like factor 13

KLF4
NM_004235
Kruppel-like factor 4 (gut)

KLHL24
NM_017644
DRE1 protein

KRAS
NM_004985
c-K-ras2 protein isoform b

LAMC1
NM_002293
laminin, gamma 1 precursor

LARP4
NM_052879
c-Mpl binding protein isoform a

LARP4
NM_199188
c-Mpl binding protein isoform b

LARP4
NM_199190
c-Mpl binding protein isoform c

LARP5
NM_015155
La ribonucleoprotein domain family, member 5

LASS2
NM_013384
LAG1 longevity assurance homolog 2 isoform 2

LASS2
NM_022075
LAG1 longevity assurance homolog 2 isoform 1

LASS2
NM_181746
LAG1 longevity assurance homolog 2 isoform 1

LHX2
NM_004789
LIM homeobox protein 2

LIN28B
NM_001004317
lin-28 homolog B

LITAF
NM_004862
LPS-induced TNF-alpha factor

LMAN2L
NM_030805
lectin, mannose-binding 2-like

LMBRD2
NM_001007527
LMBR1 domain containing 2

LMNA
NM_170707
lamin A/C isoform 1 precursor

LMNA
NM_170708
lamin A/C isoform 3

LMNB1
NM_005573
lamin B1

LNK
NM_005475
lymphocyte adaptor protein

LOC144097
NM_138471
hypothetical protein LOC144097

LOC153364
NM_203406
similar to metallo-beta-lactamase superfamily

LOC285382
NM_001025266
hypothetical protein LOC285382

LOC339745
NM_001001664
hypothetical protein LOC339745

LONRF1
NM_152271
hypothetical protein LOC91694

LPIN1
NM_145693
lipin 1

LPP
NM_005578
LIM domain containing preferred translocation

LRIG1
NM_015541
leucine-rich repeats and immunoglobulin-like

LRP6
NM_002336
low density lipoprotein receptor-related protein

LRRC57
NM_153260
hypothetical protein LOC255252

LSM16
NM_025083
LSM16 homolog (EDC3, S. cerevisiae)

LYCAT
NM_001002257
lysocardiolipin acyltransferase isoform 2

LYCAT
NM_182551
lysocardiolipin acyltransferase isoform 1

MACF1
NM_012090
microfilament and actin filament cross-linker

MACF1
NM_033044
microfilament and actin filament cross-linker

MAGI2
NM_012301
membrane associated guanylate kinase, WW and PDZ

MAP1B
NM_005909
microtubule-associated protein 1B isoform 1

MAP1B
NM_032010
microtubule-associated protein 1B isoform 2

MAP2K4
NM_003010
mitogen-activated protein kinase kinase 4

MAP7
NM_003980
microtubule-associated protein 7

MAPK14
NM_001315
mitogen-activated protein kinase 14 isoform 1

MAPK14
NM_139012
mitogen-activated protein kinase 14 isoform 2

MAPK14
NM_139014
mitogen-activated protein kinase 14 isoform 4

MAPK4
NM_002747
mitogen-activated protein kinase 4

MDGA1
NM_153487
MAM domain containing

MECP2
NM_004992
methyl CpG binding protein 2

MICALCL
NM_032867
hypothetical protein LOC84953

MIPOL1
NM_138731
mirror-image polydactyly 1

MITF
NM_000248
microphthalmia-associated transcription factor

MITF
NM_006722
microphthalmia-associated transcription factor

MITF
NM_198158
microphthalmia-associated transcription factor

MITF
NM_198159
microphthalmia-associated transcription factor

MITF
NM_198177
microphthalmia-associated transcription factor

MITF
NM_198178
microphthalmia-associated transcription factor

MKLN1
NM_013255
muskelin 1, intracellular mediator containing

MKRN3
NM_005664
makorin, ring finger protein, 3

MLLT3
NM_004529
myeloid/lymphoid or mixed-lineage leukemia

MN1
NM_002430
meningioma 1

MOCS1
NM_005943
molybdenum cofactor synthesis-step 1 protein

MORC4
NM_024657
zinc finger, CW type with coiled-coil domain 2

MPZL1
NM_003953
myelin protein zero-like 1 isoform a

MPZL1
NM_024569
myelin protein zero-like 1 isoform b

MTF2
NM_007358
metal response element-binding transcription

MTMR12
NM_019061
myotubularin related protein 12

MTPN
NM_145808
Myotrophin

MYADM
NM_001020818
myeloid-associated differentiation marker

MYADM
NM_001020819
myeloid-associated differentiation marker

MYADM
NM_001020820
myeloid-associated differentiation marker

MYADM
NM_001020821
myeloid-associated differentiation marker

MYADM
NM_138373
myeloid-associated differentiation marker

MYCBP
NM_012333
c-myc binding protein

MYLIP
NM_013262
myosin regulatory light chain interacting

MYNN
NM_018657
Myoneurin

MYO10
NM_012334
myosin X

MYO1C
NM_033375
myosin IC

MYO9B
NM_004145
myosin IXB

MYRIP
NM_015460
myosin VIIA and Rab interacting protein

NAB1
NM_005966
NGFI-A binding protein 1

NARG1
NM_057175
NMDA receptor regulated 1

NAV1
NM_020443
neuron navigator 1

NAV2
NM_145117
neuron navigator 2 isoform 2

NAV2
NM_182964
neuron navigator 2 isoform 1

NAV3
NM_014903
neuron navigator 3

NCKIPSD
NM_016453
NCK interacting protein with SH3 domain isoform

NCKIPSD
NM_184231
NCK interacting protein with SH3 domain isoform

NCOR2
NM_006312
nuclear receptor co-repressor 2

NDFIP1
NM_030571
Nedd4 family interacting protein 1

NEGR1
NM_173808
neuronal growth regulator 1

NEK4
NM_003157
NIMA (never in mitosis gene a)-related kinase 4

NFIB
NM_005596
nuclear factor I/B

NFIX
NM_002501
nuclear factor I/X (CCAAT-binding transcription

NOPE
NM_020962
DDM36

NPLOC4
NM_017921
nuclear protein localization 4

NPTN
NM_012428
neuroplastin isoform b precursor

NPTN
NM_017455
neuroplastin isoform a precursor

NR3C1
NM_000176
nuclear receptor subfamily 3, group C, member 1

NR3C1
NM_001018074
nuclear receptor subfamily 3, group C, member 1

NR3C1
NM_001018075
nuclear receptor subfamily 3, group C, member 1

NR3C1
NM_001018076
nuclear receptor subfamily 3, group C, member 1

NR3C1
NM_001018077
nuclear receptor subfamily 3, group C, member 1

NR3C1
NM_001024094
nuclear receptor subfamily 3, group C, member 1

NR3C2
NM_000901
nuclear receptor subfamily 3, group C, member 2

NR5A2
NM_003822
nuclear receptor subfamily 5, group A, member 2

NR5A2
NM_205860
nuclear receptor subfamily 5, group A, member 2

NRP1
NM_003873
neuropilin 1 isoform a

NRP2
NM_018534
neuropilin 2 isoform 4 precursor

NRP2
NM_201267
neuropilin 2 isoform 5 precursor

NT5M
NM_020201
5′,3′-nucleotidase, mitochondrial precursor

NTRK2
NM_001018064
neurotrophic tyrosine kinase, receptor, type 2

NTRK2
NM_006180
neurotrophic tyrosine kinase, receptor, type 2

NUP35
NM_001008544
nucleoporin 35 kDa isoform b

NUPL1
NM_001008564
nucleoporin like 1 isoform b

NUPL1
NM_014089
nucleoporin like 1 isoform a

OACT2
NM_138799
O-acyltransferase (membrane bound) domain

OACT5
NM_005768
gene rich cluster, C3f gene

OGT
NM_003605
O-linked GlcNAc transferase isoform 3

OPN3
NM_001030012
opsin 3 isoform 3

OPN3
NM_001030011
opsin 3 isoform 2

OPRS1
NM_005866
opioid receptor, sigma 1 isoform 1

OPRS1
NM_147157
opioid receptor, sigma 1 isoform 2

OPRS1
NM_147158
opioid receptor, sigma 1 isoform 3

OSBP
NM_002556
oxysterol binding protein

OSBP2
NM_030758
oxysterol binding protein 2 isoform a

OSBPL11
NM_022776
oxysterol-binding protein-like protein 11

OSBPL3
NM_015550
oxysterol-binding protein-like protein 3 isoform

OSBPL3
NM_145320
oxysterol-binding protein-like protein 3 isoform

OSBPL3
NM_145321
oxysterol-binding protein-like protein 3 isoform

OSBPL3
NM_145322
oxysterol-binding protein-like protein 3 isoform

OSBPL5
NM_020896
oxysterol-binding protein-like protein 5 isoform

OSBPL5
NM_145638
oxysterol-binding protein-like protein 5 isoform

OSBPL6
NM_032523
oxysterol-binding protein-like protein 6 isoform

OSBPL6
NM_145739
oxysterol-binding protein-like protein 6 isoform

OTUD4
NM_199324
OTU domain containing 4 protein isoform 1

OXSR1
NM_005109
oxidative-stress responsive 1

PALLD
NM_016081
Palladin

PAPOLG
NM_022894
poly(A) polymerase gamma

PAQR8
NM_133367
progestin and adipoQ receptor family member

PARP16
NM_017851
poly (ADP-ribose) polymerase family, member 16

PBEF1
NM_005746
pre-B-cell colony enhancing factor 1 isoform a

PBX3
NM_006195
pre-B-cell leukemia transcription factor 3

PCDH8
NM_002590
protocadherin 8 isoform 1 precursor

PCDH8
NM_032949
protocadherin 8 isoform 2 precursor

PCSK6
NM_002570
paired basic amino acid cleaving system 4

PCSK6
NM_138319
paired basic amino acid cleaving system 4

PCTK3
NM_002596
PCTAIRE protein kinase 3 isoform b

PCTK3
NM_212502
PCTAIRE protein kinase 3 isoform b

PCTK3
NM_212503
PCTAIRE protein kinase 3 isoform a

PCYOX1
NM_016297
prenylcysteine oxidase 1

PDCD10
NM_007217
programmed cell death 10

PDCD10
NM_145859
programmed cell death 10

PDCD10
NM_145860
programmed cell death 10

PDE2A
NM_002599
phosphodiesterase 2A, cGMP-stimulated

PDE4A
NM_006202
phosphodiesterase 4A, cAMP-specific

PDE7B
NM_018945
phosphodiesterase 7B

PDZD2
NM_178140
PDZ domain containing 2

PEA15
NM_003768
phosphoprotein enriched in astrocytes 15

PEG3
NM_006210
paternally expressed 3

PELI1
NM_020651
pellino protein

PHC2
NM_004427
polyhomeotic 2-like isoform b

PHC2
NM_198040
polyhomeotic 2-like isoform a

PHF20L1
NM_024878
PHD finger protein 20-like 1 isoform 3

PHF20L1
NM_198513
PHD finger protein 20-like 1 isoform 2

PHF6
NM_001015877
PHD finger protein 6 isoform 1

PHF6
NM_032458
PHD finger protein 6 isoform 1

PHLDB1
NM_015157
pleckstrin homology-like domain, family B,

PHTF2
NM_020432
putative homeodomain transcription factor 2

PICALM
NM_001008660
phosphatidylinositol-binding clathrin assembly

PICALM
NM_007166
phosphatidylinositol-binding clathrin assembly

PIK3CA
NM_006218
phosphoinositide-3-kinase, catalytic, alpha

PLAGL2
NM_002657
pleiomorphic adenoma gene-like 2

PLCXD3
NM_001005473
phosphatidylinositol-specific phospholipase C, X

PLDN
NM_012388
Pallidin

PLEKHA6
NM_014935
phosphoinositol 3-phosphate-binding protein-3

PLEKHC1
NM_006832
pleckstrin homology domain containing, family C

PLEKHH1
NM_020715
pleckstrin homology domain containing, family H

PLSCR3
NM_020360
phospholipid scramblase 3

PLXNA3
NM_017514
plexin A3

PNN
NM_002687
pinin, desmosome associated protein

PODXL
NM_001018111
podocalyxin-like precursor isoform 1

PODXL
NM_005397
podocalyxin-like precursor isoform 2

PPARA
NM_001001928
peroxisome proliferative activated receptor,

PPARA
NM_001001929
peroxisome proliferative activated receptor,

PPARA
NM_001001930
peroxisome proliferative activated receptor,

PPARA
NM_005036
peroxisome proliferative activated receptor,

PPFIBP2
NM_003621
PTPRF interacting protein, binding protein 2

PPM1F
NM_014634
protein phosphatase 1F

PPP1R13L
NM_006663
protein phosphatase 1, regulatory (inhibitor)

PPP2R5E
NM_006246
epsilon isoform of regulatory subunit B56,

PPP4R1
NM_005134
protein phosphatase 4, regulatory subunit 1

PRKD1
NM_002742
protein kinase D1

PRPF39
NM_017922
PRP39 pre-mRNA processing factor 39 homolog

PRRX1
NM_006902
paired mesoderm homeobox 1 isoform pmx-1a

PRRX1
NM_022716
paired mesoderm homeobox 1 isoform pmx-1b

PTBP1
NM_002819
polypyrimidine tract-binding protein 1 isoform

PTBP1
NM_031990
polypyrimidine tract-binding protein 1 isoform

PTBP1
NM_031991
polypyrimidine tract-binding protein 1 isoform

PTBP1
NM_175847
polypyrimidine tract-binding protein 1 isoform

PTBP2
NM_021190
polypyrimidine tract binding protein 2

PTPN1
NM_002827
protein tyrosine phosphatase, non-receptor type

PTPN12
NM_002835
protein tyrosine phosphatase, non-receptor type

PTPN9
NM_002833
protein tyrosine phosphatase, non-receptor type

PTTG1IP
NM_004339
pituitary tumor-transforming gene 1

PURB
NM_033224
purine-rich element binding protein B

QKI
NM_206853
quaking homolog, KH domain RNA binding isoform

QKI
NM_206854
quaking homolog, KH domain RNA binding isoform

QKI
NM_206855
quaking homolog, KH domain RNA binding isoform

QKI
NM_006775
quaking homolog, KH domain RNA binding isoform

QRICH1
NM_017730
hypothetical protein LOC54870

QRICH1
NM_198880
hypothetical protein LOC54870

RAB10
NM_016131
ras-related GTP-binding protein RAB10

RAB11A
NM_004663
Ras-related protein Rab-11A

RAB1B
NM_030981
RAB1B, member RAS oncogene family

RAB27A
NM_004580
Ras-related protein Rab-27A

RAB27A
NM_183234
Ras-related protein Rab-27A

RAB27A
NM_183235
Ras-related protein Rab-27A

RAB27A
NM_183236
Ras-related protein Rab-27A

RAB34
NM_031934
RAB39

RAB43
NM_198490
RAB43 protein

RAB6A
NM_002869
RAB6A, member RAS oncogene family isoform a

RAB6A
NM_198896
RAB6A, member RAS oncogene family isoform b

RAD17
NM_002873
RAD17 homolog isoform 1

RAD17
NM_133338
RAD17 homolog isoform 1

RAD17
NM_133339
RAD17 homolog isoform 2

RAD17
NM_133340
RAD17 homolog isoform 3

RAD17
NM_133341
RAD17 homolog isoform 4

RAD17
NM_133342
RAD17 homolog isoform 1

RAD17
NM_133343
RAD17 homolog isoform 1

RAD17
NM_133344
RAD17 homolog isoform 1

RAI14
NM_015577
retinoic acid induced 14

RALA
NM_005402
ras related v-ral simian leukemia viral oncogene

RALGPS1
NM_014636
Ral GEF with PH domain and SH3 binding motif 1

RANBP10
NM_020850
RAN binding protein 10

RAP1B
NM_001010942
RAP1B, member of RAS oncogene family

RAP1B
NM_015646
RAP1B, member of RAS oncogene family

RAP2A
NM_021033
RAP2A, member of RAS oncogene family

RAP2C
NM_021183
RAP2C, member of RAS oncogene family

RASGEF1A
NM_145313
RasGEF domain family, member 1A

RASL10B
NM_033315
RAS-like, family 10, member B

RAVER1
NM_133452
RAVER1

RAVER2
NM_018211
ribonucleoprotein, PTB-binding 2

RBM24
NM_153020
hypothetical protein LOC221662

RBM33
NM_001008408
hypothetical protein LOC155435

RBMS1
NM_002897
RNA binding motif, single stranded interacting

RBMS1
NM_016836
RNA binding motif, single stranded interacting

RBMS1
NM_016839
RNA binding motif, single stranded interacting

REEP1
NM_022912
receptor expression enhancing protein 1

RERE
NM_012102
atrophin-1 like protein

RFFL
NM_001017368
Rififylin

RFFL
NM_057178
Rififylin

RFX1
NM_002918
regulatory factor X1

RGS9
NM_003835
regulator of G-protein signalling 9

RHBDL3
NM_138328
rhomboid, veinlet-like 3

RHOG
NM_001665
ras homolog gene family, member G

RICTOR
NM_152756
rapamycin-insensitive companion of mTOR

RNF11
NM_014372
ring finger protein 11

RNF144
NM_014746
ring finger protein 144

RNF165
NM_152470
ring finger protein 165

ROD1
NM_005156
ROD1 regulator of differentiation 1

RPIA
NM_144563
ribose 5-phosphate isomerase A (ribose

RPS6KB1
NM_003161
ribosomal protein S6 kinase, 70 kDa, polypeptide

RREB1
NM_001003698
ras responsive element binding protein 1 isoform

RREB1
NM_001003699
ras responsive element binding protein 1 isoform

RREB1
NM_002955
ras responsive element binding protein 1 isoform

RTN3
NM_006054
reticulon 3 isoform a

RTN3
NM_201428
reticulon 3 isoform b

RTN3
NM_201429
reticulon 3 isoform c

RTN3
NM_201430
reticulon 3 isoform d

RWDD4A
NM_152682
hypothetical protein LOC201965

RXRA
NM_002957
retinoid X receptor, alpha

RYR2
NM_001035
ryanodine receptor 2

RYR3
NM_001036
ryanodine receptor 3

SAPS2
NM_014678
hypothetical protein LOC9701

SASH1
NM_015278
SAM and SH3 domain containing 1

SCAMP2
NM_005697
secretory carrier membrane protein 2

SCD
NM_005063
stearoyl-CoA desaturase

SCN4B
NM_174934
sodium channel, voltage-gated, type IV, beta

SDAD1
NM_018115
SDA1 domain containing 1

SDC2
NM_002998
syndecan 2 precursor

SDCBP
NM_001007067
syntenin isoform 1

SDCBP
NM_001007068
syntenin isoform 2

SDCBP
NM_001007069
syntenin isoform 3

SDCBP
NM_001007070
syntenin isoform 3

SDCBP
NM_005625
syntenin isoform 1

SEC13L1
NM_030673
SEC13-like 1 isoform a

SEC13L1
NM_183352
SEC13-like 1 isoform b

SEC61A2
NM_018144
Sec61 alpha form 2

SELI
NM_033505
selenoprotein I

SELS
NM_018445
selenoprotein S

SEMA4F
NM_004263
semaphorin W

SEMA6A
NM_020796
sema domain, transmembrane domain (TM), and

SEMA6C
NM_030913
semaphorin Y

SEMA6D
NM_020858
semaphorin 6D isoform 1 precursor

SEMA6D
NM_153616
semaphorin 6D isoform 2 precursor

SEMA6D
NM_153617
semaphorin 6D isoform 3 precursor

SEMA6D
NM_153618
semaphorin 6D isoform 4 precursor

SEMA6D
NM_153619
semaphorin 6D isoform 5 precursor

SEPT11
NM_018243
septin 11

SERINC2
NM_178865
tumor differentially expressed 2-like

SERP1
NM_014445
stress-associated endoplasmic reticulum protein

SERTAD3
NM_013368
RPA-binding trans-activator

SERTAD3
NM_203344
RPA-binding trans-activator

SESTD1
NM_178123
SEC14 and spectrin domains 1

SFRS12
NM_139168
splicing factor, arginine/serine-rich 12

SH3BP5L
NM_030645
SH3-binding domain protein 5-like

SHRM
NM_020859
Shroom

SIRT1
NM_012238
sirtuin 1

SIX4
NM_017420
sine oculis homeobox homolog 4

SLBP
NM_006527
histone stem-loop binding protein

SLC16A1
NM_003051
solute carrier family 16, member 1

SLC16A14
NM_152527
solute carrier family 16 (monocarboxylic acid

SLC1A4
NM_003038
solute carrier family 1, member 4

SLC25A20
NM_000387
carnitine/acylcarnitine translocase

SLC25A25
NM_001006641
solute carrier family 25, member 25 isoform b

SLC25A25
NM_001006642
solute carrier family 25, member 25 isoform c

SLC25A25
NM_001006643
solute carrier family 25, member 25 isoform d

SLC25A25
NM_052901
solute carrier family 25, member 25 isoform a

SLC31A2
NM_001860
solute carrier family 31 (copper transporters),

SLC35A1
NM_006416
solute carrier family 35 (CMP-sialic acid

SLC35F5
NM_025181
solute carrier family 35, member F5

SLC41A2
NM_032148
solute carrier family 41, member 2

SLC7A8
NM_012244
solute carrier family 7 (cationic amino acid

SLC7A8
NM_182728
solute carrier family 7 (cationic amino acid

SLITRK6
NM_032229
slit and trk like 6

SLK
NM_014720
serine/threonine kinase 2

SLMAP
NM_007159
sarcolemma associated protein

SMARCAD1
NM_020159
SWI/SNF-related, matrix-associated

SNIP1
NM_024700
Smad nuclear interacting protein

SNX4
NM_003794
sorting nexin 4

SNX6
NM_021249
sorting nexin 6 isoform a

SNX6
NM_152233
sorting nexin 6 isoform b

SORCS2
NM_020777
VPS10 domain receptor protein SORCS 2

SOX9
NM_000346
transcription factor SOX9

SP2
NM_003110
Sp2 transcription factor

SP3
NM_001017371
Sp3 transcription factor isoform 2

SP3
NM_003111
Sp3 transcription factor isoform 1

SPRED2
NM_181784
sprouty-related protein with EVH-1 domain 2

SPRY1
NM_005841
sprouty homolog 1, antagonist of FGF signaling

SPRY1
NM_199327
sprouty homolog 1, antagonist of FGF signaling

SPRY2
NM_005842
sprouty 2

SRGAP3
NM_001033116
SLIT-ROBO Rho GTPase activating protein 3

SRGAP3
NM_001033117
SLIT-ROBO Rho GTPase activating protein 3

SRGAP3
NM_014850
SLIT-ROBO Rho GTPase activating protein 3

STAG2
NM_006603
stromal antigen 2

STC1
NM_003155
stanniocalcin 1 precursor

STK4
NM_006282
serine/threonine kinase 4

SUGT1
NM_006704
suppressor of G2 allele of SKP1

SURF4
NM_033161
surfeit 4

SYNC1
NM_030786
syncoilin, intermediate filament 1

SYT11
NM_152280
synaptotagmin 12

TACC1
NM_006283
transforming, acidic coiled-coil containing

TACC2
NM_006997
transforming, acidic coiled-coil containing

TACC2
NM_206860
transforming, acidic coiled-coil containing

TACC2
NM_206861
transforming, acidic coiled-coil containing

TACC2
NM_206862
transforming, acidic coiled-coil containing

TBC1D14
NM_020773
TBC1 domain family, member 14

TCBA1
NM_153355
T-cell lymphoma breakpoint-associated target 1

TEAD1
NM_021961
TEA domain family member 1

TEX261
NM_144582
testis expressed sequence 261

TFDP2
NM_006286
transcription factor Dp-2 (E2F dimerization

THAP2
NM_031435
THAP domain containing, apoptosis associated

TIPRL
NM_152902
TIP41, TOR signalling pathway regulator-like

TLL1
NM_012464
tolloid-like 1

TLL2
NM_012465
tolloid-like 2

TLOC1
NM_003262
translocation protein 1

TMCC3
NM_020698
transmembrane and coiled-coil domains 3

TMED1
NM_006858
interleukin 1 receptor-like 1 ligand precursor

TMEM109
NM_024092
hypothetical protein LOC79073

TMEM129
NM_138385
hypothetical protein LOC92305

TMEM134
NM_025124
hypothetical protein LOC80194

TMEPAI
NM_020182
transmembrane prostate androgen-induced protein

TMEPAI
NM_199169
transmembrane prostate androgen-induced protein

TMEPAI
NM_199170
transmembrane prostate androgen-induced protein

TMEPAI
NM_199171
transmembrane prostate androgen-induced protein

TNRC6B
NM_001024843
trinucleotide repeat containing 6B isoform 2

TNRC6B
NM_015088
trinucleotide repeat containing 6B isoform 1

TOB2
NM_016272
transducer of ERBB2, 2

TOR3A
NM_022371
torsin family 3, member A

TOX
NM_014729
thymus high mobility group box protein TOX

TPD52L2
NM_003288
tumor protein D52-like 2 isoform e

TPD52L2
NM_199359
tumor protein D52-like 2 isoform f

TPD52L2
NM_199360
tumor protein D52-like 2 isoform a

TPD52L2
NM_199361
tumor protein D52-like 2 isoform b

TPD52L2
NM_199362
tumor protein D52-like 2 isoform c

TPD52L2
NM_199363
tumor protein D52-like 2 isoform d

TRAM2
NM_012288
translocation-associated membrane protein 2

TRIM2
NM_015271
tripartite motif-containing 2

TRIM9
NM_015163
tripartite motif protein 9 isoform 1

TUBB6
NM_032525
tubulin, beta 6

UBE1L2
NM_018227
hypothetical protein LOC55236

UBE2B
NM_003337
ubiquitin-conjugating enzyme E2B

UBL3
NM_007106
ubiquitin-like 3

UBOX5
NM_014948
U-box domain containing 5 isoform a

UBOX5
NM_199415
U-box domain containing 5 isoform b

UGT8
NM_003360
UDP glycosyltransferase 8 (UDP-galactose

ULK2
NM_014683
unc-51-like kinase 2

USP14
NM_005151
ubiquitin specific protease 14 isoform a

USP37
NM_020935
ubiquitin specific protease 37

USP48
NM_032236
ubiquitin specific protease 48 isoform a

VAMP3
NM_004781
vesicle-associated membrane protein 3

VAT1
NM_006373
vesicle amine transport protein 1

VDAC2
NM_003375
voltage-dependent anion channel 2

VDAC3
NM_005662
voltage-dependent anion channel 3

VPS13A
NM_001018037
vacuolar protein sorting 13A isoform C

VPS13A
NM_033305
vacuolar protein sorting 13A isoform A

VPS37B
NM_024667
vacuolar protein sorting 37B

VSNL1
NM_003385
visinin-like 1

WAPAL
NM_015045
KIAA0261

WASPIP
NM_003387
WASP-interacting protein

WDFY1
NM_020830
WD repeat and FYVE domain containing 1

WDFY3
NM_014991
WD repeat and FYVE domain containing 3 isoform

WDFY3
NM_178585
WD repeat and FYVE domain containing 3 isoform

WDR40B
NM_178470
WD repeat domain 40B

WIRE
NM_133264
WIRE protein

WTAP
NM_152857
Wilms' tumour 1-associating protein isoform 2

WTAP
NM_152858
Wilms' tumour 1-associating protein isoform 2

XKR6
NM_173683
XK-related protein 6 isoform b

XKR6
NM_001012239
XK-related protein 6 isoform a

XPO4
NM_022459
exportin 4

YEATS2
NM_018023
YEATS domain containing 2

YIPF6
NM_173834
Yip1 domain family, member 6

YOD1
NM_018566
hypothetical protein LOC55432

YTHDF1
NM_017798
YTH domain family, member 1

ZBED4
NM_014838
zinc finger, BED domain containing 4

ZBTB39
NM_014830
zinc finger and BTB domain containing 39

ZBTB5
NM_014872
zinc finger and BTB domain containing 5

ZCCHC14
NM_015144
zinc finger, CCHC domain containing 14

ZDHHC16
NM_032327
Abl-philin 2 isoform 1

ZDHHC16
NM_198043
Abl-philin 2 isoform 2

ZDHHC16
NM_198044
Abl-philin 2 isoform 3

ZDHHC16
NM_198045
Abl-philin 2 isoform 4

ZDHHC16
NM_198046
Abl-philin 2 isoform 1

ZDHHC20
NM_153251
DHHC-containing protein 20

ZDHHC3
NM_016598
DHHC1 protein

ZFAND3
NM_021943
testis expressed sequence 27

ZFPM2
NM_012082
zinc finger protein, multitype 2

ZNF148
NM_021964
zinc finger protein 148 (pHZ-52)

ZNF219
NM_016423
zinc finger protein 219

ZNF336
NM_022482
zinc finger protein 336

ZNF447
NM_023926
zinc finger protein 447

ZNF608
NM_020747
zinc finger protein 608

ZNF654
NM_018293
zinc finger protein 654

ZNF706
NM_016096
HSPC038 protein

The predicted gene targets that exhibited altered mRNA expression levels in human cancer cells, following transfection with Pre-miR hsa-miR-124a, are shown in Table 4.

TABLE 4

Predicted hsa-miR-124a targets that exhibited altered mRNA expression levels in

human cancer cells after transfection with Pre-miR hsa-miR-124a.

RefSeq

Gene Symbol
Transcript ID
Description

SEPT11
NM_018243
septin 11

ACVR2A
NM_001616
activin A receptor, type IIA precursor

ADCY1
NM_021116
brain adenylate cyclase 1

ALCAM
NM_001627
activated leukocyte cell adhesion molecule

ALG2
NM_033087
alpha-1,3-mannosyltransferase ALG2 isoform 1

ALG2
NM_197973
alpha-1,3-mannosyltransferase ALG2 isoform 2

ANKFY1
NM_016376
ankyrin repeat and FYVE domain containing 1

ANXA5
NM_001154
annexin 5

ANXA7
NM_001156
annexin VII isoform 1

ANXA7
NM_004034
annexin VII isoform 2

AP3M1
NM_012095
adaptor-related protein complex 3, mu 1 subunit

AP3M1
NM_207012
adaptor-related protein complex 3, mu 1 subunit

ARFIP1
NM_001025593
ADP-ribosylation factor interacting protein 1

ARFIP1
NM_001025595
ADP-ribosylation factor interacting protein 1

ARFIP1
NM_014447
ADP-ribosylation factor interacting protein 1

ARHGDIA
NM_004309
Rho GDP dissociation inhibitor (GDI) alpha

ARPP-19
NM_006628
cyclic AMP phosphoprotein, 19 kD

ASCIZ
NM_015251
ATM/ATR-Substrate Chk2-Interacting Zn2+-finger

ATP6V0E
NM_003945
ATPase, H+ transporting, lysosomal, V0 subunit

ATRX
NM_000489
transcriptional regulator ATRX isoform 1

ATRX
NM_138270
transcriptional regulator ATRX isoform 2

ATRX
NM_138271
transcriptional regulator ATRX isoform 3

B4GALT1
NM_001497
UDP-Gal:betaGlcNAc beta 1,4-

BCL2L11
NM_006538
BCL2-like 11 isoform 6

BCL2L11
NM_138621
BCL2-like 11 isoform 1

BCL2L11
NM_138622
BCL2-like 11 isoform 2

BCL2L11
NM_138623
BCL2-like 11 isoform 3

BCL2L11
NM_138624
BCL2-like 11 isoform 4

BCL2L11
NM_138626
BCL2-like 11 isoform 7

BCL2L11
NM_138627
BCL2-like 11 isoform 8

BCL2L11
NM_207003
BCL2-like 11 isoform 10

C11orf9
NM_013279
hypothetical protein LOC745

C15orf29
NM_024713
hypothetical protein LOC79768

C1orf108
NM_024595
hypothetical protein LOC79647

C1orf121
NM_016076
hypothetical protein LOC51029

CAPN2
NM_001748
calpain 2, large subunit

CASC4
NM_138423
cancer susceptibility candidate 4 isoform a

CASC4
NM_177974
cancer susceptibility candidate 4 isoform b

CBFB
NM_022845
core-binding factor, beta subunit isoform 1

CBFB
NM_001755
core-binding factor, beta subunit isoform 2

CCDC28A
NM_015439
hypothetical protein LOC25901

CCL2
NM_002982
small inducible cytokine A2 precursor

CD164
NM_006016
CD164 antigen, sialomucin

CDK4
NM_000075
cyclin-dependent kinase 4

CDK6
NM_001259
cyclin-dependent kinase 6

CEACAM1
NM_001024912
carcinoembryonic antigen-related cell adhesion

CEACAM1
NM_001712
carcinoembryonic antigen-related cell adhesion

CFL2
NM_021914
cofilin 2

CFL2
NM_138638
cofilin 2

CHMP2B
NM_014043
chromatin modifying protein 2B

CHSY1
NM_014918
carbohydrate (chondroitin) synthase 1

COL12A1
NM_004370
alpha 1 type XII collagen long isoform

COL12A1
NM_080645
alpha 1 type XII collagen short isoform

COL4A1
NM_001845
alpha 1 type IV collagen preproprotein

DHX40
NM_024612
DEAH (Asp-Glu-Ala-His) box polypeptide 40

DKFZp564K142
NM_032121
implantation-associated protein

EIF3S1
NM_003758
eukaryotic translation initiation factor 3,

ELK3
NM_005230
ELK3 protein

ELL2
NM_012081
elongation factor, RNA polymerase II, 2

ELOVL5
NM_021814
homolog of yeast long chain polyunsaturated

ETS1
NM_005238
v-ets erythroblastosis virus E26 oncogene

ETV1
NM_004956
ets variant gene 1

EYA4
NM_004100
eyes absent 4 isoform a

EYA4
NM_172103
eyes absent 4 isoform b

EYA4
NM_172104
eyes absent 4 isoform c

EYA4
NM_172105
eyes absent 4 isoform d

F11R
NM_016946
F11 receptor isoform a precursor

F11R
NM_144501
F11 receptor isoform a precursor

F11R
NM_144502
F11 receptor isoform b

F11R
NM_144503
F11 receptor isoform a precursor

F11R
NM_144504
F11 receptor isoform a precursor

FLJ20054
NM_019049
hypothetical protein LOC54530

FLJ22222
NM_175902
hypothetical protein LOC79701 isoform 2

FLJ22222
NM_024648
hypothetical protein LOC79701 isoform 1

FLJ33814
NM_173510
hypothetical protein LOC150275

FOXQ1
NM_033260
forkhead box Q1

GAS2L1
NM_006478
growth arrest-specific 2 like 1 isoform a

GAS2L1
NM_152236
growth arrest-specific 2 like 1 isoform a

GAS2L1
NM_152237
growth arrest-specific 2 like 1 isoform b

GLTP
NM_016433
glycolipid transfer protein

GNA13
NM_006572
guanine nucleotide binding protein (G protein),

GOLT1B
NM_016072
golgi transport 1 homolog B

HDAC4
NM_006037
histone deacetylase 4

HDAC5
NM_001015053
histone deacetylase 5 isoform 3

HDAC5
NM_005474
histone deacetylase 5 isoform 1

HIAT1
NM_033055
hippocampus abundant transcript 1

HIATL1
NM_032558
hypothetical protein LOC84641

HMG2L1
NM_001003681
high-mobility group protein 2-like 1 isoform b

HMG2L1
NM_005487
high-mobility group protein 2-like 1 isoform a

HMG2L1
NM_014250
high-mobility group protein 2-like 1 isoform a

IQGAP1
NM_003870
IQ motif containing GTPase activating protein 1

KIAA0494
NM_014774
hypothetical protein LOC9813

KIAA1815
NM_024896
hypothetical protein LOC79956

KLF4
NM_004235
Kruppel-like factor 4 (gut)

LAMC1
NM_002293
laminin, gamma 1 precursor

LASS2
NM_013384
LAG1 longevity assurance homolog 2 isoform 2

LASS2
NM_022075
LAG1 longevity assurance homolog 2 isoform 1

LASS2
NM_181746
LAG1 longevity assurance homolog 2 isoform 1

LHX2
NM_004789
LIM homeobox protein 2

LIN28B
NM_001004317
lin-28 homolog B

LITAF
NM_004862
LPS-induced TNF-alpha factor

LMAN2L
NM_030805
lectin, mannose-binding 2-like

LMNA
NM_170707
lamin A/C isoform 1 precursor

LMNA
NM_170708
lamin A/C isoform 3

LMNB1
NM_005573
lamin B1

LONRF1
NM_152271
hypothetical protein LOC91694

LYCAT
NM_001002257
lysocardiolipin acyltransferase isoform 2

LYCAT
NM_182551
lysocardiolipin acyltransferase isoform 1

MAPK14
NM_001315
mitogen-activated protein kinase 14 isoform 1

MAPK14
NM_139012
mitogen-activated protein kinase 14 isoform 2

MAPK14
NM_139014
mitogen-activated protein kinase 14 isoform 4

MLLT3
NM_004529
myeloid/lymphoid or mixed-lineage leukemia

MPZL1
NM_003953
myelin protein zero-like 1 isoform a

MPZL1
NM_024569
myelin protein zero-like 1 isoform b

MTF2
NM_007358
metal response element-binding transcription

MYADM
NM_001020818
myeloid-associated differentiation marker

MYADM
NM_001020819
myeloid-associated differentiation marker

MYADM
NM_001020820
myeloid-associated differentiation marker

MYADM
NM_001020821
myeloid-associated differentiation marker

MYADM
NM_138373
myeloid-associated differentiation marker

MYCBP
NM_012333
c-myc binding protein

MYO10
NM_012334
myosin X

NARG1
NM_057175
NMDA receptor regulated 1

NEK4
NM_003157
NIMA (never in mitosis gene a)-related kinase 4

NFIB
NM_005596
nuclear factor I/B

NOPE
NM_020962
DDM36

NRP2
NM_018534
neuropilin 2 isoform 4 precursor

NRP2
NM_201267
neuropilin 2 isoform 5 precursor

OACT2
NM_138799
O-acyltransferase (membrane bound) domain

OPN3
NM_001030012
opsin 3 isoform 3

OPN3
NM_001030011
opsin 3 isoform 2

OPRS1
NM_005866
opioid receptor, sigma 1 isoform 1

OPRS1
NM_147157
opioid receptor, sigma 1 isoform 2

OPRS1
NM_147158
opioid receptor, sigma 1 isoform 3

OSBP
NM_002556
oxysterol binding protein

OSBPL3
NM_015550
oxysterol-binding protein-like protein 3 isoform

OSBPL3
NM_145320
oxysterol-binding protein-like protein 3 isoform

OSBPL3
NM_145321
oxysterol-binding protein-like protein 3 isoform

OSBPL3
NM_145322
oxysterol-binding protein-like protein 3 isoform

OTUD4
NM_199324
OTU domain containing 4 protein isoform 1

OXSR1
NM_005109
oxidative-stress responsive 1

PDCD10
NM_007217
programmed cell death 10

PDCD10
NM_145859
programmed cell death 10

PDCD10
NM_145860
programmed cell death 10

PEA15
NM_003768
phosphoprotein enriched in astrocytes 15

PELI1
NM_020651
pellino protein

PHF20L1
NM_024878
PHD finger protein 20-like 1 isoform 3

PHF20L1
NM_198513
PHD finger protein 20-like 1 isoform 2

PHF6
NM_001015877
PHD finger protein 6 isoform 1

PHF6
NM_032458
PHD finger protein 6 isoform 1

PIK3CA
NM_006218
phosphoinositide-3-kinase, catalytic, alpha

PLAGL2
NM_002657
pleiomorphic adenoma gene-like 2

PLDN
NM_012388
Pallidin

PLEKHC1
NM_006832
pleckstrin homology domain containing, family C

PODXL
NM_001018111
podocalyxin-like precursor isoform 1

PODXL
NM_005397
podocalyxin-like precursor isoform 2

PPP2R5E
NM_006246
epsilon isoform of regulatory subunit B56,

PTBP1
NM_002819
polypyrimidine tract-binding protein 1 isoform

PTBP1
NM_031990
polypyrimidine tract-binding protein 1 isoform

PTBP1
NM_031991
polypyrimidine tract-binding protein 1 isoform

PTBP1
NM_175847
polypyrimidine tract-binding protein 1 isoform

PTBP2
NM_021190
polypyrimidine tract binding protein 2

PTPN12
NM_002835
protein tyrosine phosphatase, non-receptor type

PTTG1IP
NM_004339
pituitary tumor-transforming gene 1

QKI
NM_206853
quaking homolog, KH domain RNA binding isoform

QKI
NM_206854
quaking homolog, KH domain RNA binding isoform

QKI
NM_206855
quaking homolog, KH domain RNA binding isoform

QKI
NM_006775
quaking homolog, KH domain RNA binding isoform

RAB27A
NM_004580
Ras-related protein Rab-27A

RAB27A
NM_183234
Ras-related protein Rab-27A

RAB27A
NM_183235
Ras-related protein Rab-27A

RAB27A
NM_183236
Ras-related protein Rab-27A

RAB34
NM_031934
RAB39

RAB6A
NM_002869
RAB6A, member RAS oncogene family isoform a

RAB6A
NM_198896
RAB6A, member RAS oncogene family isoform b

RAI14
NM_015577
retinoic acid induced 14

RALA
NM_005402
ras related v-ral simian leukemia viral oncogene

RALGPS1
NM_014636
Ral GEF with PH domain and SH3 binding motif 1

RAP1B
NM_001010942
RAP1B, member of RAS oncogene family

RAP1B
NM_015646
RAP1B, member of RAS oncogene family

RAP2A
NM_021033
RAP2A, member of RAS oncogene family

RAP2C
NM_021183
RAP2C, member of RAS oncogene family

RASGEF1A
NM_145313
RasGEF domain family, member 1A

RBMS1
NM_002897
RNA binding motif, single stranded interacting

RBMS1
NM_016836
RNA binding motif, single stranded interacting

RBMS1
NM_016839
RNA binding motif, single stranded interacting

RERE
NM_012102
atrophin-1 like protein

RFFL
NM_001017368
Rififylin

RFFL
NM_057178
Rififylin

RHOG
NM_001665
ras homolog gene family, member G

ROD1
NM_005156
ROD1 regulator of differentiation 1

RPIA
NM_144563
ribose 5-phosphate isomerase A (ribose

RWDD4A
NM_152682
hypothetical protein LOC201965

SCD
NM_005063
stearoyl-CoA desaturase

SDAD1
NM_018115
SDA1 domain containing 1

SDCBP
NM_001007067
syntenin isoform 1

SDCBP
NM_001007068
syntenin isoform 2

SDCBP
NM_001007069
syntenin isoform 3

SDCBP
NM_001007070
syntenin isoform 3

SDCBP
NM_005625
syntenin isoform 1

SEC13L1
NM_030673
SEC13-like 1 isoform a

SEC13L1
NM_183352
SEC13-like 1 isoform b

SERP1
NM_014445
stress-associated endoplasmic reticulum protein

SLBP
NM_006527
histone stem-loop binding protein

SLC16A1
NM_003051
solute carrier family 16, member 1

SLC16A14
NM_152527
solute carrier family 16 (monocarboxylic acid

SLC35F5
NM_025181
solute carrier family 35, member F5

SLC41A2
NM_032148
solute carrier family 41, member 2

SLK
NM_014720
serine/threonine kinase 2

SNX6
NM_021249
sorting nexin 6 isoform a

SNX6
NM_152233
sorting nexin 6 isoform b

SOX9
NM_000346
transcription factor SOX9

STC1
NM_003155
stanniocalcin 1 precursor

SUGT1
NM_006704
suppressor of G2 allele of SKP1

SURF4
NM_033161
surfeit 4

SYT11
NM_152280
synaptotagmin 12

TACC1
NM_006283
transforming, acidic coiled-coil containing

TEX261
NM_144582
testis expressed sequence 261

TIPRL
NM_152902
TIP41, TOR signalling pathway regulator-like

TLOC1
NM_003262
translocation protein 1

TPD52L2
NM_003288
tumor protein D52-like 2 isoform e

TPD52L2
NM_199359
tumor protein D52-like 2 isoform f

TPD52L2
NM_199360
tumor protein D52-like 2 isoform a

TPD52L2
NM_199361
tumor protein D52-like 2 isoform b

TPD52L2
NM_199362
tumor protein D52-like 2 isoform c

TPD52L2
NM_199363
tumor protein D52-like 2 isoform d

TRIM9
NM_015163
tripartite motif protein 9 isoform 1

TUBB6
NM_032525
tubulin, beta 6

UBE2B
NM_003337
ubiquitin-conjugating enzyme E2B

UGT8
NM_003360
UDP glycosyltransferase 8 (UDP-galactose

USP14
NM_005151
ubiquitin specific protease 14 isoform a

USP37
NM_020935
ubiquitin specific protease 37

USP48
NM_032236
ubiquitin specific protease 48 isoform a

VAMP3
NM_004781
vesicle-associated membrane protein 3

VAT1
NM_006373
vesicle amine transport protein 1

VDAC2
NM_003375
voltage-dependent anion channel 2

VDAC3
NM_005662
voltage-dependent anion channel 3

YIPF6
NM_173834
Yip1 domain family, member 6

YOD1
NM_018566
hypothetical protein LOC55432

YTHDF1
NM_017798
YTH domain family, member 1

The predicted gene targets of hsa-miR-124a whose mRNA expression levels are affected by hsa-miR-124a represent particularly useful candidates for cancer therapy and therapy of other diseases through manipulation of their expression levels.

Example 4
Cancer Related Gene Expression Altered by Hsa-miR-124a

Cell proliferation and survival pathways are commonly altered in tumors (Hanahan and Weinberg, 2000). The inventors have shown that hsa-miR-124a directly or indirectly regulates the transcripts of proteins that are critical in the regulation of these pathways. Many of these targets have inherent oncogenic or tumor suppressor activity. Hsa-miR-124a targets that are associated with various cancer types are shown in Table 5.

TABLE 5

Tumor associated mRNAs altered by hsa-miR-124a having prognostic or therapeutic

value for the treatment of various malignancies.

Gene

Symbol
Gene Title
Cellular Process
Cancer Type
Reference

AKAP12
Akap-
Signal
CRC, PC,
(Xia et al., 2001; Wikman et al., 2002;

12/SSeCKS/Gravin
transduction
LC, GC,
Boultwood et al., 2004; Choi et al., 2004;

AML, CML
Keen and Taylor, 2004; Mori et al.,

2006; Reiter et al., 2006; Ulisse et al.,

2006)

AURKA/STK6
aurora kinase A
chromosomal
BC, CRC,
(Keen and Taylor, 2004; Reiter et al.,

stability
PaC, OC, GC,
2006; Ulisse et al., 2006)

SCCHN, TC

AURKB/STK12
aurora kinase B
chromosomal
PC, NSCLC,
(Keen and Taylor, 2004; Smith et al.,

stability
BC, CRC
2005; Chieffi et al., 2006)

BCL10
BCL-10
signal
MALT BCL
(Thome, 2004)

transduction

BCL2L11
Bim
apoptosis
M, MCL,
(Gomez-Bougie et al., 2004; Austin and

NSCLC, G,
Cook, 2005; Li et al., 2005; Tagawa et

al., 2005)

BRAF
B-Raf
signal
M, TC, CRC,
(Tuveson et al., 2003; Beeram et al.,

transduction
OepC, AML,
2005)

SCCHN,

NSCLC, GC,

OC, NHL,

CC

BRCA1
BRCA-1
chromosomal
BC, OC
(Wooster and Weber, 2003)

stability

BRCA2
BRCA-2
chromosomal
BC, OC
(Wooster and Weber, 2003)

stability

BUB1
BUB1
chromosomal
AML, SGT,
(Cahill et al., 1998; Qian et al., 2002; Ru

stability
ALL, HL, L,
et al., 2002; Grabsch et al., 2003;

CRC, GC
Shigeishi et al., 2006)

BUB1B
BUBR1
chromosomal
LC, GC
(Seike et al., 2002; Grabsch et al., 2003)

stability

CCNA2
cyclin A2
cell cycle
AML
(Qian et al., 2002)

CCNB1
cyclin B1
cell cycle
HCC, BC,
(Egloff et al., 2006)

CHN, PC,

CRC, LC

CCNE2
cyclin E2
cell cycle
BC, LC, OC,
(Payton and Coats, 2002; Payton et al.,

EC
2002)

CDC2
CDK1
cell cycle
NHL, CRC,
(Wolowiec et al., 1999; Egilmez et al.,

SCCHN,
2001; Chang et al., 2005; Hansel et al.,

OepC
2005)

CDC20
cell division cycle
cell cycle
GC
(Kim et al., 2005)

20

CDC23
cell division cycle
cell cycle
CRC
(Wang et al., 2003)

23

CDC25A
cell division cycle
cell cycle
HCC, OepC,
(Kristjansdottir and Rudolph, 2004)

25A

BC, CRC,

CHN,

NSCLC, OC,

TC, NHL

CDC6
cell division cycle 6
cell cycle
PC, CeC,
(Robles et al., 2002; Karakaidos et al.,

NSCLC
2004; Semple and Duncker, 2004;

Murphy et al., 2005)

CDK2
CDK-2
cell cycle
OC, CRC, PC
(Cipriano and Chen, 1998; Marone et al.,

1998; Yamamoto et al., 1998)

CDK4
CDK-4
cell cycle
G, GB, BC,
(Malumbres and Barbacid, 2001)

LC, GC, EC,

L, OS, OC,

TT, HCC,

CHN

CDK6
CDK-6
cell cycle
G, GB, GBM,
(Costello et al., 1997; Lam et al., 2000;

MB, B-cell
Hayette et al., 2003; Mendrzyk et al.,

CLL
2005)

CDKN2C
CDK inhibitor 2C
cell cycle
HB, MB,
(Iolascon et al., 1998; Kulkarni et al.,

HCC, HL,
2002; Morishita et al., 2004; Sanchez-

MM
Aguilera et al., 2004)

CDT1
Cdt1
chromosomal
NSCLC
(Karakaidos et al., 2004)

stability

CHUK
IKK alpha
signal
LSCC, BC
(Cao et al., 2001; Nakayama et al., 2001;

transduction

Romieu-Mourez et al., 2001)

CKS1B
Cks1
cell cycle
NSCLC, BC,
(Inui et al., 2003; Shapira et al., 2005;

CRC
Slotky et al., 2005)

ETS1
Ets-1
transcription
L, BCL,
(Sacchi et al., 1988; Dreyfus et al., 1989;

NHL, GC,
Kerckaert et al., 1990; Crossen and

PaC, TC, AC,
Morrison, 1993; Crossen et al., 1995;

SCCHN,
Nakayama et al., 1996; Ito et al., 1998;

HCC, MG,
Kitange et al., 1999; Nakayama et al.,

OC, BC, LC,
1999; Ito et al., 2000; Kitange et al.,

CeC, EC,
2000; Ozaki et al., 2000; Saeki et al.,

CRC, M, PC,
2000; Behrens et al., 2001; Davidson et

ALL
al., 2001; Sasaki et al., 2001; Fujimoto et

al., 2002a; Fujimoto et al., 2002b; Span

et al., 2002; Dittmer, 2003; Tokuhara et

al., 2003; Buggy et al., 2004;

Rothhammer et al., 2004; Alipov et al.,

2005)

FAS
Fas
apoptosis
NSCLC, G,
(Moller et al., 1994; Gratas et al., 1998;

L, CRC,
Martinez-Lorenzo et al., 1998; Shinoura

OepC
et al., 2000; Viard-Leveugle et al., 2003),

FGF2
FGF-2
signal
BC, RCC,
(Chandler et al., 1999)

transduction
OC, M,

NSCLC

FGFR3
FGF receptor-3
signal
BldC, CRC,
(L'Hote and Knowles, 2005)

transduction
CeC, MM

FOXM1
forkhead box M1
transcription
GB, LC, PC
(Kalin et al., 2006; Kim et al., 2006; Liu

et al., 2006)

FOXO1A
FOXO1, FKHR
transcription
RMS, EC
(Barr, 2001; Goto et al., 2007)

FZD7
Frizzled-7
signal
OepC, GC,
(Tanaka et al., 1998; Kirikoshi et al.,

transduction
HCC
2001; Merle et al., 2004)

GMNN
geminin
DNA replication
CRC, BC,
(Wohlschlegel et al., 2002; Bravou et al.,

CeC
2005; Shetty et al., 2005)

IGFBP1
IGFBP-1
signal
BC, CRC
(Firth and Baxter, 2002)

transduction

IGFBP3
IGFBP-3
signal
BC, PC, LC,
(Firth and Baxter, 2002)

transduction
CRC

IL8
IL-8
signal
BC, CRC,
(Akiba et al., 2001; Sparmann and Bar-

transduction
PaC, NSCLC,
Sagi, 2004)

PC, HCC

LHFP
lipoma HMGIC
transcription
Li
(Petit et al., 1999)

fusion partner

MCAM
MCAM
cell adhesion
M, AS, KS,
(McGary et al., 2002)

LMS

MCL1
Mcl-1
apoptosis
HCC, MM,
(Krajewska et al., 1996; Kitada et al.,

TT, CLL,
1998; Cho-Vega et al., 2004; Rust et al.,

ALCL, BCL,
2005; Sano et al., 2005; Wuilleme-

PC
Toumi et al., 2005; Fleischer et al., 2006;

Sieghart et al., 2006)

MDM2
Mdm2
proteasomal
AC, GB, BC,
(Momand et al., 1998)

degradation
CeC, OepC,

L, HB,

NSCLC,

NPC, NB,

OS, OC,

EWS, Li, LS,

Schw, TT,

UC, WT,

RMS

MXI1
Max-interacting
transcription
M, PC, GB
(Wechsler et al., 1997; Prochownik et al.,

protein 1

1998; Ariyanayagam-Baksh et al., 2003)

MYBL1
A-Myb
transcription
BL
(Golay et al., 1996)

MYBL2
Myb L2
transcription
BC, NSCLC,
(Tanner et al., 2000; Bar-Shira et al.,

PC, OC
2002; Borczuk et al., 2003; Ginestier et

al., 2006)

NRG1
neuregulin 1
signal
BC, PaC, G
(Adelaide et al., 2003; Ritch et al., 2003;

transduction

Prentice et al., 2005)

PBX1
PBX-1
transcription
ALL
(Aspland et al., 2001)

PDGFD
PDGF-D
signal
GB, MB,
(Li et al., 2003)

transduction
EWS

PDGFRL
PDGFR-like,
signal
CRC,
(Fujiwara et al., 1995; Komiya et al.,

PRLTS
transduction
NSCLC,
1997)

HCC, PC

PIK3CA
PI 3-kinase, p110
signal
BC, CRC,
(Bader and Vogt, 2004; Bader et al.,

alpha
transduction
LC, OC, G,
2005)

GB, HCC,

GC, CeC

PLCB1
PLC-betal
signal
AML
(Lo Vasco et al., 2004)

transduction

PLK1
polo-like kinase 1
chromosomal
NSCLC,
(Strebhardt and Ullrich, 2006)

stability
OrpC, OepC,

GC, M, BC,

OC, BC,

CRC, GB,

PapC, PaC,

PC, HB, NHL

PRKCA
PKC alpha
signal
BldC, PC,
(Koivunen et al., 2006; Weichert et al.,

transduction
EC, BC,
2003; Jiang et al., 2004; Lahn and

CRC, HCC,
Sundell, 2004)

M, GC, OC

RASSF2
RASSF2
signal
GC, CRC, OC
(Akino et al., 2005; Endoh et al., 2005;

transduction

Lambros et al., 2005)

RB1
Rb
cell cycle
RB, SCLC,
(Sherr and McCormick, 2002; Dyer and

NSCLC
Bremner, 2005)

RBL1
p107
cell cycle
BCL, PC,
(Takimoto et al., 1998; Claudio et al.,

CRC, TC
2002; Wu et al., 2002; Ito et al., 2003)

RRAS
R-RAS
signal
CeC, BC
(Yu and Feig, 2002; Rincon-Arano et al.,

transduction

2003)

SKP2
SKP-2
proteasomal
PaC, OC, BC,
(Kamata et al., 2005; Saigusa et al.,

degradation
MFS, GB,
2005; Shibahara et al., 2005; Takanami,

EC, NSCLC,
2005; Einama et al., 2006; Huang et al.,

PC
2006; Sui et al., 2006; Traub et al.,

2006),

SRC
c-Src
signal
CRC, HCC,
(Yeatman, 2004)

transduction
PaC, GC,

OepC, BC,

OC, LC

SRI
Sorcin
multi drug
OC, BC,
(Parekh et al., 2002; Tan et al., 2003)

resistance
AML

TACC1
TACC1
cell cycle
BC, OC
(Cully et al., 2005; Lauffart et al., 2005)

TACC3
TACC3
cell cycle
OC, NSCLC,
(Lauffart et al., 2005; Jung et al., 2006)

TACSTD1
tumor-associated
cell adhesion,
NSCLC, CRC
(Xi et al., 2006a; Xi et al., 2006b)

calcium signal
vesicle

transducer 1
trafficking

TGFB2
TGF beta-2
signal
PaC, CRC,
(Krasagakis et al., 1998; Jonson et al.,

transduction
BC, M
2001; Nakagawa et al., 2004; Beisner et

al., 2006)

TGFBR2
TGF beta receptor
signal
BC, CRC
(Markowitz, 2000; Lucke et al., 2001;

type II
transduction

Biswas et al., 2004)

TGFBR3
TGF beta receptor
signal
CeC, high
(Venkatasubbarao et al., 2000;

III
transduction
grade NHL,
Bandyopadhyay et al., 2002; Woszczyk

CRC, BC
et al., 2004; Soufla et al., 2005)

VAV3
Vav3
signal
PC
(Dong et al., 2006)

transduction

Abbreviations:

AC, astrocytoma;

ALCL, anaplastic large cell lymphoma;

ALL, acute lymphoblastic leukemia;

AML, acute myeloid leukemia;

AS, angiosarcoma;

BC, breast carcinoma;

BCL, B-cell lymphoma;

BL, Burkitt's lymphoma;

BldC, bladder carcinoma;

CC, cholangiocarcinoma;

CeC, cervical carcinoma;

CHN, carcinoma of the head and neck;

CLL, chronic lymphoblastic leukemia;

CML, chronic myeloid leukemia;

CRC, colorectal carcinoma;

EC, endometrial carcinoma;

EWS, Ewing's sarcoma;

G, glioma;

GB, glioblastoma;

GBM, glioblastoma multiforme;

GC, gastric carcinoma;

HB, hepatoblastoma;

HCC, hepatocellular carcinoma;

HL, Hodgkin lymphoma;

KS, Kaposi's sarcoma;

L, leukemia;

LC, lung carcinoma;

Li, lipoma;

LMS, leiomyosarcoma;

LS, liposarcoma;

LSCC, laryngeal squamous cell carcinoma;

M, melanoma;

MALT BCL, mucosa-associated lymphoid tissue B-cell lymphoma;

MB, medulloblastoma;

MCL, mantle cell lymphoma;

MFS, myxofibrosarcoma;

MG, meningioma;

MM, multiple myeloma;

NB, neuroblastoma,

NHL, non-Hodgkin lymphoma;

NPC, nasopharyngeal carcinoma;

NSCLC, non-small cell lung carcinoma;

OC, ovarian carcinoma;

OepC, oesophageal carcinoma;

OrpC, oropharyngeal carcinoma;

OS, osteosarcoma;

PaC, pancreatic carcinoma;

PapC, papillary carcinoma;

PC, prostate carcinoma;

RB, retinoblastoma;

RCC, renal cell carcinoma;

RMS, rhabdomyosarcoma;

SCCHN, squamous cell carcinoma of the head and neck;

Schw, schwannoma;

SCLC, small cell lung cancer;

SGT, salivary gland tumor;

TC, thyroid carcinoma;

TT, testicular tumor;

UC, urothelial carcinoma;

WT, Wilm's tumor

Hsa-miR-124a targets of particular interest are genes and their products that function in the regulation of intracellular signal transduction in response to mitotic or apoptotic stimuli. When deregulated, many of these proteins contribute to the malignant phenotype in vitro and in vivo. Hsa-miR-124a affects intracellular signaling at various layers and controls the expression of secretory proteins, transmembrane growth factor receptors as well as cytoplasmic signaling molecules. Among secretory proteins are fibroblast growth factor 2 (FGF2), insulin growth factor binding protein 1 and 3 (IGFBP1, IGFBP3), transforming growth factor β-2 (TGFB2) and the inflammatory chemokine interleukin 8. FGF-2 is a secretory protein with potent mitogenic and angiogenic activity that transmits the signal into cells via transmembrane receptors (FGFRs) composed of 2-3 extracellular immunoglobulin-like domains and an intracellular tyrosine kinase domain (Chandler et al., 1999). FGF-2 mRNAs levels are increased in renal, oral and non-small lung cancer cells (Chandler et al., 1999). Similarly, IL-8 is frequently upregulated in various cancers and correlates with tumor vascularization, metastasis and poor prognosis (Rosenkilde and Schwartz, 2004; Sparmann and Bar-Sagi, 2004). TGFB2 is the corresponding ligand to TGF-β receptors (TGFBR), a class of receptors that may function as tumor suppressors (Massague et al., 2000).

Membrane-associated proteins regulated by hsa-miR-124a are platelet-derived growth factor receptor-like (PDGFRL; also referred to as PDGF receptor beta-like tumor suppressor, PRLTS) and the Ras association domain family protein 2 (RASSF2). RASSF2 is a tumor suppressor candidate that is frequently downregulated in lung tumor cell lines (Vos et al., 2003). RASSF2 interacts with K-Ras and promotes cell cycle arrest and apoptosis. PDGFRL also functions as a tumor suppressor that shows loss of function in a broad variety of cancers either by loss of heterozygosity (LOH) or missense and frame-shift mutation (Fujiwara et al., 1995; Komiya et al., 1997). Since treatment of cancer cells with hsa-miR-124a leads to reduced expression levels of FGF2, IL8 and IGFBPs, and to increased expression levels of TGFB2, RASSF2 and PDGFRL, hsa-miR-124a is likely to induce a therapeutic response in cancer patients that show aberrant expression or function of these growth-stimulatory or inhibitory proteins.

Intracellular signaling molecules regulated by hsa-miR-124a include IkappaB kinase alpha (IKKalpha, CHUK), c-Src (SRC), the catalytic subunit of class IA phosphoinositide 3-kinases p110α (PIK3CA) and phospholipase C beta-1 (PLCB1). PLC beta-1 catalyzes the generation of inositol-1,4,5-trisphosphate (IP3) and diacylglycerol (DAG) from phosphatidylinositol-bis-phosphate (PIP2), regulating proliferative signals and checkpoints of the cell cycle (Lo Vasco et al., 2004). IKKalpha is a positive regulator of the intracellular signaling cascade and functions to activate the transcription factor nuclear factor kappa B (NFkappaB) (Karin et al., 2002). NFkappaB is constitutively activated in several cancer types and promotes anti-apoptotic and survival pathways. The proto-oncoprotein c-Src is the human homolog of avian v-Src that has been isolated as the tumorigenic component of Rous Sarcoma virus (RSV) (Rous, 1911; Stehelin et al., 1976; Yeatman, 2004). c-Src is a membrane-associated tyrosine kinase that is activated in response to intracellular signaling or indirectly to extracellular stimuli by binding to activated receptor tyrosine kinases, including EGFR, ERBB2, PDGFR and FGFR. Src is a crucial molecule in a complex network of interacting proteins, regulating cell adhesion, motility, invasion and proliferation. c-Src is frequently overexpressed or hyperactivated in numerous cancer types (Yeatman, 2004). The gene product of PIK3CA activates the Akt signaling pathway in response to most upstream receptor tyrosine kinases (Vanhaesebroeck et al., 1997). PIK3CA frequently acquires a gain of function in the vast majority of human cancers, either by amplification or overexpression, such as in ovarian and cervical cancers, or by activating somatic mutations (Bader and Vogt, 2004; Bader et al., 2005). PIK3CA has become a novel drug target in the pharmaceutical industry and is also a predicted target of hsa-miR-124a (Table 3). Based on our data, hsa-miR-124a negatively regulates these proteins and therefore is likely to function as a tumor-suppressor miRNA.

Another class of genes and their corresponding proteins that are regulated by hsa-miR-124a, functions in the progression of the cell cycle. Some of these proteins are critical in the transition through G1 and S phases, such as cyclins A2 and E2 (CCNA2, CCNE2), cyclin dependent kinases 2, 4 and 6 (CDK2, CDK4, CDK6) and cell division cycle 6 (CDC6). Others are required for progressing through the G2/M spindle checkpoint and proper segregation of sister chromatids during mitosis to maintain chromosomal stability. These include aurora kinases A and B (AURKA, a.k.a. STK6; AURKB, a.k.a. STK12), breast cancer 1 and 2 (BRCA1; BRCA2), budding uninhibited by benzimidazoles 1 (BUB1), budding uninhibited by benzimidazoles 1 beta (BUB1B), polo-like kinase 1 (PLK1), cyclin dependent kinase 1 (CDK1, a.k.a. CDC2), cyclins B1 and B2 (CCNB1, CCNB2), and cell division cycle 20 and 23 (CDC20, CDC23, a.k.a. anaphase promoting complex subunit 8). Most of these transcripts are regulated in a manner that suggests that hsa-miR-124a blocks cell cycle progression. All of these targets also have an evident role in carcinogenesis.

For instance, the tumor suppressor proteins BRCA1 and BRCA2, as well as the growth-promoting aurora kinases A and B show deregulated expression in a various solid tumors, e.g. carcinomas of the breast, ovary, thyroid gland, lung, prostate and colorectum (Wooster and Weber, 2003; Keen and Taylor, 2004; Turner et al., 2004; Smith et al., 2005; Chieffi et al., 2006; Ulisse et al., 2006). Aurora kinases are preferred drug targets in the pharmaceutical industry. PLK1 (also referred to as serine-threonine protein kinase 13; STPK13) is a protein kinase that regulates mitotic spindle function to maintain chromosomal stability (Strebhardt and Ullrich, 2006). PLK1 expression is tightly regulated during the cell cycle and peaks in M phase. PLK1 is inherently oncogenic and directly inhibits the tumor suppressor function of p53 (Ando et al., 2004). Overexpression of PLK1 induces a polynucleated phenotype and cellular transformation of NIH3T3 cells (Mundt et al., 1997; Smith et al., 1997). Likewise, PLK1 shows increased expression levels in most solid tumors, including carcinomas of the breast, colon, lung, stomach and prostate (Table 5). PLK1 overexpression is associated with disease progression and, when depleted, induces apoptosis in cancer cells (Liu and Erikson, 2003; Strebhardt and Ullrich, 2006). Currently, PLK1 is being tested as a target of various small molecule inhibitors for future therapeutic intervention (Strebhardt and Ullrich, 2006).

CDC6 is regulated in response to mitogenic signals through transcriptional control mechanisms involving E2F proteins and is required for initiation of DNA replication in mammalian cells. CDC6 is overexpressed in various human cancers and has inherent oncogenic potential (Karakaidos et al., 2004; Semple and Duncker, 2004; Murphy et al., 2005; Gonzalez et al., 2006). Cyclins are co-factors of cyclin-dependent kinases (CDKs) (Malumbres and Barbacid, 2001). The expression of cyclins is tightly controlled during the cell cycle to govern the activity of individual CDKs. Cyclin A2 and cyclin E2 associate with CDK2 during S phase; cyclin D1 is the predominant co-factor of CDK4/6 in G1 phase. Most cyclins are promoters of cell growth, and several, such as cyclin A2, B1, or E2, are frequently expressed at high levels in various tumor types (Payton and Coats, 2002; Payton et al., 2002; Qian et al., 2002; Egloff et al., 2006). CDK4 and CDK6 form active complexes with D-type cyclins, including D1, D2 and D3. The primary function of CDK2, CDK4 and CDK6 is to inactivate members of the retinoblastoma protein family. CDK2, CDK4 and CDK6 are overexpressed in numerous cancers and are currently being explored as a potential cancer drug targets (Costello et al., 1997; Cipriano and Chen, 1998; Marone et al., 1998; Yamamoto et al., 1998; Lam et al., 2000; Malumbres and Barbacid, 2001; Hayette et al., 2003; Mendrzyk et al., 2005).

CDK1 (CDC2) is a catalytic subunit of a protein kinase complex, called the M-phase promoting factor that induces entry into mitosis and is universal among eukaryotes. Activation of CDK1 requires binding to B cyclins and dephosphorylation by CDC25. Similar to other CDKs, CDK1 is expressed at increased levels in various cancers (Table 5). The CDC25 protein phosphatase family plays a critical role in activating cyclin-dependent kinases (CDKs) via dephosphorylation of conserved threonine 15 and tyrosine 15 inhibitory phosphorylation sites. While CDC25C is primarily responsible for activating CDK1 to overcome G2/M checkpoint and allow mitotic entry, the primary substrate of CDC25A is CDK2 and CDK6 which, when active, allows progression through the G1/S and intra-S checkpoints (Kristjansdottir and Rudolph, 2004). CDC25A is frequently amplified and overexpressed in human cancers, including cancers of the breast, lung, rectum and brain (Kristjansdottir and Rudolph, 2004).

Other molecules regulated by hsa-miR-124a that indirectly control cell cycle progression are SKP2, MDM2 and AKAP12. AKAP12, also referred to as gravin or SSeCKS (Src suppressed C kinase substrate), functions as a kinase scaffold protein that tethers the enzyme-substrate interaction (Nauert et al., 1997). Expression of AKAP12 interferes with oncogenic cell transformation induced by the Src or Jun oncoproteins in vitro and is lost or reduced in numerous cancers, such as leukemia and carcinomas of the rectum, lung and stomach (Lin and Gelman, 1997; Cohen et al., 2001; Xia et al., 2001; Wikman et al., 2002; Boultwood et al., 2004; Choi et al., 2004; Mori et al., 2006). An apparent anti-oncogenic activity of AKAP12 in prostate and gastric cancers marks this protein as a putative tumor suppressor (Xia et al., 2001; Choi et al., 2004). Skp2 is a component of the multi-subunit E3 ubiquitin ligase complex that ear-marks proteins for proteasomal degradation. A well characterized target is the CDK inhibitor p27 which offers an explanation for the cell cycle promoting activity of Skp2 (Carrano et al., 1999). Skp2 is inherently oncogenic and shows elevated levels in various cancer types (Gstaiger et al., 2001; Kamata et al., 2005; Saigusa et al., 2005; Einama et al., 2006).

Hsa-miR-124a also governs the expression of FAS, Bim (BCL2L11) and MCL1, all of which are functionally linked to the apoptotic pathway. Bim and MCL 1 are members of the BCL-2 (B cell lymphoma 2) gene family. MCL1 gives rise to two alternatively spliced gene products with opposing functions (Bae et al., 2000). The predominant species is MCL1-L that has anti-apoptotic activity. High levels of MCL1 are correlated with poor prognosis of patients with ovarian carcinoma and is indicative for leukemic relapse (Kaufmann et al., 1998; Shigemasa et al., 2002). RNA interference against MCL1 induces a therapeutic response in gastric and hepatocellular carcinoma cells (Schulze-Bergkamen et al., 2006; Zangemeister-Wittke and Huwiler, 2006).

In contrast to MCL1, Bim induces apoptosis by binding to and antagonizing anti-apoptotic members of the Bcl-2 family. Interactions have been observed with Bcl-2, Bcl-xL, Mcl-1, Bcl-w, Bfl-1 and BHRF-1 (Hsu et al., 1998; O'Connor et al., 1998). Loss of Bim promotes oncogenesis, suggesting a tumor suppressor role for Bim (Egle et al., 2004). In agreement with this observation is the fact that Bim is frequently lost or expressed at reduced levels in many cancers (Gomez-Bougie et al., 2004; Austin and Cook, 2005; Li et al., 2005; Tagawa et al., 2005). FAS, also known as CD95 or APO-1, is a transmembrane cell surface receptor that functions in the transduction of apoptotic signals in response to its ligand FasL (Houston and O'Connell, 2004). Reduced FAS expression is a common mechanism of cells to decrease the sensitivity to FasL-mediated cell death. Similarly, many different cancer types show lost or decreased Fas expression levels (Table 5). In colorectal carcinoma, FAS expression is progressively reduced in the transformation of normal epithelium to benign neoplasm, adenocarcinomas and metastases (Moller et al., 1994). Thus, despite expression of FasL, tumor cells may escape the FasL induced apoptotic signal. Transient transfection of hsa-miR-124a increases expression of FAS and Bim and decreases MCL1 transcripts and therefore may antagonize the anti-apoptotic phenotype of cancer cells.

Transcription factors regulated by hsa-miR-124a include the mammalian homolog of the v-Ets oncoprotein (ETS1), the forkhead box/winged-helix transcription factors FOXO1 (FOXO1A) and FOXM1, as well as the v-myb myeloblastosis viral oncogene homolog-like proteins A-MYB (MYBL1) and MYB-L2 (MYBL2). The transcription factor Ets-1 (ETS1) is the mammalian homolog of the v-Ets oncoprotein originally isolated from the transforming erythroblastosis virus E26 (Leprince et al., 1983). Similar to viral Ets, the endogenous proto-oncoprotein Ets-1 has oncogenic potential and transforms murine NIH3T3 fibroblasts in culture (Dittmer, 2003). Ets-1 stimulates angiogenesis by regulating VEGF expression levels. Ets-1 plays a role in making tumors more invasive and is indicative for poor prognosis (Dittmer, 2003). Ets-1 is upregulated in a vast variety of solid tumors and malignancies of the hematopoietic system (Dittmer, 2003). The ETS1 gene is also frequently subject to chromosomal translocation in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and may be critical in the development of the disease (Sacchi et al., 1986; Goyns et al., 1987).

FoxM1 controls the expression of cell cycle genes, such as cyclins B and D (Wang et al., 2001). FoxM1 is expressed at high levels in human glioblastomas and shows tumorigenic activity in various model systems (Kalin et al., 2006; Kim et al., 2006; Liu et al., 2006). Mice deficient in FoxM1 fail to develop chemically induced hepatocellular carcinomas (Kalinichenko et al., 2004). In contrast to Ets-1 and FoxM1, FOXO1, also known as FKHR, belongs to a class of lineage-restricted tumor suppressor proteins with redundant functions, including FOXO3a and FOXO4 (Vogt et al., 2005; Paik et al., 2007). FOXO proteins are pro-apoptotic by transcribing the FasL gene and induce cell cycle arrest by upregulating the CDK inhibitor p27kip1 (Carter and Brunet, 2007). FOXO1 also induces the expression of the CDK inhibitor p21cip1 and the pro-apoptotic protein Bim, and reduces expression of the cyclins D1 and D2 (Bader et al., 2005). In alveolar rhabdomyosarcoma, the FOXO1 gene frequently undergoes chromosomal rearrangements which fuses C-terminal sequences of FOXO1 to N-terminal sequences of PAX3 or PAX7, resulting in a hybrid protein with altered DNA-binding specificity (Vogt et al., 2005). A recombinant FOXO1 protein carries a transcriptional repressor domain, instead of the FOXO1-specific activator domain, is oncogenic in cell culture (Aoki et al., 2004). Since transfection of hsa-miR-124a leads to elevated mRNA levels of FOXO1 and reduced levels of FOXM1 and ETS1, hsa-miR-124a may induce a therapeutic response in cancer cells by regulating these targets.

Based on the function of most targets and how they are regulated by hsa-miR-124a, hsa-miR-124a appears to function as a tumor suppressor miRNA. However, hsa-miR-124a also regulates cancer-associated genes in a fashion indicating that this miRNA might promote tumorigenesis and that inhibition of hsa-miR-124a might be able to intercept with tumor development when appropriate. Among these targets are the retinoblastoma tumor suppressor proteins Rb (RB1) and p107 (RBL1), MDM2, B Raf (BRAF), platelet-derived growth factor D (PDGFD), protein kinase C-alpha (PRKCA) and transforming growth factor-beta receptors 2 and 3 (TGFBR2, TGFBR3). TGFBR-2 and TGFBR-3 are putative tumor suppressors. TGFBR-2 forms a functional complex with TGFBR-1 and is the primary receptor for TGF-β (Massague et al., 2000). A central role of TGF-β is inhibition of cellular growth of numerous cell types, such as epithelial, endothelial, hematopoietic neural and mesenchymal cells. Many mammary and colorectal carcinomas with microsatellite instability harbor inactivating mutations of TGFBR-2, and therefore escape the growth-inhibitory function of TGF-β (Markowitz et al., 1995; Lucke et al., 2001). TGFBR-3, also referred to as beta-glycan, binds all three TGF-β isoforms with high affinity. TGFBR-3 associates with TGFBR-2 to signal to downstream effector molecules (Blobe et al., 2001). Similar to TGFBR-2, TGFBR-3 is frequently downregulated in multiple cancer types (Table 5) (Hishikawa et al., 1999; Lin et al., 2005).

PRKCA belongs to a family of serine-threonine kinases that are activated in response to signaling induced by receptor tyrosine kinases. Functional studies have suggested that PKCs play a role in carcinogenesis and maintenance of the malignant phenotype (Koivunen et al., 2006). PRKCA is overexpressed in endometrial, prostate and high grade urinary bladder carcinomas (Koivunen et al., 2006). PRKCA activity is linked to increased motility and invasion of cancer cells, a phenotype that can be reversed by PRKCA inhibition (Koivunen et al., 2004). PDGFs are structurally related to the v-sis oncogene of simian sarcoma virus, and compelling evidence has demonstrated the transforming activity of PDGF-D in NIH3T3 cells (Li et al., 2003). PDGF-D is expressed in many tumors and tumor cell lines, including glioblastoma, medulloblastoma, Ewing family tumor cell lines and several other tumor cell lines (Li et al., 2003). PDGFD-induced tumors displayed signs of increased vascularization with elevated levels of VEGF (vascular endothelial growth factor), suggesting that PDGFD is angiogenic. Therefore, PDGFD is currently investigated as a potential drug target in the intervention of cancer signaling (Pietras et al., 2003).

Human MDM2 functions as an E3 ubiquitin ligase and inhibitor of the p53 tumor suppressor (Momand et al., 1998; Bartel et al., 2002). MDM2 directly binds to p53, facilitates nuclear export and marks p53 for proteasomal degradation. MDM2 is amplified or overexpressed in approximately one third of human malignancies, including sarcomas of soft tissue and bone. To date, MDM2 amplification has been observed in at least 19 tumor types with varying frequencies (Momand et al., 1998; Bartel et al., 2002). In accord, overexpression of MDM2 leads to oncogenic transformation of NIH3T3 and Rat2 cells (Fakharzadeh et al., 1991). The pocket proteins RB1 and RBL1, also known as p107, interact with the E2F family of transcription factors and block cell cycle progression and DNA replication (Sherr and McCormick, 2002). Accordingly, a large subset of cancers show deregulated expression of RB1 or RBL1 (Takimoto et al., 1998; Claudio et al., 2002; Sherr and McCormick, 2002; Wu et al., 2002; Ito et al., 2003; Dyer and Bremner, 2005).

B-Raf (BRAF) belongs to a family of Raf serine-threonine kinases that are homologous to the viral oncoproteins isolated from transforming murine or avian viruses (Coll et al., 1983; Jansen et al., 1983; Rapp et al., 1983). Raf proteins are activated by the RAS GTPase and activate the mitogen-activated protein kinase pathway (MAPK). B-Raf is frequently hyperactivated by somatic mutation in a broad variety of cancers (Tuveson et al., 2003; Beeram et al., 2005). Raf kinases and B-Raf in particular have long been preferred drug targets; sorafenib (Nexavar; Bayer) represents an example of an FDA-approved inhibitory small molecule that specifically targets this inherently oncogenic protein (Beeram et al., 2005).

In summary, hsa-miR-124a governs the activity of proteins that are critical regulators of cell proliferation and tumor development. These targets are frequently deregulated in human cancers. Based on this review of the genes and related pathways that are regulated by miR-124a, introduction of hsa-miR-124a or inhibitory anti-hsa-miR-124a into a variety of cancer cell types would likely result in a therapeutic response.

Example 5
Hsa-miR-124a is a Regulator of Cell Cycle Progression

A review of genes that are differentially expressed in response to introduction of hsa-miR-124a (Table 1) revealed that hsa-miR-124a controls many genes that function in the regulation of the cell cycle. Although some of these genes have not yet been directly linked to human disease, they are essential in the proper progression of the cell cycle in normal cells. A summary of these gene products and their role during the cell cycle is provided in FIG. 1 and Table 6. Comprehensive information about the cell cycle and these molecules has been reviewed in Kops et al., 2005; Bell and Dutta, 2002; Malumbres and Barbacid, 2001; Kastan and Lim, 2000; Sherr and Roberts, 1999 and references therein and can also be found in the OMIM Entrez and Gene Entrez sections of the NCBI website at the world wide web address ncbi.nlm.nih.gov/sites/entrez. Considering the function of these proteins and how they are regulated by hsa-miR-124a, hsa-miR-124a appears to block cell cycle progression during all major phases: G1, S, G2 and M phase (FIG. 1, Table 1, Table 6). Therefore, hsa-miR-124a-based therapies are contemplated as being particularly useful in the treatment of neoplastic and other hyperproliferative disorders. In addition, it is contemplated that hsa-miR-124a inhibitors can be for clinical applications that are directed toward tissue regeneration, such as skin regeneration or the generation of tissue grafts. Since hsa-miR-124a is highly expressed in neuronal cells and plays an important role in the development of the central nervous system, hsa-miR-124a or hsa-miR-124a inhibitors it is contemplated that it can be useful in the regeneration of neuron cells to treat brain disorders that include but are not limited to brain tumors, neuronal degeneration, mental retardation, multiple sclerosis, Parkinson's disease or Alzheimer's disease (Kapsimali et al., 2007; Makeyev et al., 2007; Visvanathan et al., 2007; Cao et al., 2007; Lukiw, 2007; Mishima et al., 2007; Smirnova et al., 2005).

TABLE 6

Summary of information about miR-124a-controlled genes shown in FIG. 1. n/a not

applicable because not directly involved in the cell cycle.

Cycle of

Icon
Gene Title
Name
Action
Protein Function

APC
n/a
anaphase-promoting
M phase,
multiprotein complex including CDC16,

complex
spindle
CDC23, CDC27; E3 ubiquitin ligase; induces

checkpoint
degradation of securin

ATM
ATM
ataxia-telangiectasia
R2
kinase; induces cell cycle arrest upon DNA

mutated
restriction
damage; substrates include CHEK2, p53 and

point
MDM2

AURKA
AURKA,
aurora kinase A
M phase,
proper formation of the spindle apparatus

STK15

spindle

checkpoint

AURKB
AURKB,
aurora kinase B
M phase,
serine/threonine kinase; regulates amphitelic

STK12

spindle
attachment of spindle microtubuli to the

checkpoint
kinetochore; vs. monotelic, merotelic, syntelic

attachments

BRCA1
BRCA1
breast cancer 1
R2
required for DNA repair induced by DNA

restriction
damage; ATM/ATR signaling; peeks in G1/M

point
phase; more universal role in transcription,

chromatin remodelling

BRCA2
BRCA2
breast cancer 2
R2
required for DNA repair induced by DNA

restriction
damage (doublestranded DNA breaks);

point
activated by ATM/ATR signaling; peeks in

G2/M phase; required in homologous

recombination during meiosis

BUB1
BUB1
budding uninhibited
M phase,
kinase; phosphorylates and inhibits cdc20

by benzimidazoles 1
spindle

checkpoint

BUB1B
BUB1B,
budding uninhibited
M phase,
kinase; directly binds to cdc20 and inhibits

BUBR1
by benzimidazoles
spindle
APC activity

1B
checkpoint

BUB3
BUB3
budding uninhibited
M phase,
localizes BUB1 and BUB1B to kinetochores

by benzimidazoles 3
spindle

checkpoint

cdc2
CDC2
cell division cycle
G2/M phase
kinase; phosphorylates cytoskeleton proteins

2, cyclin-dependen
transition
and is necessary for inducing mitosis,

kinase 1 (CDK1)

phosphorylates and activates APC

cdc20
CDC20
cell division cycle
M phase,
cofactor of APC necessary for APC activity

20
spindle

checkpoint

cdc25A
CDC25A
cell division cycle
G1/S phase
phosphatase; removes inhibitory phosphate

25A
transition
groups from CDK2, CDK4 and CDK6

cdc25C
CDC25C
cell division cycle
G2/M phase
phosphatase; removes inhibitory phosphate

25C
transition
groups from cdc2

cdc6
CDC6
cell division cycle 6
replication
component of the pre-replication complex

(pre-RC); required for recruitment of MCM

proteins to the pre-RC

CDK2
CDK2
cyclin-dependent
G1/S phase
serine/threonine kinase; phosphorylates and

kinase 2
transition
inactivates members of the retinoblastoma

protein family

CDK4
CDK4
cyclin-dependent
G1/S phase
serine/threonine kinase; phosphorylates and

kinase 4
transition
inactivates members of the retinoblastoma

protein family

CDK6
CDK6
cyclin-dependent
G1/S phase
serine/threonine kinase; phosphorylates and

kinase 6
transition
inactivates members of the retinoblastoma

protein family

Cdt1
CDT1
chromatin licensing
replication
component of the pre-replication complex

and DNA

(pre-RC); cooperatively with cdc6 recruits

replication factor 1

MCM proteins to the pre-RC

CENPE
CENPE
centromeric protein E
M phase,
cofactor of BUB1B: activates BUB1B when

spindle
bound to free kinetochores; inactivates

checkpoint
BUB1B when bound to kinetochore

microtubuli

CHEK1
CHEK1
checkpoint kinase 1
G2/M phase
serine/threonine kinase; phosphorylates and

transition
inhibits CDC25B and CDC25C

CHEK2
CHEK2
checkpoint kinase 2
G1/S and
serine/threonine kinase; phosphorylates and

G2/M
inhibits CDC25A, CDC25B and CDC25C

transitions

cohesin
n/a
cohesin protein
M phase
multiprotein complex that holds sister

complex

chromatids together; components include

RAD21, SMC genes

cyc A2
CCNA2
cyclin A2
G1/S phase
cofactor of CDK2; necessary for CDK activity

transition

cyc B1
CCNB1
cyclin B1
G2/M phase
cofactor of cdc2 (CDK1); necessary for cdc2

transition
activity

cyc B2
CCNB2
cyclin B2
G2/M phase
cofactor of cdc2 (CDK1); necessary for cdc2

transition
activity

cyc D
CCND1,
cyclin D
G1/S phase
cofactor of CDK4 and CDK6; necessary for

CCND2,

transition
CDK activity

CCND3

cyc E2
CCNE2
cyclin E2
G1/S phase
cofactor of CDK2; necessary for CDK activity

transition

Emi1
FXBO5
early mitotic
M phase
binds to APC and inhibits it

inhibitor 1

FoxM1
FOXM1
forkhead box M1
all but G0
transcription factor; regulates expression of

many G2/M-specific genes; induces

expression of D and B type cyclins

Foxo1
FOXO1A
forkhead/winged
G1 phase
suppresses transcription of cyclin D and

helix transcription

activates transcription of p21 and p27

factor O1

Foxo3a
FOXO3A
forkhead/winged
G1 phase
suppresses transcription of cyclin D and

helix transcription

activates transcription of p21 and p27

factor O3a

Foxo4
FOXO4,
forkhead/winged
G1 phase
suppresses transcription of cyclin D and

MLLT1
helix transcription

activates transcription of p21 and p27

factor O4

GSK3
GSK3B
glycogen synthase 3
n/a
serine/threonine kinase; phosphorylates cyclin

D1 and induces cytoplasmic translocation and

proteasomal degradation of cyclin D1

Ki67
MKI67
antigen identified
all but G0
Unknown; cellular marker for cell

by monoclonal

proliferation

antibody Ki-67

MAD1
MAD1L1
mitotic arrest
M phase,
coiled coil protein; binds to and recruits

deficient homolog 1
spindle
MAD2 to unattached kinetochores

checkpoint

MAD2
MAD2L1
mitotic arrest
M phase,
part of APC inhibitory complex; binds to

deficient homolog 2
spindle
cdc20 and inhibits APC activity

checkpoint

MCM1-
MCM1,
minichromosome
replication
required for initiation and elongation of DNA

10
MCM2, ...etc.
maintenance

replication; function as replication fork

complex component

MDM2
MDM2
murine double-
n/a
E3 ubiquitin ligase; induces proteasomal

minute 2 homolog

degradation of p53

MPS1
MPS1
monopolar spindle 1
M phase,
kinase; required for spindle pole body

spindle
duplication and spindle checkpoint function

checkpoint

ORC1-6
ORC1L,
origin of
replication
binds to DNA at origins of replication;

ORC2L, ...etc.
recognition

initiates replication; recruites proteins of the

complex subunit

pre-replication complex (pre-RC)

p107
RBL1
retinoblastoma
G1/S phase
binds to and inactivates E2F transcription

protein p107
transition
factors that are necessary for the G1/S

transition

p16
CDKN2A
p16 INK4a
G1/S phase
CDK inhibitor, binds to and inactivates CDK4

transition
and CDK6

p21
CDKN1A
p21 CIP1/WAF1
G1/S phase
CDK inhibitor, binds to and inactivates CDK2

transition

p27
CDKN1B
p27 KIP1
G1/S phase
CDK inhibitor, binds to and inactivates CDK2

transition
and other CDKs

p53
TP53
tumor suppressor
R1 and R2
transcription factor; induces transcription of

protein 53
restriction
p21

points

PIK3CA
PIK3CA
phosphatidylinositol
n/a
lipid kinase; induces nuclear translocation of

3-kinase, p110alpha

MDM2; indirectly inactivates the FOXO1,

catalytic subunit

FOXO3a and FOXO4 tumor suppressors, as

well as GSK3

PLK1
PLK1
polo-like kinase 1
M phase,
serine/threonine kinase; peeks in M phase;

spindle
phosphorylates cohesin and induces

checkpoint
dissociation from sister chromatids;

phosphorylates cdc25C and activates it;

phosphorylates cdc2 and activates it;

phosphorylates Emi1 and induces proteasomal

degradation

Rb
RB1
retinoblastoma
G1/S phase
binds to and inactivates E2F transcription

protein
transition
factors that are necessary for the G1/S

transition

securin
PTTG1
pituitary tumor-
M phase
binds and inhibits separase

transforming 1

separase
ESPL1
extra spindle pole
M phase
peptidase; cleaves cohesin and induces

bodies homolog 1,

dissociation of sister chromatids

separin

Skp2
SKP2
S-phase kinase-
n/a
E3 ubiquitin ligase; induces proteasomal

associated protein 2

degradation of p27 and Foxo proteins

Example 6
Delivery of Synthetic Hsa-miR-124a Inhibits Proliferation of Lung Cancer Cells

The inventors have previously demonstrated that hsa-miR-124a is involved in the regulation of numerous cell activities that represent intervention points for cancer therapy and for therapy of other diseases and disorders (U.S. patent application Ser. No. 11/141,707 filed May 31, 2005 and Ser. No. 11/273,640 filed Nov. 14, 2005). For example, overexpression of hsa-miR-124a decreases the proliferation and/or viability of certain normal or cancerous cell lines.

The development of effective therapeutic regimes requires evidence that demonstrates efficacy and utility of the therapeutic in various cancer models and multiple cancer cell lines that represent the same disease. The inventors assessed the therapeutic effect of hsa-miR-124a for lung cancer by using 12 individual lung cancer cell lines. To measure cellular proliferation of lung cancer cells, the following non-small cell lung cancer (NSCLC) cells were used: cells derived from lung adenocarcinoma (A549, H1299, H522, H838, Calu-3, HCC827, HCC2935), cells derived from lung squamous cell carcinoma (H520, H226), cells derived from lung adenosquamous cell carcinoma (H596), cells derived from lung bronchioalveolar carcinoma (H1650), and cells derived from lung large cell carcinoma (H460). Synthetic hsa-miR-124a (Pre-miR™-hsa-miR-124a, Ambion cat. no. AM17100) or negative control (NC) miRNA (Pre-miR™ microRNA Precursor Molecule-Negative Control #2; Ambion cat. no. AM17111) was delivered via lipid-based transfection into A549, H1299, H522, H838, Calu-3, HCC827, HCC2935, H520, H596, H1650, and H460 cells and via electroporation into H226 cells.

Lipid-based reverse transfections were carried out in triplicate according to a published protocol and the following parameters: 5,000-12,000 cells per 96 well, 0.1-0.2 μl Lipofectamine™ 2000 (cat. no. 11668-019, Invitrogen Corp., Carlsbad, Calif., USA) in 20 μl OptiMEM (Invitrogen), 30 nM final concentration of miRNA in 100 μl (Ovcharenko et al., 2005). Electroporation of H226 cells was carried out using the BioRad Gene Pulser Xcell™ instrument (BioRad Laboratories Inc., Hercules, Calif., USA) with the following settings: 5×10⁶cells with 5 μg miRNA in 200 μl OptiMEM (1.6 μM miRNA), square wave pulse at 250 V for 5 ms. Electroporated H226 cells were seeded at 7,000 cells per 96-well in a total volume of 100 μl. All cells except for Calu-3 cells were harvested 72 hours post transfection or electroporation for assessment of cellular proliferation. Calu-3 cells were harvested 10 days post transfection.

Proliferation assays were performed using Alamar Blue (Invitrogen) following the manufacturer's instructions. As a control for inhibition of cellular proliferation, siRNA against the motor protein kinesin 11, also known as Eg5, was used. Eg5 is essential for cellular survival of most eukaryotic cells and a lack thereof leads to reduced cell proliferation and cell death (Weil et al., 2002). siEg5 was used in lipid-based transfection following the same experimental parameters that apply to miRNA. The inventors also used a DNA topoisomerase II inhibitor, etoposide, at final concentrations of 10 μM and 50 μM as an internal standard for the potency of miRNAs. Etoposide is an FDA-approved DNA topoisomerase II inhibitor in the treatment of lung cancer. IC50 values for various lung cancer cells have been reported to range between <1-μM for SCLC and NSCLC cells (Ohsaki et al., 1992; Tsai et al., 1993). Percent (%) proliferation values from the Alamar Blue assay were normalized to values from cells treated with negative control miRNA. Percent proliferation of hsa-miR-124a treated cells relative to cells treated with negative control miRNA (100%) are shown below in Table 7 and in FIG. 2.

TABLE 7

Percent (%) proliferation of lung cancer cell lines treated with hsa-miR-124a, Eg5-

specific siRNA (siEg5), etoposide, or negative control miRNA (NC).

hsa-miR-124a
siEg5
etoposide
etoposide
NC

(39 nM)
(30 nM)
(10 μM)
(50 μM)
(30 nM)

%
%
%
%
%
%
%
%
%
%

Cells
Proliferation
SD
Proliferation
SD
Proliferation
SD
Proliferation
SD
Proliferation
SD

A549
70.74
20.55
37.84
1.06
49.13
2.55
42.18
3.57
100.00
19.53

H1299
64.70
2.17
54.32
2.83
79.65
5.02
54.38
2.73
100.00
8.89

H460
17.03
1.45
27.97
0.33
32.13
1.14
27.82
0.58
100.00
2.52

H520
71.10
1.46
70.40
3.49
66.80
3.93
48.53
2.54
100.00
4.15

H522
77.69
1.15
53.45
2.35
82.13
3.14
61.08
2.65
100.00
7.48

H838
53.79
7.09
69.14
4.15
89.71
6.17
36.97
0.62
100.00
7.74

H596
87.37
4.98
83.48
2.82
88.75
1.11
73.39
2.67
100.00
1.89

H1650
69.57
2.30
87.96
1.73
90.98
8.44
60.31
4.59
100.00
7.21

HCC827
78.08
4.94
91.68
8.89
98.95
3.00
82.53
7.75
100.00
4.32

Calu-3
23.45
2.51
34.59
1.33
20.81
0.19
13.53
0.64
100.00
5.54

H226
77.16
1.42
n.d.
n.d.
28.17
2.32
9.33
2.70
100.00
2.43

HCC2935
74.26
6.18
63.61
6.12
n.d.
n.d.
n.d.
n.d.
100.00
13.92

Values are normalized to values obtained from cells transfected with negative control miRNA (100% proliferation).

NC, negative control miRNA;

siEg5, Eg5-specific siRNA;

SD, standard deviation;

n.d., not determined.

Delivery of hsa-miR-124a inhibits cellular proliferation of lung cancer cells A549, H1299, H522, H838, Calu-3, HCC827, HCC2935, H520, H596, H1650, H460 and H226 (Table 7 and FIG. 2). On average, hsa-miR-124a inhibits cellular proliferation by 36.25% (Table 7, FIG. 2). Hsa-miR-124a has maximal inhibitory activity in H460 cells, reducing proliferation by 83%. The growth-inhibitory activity of hsa-miR-124a is comparable to that of etoposide at concentrations ≧10 μM. Since hsa-miR-124a induces a therapeutic response in all lung cancer cells tested, hsa-miR-124a may provide therapeutic benefit to a broad range of patients with lung cancer and other malignancies.

The inventors determined sensitivity and specificity of hsa-miR-124a by administering hsa-miR-124a or negative control miRNA at increasing concentrations, ranging from 0 pM to 3,000 pM (FIG. 3). Delivery of miRNA and assessment of cellular proliferation of A549, H1299 and H460 cells were done as described above. Proliferation values from the Alamar Blue assay were normalized to values obtained from mock-transfected cells (0 pM=100% proliferation). Increasing amounts of negative control miRNA (NC) had no effect on cellular proliferation of A549, H1299 or H460 cells (Table 8; FIG. 3). In contrast, the growth-inhibitory phenotype of hsa-miR-124a is dose-dependent and correlates with increasing amounts of hsa-miR-124a (Table 8; FIG. 3). Hsa-miR-124a induces a specific therapeutic response at concentrations as low as 300 pM.

TABLE 8

Dose-dependent inhibition of cellular proliferation of lung cancer cell lines by hsa-miR-124a.

A549
H1299
H460

hsa-miR-124a
NC
hsa-miR-124a
NC
hsa-miR-124a
NC

Concentration
%

%

%

%

%

%

(pM)
Proliferation
% SD
Proliferation
% SD
Proliferation
% SD
Proliferation
% SD
Proliferation
% SD
Proliferation
% SD

0
100.00
2.61
100.00
2.61
100.00
3.28
100.00
3.28
100.00
8.84
100.00
8.84

3
102.71
0.07
102.82
2.23
93.92
2.51
96.51
0.51
111.99
4.17
107.60
0.79

30
96.22
2.16
99.36
3.51
90.66
3.54
95.89
0.61
103.59
2.03
108.04
1.46

300
82.92
1.81
105.53
3.72
79.78
1.39
94.45
1.99
58.11
2.81
106.99
4.74

3000
70.83
0.98
101.30
6.35
60.04
1.74
94.56
1.24
24.51
1.24
91.41
2.14

Values are normalized to values obtained from mock-transfected cells (0 pM miRNA).

NC, negative control miRNA;

SD, standard deviation.

To evaluate the therapeutic activity of hsa-miR-124a over an extended period of time, the inventors conducted growth curve experiments in the presence of miRNA for up to 31 days in H226 lung cancer cells. Since in vitro transfections of naked interfering RNAs, such as synthetic miRNA, are transient by nature and compromised by the dilution of the oligo during ongoing cell divisions, miRNA was administered at multiple time points (Bartlett et al., 2006; Bartlett et al., 2007). To accommodate miRNA delivery into a large quantity of cells, hsa-miR-124a or negative control miRNA were delivered by the electroporation method. Briefly, 1×10⁶H226 cells were electroporated in triplicate with 1.6 μM hsa-miR-124a or negative control using the BioRad Gene Pulser Xcell™ instrument (BioRad Laboratories Inc., Hercules, Calif., USA), seeded, and propagated in regular growth medium. When the control cells reached confluence (days 6, 17 and 25), cells were harvested, counted, and electroporated again with the respective miRNAs. To ensure similar treatment of both conditions as well as to accommodate exponential growth, the cell numbers used for the second and third electroporation were titrated down to the lowest count. The population doubling was calculated from these electroporation events using the formula PD=ln(Nf/N0)/ln 2 and adjusting for the fact that approximately 72% of newly seeded cells adhere to the plate. Cell counts were extrapolated and plotted on a linear scale (FIG. 4). Arrows represent electroporation days. Standard deviations are included in the graphs.

Repeated administration of hsa-miR-124a robustly inhibited proliferation of human lung cancer cells (FIG. 4). In contrast, cells treated with negative control miRNA showed normal exponential growth. hsa-miR-124a treatment resulted in 96.3% inhibition of H226 cell growth on day 31 (3.7% remaining cells) relative to the proliferation of control cells (100%).

The data suggest that hsa-miR-124a provides a useful therapeutic tool in the treatment of human lung cancer cells.

Example 7
Hsa-miR-124a in Combination with Specific Human Micro-RNAs Synergistically Inhibits Proliferation of Lung Cancer Cell Lines

miRNAs function in multiple pathways controlling multiple cellular processes. Cancer cells frequently show aberrations in several different pathways, which determine their oncogenic properties. Therefore, administration of multiple miRNAs to cancer patients may result in a superior therapeutic benefit over administration of a single miRNA. The inventors assessed the efficacy of pair-wise miRNA combinations, administering hsa-miR-124a concurrently with either hsa-miR-34a, hsa-miR-126, hsa-miR-147, hsa-let-7b, hsa-let-7c or hsa-let-7g (Pre-miR™ miRNA, Ambion cat. no. AM17100). H460 lung cancer cells were transiently reverse-transfected in triplicates with each miRNA at a final concentration of 300 pM, resulting in 600 pM of oligonucleotide. For negative controls, 600 pM of Pre-miR™ microRNA Precursor Molecule-Negative Control #2 (Ambion cat. no. AM17111) were used. To correlate the effect of various combinations with the effect of the sole miRNA, each miRNA at 300 pM was also combined with 300 pM negative control miRNA. Reverse transfection was performed using the following parameters: 7,000 cells per well of a 96 well plate, 0.15 μl Lipofectamine™ 2000 (Invitrogen) in 20 μl OptiMEM (Invitrogen), 100 μl total transfection volume. As an internal control for the potency of miRNA, etoposide was added at 10 μM and 50 μM to mock-transfected cells 24 hours after transfection for the following 48 hours. Cells were harvested 72 hours after transfection and subjected to Alamar Blue assays (Invitrogen). Percent proliferation values from the Alamar Blue assay were normalized to those obtained from cells treated with 600 μM negative control miRNA. Data are expressed as % proliferation relative to negative control miRNA-treated cells.

Transfection of 300 pM hsa-miR-124a reduces proliferation of H460 cells by 30.57% (Table 9; FIG. 5). Additive activity of pair-wise combinations (e.g. hsa-miR-124a plus hsa-let-7g) is defined as an activity that is greater than the sole activity of each miRNA (e.g., the activity of hsa-miR-124a plus hsa-let-7g is greater than that observed for hsa-miR-124a plus NC and the activity of hsa-miR-124a plus hsa-let-7g is greater than that observed for hsa-let-7g plus NC). Synergistic activity of pair-wise combinations is defined as an activity that is greater than the sum of the sole activity of each miRNA (e.g., the activity of hsa-miR-124a plus hsa-let-7g is greater than that observed for the sum of the activity of hsa-miR-124a plus NC and the activity of hsa-let-7g plus NC). The data indicate that hsa-miR-124a combined with hsa-miR-34a, hsa-miR-126, hsa-miR-147, hsa-let-7b, hsa-let-7c, or hsa-let-7g results in synergistic activity (Table 9, FIG. 5). Therefore, it is contemplated that administering combinations of hsa-miR-124a with other miRNAs to cancer patients can induce a superior therapeutic response in the treatment of lung cancer. The combinatorial use of miRNAs represents a potentially useful therapy for cancer and other diseases.

TABLE 9

Cellular proliferation of H460 lung cancer cells in the presence of

pair-wise miR-124a miRNA combinations.

%

Proliferation
% SD

miRNA [300 pM] +

miRNA [300 pM]

NC + NC
100.00
1.45

NC + miR-34a
99.58
1.66

NC + miR-124a
69.43
1.38

NC + miR-126
89.46
2.27

NC + miR-147
76.97
1.46

NC + let-7b
74.92
3.38

NC + let-7c
86.74
2.28

NC + let-7g
91.41
3.26

miR-124a + miR-34a
49.12
3.13

miR-124a + miR-126
46.49
4.89

miR-124a + 147
42.81
1.73

miR-124a + let-7b
39.77
7.61

miR-124a + let-7c
37.35
3.08

miR-124a + let-7g
35.15
0.84

Etoposide

10 μM
20.19
1.89

50 μM
14.94
0.31

Values are normalized to values obtained from cells transfected with 600 pM negative control (NC) miRNA.

SD, standard deviation.

Example 8
Delivery of Synthetic Hsa-miR-124a Inhibits Tumor Growth of Lung Cancer Cells in Mice

The inventors assessed the growth-inhibitory activity of hsa-miR-124a in human lung cancer xenografts grown in immunodeficient mice. Hsa-miR-124a was delivered into A549 and H460 lung cancer cells via electroporation using the Gene Pulser Xcell™ (BioRad) with the following settings: 15×10⁶cells with 5 μg miRNA in 200 μl OptiMEM, square wave pulse at 150 V for 10 ms. Electroporated cells (5×10⁶) were mixed with BD Matrigel™, (BD Biosciences; San Jose, Calif., USA; cat. no. 356237) in a 1:1 ratio and injected subcutaneously into the flank of NOD/SCID mice (Jackson Laboratories; Bar Harbor, Me., USA). As a negative control, A549 and H460 cells were electroporated with negative control (NC) miRNA (Pre-miR™ microRNA Precursor Molecule-Negative Control #2; Ambion cat. no. AM17111) as described above. To assess the anti-oncogenic activity of hsa-miR-124a, a group of 4 animals was injected with A459 cells and a group of 6 animals was injected with H460 cells. NC miRNA-treated cells were injected into the opposite flank of the same animal to control for animal-to-animal variability. Once tumors reached a measurable size (A549: 9 days post injection; H460: 5 days post injection), the length and width of tumors were determined every day for up to 8 days. Tumor volumes were calculated using the formula, Volume=length×width×width/2, in which the length is greater than the width. For animals carrying A549 xenografts, tumor volumes derived from NC-treated cells and hsa-miR-124a-treated cells were averaged and plotted over time (FIG. 6). The p value, indicating statistical significance, is shown for values obtained on day 16 (p=0.0036). For animals carrying H460 xenografts, tumor volumes of individual mice are shown (FIG. 7).

Administration of hsa-miR-124a into the A549 and H460 lung cancer xenografts inhibited tumor growth in vivo (FIG. 6 and FIG. 7). Cancer cells that received negative control miRNA developed tumors more rapidly than cells treated with hsa-miR-124a. Administration of hsa-miR-124a into A549 delayed and suppressed the onset of tumor growth.

Delivery of hsa-miR-124a into human lung cancer cells prior to implantation into the animal inhibited the formation of lung tumor xenografts. These results demonstrate the anti-oncogenic activity of hsa-miR-124a and suggest that hsa-miR-124a provides a powerful therapeutic tool to treat established lung tumors. To explore this possibility, 3×10⁶human H460 non-small lung cancer cells were mixed with BD Matrigel™, (BD Biosciences; San Jose, Calif., USA; cat. no. 356237) in a 1:1 ratio and subcutaneously injected into the lower back of each of 23 NOD/SCID mice (Jackson Laboratories; Bar Harbor, Me., USA). Once animals developed palpable tumors (day 11 post xenograft implantation), each animal in a group of six animals received intratumoral injections of 6.25 μg hsa-miR-124a (Dharmacon, Lafayette, Colo.) formulated with the lipid-based siPORT™ amine delivery agent (Ambion, Austin, Tex.; cat. no. AM4502) on days 11, 14 and 17. Each animal in a control group of six animals received intratumoral injections of 6.25 μg negative control miRNA (NC; Dharmacon, Lafayette, Colo.), following the same injection schedule that was used for hsa-miR-124a. Given an average mouse weight of 20 g, this dose equals 0.3125 mg/kg. In addition, a group of six H460 tumor-bearing mice received intratumoral injections of the siPORT™ amine delivery formulation lacking any oligonucleotide, and a group of five animals received intratumoral injections of phosphate-buffered saline (PBS). Caliper measurements were taken every 1-2 days, and tumor volumes were calculated using the formula, Volume=length×width×width/2, in which the length is greater than the width.

As shown in FIG. 8, three doses of hsa-miR-124a robustly inhibited growth of established H460 lung tumors (white squares). On day 19, the average volume of tumors treated with hsa-miR-124a was 122 mm³. In contrast, tumors treated with negative control miRNA (black diamonds) grew at a steady pace and yielded tumors with an average size of 421 mm³on day 19. Negative control tumors developed as quickly as tumors treated with either PBS or the siPORT amine only control, indicating that the therapeutic activity of hsa-miR-124a is specific.

The data indicate that hsa-miR-124a represents a particularly useful candidate in the treatment of patients with lung cancer. The therapeutic activity of hsa-miR-124a is highlighted by the fact that hsa-miR-124a inhibits tumor growth of tumors that had developed prior to treatment.

In addition, the data demonstrate the therapeutic utility of hsa-miR-124a in a lipid-based formulation.

Example 9
Delivery of Synthetic Hsa-miR-124a Inhibits Proliferation of Human Prostate Cancer Cells

The inventors assessed the therapeutic effect of hsa-miR-124a for prostate cancer by using four individual human prostate cancer cell lines. To measure cellular proliferation of prostate cancer cells, the following prostate cancer cell lines were used: PPC-1, derived from a bone metastasis; Dul45, derived from a brain metastasis; RWPE2, derived from prostate cells immortalized by human papillomavirus 18 and transformed by the K-RAS oncogene; and LNCaP, derived from a lymph node metastasis (Bello et al., 1997; Pretlow et al., 1993; Stone et al., 1978; Brothman et al., 1991; Horoszewicz et al., 1980). PPC-1 and Dul45 cells lack expression of the prostate-specific antigen (PSA) and are independent of androgen receptor (AR) signaling. In contrast, RWPE2 and LNCaP cells test positive for PSA and AR. Cells were transfected with synthetic hsa-miR-124a (Pre-miR™-hsa-miR-124a, Ambion cat. no. AM17100) or negative control miRNA (NC; Pre-miR™ microRNA Precursor Molecule-Negative Control #2; Ambion cat. no. AM17111) in a 96-well plate format using a lipid-based transfection reagent. Lipid-based reverse transfections were carried out in triplicate according to a published protocol (Ovcharenko et al. 2005) and the following parameters: Cells (6,000-7,000 per 96 well), 0.1-0.2 μl Lipofectamine™ 2000 (cat. no. 11668-019, Invitrogen Corp., Carlsbad, Calif., USA) in 20 μl OptiMEM (Invitrogen), 30 nM final concentration of miRNA in 100 μl. Proliferation was assessed 4-7 days post-transfection using Alamar Blue™ (Invitrogen) following the manufacturer's instructions. As a control for inhibition of cellular proliferation, siRNA against the motor protein kinesin 11, also known as Eg5, was used. Eg5 is essential for cellular survival of most eukaryotic cells and a lack thereof leads to reduced cell proliferation and cell death (Weil et al. 2002). siEg5 was used in lipid-based transfection following the same experimental parameters that apply to miRNA. Fluorescent light units (FLU) were measured after 3 hours, normalized to the control, and plotted as percent change in proliferation. Percent proliferation of hsa-miR-124a-treated cells relative to cells treated with negative control miRNA (100%) is shown in Table 10 and in FIG. 9.

TABLE 10

Percent (%) proliferation of human prostate cancer cell lines treated

with hsa-miR-124a, Eg5-specific siRNA (siEg5), or negative

control miRNA (NC).

hsa-miR-124a

(30 nM)
siEg5 (30 nM)
NC (30 nM)

%

%

%

Cells
proliferation
% SD
proliferation
% SD
proliferation
% SD

PPC-1
45.91
4.34
52.90
6.97
100.00
5.82

LNCaP
72.42
7.43
66.01
6.26
100.00
10.73

Du145
68.38
3.02
44.47
4.23
100.00
4.12

RWPE2
70.61
9.74
61.87
6.56
100.00
12.28

Values are normalized to values obtained from cells transfected with negative control miRNA (100% proliferation).

NC, negative control miRNA;

siEg5, Eg5-specific siRNA;

SD, standard deviation.

Delivery of hsa-miR-124a inhibits cellular proliferation of human prostate cancer cells PPC-1, Du145, LNCaP and RWPE2 (Table 10 and FIG. 9). On average, hsa-miR-124a inhibits cellular proliferation by 35.67%. The growth-inhibitory activity of hsa-miR-124a is comparable to that of Eg5-directed siRNA. Since hsa-miR-124a induces a therapeutic response in all prostate cancer cells tested, it is contemplated that hsa-miR-124a can provide therapeutic benefit to a broad range of patients with prostate cancer and other malignancies.

To evaluate the therapeutic activity of hsa-miR124a over an extended period of time, we conducted growth curve experiments in the presence of miRNA for up to 21 days. Since in vitro transfections of naked interfering RNAs, such as synthetic miRNA, are transient by nature and compromised by the dilution of the oligo during ongoing cell divisions, we administered miRNA at multiple time points (Bartlett et al., 2006; Bartlett et al., 2007). To accommodate miRNA delivery into a large quantity of cells, we employed the electroporation method to deliver hsa-miR-124a or negative control miRNA into PPC-1, PC3, and Du145 human prostate cancer cells. Briefly, 1×10⁶PPC-1 or PC3 cells, and 0.5×10⁶Du145 cells were electroporated with 1.6 μM hsa-miR-124a or negative control using the BioRad Gene Pulser Xcell™ instrument (BioRad Laboratories Inc., Hercules, Calif., USA), seeded, and propagated in regular growth medium. Experiments with PC3 and Du145 cells were carried out in triplicates. When the control cells reached confluence (days 4 and 11 for PPC-1; days 7 and 14 for PC3 and Du145), cells were harvested, counted, and electroporated again with the respective miRNAs. To ensure similar treatment of both conditions as well as to accommodate exponential growth, the cell numbers used for the second and third electroporation were titrated down to the lowest count. The population doubling was calculated from these electroporation events using the formula PD=ln(Nf/N0)/ln 2, and cell counts were extrapolated and plotted on a linear scale (FIG. 10). Arrows represent electroporation days. Standard deviations are shown in the graphs.

Repeated administration of hsa-miR-124a robustly inhibited proliferation of human prostate cancer cells (FIG. 10). In contrast, cells treated with negative control miRNA showed normal exponential growth. hsa-miR-124a treatment resulted in complete inhibition (99.9%) of PPC-1 cell growth by day 18; hsa-miR-124a treatment also resulted in 76.4% inhibition of PC3 cell growth on day 21 (23.6% remaining cells), and 86.2% inhibition of Du145 cell growth on day 20 (13.8% remaining cells) relative to the proliferation of control cells (100%).

The data suggest that hsa-miR-124a provides a useful therapeutic tool in the treatment of human prostate cancer cells.

Example 10
Delivery of Synthetic Hsa-miR-124a Inhibits Tumor Growth of Human Prostate Cancer Xenografts in Mice

The in vitro studies demonstrate the therapeutic activity of hsa-miR-124a in cultured human prostate cancer cells. Therefore, hsa-miR-124a is likely to interfere with prostate tumor growth in the animal. To explore this possibility, the therapeutic potential of synthetic hsa-miR-124a miRNA was evaluated in the animal using the PC3 human prostate cancer xenograft. As described in Example 8, 5×10⁶PC3 cells per animal were mixed with BD Matrigel™, (BD Biosciences; San Jose, Calif., USA; cat. no. 356237) in a 1:1 ratio and implanted subcutaneously into the lower back of NOD/SCID mice (Jackson Laboratories; Bar Harbor, Me., USA). Once animals developed palpable tumors (day 38 post xenograft implantation), each animal in a group of 4 animals received intratumoral injections of 6.25 μl hsa-miR-124a (Dharmacon, Lafayette, Colo.) formulated with the lipid-based siPORT™ amine delivery agent (Ambion, Austin, Tex.; cat. no. AM4502) on days 38 and 40. Each animal in a control group of 4 animals received intratumoral injections of 6.25 μg negative control miRNA (NC; Dharmacon, Lafayette, Colo.), following the same injection schedule that was used for hsa-miR-124a. Given an average mouse weight of 20 g, this dose equals 0.3125 mg/kg. Caliper measurements were taken daily, and tumor volumes were calculated using the formula, Volume=length×width×width/2, in which the length is greater than the width. Repeated dosing with hsa-miR-124a blocked tumor growth of the human PC3 prostate cancer xenograft (FIG. 11). On day 42, the average size of tumors treated with hsa-miR-124a was 37.1% less than that of tumors treated with negative control miRNA.

The data suggest that hsa-miR-124a provides a useful therapeutic tool in the treatment of patients with prostate cancer. The therapeutic activity of hsa-miR-124a is highlighted by the fact that hsa-miR-124a inhibits tumor growth of tumors that had developed prior to treatment.

In addition, the data demonstrate the therapeutic utility of hsa-miR-124a in a lipid-based formulation.

Example 11
Delivery of Synthetic Hsa-miR-124a Inhibits Proliferation of Human Liver Cancer Cells

The inventors assessed the therapeutic effect of hsa-miR-124a for liver cancer by using five individual human liver cancer cell lines. To measure cellular proliferation of liver cancer cells, the following liver cancer cell lines were used: HepG2, hepatocellular carcinoma derived from the liver; C3A, hepatocellular carcinoma derived from the liver; SK-Hep-1, adenocarcinoma derived from ascites; SNU-398, hepatocellular carcinoma derived from the liver; and PLC/PRF/5, Alexander cells derived from a hepatoma. Cells were transfected with synthetic hsa-miR-124a (Pre-miR™-hsa-miR-124a, Ambion cat. no. AM17100) or negative control miRNA (NC; Pre-miR™ microRNA Precursor Molecule-Negative Control #2; Ambion cat. no. AM17111) in a 96-well plate format using a lipid-based transfection reagent. Lipid-based reverse transfections were carried out in triplicate according to a published protocol (Ovcharenko et al. 2005) and the following parameters: Cells (6,000-7,000 per well), 0.1-0.15 μl Lipofectamine™ 2000 (cat. no. 11668-019, Invitrogen Corp., Carlsbad, Calif., USA) in 20 μl OptiMEM (Invitrogen), 30 nM final concentration of miRNA in 100 μl. Proliferation was assessed 4-7 days post-transfection using Alamar Blue™ (Invitrogen) following the manufacturer's instructions. As a control for inhibition of cellular proliferation, siRNA against the motor protein kinesin 11, also known as Eg5, was used. Eg5 is essential for cellular survival of most eukaryotic cells and a lack thereof leads to reduced cell proliferation and cell death (Weil et al. 2002). siEg5 was used in lipid-based transfection following the same experimental parameters that apply to miRNA. Fluorescent light units (FLU) were measured after 2-4 hours, normalized to the negative control, and plotted as percent change in proliferation. Percent proliferation of hsa-miR-124a-treated cells relative to cells treated with negative control miRNA (100%) is shown in Table 11 and in FIG. 12.

TABLE 11

Percent (%) proliferation of human liver cancer cell lines treated with

hsa-miR-124a, Eg5-specific siRNA (siEg5), or negative control miRNA (NC).

hsa-miR-124a

(30 nM)
siEg5 (30 nM)
NC (30 nM)

Cells
% proliferation
% SD
% proliferation
% SD
% proliferation
% SD

SNU-398
38.67
6.75
25.26
3.23
100.00
8.01

SK-Hep-1
75.7
2.94
34.68
5.13
100.00
3.21

C3A
41.09
3.59
40.63
23.48
100.00
7.49

HepG2
77.67
6.61
46.51
0.66
100.00
1.06

PLC/PRF/5
65.12
7.84
62.8
12.84
100.00
9.85

Values are normalized to values obtained from cells transfected with negative control miRNA (100% proliferation).

NC, negative control miRNA;

siEg5, Eg5-specific siRNA;

SD, standard deviation.

Delivery of hsa-miR-124a inhibits cellular proliferation of liver cancer cells SNU-398, SK-Hep-1, C3A, HepG2 and PLC/PRF/5 (Table 11 and FIG. 12). On average, hsa-miR-124a inhibits cellular proliferation by 40.35% (Table 11, FIG. 12). Hsa-miR-124a has maximal inhibitory activity in SNU-398 cells, reducing proliferation by 61%. Since hsa-miR-124a induces a therapeutic response in all liver cancer cells tested, it is contemplated that hsa-miR-124a can provide therapeutic benefit to a broad range of patients with liver cancer and other malignancies.

REFERENCES

The following references, to the extent that they provide exemplary procedural or other details supplementary to those set forth herein, are specifically incorporated herein by reference.

U.S. Pat. No. 4,337,063
U.S. Pat. No. 4,404,289
U.S. Pat. No. 4,405,711
U.S. Pat. No. 4,659,774
U.S. Pat. No. 4,682,195
U.S. Pat. No. 4,683,202
U.S. Pat. No. 4,704,362
U.S. Pat. No. 4,816,571
U.S. Pat. No. 4,870,287
U.S. Pat. No. 4,959,463
U.S. Pat. No. 5,141,813
U.S. Pat. No. 5,143,854
U.S. Pat. No. 5,202,231
U.S. Pat. No. 5,214,136
U.S. Pat. No. 5,221,619
U.S. Pat. No. 5,223,618
U.S. Pat. No. 5,242,974
U.S. Pat. No. 5,264,566
U.S. Pat. No. 5,268,486
U.S. Pat. No. 5,288,644
U.S. Pat. No. 5,324,633
U.S. Pat. No. 5,378,825
U.S. Pat. No. 5,384,261
U.S. Pat. No. 5,399,363
U.S. Pat. No. 5,405,783
U.S. Pat. No. 5,412,087
U.S. Pat. No. 5,424,186
U.S. Pat. No. 5,428,148
U.S. Pat. No. 5,429,807
U.S. Pat. No. 5,432,049
U.S. Pat. No. 5,436,327
U.S. Pat. No. 5,445,934
U.S. Pat. No. 5,446,137
U.S. Pat. No. 5,466,468
U.S. Pat. No. 5,466,786
U.S. Pat. No. 5,468,613
U.S. Pat. No. 5,470,710
U.S. Pat. No. 5,470,967
U.S. Pat. No. 5,472,672
U.S. Pat. No. 5,480,980
U.S. Pat. No. 5,492,806
U.S. Pat. No. 5,503,980
U.S. Pat. No. 5,510,270
U.S. Pat. No. 5,525,464
U.S. Pat. No. 5,527,681
U.S. Pat. No. 5,529,756
U.S. Pat. No. 5,532,128
U.S. Pat. No. 5,543,158
U.S. Pat. No. 5,545,531
U.S. Pat. No. 5,547,839
U.S. Pat. No. 5,554,501
U.S. Pat. No. 5,554,744
U.S. Pat. No. 5,556,752
U.S. Pat. No. 5,561,071
U.S. Pat. No. 5,571,639
U.S. Pat. No. 5,574,146
U.S. Pat. No. 5,580,726
U.S. Pat. No. 5,580,732
U.S. Pat. No. 5,583,013
U.S. Pat. No. 5,593,839
U.S. Pat. No. 5,599,672
U.S. Pat. No. 5,599,695
U.S. Pat. No. 5,602,240
U.S. Pat. No. 5,602,244
U.S. Pat. No. 5,610,287
U.S. Pat. No. 5,610,289
U.S. Pat. No. 5,614,617
U.S. Pat. No. 5,623,070
U.S. Pat. No. 5,624,711
U.S. Pat. No. 5,631,134
U.S. Pat. No. 5,637,683
U.S. Pat. No. 5,639,603
U.S. Pat. No. 5,641,515
U.S. Pat. No. 5,645,897
U.S. Pat. No. 5,652,099
U.S. Pat. No. 5,654,413
U.S. Pat. No. 5,658,734
U.S. Pat. No. 5,661,028
U.S. Pat. No. 5,665,547
U.S. Pat. No. 5,667,972
U.S. Pat. No. 5,670,663
U.S. Pat. No. 5,672,697
U.S. Pat. No. 5,677,195
U.S. Pat. No. 5,681,947
U.S. Pat. No. 5,695,940
U.S. Pat. No. 5,700,637
U.S. Pat. No. 5,700,922
U.S. Pat. No. 5,705,629
U.S. Pat. No. 5,708,153
U.S. Pat. No. 5,708,154
U.S. Pat. No. 5,714,606
U.S. Pat. No. 5,728,525
U.S. Pat. No. 5,739,169
U.S. Pat. No. 5,744,305
U.S. Pat. No. 5,760,395
U.S. Pat. No. 5,763,167
U.S. Pat. No. 5,770,358
U.S. Pat. No. 5,777,092
U.S. Pat. No. 5,789,162
U.S. Pat. No. 5,792,847
U.S. Pat. No. 5,800,992
U.S. Pat. No. 5,801,005
U.S. Pat. No. 5,807,522
U.S. Pat. No. 5,824,311
U.S. Pat. No. 5,830,645
U.S. Pat. No. 5,830,880
U.S. Pat. No. 5,837,196
U.S. Pat. No. 5,846,225
U.S. Pat. No. 5,846,945
U.S. Pat. No. 5,847,219
U.S. Pat. No. 5,856,174
U.S. Pat. No. 5,858,988
U.S. Pat. No. 5,859,221
U.S. Pat. No. 5,871,928
U.S. Pat. No. 5,872,232
U.S. Pat. No. 5,876,932
U.S. Pat. No. 5,886,165
U.S. Pat. No. 5,919,626
U.S. Pat. No. 5,922,591
U.S. Pat. No. 6,004,755
U.S. Pat. No. 6,040,193
U.S. Pat. No. 6,087,102
U.S. Pat. No. 6,251,666
U.S. Pat. No. 6,368,799
U.S. Pat. No. 6,383,749
U.S. Pat. No. 6,617,112
U.S. Pat. No. 6,638,717
U.S. Pat. No. 6,720,138
U.S. Pat. No. 6,723,509
U.S. application Ser. No. 09/545,207
U.S. application Ser. No. 10/667,126
U.S. application Ser. No. 11/141,707
U.S. application Ser. No. 11/273,640
U.S. application Ser. No. 11/349,727
U.S. Prov. Appln. 60/575,743
U.S. Prov. Appln. 60/649,584
U.S. Prov. Appln. 60/650,807
Adelaide et al., Genes Chromosomes Cancer, 37(4):333-345, 2003.
Akiba et al., Int J Oncol, 18(2):257-264, 2001.
Akino et al., Gastroenterology, 129(1):156-169, 2005.
Alipov et al., Histopathology, 46(2):202-208, 2005.
Ando et al., J Biol Chem, 279(24):25549-25561, 2004.
Aoki et al., Proc Natl Acad Sci USA, 101(37):13613-13617, 2004.
Arap et al., Cancer Res., 55(6):1351-1354, 1995.
Ariyanayagam-Baksh et al., Mod Pathol, 16(10):992-995, 2003.
Aspland et al., Oncogene, 20(40):5708-5717, 2001.
Austin and Cook, J Biol Chem, 280(39):33280-33288, 2005.
Austin-Ward and Villaseca, Revista Medica de Chile, 126(7):838-845, 1998.
Bader and Vogt, Oncogene, 23(18):3145-3150, 2004.
Bader et al., Nat Rev Cancer, 5(12):921-929, 2005.
Bae et al., J Biol Chem, 275(33):25255-25261, 2000.
Bagga et al., Cell, 122(4):553-563, 2005.
Bandyopadhyay et al., Oncogene, 21(22):3541-3551, 2002.
Barr, Oncogene, 20(40):5736-5746, 2001.
Bar-Shira et al., Cancer Res. 62(23):6803-6807, 2002.
Bartel et al., Cancer Cell, 2(1):9-15, 2002.
Bartlett et al., Nucleic Acids Res. 34(1):322-33, 2006
Bartlett et al., Biotechnol Bioeng. 97(4):909-2, 2007.
Beeram et al., J Clin Oncol, 23(27):6771-6790, 2005.
Behrens et al., J Pathol, 194(1):43-50, 2001.
Beisner et al., Cancer Res, 66(15):7554-7561, 2006.
Bell and Dutta, Annu Rev Biochem, 71:333-374, 2002.
Bello et al., Carcinogenesis, 18(6):1215-1223, 1997.
Biswas et al., Cancer Res, 64(14):4687-4692, 2004.
Blobe et al., J Biol Chem, 276(27):24627-24637, 2001.
Borczuk et al., Am J Pathol, 163(5):1949-1960, 2003.
Boultwood et al., Br J Haematol, 126(4):508-511, 2004.
Bravou et al., Int J Oncol, 27(6):1511-1518, 2005.
Brothman et al., J Urol., 145(5):1088-1091, 1991.
Buggy et al., Br J Cancer, 91(7):1308-1315, 2004.
Bukowski et al., Clinical Cancer Res., 4(10):2337-2347, 1998.
Cahill et al., Nature, 392(6673):300-303, 1998.
Caldas et al., Cancer Res., 54:3568-3573, 1994.
Calin and Croce, Nat Rev Cancer, 6(11):857-866, 2006.
Cao et al., Cell, 107(6):763-775, 2001.
Cao et al., Genes Dev, 21(5):531-536, 2007.
Carrano et al., Nat Cell Biol, 1(4):193-199, 1999.
Carrington and Ambros, Science, 301(5631):336-338, 2003.
Carter and Brunet, Curr Biol, 17(4):R113-114, 2007.
Chandler et al., Int J Cancer, 81(3):451-458, 1999.
Chang et al., Int J Cancer, 114(6):942-949, 2005.
Chendrimada et al., Nature, 447(7146):823-828, 2007.
Cheng et al., Cancer Res., 54(21):5547-5551, 1994.
Chieffi et al., Prostate, 66(3):326-333, 2006.
Choi et al., Oncogene, 23(42):7095-7103, 2004.
Cho-Vega et al., Hum Pathol, 35(9):1095-1100, 2004.
Christodoulides et al., Microbiology, 144(Pt 11):3027-3037, 1998.
Cipriano and Chen, Oncogene, 17(12):1549-1556, 1998.
Claudio et al., Clin Cancer Res, 8(6):1808-1815, 2002.
Cohen et al., Oncogene, 20(2):141-146, 2001.
Coll et al., Embo J, 2(12):2189-2194, 1983.
Costello et al., Cancer Res, 57(7):1250-1254, 1997.
Crossen and Morrison, Hum Genet, 91(4):380-382, 1993.
Crossen et al., Cancer Genet Cytogenet, 79(1):70-73, 1995.
Cully et al., Cancer Res, 65(22):10363-10370, 2005.
Cummins et al., In: IRT: Nucleosides and nucleosides, La Jolla Calif., 72, 1996.
Davidson et al., Clin Cancer Res, 7(3):551-557, 2001.
Davidson et al., J. Immunother., 21(5):389-398, 1998.
Denli et al., Trends Biochem. Sci., 28:196, 2003.
Didenko, Biotechniques, 31(5):1106-1116, 1118, 1120-1121, 2001.
Dillman, Cancer Biother. Radiopharm., 14(1):5-10, 1999.
Dittmer, Mol Cancer, 2:29, 2003.
Dong et al., Mol Endocrinol, 20(10):2315-2325, 2006.
Dreyfus et al., Nouv Rev Fr Hematol, 31(3):217-221, 1989.
Dyer and Bremner, Nat Rev Cancer, 5(2):91-101, 2005.
Egilmez et al., J Exp Clin Cancer Res, 20(4):549-552, 2001.
Egle et al., Proc Natl Acad Sci USA, 101(16):6164-6169, 2004.
Egloff et al., Cancer Res, 66(1):6-9, 2006.
Einama et al., Pancreas, 32(4):376-381, 2006.
Emptage et al., Neuron, 29(1):197-208, 2001.
Endoh et al., Br J Cancer, 93(12):1395-1399, 2005.
EP 266,032
EP 373 203
EP 785 280
EP 799 897
Esquela-Kerscher and Slack, Nat Rev Cancer, 6(4):259-269, 2006.
Fakharzadeh et al., Embo J, 10(6):1565-1569, 1991.
Firth and Baxter, Endocr Rev, 23(6):824-854, 2002.
Fisher, J Royal Statistical Soc, 85(1):87-94, 1922.
Fleischer et al., Int J Oncol, 28(1):25-32, 2006.
Fodor et al., Biochemistry, 30(33):8102-8108, 1991.
Froehler et al., Nucleic Acids Res., 14(13):5399-5407, 1986.
Fujimoto et al., Ann Oncol, 13(10):1598-1604, 2002a.
Fujimoto et al., Ann Oncol, 13(10):1605-1611, 2002b.
Fujiwara et al., Oncogene, 10(5):891-895, 1995.
Ginestier et al., Clin Cancer Res, 12(15):4533-4544, 2006.
Golay et al., Blood, 87(5):1900-1911, 1996.
Gomez-Bougie et al., Eur J Immunol, 34(11):3156-3164, 2004.
Gonzalez et al., Nature, 440(7084):702-706, 2006.
Goto et al., Oncogene, 2007.
Goyns et al., Br J Cancer, 56(5):611-613, 1987.
Grabsch et al., J Pathol, 200(1):16-22, 2003.
Gratas et al., Cancer Res, 58(10):2057-2062, 1998.
Griffey et al., J. Mass Spectrom, 32(3):305-13, 1997.
Gstaiger et al., Proc Natl Acad Sci USA, 98(9):5043-5048, 2001.
Hanahan and Weinberg, Cell, 100(1):57-70, 2000.
Hanibuchi et al., Int. J. Cancer, 78(4):480-485, 1998.
Hansel et al., Am J Surg Pathol, 29(3):390-399, 2005.
Hayette et al., Blood, 102(4):1549-1550, 2003.
Hellstrand et al., Acta Oncologica, 37(4):347-353, 1998.
Hishikawa et al., J Biol Chem, 274(52):37461-37466, 1999.
Horoszewicz et al., Prog Clin Biol Res., 37:115-32, 1980.
Houston and O'Connell, Curr Opin Pharmacol, 4(4):321-326, 2004.
Hsu et al., Mol Endocrinol, 12(9):1432-1440, 1998.
Huang et al., Clin Cancer Res, 12(2):487-498, 2006.
Hui and Hashimoto, Infection Immun., 66(11):5329-5336, 1998.
Hussussian et al., Nat. Genet., 8(1):15-21, 1994.
Inui et al., Biochem Biophys Res Commun, 303(3):978-984, 2003.
Iolascon et al., Hepatology, 27(4):989-995, 1998.
Itakura and Riggs, Science, 209:1401-1405, 1980.
Ito et al., Am J Clin Pathol, 114(5):719-725, 2000.
Ito et al., Anticancer Res, 23(5A):3819-3824, 2003.
Ito et al., Mod Pathol, 11(2):209-215, 1998.
Jansen et al., Embo J, 2(11): 1969-1975, 1983.
Jiang et al., Cancer Res, 64(16):5787-5794, 2004.
Jonson et al., Int J Oncol, 19(1):71-81, 2001.
Ju et al., Gene Ther., 7(19):1672-1679, 2000.
Jung et al., Pathol Int, 56(9):503-509, 2006.
Kalin et al., Cancer Res, 66(3):1712-1720, 2006.
Kalinichenko et al., Genes Dev, 18(7):830-850, 2004.
Kamata et al., J Cancer Res Clin Oncol, 131(9):591-596, 2005.
Kamb et al., Nat. Genet., 8(1):23-26, 1994.
Kamb et al., Science, 2674:436-440, 1994.
Kapsimali et al., Genome Biol, 8(8):R173 [Epub ahead of print] 2007.
Karakaidos et al., Am J Pathol, 165(4):1351-1365, 2004.
Karin et al., Nat Rev Cancer, 2(4):301-310, 2002.
Kastan and Lim, Nat Rev Mol Cell Biol, 1(3):179-186, 2000.
Kaufmann et al., Blood, 91(3):991-1000, 1998.
Keen and Taylor, Nat Rev Cancer, 4(12):927-936, 2004.
Kerckaert et al., Leukemia, 4(1):16-19, 1990.
Kim et al., Cancer Res, 66(4):2153-2161, 2006.
Kim et al., Clin Cancer Res, 11(2 Pt 1):473-482, 2005.
Kiriakidou et al., Cell, 129(6): 1141-1151, 2007.
Kirikoshi et al., Int J Oncol, 19(1):111-115, 2001.
Kitada et al., Blood, 91(9):3379-3389, 1998.
Kitange et al., Cancer, 89(11):2292-2300, 2000.
Kitange et al., Mod Pathol, 12(6):618-626, 1999.
Klostermeier and Millar, Biopolymers, 61(3):159-79, 2001-2002.
Koivunen et al., Cancer Lett, 235(1):1-10, 2006.
Koivunen et al., Cancer Res, 64(16):5693-5701, 2004.
Komiya et al., Jpn J Cancer Res, 88(4):389-393, 1997.
Kops et al., Nat Rev Cancer, 5(10):773-785, 2005.
Kornberg and Baker, In: DNA Replication, 2d Ed., Freeman, San Francisco, 1992.
Krajewska et al., Am J Pathol, 148(5):1567-1576, 1996.
Krasagakis et al., Br J Cancer, 77(9):1492-1494, 1998.
Krek et al., Nat Genet, 37(5):495-500, 2005.
Kristjansdottir and Rudolph, Chem Biol, 11(8):1043-1051, 2004.
Kulkarni et al., Leukemia, 16(1):127-134, 2002.
Lagos-Quintana et al., Rna, 9(2):175-179, 2003.
Lahn and Sundell, Melanoma Res, 14(2):85-89, 2004.
Lam et al., Br J Neurosurg, 14(1):28-32, 2000.
Lambros et al., J Pathol, 205(1):29-40, 2005.
Lau et al., Science, 294(5543):858-862, 2001.
Lauffart et al., BMC Womens Health, 5:8, 2005.
Lee and Ambros, Science, 294(5543):862-864, 2001.
Leprince et al., Nature, 306(5941):395-397, 1983.
L'Hote and Knowles, Exp Cell Res, 304(2):417-431, 2005.
Li et al., Cell Death Differ, 12(3):292-303, 2005.
Li et al., Oncogene, 22(10):1501-1510, 2003.
Lim et al., Nature, 433(7027):769-773, 2005.
Lin and Gelman, Cancer Res, 57(11):2304-2312, 1997.
Lin et al., Gastroenterology, 128(1):9-23, 2005.
Liu and Erikson, Proc Natl Acad Sci USA, 100(10):5789-5794, 2003.
Liu et al., Cancer Res, 66(7):3593-3602, 2006.
Lo Vasco et al., Leukemia, 18(6):1122-1126, 2004.
Lucke et al., Cancer Res, 61(2):482-485, 2001.
Lujambio et al., Cancer Res, 67(4):1424-1429, 2007.
Lukiw, Neuroreport, 18(3):297-300, 2007.
Makeyev et al., Mol Cell, 27(3):435-448, 2007.
Malumbres and Barbacid, Nat Rev Cancer, 1(3):222-231, 2001.
Markowitz et al., Science, 268(5215):1336-1338, 1995.
Markowitz, Biochim Biophys Acta, 1470(1):M13-20, 2000.
Marone et al., Int J Cancer, 75(1):34-39, 1998.
Marsters et al., Recent Prog. Horm. Res., 54:225-234, 1999.
Martinez-Lorenzo et al., Int J Cancer, 75(3):473-481, 1998.
Massague et al., Cell, 103(2):295-309, 2000.
McGary et al., Cancer Biol Ther, 1(5):459-465, 2002.
Mendrzyk et al., J Clin Oncol, 23(34):8853-8862, 2005.
Merle et al., Gastroenterology, 127(4):1110-1122, 2004.
Mishima et al., Brain Res, 1131(1):37-43, Epub Dec. 19, 2006. 2007.
Moller et al., Int J Cancer, 57(3):371-377, 1994.
Momand et al., Nucleic Acids Res, 26(15):3453-3459, 1998.
Mori et al., Cancer Res., 54(13):3396-3397, 1994.
Mori et al., Gastroenterology, 131(3):797-808, 2006.
Morishita et al., Hepatology, 40(3):677-686, 2004.
Mundt et al., Biochem Biophys Res Commun, 239(2):377-385, 1997.
Murphy et al., J Clin Pathol, 58(5):525-534, 2005.
Nakagawa et al., Oncogene, 23(44):7366-7377, 2004.
Nakayama et al., Am J Pathol, 149(6):1931-1939, 1996.
Nakayama et al., Cancer, 92(12):3037-3044, 2001.
Nakayama et al., Mod Pathol, 12(1):61-68, 1999.
Nauert et al., Curr Biol, 7(1):52-62, 1997.
Nobori et al., Nature (London), 368:753-756, 1995.
O'Connor et al., Embo J, 17(2):384-395, 1998.
Ohsaki et al., Cancer Res, 52(13):3534-3538, 1992.
Okamoto et al., Proc. Natl. Acad. Sci. USA, 91(23):11045-11049, 1994.
Olsen et al., Dev. Biol., 216:671, 1999.
Orlow et al., Cancer Res, 54(11):2848-2851, 1994.
Orlow et al., Int. J. Oncol., 15(1):17-24, 1994.
Ovcharenko et al., Rna, 11(6):985-993, 2005.
Ozaki et al., Cancer Res, 60(22):6519-6525, 2000.
Paik et al., Cell, 128(2):309-323, 2007.
Parekh et al., Biochem Pharmacol, 63(6):1149-1158, 2002.
Payton and Coats, Int J Biochem Cell Biol, 34(4):315-320, 2002.
Payton et al., Oncogene, 21(55):8529-8534, 2002.
PCT Appln. WO 0138580
PCT Appln. WO 0168255
PCT Appln. WO 03020898
PCT Appln. WO 03022421
PCT Appln. WO 03023058
PCT Appln. WO 03029485
PCT Appln. WO 03040410
PCT Appln. WO 03053586
PCT Appln. WO 03066906
PCT Appln. WO 03067217
PCT Appln. WO 03076928
PCT Appln. WO 03087297
PCT Appln. WO 03091426
PCT Appln. WO 03093810
PCT Appln. WO 03100012
PCT Appln. WO 03100448A1
PCT Appln. WO 04020085
PCT Appln. WO 04027093
PCT Appln. WO 09923256
PCT Appln. WO 09936760
PCT Appln. WO 93/17126
PCT Appln. WO 95/11995
PCT Appln. WO 95/21265
PCT Appln. WO 95/21944
PCT Appln. WO 95/21944
PCT Appln. WO 95/35505
PCT Appln. WO 96/31622
PCT Appln. WO 97/10365
PCT Appln. WO 97/27317
PCT Appln. WO 9743450
PCT Appln. WO 99/35505
Petit et al., Genomics, 57(3):438-441, 1999.
Pietras et al., Cancer Cell, 3(5):439-443, 2003.
Pietras et al., Oncogene, 17(17):2235-2249, 1998.
Prentice et al., Oncogene, 24(49):7281-7289, 2005.
Pretlow et al., Natl Cancer Inst., 85(24):2004-2007, 1993.
Prochownik et al., Genes Chromosomes Cancer, 22(4):295-304, 1998.
Pruitt et al., Nucleic Acids Res, 33(Database issue):D501-504, 2005.
Qian et al., Proc Natl Acad Sci USA, 99(23):14925-14930, 2002.
Qin et al., Proc. Natl. Acad. Sci. USA, 95(24):14411-14416, 1998.
Rapp et al., Proc Natl Acad Sci USA, 80(14):4218-4222, 1983.
Reiter et al., Clin Cancer Res, 12(17):5136-5141, 2006.
Remington's Pharmaceutical Sciences” 15^thEd., 1035-1038 and 1570-1580, 1990.
Remington's Pharmaceutical Sciences” 15^thEd., 1035-1038 and 1570-1580, 1990.
Rincon-Arano et al., Cancer, 97(3):575-585, 2003.
Ritch et al., J Biol Chem, 278(23):20971-20978, 2003.
Robles et al., J Biol Chem., 277(28):25431-25438, 2002.
Romieu-Mourez et al., Cancer Res, 61(9):3810-3818, 2001.
Rosenkilde and Schwartz, Apmis, 112(7-8):481-495, 2004.
Rothhammer et al., Cell Mol Life Sci, 61(1):118-128, 2004.
Rous, J Exp Med, 13:397-411, 1911.
Ru et al., Oncogene, 21(30):4673-4679, 2002.
Rust et al., J Clin Pathol, 58(5):520-524, 2005.
Sacchi et al., Leukemia, 2(1):12-18, 1988.
Sacchi et al., Science, 231(4736):379-382, 1986.
Saeki et al., Cancer, 89(8):1670-1676, 2000.
Saigusa et al., Cancer Sci, 96(10):676-683, 2005.
Sanchez-Aguilera et al., Blood, 103(6):2351-2357, 2004.
Sano et al., Histopathology, 46(5):532-539, 2005.
Sasaki et al., J Surg Res, 101(2):242-247, 2001.
Schulze-Bergkamen et al., BMC Cancer, 6:232, 2006.
Seggerson et al., Dev. Biol., 243:215, 2002.
Seike et al., Lung Cancer, 38(3):229-234, 2002.
Semple and Duncker, Biotechnol Adv, 22(8):621-631, 2004.
Serrano et al., Nature, 366:704-707, 1993.
Serrano et al., Science, 267(5195):249-252, 1995.
Shapira et al., Cancer, 103(7):1336-1346, 2005.
Sherr and McCormick, Cancer Cell, 2(2):103-112, 2002.
Sherr and Roberts, Genes Dev, 13(12):1501-1512, 1999.
Shetty et al., Br J Cancer, 93(11):1295-1300, 2005.
Shibahara et al., Anticancer Res, 25(3B):1881-1888, 2005.
Shigeishi et al., Oncol Rep, 15(4):933-938, 2006.
Shigemasa et al., Jpn J Cancer Res, 93(5):542-550, 2002.
Shinoura et al., Cancer Gene Ther, 7(2):224-232, 2000.
Sieghart et al., J Hepatol, 44(1):151-157, 2006.
Slotky et al., Breast Cancer Res, 7(5):R737-744, 2005.
Smirnova et al., Eur J Neurosci, 21(6):1469-1477, 2005.
Smith et al., Biochem Biophys Res Commun, 234(2):397-405, 1997.
Smith et al., Br J Cancer, 93(6):719-729, 2005.
Soufla et al., Cancer Lett, 221(1):105-118, 2005.
Span et al., Oncogene, 21(55):8506-8509, 2002.
Sparmann and Bar-Sagi, Cancer Cell, 6(5):447-458, 2004.
Stehelin et al., Nature, 260(5547):170-173, 1976.
Stone et al., Int J Cancer., 21(3):274-81, 1978.
Strebhardt and Ullrich, Nat Rev Cancer, 6(4):321-330, 2006.
Sui et al., Oncol Rep, 15(4):765-771, 2006.
Tagawa et al., Oncogene, 24(8):1348-1358, 2005.
Takanami, Oncol Rep, 13(4):727-731, 2005.
Takimoto et al., Biochem Biophys Res Commun, 251(1):264-268, 1998.
Tan et al., Leuk Res, 27(2):125-131, 2003.
Tanaka et al., Proc Natl Acad Sci USA, 95(17):10164-10169, 1998.
Tanner et al., Clin Cancer Res, 6(5):1833-1839, 2000.
Thome, Nat Rev Immunol, 4(5):348-359, 2004.
Tokuhara et al., Int Surg, 88(1):25-33, 2003.
Traub et al., Breast Cancer Res Treat, 99(2):185-191, 2006.
Tsai et al., J Natl Cancer Inst, 85(11):897-901, 1993.
Turner et al., Nat Rev Cancer, 4(10):814-819, 2004.
Tuveson et al., Cancer Cell, 4(2):95-98, 2003.
U.K. Patent 1,529,202
U.K. Patent 8 803 000
Ulisse et al., Int J Cancer, 119(2):275-282, 2006.
Vanhaesebroeck et al., Trends Biochem Sci, 22(7):267-272, 1997.
Venkatasubbarao et al., Anticancer Res, 20(1A):43-51, 2000.
Viard-Leveugle et al., J Pathol, 201(2):268-277, 2003.
Visvanathan et al., Genes Dev, 21(7):744-749, 2007.
Vogt et al., Cell Cycle, 4(7):908-913, 2005.
Vos et al., J Biol Chem, 278(30):28045-28051, 2003.
Wang et al., Oncogene, 22(10):1486-1490, 2003.
Wang et al., Proc Natl Acad Sci USA, 98(20):11468-11473, 2001.
Wechsler et al., Cancer Res, 57(21):4905-4912, 1997.
Weichert et al., Int J Oncol, 23(3):633-639, 2003.
Weil et al., Biotechniques, 33(6):1244-1248, 2002.
Wiemer, Eur J Cancer, 43(10):1529-1544, 2007.
Wikman et al., Oncogene, 21(37):5804-5813, 2002.
Wohlschlegel et al., Am J Pathol, 161(1):267-273, 2002.
Wolowiec et al., Leuk Lymphoma, 35(1-2):147-157, 1999.
Wooster and Weber, N Engl J Med, 348(23):2339-2347, 2003.
Woszczyk et al., Med Sci Monit, 10(1):CR33-37, 2004.
Wu et al., Eur J Cancer, 38(14):1838-1848, 2002.
Wuilleme-Toumi et al., Leukemia, 19(7):1248-1252, 2005.
Xi et al., Clin Cancer Res, 12(8):2484-2491, 2006a.
Xi et al., Clin Chem, 52(3):520-523, 2006b.
Xia et al., Cancer Res, 61(14):5644-5651, 2001.
Yamamoto et al., Int J Oncol, 13(2):233-239, 1998.
Yeatman, Nat Rev Cancer, 4(6):470-480, 2004.
Yu and Feig, Oncogene, 21(49):7557-7568, 2002.
Zangemeister-Wittke and Huwiler, Cancer Biol Ther, 5(10):1355-1356, 2006.

miR-124 Regulated Genes and Pathways as Targets for Therapeutic Intervention

Information

Publication Number

Date Filed

Date Published

Inventors

Original Assignees

CPC

US Classifications

International Classifications

Abstract

Description

Claims

Parent Case Info

Provisional Applications (1)